

Oxford University Hospitals NHS Foundation Trust Formulary

FORMULARY (Y): the medicine can be used as per its licence.

RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction.

NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC.

UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction.

SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction.

EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction.

UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC.

SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC.

EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC.

CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use.

NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).

Medicines Management and Therapeutics Committee
(send Comments to medicines.effectiveness@ouh.nhs.uk)

Axicabtagene ciloleucel

AXICABTAGENE CILOLEUCEL 40million-200million cells in 68ml INFUSION (YESCARTA) R

Brexucabtagene autoleucel

BREXUCABTAGENE AUTOLEUCEL 40million-200million cells in 68ml INFUSION (TECARTUS) R

Brigatinib

BRIGATINIB 90mg and 180mg TABLET INITIATION PACK R

As per NICE TA 571 (Brigatinib for treating ALK-positive advanced NSCLC after crizotinib) and NICE TA 670 (Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor)

NIRAPARIB

NIRAPARIB 100mg TABLETS R

Patent blue V

PATENT BLUE DYE 2.5% PRE FILLED SYRINGES 2ml UNR

Ponesimod

PONESIMOD 20mg TABLETS R

Restricted for treatment of relapsing, remitting multiple sclerosis with active disease as per NICE TA767. MMTc, December 2022

Tisagenlecleucel

TISAGENLECLEUCEL 1.2million-600million cells INFUSION (KYMRIAHA) R

01 Gastro-intestinal system

01.01 Dyspepsia and gastro-oesophageal reflux disease

01.01 Dyspepsia and gastro-oesophageal reflux disease

MAGNESIUM TRISILICATE

MAGNESIUM TRISILICATE MIXTURE BP NF

01.01.01 Antacids and simeticone

ALUMINIUM HYDROXIDE

ALUMINIUM HYDROXIDE 475mg CAPSULES	R	For use by Renal patients only. Medicines Effectiveness, September 2014.
------------------------------------	---	--

CO-MAGALDROX

CO-MAGALDROX 195/220 LIQUID	Y
-----------------------------	---

CO-MAGALDROX 300/600 LIQUID	NF
-----------------------------	----

CO-SIMALCITE

CO-SIMALCITE SUSPENSION 500ml	R	Restricted to Katharine House Hospice. Medicines Effectiveness, May 2013.
-------------------------------	---	---

SIMETICONE

SIMETICONE 40mg/ml LIQUID	Y
---------------------------	---

01.01.02 Compound alginates and proprietary indigestion preparations

GAVISCON

GAVISCON INFANT SACHETS	Y
-------------------------	---

GAVISCON ADVANCE TABLETS	NF
--------------------------	----

PEPTAC LIQUID

PEPTAC LIQUID	Y
---------------	---

01.02 Antispasmodics and other drugs altering gut motility

01.02 Antisecretory drugs and mucosal protectants

HYOSCINE BUTYLBROMIDE

HYOSCINE BUTYLBROMIDE 10mg TABLETS	Y	ORDER WHEN PACK SIZE 56 NOT AVAILABLE
------------------------------------	---	--

01.02 Antispasmodics and other drugs altering gut motility

ALVERINE CITRATE

ALVERINE CITRATE 60mg CAPSULES	Y
--------------------------------	---

DICYCLOVERINE

DICYCLOVERINE 10mg TABLETS	Y
----------------------------	---

HYOSCINE BUTYLBROMIDE

HYOSCINE BUTYLBROMIDE 20mg IN 1ml INJECTION	Y
---	---

HYOSCINE BUTYLBROMIDE 10mg TABLETS	Y
------------------------------------	---

PEPPERMINT

PEPPERMINT OIL CAPSULES

Y

PEPPERMINT WATER

UNR

For relief of abdominal colic and distension. Medicines Effectiveness, April 2013

PROPANTHELINE

PROPANTHELINE 15mg TABLETS

Y

01.02.00 Antispasmodics

LINACLOTIDE

LINACLOTIDE 290microgram CAPSULES

NF

MEBEVERINE

MEBEVERINE 50mg/5ml S/F ORAL SUSPENSION

NF

MEBEVERINE 200mg CAPSULES M/R

NF

MEBEVERINE 135mg TABLETS

Y

01.03 Antisecretory drugs and mucosal protectants

01.03.01 H2-receptor antagonists

CIMETIDINE

CIMETIDINE 200mg TABLETS

R

For use as pre-medication in chemotherapy for adults and as first line H2 antagonist where PPI?s are contraindicated. Medicines Effectiveness July 2020

CIMETIDINE 200mg/5ml LIQUID

R

For use as pre-medication in chemotherapy for adults and as first line H2 antagonist where PPIs are contraindicated, in patients who cannot swallow tablets. Medicines Effectiveness July 2020

CIMETIDINE 400mg TABLETS

R

For use as pre-medication in chemotherapy for adults and as first line H2 antagonist where PPI?s are contraindicated. Medicines Effectiveness July 2020

FAMOTIDINE

FAMOTIDINE 40mg TABLETS

R

Restricted for use in patients who have a contraindication to Proton Pump Inhibitors Medicines Effectiveness, November 2019

FAMOTIDINE 20mg in 2ml INJECTION (NP)	UNR	
FAMOTIDINE 20mg TABLETS	R	Restricted for use in patients who have a contraindication to Proton Pump Inhibitors. Medicines Effectiveness,
NIZATIDINE		
NIZATIDINE 150mg CAPSULES	NF	
RANITIDINE		
HC RANITIDINE 50mg IN 2ml INJECTION	Y	
<i>01.03.03 Chelates and complexes</i>		
SUCRALFATE		
SUCRALFATE 1g/5ml LIQUID 200ml	Y	
SUCRALFATE 2g in 50ml ENEMA	UNR	For treatment of Chronic anal pain/bleeding after radio/chemotherapy, radiation proctitis by gastroenterologist consultant only. MMTC, January 2022
SUCRALFATE 1g TABLETS	UNR	For use by Critical Care areas only. Medicines Effectiveness, September 2014.
<i>01.03.04 Prostaglandin analogues</i>		
BIMATOPROST		
BIMATOPROST 300micrograms/ml & TIMOLOL 5mg/ml EYE DROPS TTO PACK 3ml	SR	
MISOPROSTOL		
MISOPROSTOL 200microgram TABLETS	Y	
<i>01.03.05 Proton pump inhibitors</i>		
Esomeprazole		
ESOMEPRAZOLE 40mg INJECTION	NF	
ESOMEPRAZOLE 10mg SACHETS	R	For use in patients with an enteral feeding tube sized between 6-8fr. MMTC, November 2020
ESOMEPRAZOLE 20mg TABLETS	NF	
ESOMEPRAZOLE 40mg CAPSULES	NF	
LANSOPRAZOLE		

LANSOPRAZOLE 30mg CAPSULES	Y	
LANSOPRAZOLE 15mg FASTAB	R	For patients with swallowing difficulties or feeding tubes. Medicines Effectiveness, March 2009.
LANSOPRAZOLE 15mg CAPSULES	Y	
LANSOPRAZOLE 30mg FASTAB	R	For patients with swallowing difficulties or feeding tubes. Medicines Effectiveness, March 2009.
OMEPRAZOLE		
OMEPRAZOLE 10mg/5ml LIQUID 75ml	NF	
OMEPRAZOLE 40mg INFUSION	R	For patients with endoscopic evidence OR recent peptic bleeding, on the recommendation of a senior gastroenterologist (SpR or consultant). Medicines Effectiveness, November 2004.
OMEPRAZOLE 20mg CAPSULES (Teva brand for extemp use only)	Y	
OMEPRAZOLE 20mg CAPSULES	Y	
OMEPRAZOLE 10mg CAPSULES	Y	
OMEPRAZOLE 10mg TABLETS	R	For paediatric patients only. Medicines Effectiveness, March 2009.
OMEPRAZOLE 20mg TABLETS	R	For paediatric patients only. Medicines Effectiveness, March 2009.
OMPERAZOLE		
OMEPRAZOLE 40MG CAPSULES	NF	
PANTOPRAZOLE		
PANTOPRAZOLE 40mg INJECTION	NF	
PANTOPRAZOLE 40mg E.C TABLETS	NF	
PANTOPRAZOLE 20mg TABLETS E/C	NF	
RABEPRAZOLE		

RABEPRAZOLE 10mg TABLETS E/C NF

RABEPRAZOLE 20mg TABLETS E/C NF

01.04 Acute diarrhoea

01.04.02 Antimotility drugs

CO-PHENOTROPE

CO-PHENOTROPE TABLETS (LOMOTIL) NF

KAOLIN + MORPHINE

KAOLIN AND MORPHINE MIXTURE BP NF

LOPERAMIDE

LOPERAMIDE 2mg TABLETS R For Gastroenterology and Colorectal patients requiring high doses who have swallowing difficulties (the tablets can be dispersed in water). Medicines Effectiveness, February 2013.

LOPERAMIDE 25mg/5ml LIQUID UNR For swallowing difficulties and short bowel syndrome where they need to give the smallest volume possible to aid absorption. Medicines Effectiveness, July 2009.

LOPERAMIDE 2mg CAPSULES Y

01.05 Chronic bowel disorders

01.05.00 Chronic bowel disorders

SODIUM CROMOGLICATE

SODIUM CROMOGLICATE 100mg CAPSULES NF

01.05.01 Aminosalicylates

BALSALAZIDE

BALSALAZIDE SODIUM 750mg CAPSULES NF

MESALAZINE

MESALAZINE 2g/SACHET GRANULES M/R (PENTASA) Y

MESALAZINE 3g SACHET GRANULES (SALOFALK) NF
(60)

MESALAZINE 1600mg TABLETS M/R (OCTASA) Y

MESALAZINE 1.2g TABLETS M/R NF

MESALAZINE 1g/100ml ENEMA (PENTASA)	Y	
MESALAZINE 1g/APPLICATION FOAM ENEMA	Y	
MESALAZINE 400mg TABLETS M/R (OCTASA)	Y	
MESALAZINE 1g SUPPOSITORIES (pentasa)	Y	
MESALAZINE 1g/SACHET GRANULES M/R (PENTASA)	Y	
MESALAZINE 800mg TABLETS M/R (OCTASA)	Y	
MESALAZINE 500mg TABLETS M/R (PENTASA)	Y	
MESALAZINE 500mg SACHET GRANULES (SALOFALK)	NF	
MESALAZINE 400mg TABLETS M/R (ASACOL)	R	ASACOL preparations are for long standing patients only. All new patients should be on a PENTASA preparation. Medicines Effectiveness, September 2000.

OLSALAZINE

OLSALAZINE 500mg TABLETS	Y	
OLSALAZINE 250mg CAPSULES	Y	

SULFASALAZINE

SULFASALAZINE 250mg/5ml LIQUID SUGAR FREE	Y	
SULFASALAZINE 500mg TABLETS E/C	Y	
SULFASALAZINE 500mg TABLETS	Y	

01.05.02 Corticosteroids

BUDESONIDE

BUDESONIDE 2mg in 100ml ENEMAS	NF	
BUDESONIDE MMX 9MG TABLETS M/R	R	For treatment of mild to moderate active ulcerative colitis only. MMTC, October 2018
BUDESONIDE 2mg FOAM ENEMA	R	For use in place of prednisolone rectal solution during shortage. Medicines Effectiveness, January 2021

BUDESONIDE 3mg CAPSULES E/C (BUDENOFALK)	R	For gastroenterology only. MAC, December 2010.
--	---	--

BUDESONIDE 3mg CAPSULES M/R	NF	
-----------------------------	----	--

PREDNISOLONE

PREDNISOLONE 5mg SUPPOSITORIES	Y	
--------------------------------	---	--

PREDNISOLONE 20mg/APPLICATION RECTAL FOAMNF (14 DOSE)		
---	--	--

PREDNISOLONE 20mg in 100ml ENEMA (PREDSOL)	Y	
--	---	--

01.06 Laxatives

01.06.01 Bulk-forming laxatives

ISPAGHULA HUSK

ISPAGHULA HUSK 3.5g SACHETS (PLAIN)	NF	
-------------------------------------	----	--

To be used during shortage of DAC076. Medicines Effectiveness, October 23

ISPAGHULA HUSK 3.5g SACHETS (ORANGE)	Y	
--------------------------------------	---	--

METHYLCELLULOSE

METHYLCELLULOSE 500mg TABLETS (NF)	NF	
------------------------------------	----	--

01.06.02 Stimulant laxatives

BISACODYL

BISACODYL 5MG TABLETS	Y	
-----------------------	---	--

WARNING: Dulcolax is a trade name for Bisacodyl tablets and suppositories and Sodium Picosulphate liquid. Please check selection carefully to ensure

BISACODYL 5mg SUPPOSITORIES	Y	
-----------------------------	---	--

BISACODYL 10mg SUPPOSITORIES	Y	
------------------------------	---	--

BISACODYL 5mg TABLETS	Y	
-----------------------	---	--

CO-DANTHRAMER

CO-DANTHRAMER 25/200mg in 5ml LIQUID	Y	
--------------------------------------	---	--

DOCUSATE SODIUM

DOCUSATE SODIUM 50mg/5ml LIQUID	Y	
---------------------------------	---	--

DOCUSATE SODIUM 120mg ENEMA (PK 6)	NF	
------------------------------------	----	--

DOCUSATE SODIUM 12.5mg/5ml LIQUID	Y	
-----------------------------------	---	--

DOCUSATE SODIUM 100mg CAPSULES	Y	
GLYCERIN		
GLYCERIN 4g SUPPOSITORIES ADULT	Y	
GLYCERIN 2g SUPPOSITORIES PAEDIATRIC	Y	
GLYCERIN 1g SUPPOSITORIES INFANT	Y	
KLEAN-PREP		
KLEAN PREP SACHETS	Y	
LECICARBON A		
LECICARBON A SUPPOSITORIES	NF	
LUBIPROSTONE		
LUBIPROSTONE 24microgram CAPSULES	R	To be prescribed by a consultant gastroenterologist only, for the treatment of chronic idiopathic constipation and associated symptoms in adults as per NICE TA318. MMTc July 2018
SENNA		
SENNA 7.5mg/5ml LIQUID	Y	
SENNA TABLETS TTO PK20 (OTC PK)	Y	
SENNA TABLETS TTO 10's	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.
SENNA TABLETS	Y	
SENNA LIQUID	Y	
SODIUM PICOSULFATE		
SODIUM PICOSULFATE 5mg/5ml LIQUID	Y	
<i>01.06.03 Faecal softeners</i>		
ARACHIS OIL		
ARACHIS OIL ENEMA 130ml	Y	
<i>01.06.04 Osmotic laxatives</i>		
LACTULOSE		
LACTULOSE LIQUID 300ml	Y	

MACROGOL

MACROGOL 13.7g SACHETS (LAXIDO) R

MACROGOL 13.7g SACHETS (LAXIDO) R

For the management of acute general constipation in adults as per MILV8N10. MMTC, July 2014.

MOVICOL PAEDIATRIC PLAIN SACHETS R

For paediatric use only. Medicines Effectiveness, December 2004.

MAGNESIUM HYDROXIDE

MAGNESIUM HYDROXIDE MIXTURE Y

MAGNESIUM SULPHATE

MAGNESIUM SULPHATE POWDER B.P 500g NF

PARAFFIN + MAGNESIUM HYDROXIDE

PARAFFIN LIQ & MAGNESIUM HYDROXIDE MIXTURE Y

PHOSPHATE

PHOSPHATE ENEMA (FLEET) 133ml Y

Plenvu

PLENVU ORAL POWDER SACHETS SUGAR FREE R

SODIUM CITRATE

MICRO-ENEMA 5ml Y

01.06.05 Bowel cleansing preparations

CITRAMAG

CITRAMAG SACHETS Y

GASTROGRAFIN

GASTROGRAFIN LIQUID 35ml R

For use by radiology ONLY. Medicines Effectiveness, April 2018

GASTROGRAFIN LIQUID

GASTROGRAFIN LIQUID 100ml R

For use by radiology. Also, for the treatment of small bowel obstruction (off-label use). MMTC, February 2018

MOVIPREP

MOVIPREP SACHETS	R	For bowel preparation for colonoscopies. MMTC December 2020
------------------	---	---

SODIUM PICOSULFATE

SODIUM PICOSULFATE 10mg SACHET	Y	
--------------------------------	---	--

01.06.06 Peripheral opioid-receptor antagonists

METHYLNALTREXONE

METHYLNALTREXONE 12mg INJECTION	NF	
---------------------------------	----	--

NALDEMEDINE

NALDEMEDINE 200mcg TABLETS	R	For treatment of Opioid induced constipation in patients under the care of Gastroenterology and Palliative Care MMTC, February 2021
----------------------------	---	---

NALOXEGOL

NALOXEGOL OXALATE 25MG TABLETS	R	For treating opioid induced constipation as per NICE TA345. MMTC, March 2016
--------------------------------	---	--

NALOXEGOL OXALATE 12.5MG TABLETS	R	For treating opioid induced constipation as per NICE TA345. MMTC, March 2016
----------------------------------	---	--

PRUCALOPRIDE

PRUCALOPRIDE 2mg TABLETS	R	For the treatment of chronic constipation in women as per NICE TA211. MMTC, March 2013.
--------------------------	---	---

PRUCALOPRIDE 1mg TABLETS	R	For the treatment of chronic constipation in women as per NICE TA211. MMTC, March 2013.
--------------------------	---	---

01.07 Local preparations for anal and rectal disorders

01.07.01 Soothing haemorrhoidal preparations

ANUSOL

ANUSOL HC SUPPOSITORIES	NF	
-------------------------	----	--

ANUSOL OINTMENT 25g	Y	
---------------------	---	--

ANUSOL CREAM 23g	NF	
------------------	----	--

ANUSOL SUPPOSITORIES	Y	
----------------------	---	--

ANUSOL HC

ANUSOL HC OINTMENT 30g Y

01.07.02 Compound haemorrhoidal preparations with corticosteroids

PROCTOSEDYL

PROCTOSEDYL 5mg SUPPOSITORIES R For the short term relief (not more than 7 days) of pain, irritation and pruritis associated with haemorrhoids, pruritis ani. Medicines Effectiveness, October 2017

PROCTOSEDYL OINTMENT 30g Y

SCHERIPROCT

SCHERIPROCT SUPPOSITORIES Y

SCHERIPROCT OINTMENT 30g Y

01.07.03 Rectal sclerosants

PHENOL

OILY PHENOL 5% INJECTION 5ml BP Y

01.07.04 Management of anal fissures

DILTIAZEM

DILTIAZEM 2% ANAL CREAM 30g SR For the treatment of chronic anal fissures, following treatment failure or intolerable side effects with GTN ointment only. MMTC, November 2018

GLYCERYL TRINITRATE

GLYCERYL TRINITRATE 0.4% OINTMENT 30g R For anal fissures. Medicines Effectiveness, October 2014.

01.09 Drugs affecting intestinal secretions

01.09.01 Drugs affecting biliary composition and flow

OBETICHOLIC ACID

OBETICHOLIC ACID 10mg TABLETS R Obeticholic acid is an option for treating primary biliary cholangitis, as per NICE TA443. MMTC July 2018

OBETICHOLIC ACID 5mg TABLETS R Obeticholic acid is an option for treating primary biliary cholangitis, as per NICE TA443. MMTC July 2018

URSODEOXYCHOLIC ACID

URSODEOXYCHOLIC ACID 250mg/5ml LIQUID	Y
URSODEOXYCHOLIC ACID 150mg TABLETS	Y
URSODEOXYCHOLIC ACID 250mg CAPSULES	Y

01.09.04 Pancreatin

PANCREATIN

PANCREATIN 10,000units CAPSULES	R	For use as per drug license only. Medicines Effectiveness, October 2017
PANCREATIN 25,000units CAPSULES	R	For use as per drug license only. Medicines Effectiveness, October 2017
CREON MICRO (60.36mg PANCREATIN) GRANULES 20g	Y	
PANCREX V POWDER	Y	
PANCREATIN 22,000units CAPSULES (NUTRIZYM 22)	Y	
PANCREX V CAPSULES	Y	

02 Cardiovascular system

ILOPROST

ILOPROST 50microgram in 0.5ml INJECTION	R	For use by Vascular Surgery for the treatment of limb threatening ischaemia, and by Rheumatology in Raynaud's Syndrome. Medicines Effectiveness, April 2015
---	---	--

02.01 Positive inotropic drugs

02.01.00 Antiarrhythmics other

FLECAINIDE

FLECAINIDE 150mg IN 15ml INJECTION	UNR	Unlicensed preparation ordered as replacement for licensed Flecainide injection. Medicines Effectiveness, December 2018
------------------------------------	-----	---

02.01.01 Cardiac glycosides

DIGITOXIN

DIGITOXIN 100microgram TABLETS	NF
--------------------------------	----

DIGOXIN

DIGOXIN 100micrograms IN 1ml INJECTION	SR	
DIGOXIN 125microgram TABLETS	Y	
DIGOXIN 250microgram TABLETS	Y	
DIGOXIN 500microgram in 2ml INJECTION	Y	
DIGOXIN 50microgram/ml LIQUID (60ml)	Y	
DIGOXIN IMMUNE-FAB 40mg INJECTION	Y	
DIGOXIN 62.5microgram TABLETS	Y	
<i>02.01.02 Phosphodiesterase type-3 inhibitors</i>		
MILRINONE		
MILRINONE 10mg IN 10ml INJECTION	Y	
<i>02.02 Diuretics</i>		
<i>02.02.01 Thiazides and related diuretics</i>		
BENDROFLUMETHIAZIDE		
BENDROFLUMETHIAZIDE 2.5mg TABLETS	Y	
BENDROFLUMETHIAZIDE 5mg TABLETS	Y	
CHLOROTHIAZIDE		
CHLOROTHIAZIDE 250mg in 5ml SUSPENSION	SR	Restricted to neonates and paediatric patients with swallowing difficulties. Medicines Effectiveness, February 2013
CHLOROTHIAZIDE 250mg/5ml LIQUID	UNR	Restricted to meonates and paediatric patients with swallowing difficulties. Medicines Effectiveness, February 2013.
CHLORTALIDONE		
CHLORTALIDONE 50mg TABLETS	Y	
CYCLOPENTHIAZIDE		
CYCLOPENTHIAZIDE 500microgram TABLETS	NF	
INDAPAMIDE		
INDAPAMIDE 2.5mg TABLETS	Y	
INDAPAMIDE 1.5mg M/R TABLETS	Y	

METOLAZONE

METOLAZONE 5mg TABLETS	UNR	For use by Cardiology for diuretic resistance and heart failure only. Medicines Effectiveness, April 2013.
------------------------	-----	--

XIPAMIDE

XIPAMIDE 20mg TABLETS	NF
-----------------------	----

02.02.02 Loop diuretics

BUMETANIDE

BUMETANIDE 1mg TABLETS	Y
------------------------	---

BUMETANIDE 5mg TABLETS	Y
------------------------	---

FRUSEMIDE

FUROSEMIDE 250mg IN 25ml INJECTION (UNLICENSED)	UNR	Restricted to use whilst there is a supply problem with UK brand. Medicines Effectiveness May 2018
---	-----	--

FUROSEMIDE

FUROSEMIDE 50mg IN 50ml INJECTION PRE-FILLED SYRINGE (CTASU PREP)	SR	
FUROSEMIDE 20mg IN 2ml INJECTION (UNLICENSED)	UNR	Restricted for use whilst licensed preparation is unavailable. Medicines Effectiveness, May 2018

FUROSEMIDE 20mg IN 2ml INJECTION	Y
----------------------------------	---

FUROSEMIDE 20mg TABLETS	Y
-------------------------	---

FUROSEMIDE 250mg IN 25ml INJECTION	Y
------------------------------------	---

FUROSEMIDE 500mg TABLETS	NF
--------------------------	----

FUROSEMIDE 50mg IN 5ml INJECTION	Y
----------------------------------	---

FUROSEMIDE 50mg/5ml LIQUID	R	For paediatric patients only. Medicines Effectiveness, March 2013.
----------------------------	---	--

FUROSEMIDE 40mg TABLETS	Y
-------------------------	---

TOLVAPTAN

TOLVAPTAN 7.5mg TABLETS	NF
-------------------------	----

02.02.03 Potassium-sparing diuretics and aldosterone antagonists

AMILORIDE

AMILORIDE 5mg/5ml LIQUID S/F NF

AMILORIDE 5mg TABLETS Y

EPLERENONE

EPLERENONE 25mg TABLETS R For patients who have failed on / cannot tolerate spironolactone and first-line in young male patients post-MI with a LVSD 40% or less. MMTC, October 2017

EPLERENONE 50mg TABLETS R For patients who have failed on / cannot tolerate spironolactone and first-line in young male patients post-MI with a LVSD 40% or less. MMTC, October 2017

Finerenone

FINERENONE 20mg TABLETS R ?For treating chronic kidney disease in type 2 diabetes as per NICE TA8778. MMTC, July 23

FINERENONE 10mg TABLETS R ?For treating chronic kidney disease in type 2 diabetes as per NICE TA8778. MMTC, July 23

Spirolactone

SPIRONOLACTONE 50mg TABLETS Y

SPIRONOLACTONE 50mg/5ml LIQUID SR For paediatric patients or patients with feeding tubes only. Mediciens Effectiveness, February 2013.

SPIRONOLACTONE 100mg TABLETS Y

SPIRONOLACTONE 25mg TABLETS Y

TORASEMIDE

TORASEMIDE 10mg TABLETS NF

TORASEMIDE 5mg TABLETS NF

02.02.04 Potassium-sparing diuretics with other diuretics

AMILORIDE + CYCLOPENTHIAZIDE

AMILORIDE 2.5mg / CYCLOPENTHIAZIDE 250microgram TABLETS Y

CO-AMILOZIDE

CO-AMILOZIDE 5/50mg TABLETS Y

02.02.07 Carbonic anhydrase inhibitors

DORZOLAMIDE

DORZOLAMIDE 20mg/ml EYE DROPS TTO PACK 5ml SR

02.03 Anti-arrhythmic drugs

02.01 Drugs for arrhythmias

DISOPYRAMIDE

DISOPYRAMIDE 100mg CAPSULES Y

02.01.00 Antiarrhythmics drugs

Mexiletine

MEXILETINE 200mg CAPSULES R

MEXILETINE 100mg CAPSULES R

02.03 Antiplatelet drugs

ASPIRIN

ASPIRIN 500mg IN 5ml INJECTION UNR

02.03.00 Antiplatelet drugs

Aspirin

ASPIRIN 300mg SUPPOSITORIES (UNLICENSED - USA IMPORT) UNR

02.03.02 Drugs for arrhythmias

ADENOSINE

ADENOSINE 130mg in 130ml INTRAVENOUS INFUSION SR Restricted to interventional cardiac areas only for fractional flow reserve (FFR) assessment. Fridge line. MAC, September 2010

ADENOSINE 6mg in 2ml INJECTION Y

ADENOSINE 30mg in 10ml INJECTION R

For use by Nuclear Cardiology only. Medicines Effectiveness, January 2002.

AMIODARONE

AMIODARONE 150mg in 3ml INJECTION Y

AMIODARONE 100mg TABLETS Y

AMIODARONE 200mg TABLETS	Y	
AMIODARONE 150mg in 3ml INJECTION	Y	
AMIODARONE 300mg IN 10ml SYRINGE (AURUM)	Y	
DISOPYRAMIDE		
DISOPYRAMIDE 250mg TABLETS M/R	Y	
DISOPYRAMIDE 150mg CAPSULES	Y	
DISOPYRAMIDE 100mg CAPSULES	Y	
DRONEDARONE		
DRONEDARONE 400mg TABLETS	R	For the treatment of non-permanent atrial fibrillation as per NICE TA197. MAC, December 2010.
FLECAINIDE		
FLECAINIDE 200mg CAPSULES M/R	NF	
FLECAINIDE 50mg TABLETS	Y	
FLECAINIDE 100mg TABLETS	Y	
LIDOCAINE		
LIDOCAINE 0.4% + GLUCOSE 5% 500ml INFUSION STERIFLEX 27	Y	
MEXILETINE		
MEXILETINE 360mg CAPSULES M/R	NF	
MEXILETINE 100mg CAPSULES	UNR	For refractory ventricular tachycardia; and for the treatment of myotonia in patients under the care of Dr. Hilton-Jones. MMTC, August 2013.
MIDODRINE		
MIDODRINE 2.5mg TABLETS	R	For treatment of orthostatic hypotension under the electrophysiological team only. NB: note requirements as per Shared Care Protocol for continuation in primary care. MMTC, April 2017

MIDODRINE 5mg TABLETS	R	For treatment of orthostatic hypotension under the electrophysiological team only. NB: note requirements as per Shared Care Protocol for continuation in primary care. April 2017
-----------------------	---	---

PROPAFENONE

PROPAFENONE HCL 150mg TABLETS	Y	
-------------------------------	---	--

QUINIDINE

QUINIDINE BISULPHATE 250mg TABLETS M/R	Y	
--	---	--

REGADENOSON

REGADENOSON 400micrograms IN 5ml INJECTION	R	For use by Nuclear Cardiology only for Myocardial perfusion imaging (MPI) in patients with mild to moderate asthma or COPD. MAC, May 2011.
--	---	--

02.04 Beta-adrenoceptor blocking drugs

02.04 Drugs for Hypertention

BISOPROLOL

BISOPROLOL 5mg TABLETS	Y	
------------------------	---	--

BISOPROLOL 1.25mg TABLETS	Y	
---------------------------	---	--

BISOPROLOL 2.5mg TABLETS	Y	
--------------------------	---	--

BISOPROLOL 10mg TABLETS	Y	
-------------------------	---	--

CLOPAMIDE + PINDOLOL

PINDOLOL 10 mg / CLOPAMIDE 5mg TABLETS	NF	
--	----	--

PINDOLOL

PINDOLOL 5mg TABLETS	NF	
----------------------	----	--

02.04 Hypertention

ESMOLOL

ESMOLOL 100mg in 10ml INJECTION	R	For specialist use (Cardiology or ITU) only. Medicines Effectiveness, March 2013.
---------------------------------	---	---

ESMOLOL 2.5g in 10ml INJECTION	R	For specialist use (Cardiology or ITU) only. Medicines Effectiveness, March 2013.
--------------------------------	---	---

02.04.00 Beta-adrenoceptor blocking drugs

ACEBUTOLOL

ACEBUTOLOL 200mg & HYDROCHLOROTHIAZIDE 12.5mg TABLET NF

TIMOLOL

TIMOLOL 0.1% (1mg/g) UNIT DOSE EYE GEL PRES-FREE TTO PACK 30 SR

02.04.00 Drugs for hypertention

ACEBUTOLOL

ACEBUTOLOL 100mg CAPSULES NF

ACEBUTOLOL 200mg CAPSULES NF

ATENOLOL

ATENOLOL 5mg IN 10ml INJECTION Y

ATENOLOL 50mg TABLETS Y

ATENOLOL 25mg TABLETS Y

ATENOLOL 100mg TABLETS Y

ATENOLOL 25mg/5ml LIQUID Y

CARVEDILOL

CARVEDILOL 12.5mg TABLETS R For use in Congestive Cardiac Failure (CCF) only; NOT for hypertension. Medicines Effectiveness, July 2000.

CARVEDILOL 6.25mg TABLETS R For use in Congestive Cardiac Failure (CCF) only; NOT for hypertension. Medicines Effectiveness, July 2000.

CARVEDILOL 3.125mg TABLETS R For use in Congestive Cardiac Failure (CCF) only; NOT for hypertension. Medicines Effectiveness, July 2000.

CARVEDILOL 25mg TABLETS R For use in Congestive Cardiac Failure (CCF) only; NOT for hypertension. Medicines Effectiveness, July 2000.

CELIPROLOL

CELIPROLOL 200mg TABLETS NF

CO-TENIDONE

CO-TENIDONE 50mg/12.5mg TABLETS	NF	
CO-TENIDONE 100mg/25mg TABLETS	NF	
LABETALOL		
LABETALOL 200mg TABLETS	Y	
LABETALOL 100mg in 20ml INJECTION	Y	
LABETALOL 100mg TABLETS	Y	
METOPROLOL		
METOPROLOL 200mg TABLETS M/R	NF	
METOPROLOL 5mg IN 5ml INJECTION	Y	
METOPROLOL 100mg TABLETS	Y	
METOPROLOL 50mg TABLETS	Y	
NADOLOL		
NADOLOL 80mg TABLETS	Y	
NEBIVOLOL		
NEBIVOLOL 5mg TABLETS	R	For treatment of heart failure as a third line option after bisoprolol and carvedilol. MMTC, May
NEBIVOLOL 2.5mg TABLETS	R	For treatment of heart failure as a third line option after bisoprolol and carvedilol. MMTC, May 2019
OXPRENOLOL		
OXPRENOLOL 20mg TABLETS	Y	
OXPRENOLOL 160mg TABLETS M/R	NF	
OXPRENOLOL 40mg TABLETS	Y	
PROPRANOLOL		
PROPRANOLOL 50mg/5ml LIQUID	Y	
PROPRANOLOL 80mg CAPSULES M/R	Y	
PROPRANOLOL 40mg TABLETS	Y	

PROPRANOLOL 10mg TABLETS	Y	
PROPRANOLOL 160mg CAPSULES M/R	Y	
SOTALOL		
SOTALOL 80mg TABLETS	Y	
SOTALOL 160mg TABLETS	Y	
SOTALOL 40mg TABLETS	Y	
TIMOLOL		
TIMOLOL 10mg TABLETS	Y	
<i>Beta-adrenoceptor blocking drugs</i>		
TIMOLOL		
TIMOLOL 0.25% EYE DROPS TTO PACK 5ml	SR	
<i>02.04.02 Blood Pressure conditions</i>		
<i>02.04.02 Drugs for hypotention and shock</i>		
Phenylephrine		
PHENYLEPHRINE 2mg in 20ml INJECTION	R	
<i>02.05 Hypertension and heart failure</i>		
<i>02.05 Hypertension and heart failure</i>		
PHEHTOLAMINE		
PHEHTOLAMINE 10mg IN 1ml INJECTION	UNR	For use by Cardiac Theatres only. Medicines Effectiveness, August 2013.
<i>02.05.00 Hypertension and heart failure</i>		
BIFIDOBACTERIUM		
BIFIDOBACTERIUM INFANTIS 350 MILLION, STREPTOCOCCUS THERMOPHILUS 300 MILLION &	UNR	For the prevention Necrotizing enterocolitis (NEC) in preterm neonates. MMTC, December 2019
<i>02.05.01 Vasodilator antihypertensive drugs</i>		
BOSENTAN		
BOSENTAN 125mg TABLETS	R	For digital ulceration/systemic sclerosis as 2nd line treatment following Sildenafil. MMTC October 2021

BOSENTAN 62.5mg TABLETS	R	For digital ulceration/systemic sclerosis as 2nd line treatment following Sildenafil. MMTC October 2021
Diazoxide		
DIAZOXIDE 100mg CAPSULES	UNR	
DIAZOXIDE 25mg CAPSULES	UNR	
HYDRALAZINE		
HYDRALAZINE 20mg IN 1ml INJECTION	Y	
HYDRALAZINE 50mg TABLETS	Y	
HYDRALAZINE 25mg TABLETS	Y	
MINOXIDIL		
MINOXIDIL 5mg TABLETS	Y	
MINOXIDIL 2.5mg TABLETS	Y	
MINOXIDIL 10mg TABLETS	Y	
SILDENAFIL		
SILDENAFIL 50MG TABLETS	R	For the treatment of:- Pulmonary Arterial Hypertension (PAH) as per the shared care arrangement with the Royal Brompton & Harefield Hospital NHSFT (RBH) - Congenital heart disease *For initiation by cardiologist only* MMTC, December 2016
SILDENAFIL 10mg in 12.5ml INJECTION	Y	
SILDENAFIL (as citrate) 20mg TABLETS	R	PAEDIATRICS: for paediatric Cardiology patients on longterm treatment for confirmed pulmonary arterial hypertension (PbR). NOT for short term cardiac post-op referrals on a weaning regimen, or post iNO. ADULTS: for weaning nitric oxide off on CTCCU only (consultants).NB: extemporaneous preparation made up for very young children. MMTC, February 2014.

SILDENAFIL 10mg/ml POWDER FOR ORAL
SUSPENSION

R

For paediatric Cardiology patients on longterm treatment for confirmed pulmonary arterial hypertension (PbR). NOT for short term cardiac post-op referrals on a weaning regimen, or post iNO - see alternative Extemp. Medicines Effectiveness, April 2013

SODIUM NITROPRUSSIDE

SODIUM NITROPRUSSIDE 50mg INJECTION

UNR

For phaeochromocytoma. Medicines Effectiveness, March 2013.

02.05.02 Centrally acting antihypertensive drugs

CLONIDINE

CLONIDINE 100microgram TABLETS

Y

CLONIDINE 150micrograms IN 1ml INJECTION

Y

DILTIAZEM

DILTIAZEM 300mg CAPSULES M/R (TILDIEM LA)

Y

METHYLDOPA

METHYLDOPA 125mg TABLETS

Y

METHYLDOPA 250mg TABLETS

Y

METHYLDOPA 500mg TABLETS

Y

MOXONIDINE

MOXONIDINE 300microgram TABLETS

NF

MOXONIDINE 200microgram TABLETS

NF

MOXONIDINE 400microgram TABLETS

NF

02.05.04 Alpha-adrenoceptor blocking drugs

DOXAZOSIN

DOXAZOSIN 1mg TABLETS

Y

DOXAZOSIN 2mg TABLETS

Y

DOXAZOSIN 4mg TABLETS

Y

PHENOXYBENZAMINE

PHENOXYBENZAMINE 10mg CAPSULES Y

02.05.05 Drugs affecting the renin-angiotensin system

ALISKIREN

ALISKIREN 150mg TABLETS NF

CANDESARTAN

CANDESARTAN 4mg TABLETS R For second line use in patients who do not tolerate ACE inhibitors. For use in heart failure and in hypertension. MAC, June 2006.

CANDESARTAN 8mg TABLETS R For second line use in patients who do not tolerate ACE inhibitors. For use in heart failure and in hypertension. MAC, June 2006.

CANDESARTAN 32mg TABLETS R For second line use in patients who do not tolerate ACE inhibitors. For use in heart failure and in hypertension. MAC, June 2006.

CANDESARTAN 16mg TABLETS R For second line use in patients who do not tolerate ACE inhibitors. For use in heart failure and in hypertension. MAC, June 2006.

CANDESARTAN 2mg TABLETS R For second line use in patients who do not tolerate ACE inhibitors. For use in heart failure and in hypertension. MAC, June 2006.

CAPTOPRIL

CAPTOPRIL 50mg TABLETS Y

CAPTOPRIL 25mg TABLETS Y

CAPTOPRIL 12.5mg TABLETS Y

CAPTOPRIL 25mg/5ml LIQUID R Treatment of hypertension or congestive heart failure in paediatric cardiac patients. Medicines Effectiveness, February 2013.

CO-ZIDOCAPT

CAPTOPRIL 50mg & HYDROCHLOROTHIAZIDE 25mg NF TABLETS

ENALAPRIL

ENALAPRIL 10mg TABLETS	Y
ENALAPRIL 5mg TABLETS	Y
ENALAPRIL 20mg TABLETS	Y
ENALAPRIL 2.5mg TABLETS	Y

EPROSARTAN

EPROSARTAN 400mg TABLETS	NF
EPROSARTAN 300mg TABLETS	NF
EPROSARTAN 600mg TABLETS	NF

FOSINOPRIL

FOSINOPRIL 10mg TABLETS	NF
FOSINOPRIL 20mg TABLETS	NF

IMIDAPRIL

IMIDAPRIL 20mg TABLETS	NF
------------------------	----

IRBESARTAN

IRBESARTAN 300mg & HYDROCHLOROTHIAZIDE 12.5mg TABLETS	NF	
IRBESARTAN 150mg & HYDROCHLOROTHIAZIDE 12.5mg TABLETS	NF	
IRBESARTAN 150mg TABLETS	R	For second line use in patients who do not tolerate ACE inhibitors. For use in diabetic nephropathy and in hypertension. MAC June, 2006.
IRBESARTAN 75mg TABLETS	R	For second line use in patients who do not tolerate ACE inhibitors. For use in diabetic nephropathy and in hypertension. MAC June, 2006.
IRBESARTAN 300mg TABLETS	R	For second line use in patients who do not tolerate ACE inhibitors. For use in diabetic nephropathy and in hypertension. MAC June, 2006.

IRBESARTAN + HYDROCHLOROTHIAZIDE

IRBESARTAN 300mg & HYDROCHLOROTHIAZIDE 25mg TABLETS NF

LISINOPRIL

LISINOPRIL 20mg & HYDROCHLOROTHIAZIDE 12.5mg TABLETS NF

LISINOPRIL 5mg TABLETS Y

LISINOPRIL 20mg TABLETS Y

LISINOPRIL 10mg TABLETS Y

LISINOPRIL 10mg & HYDROCHLOROTHIAZIDE 12.5mg TABLETS NF

LISINOPRIL 2.5mg TABLETS Y

LOSARTAN

LOSARTAN 25mg TABLETS R

LOSARTAN 50mg TABLETS R For second line use in patients who do not tolerate ACE-inhibitors. For more information see MIL: Guidelines for Prescribing Angiotensin-Receptor Blockers (ARB) full guidelines or quick guide. Medicines Effectiveness, June 2006.

LOSARTAN 100mg TABLETS R For second line use in patients who do not tolerate ACE-inhibitors. For more information see MIL: Guidelines for Prescribing Angiotensin-Receptor Blockers (ARB) full guidelines or quick guide. Medicines Effectiveness, June 2006.

LOSARTAN + HYDROCHLOROTHIAZIDE

LOSARTAN 100mg & HYDROCHLOROTH 12.5mg TABLETS NF

LOSARTAN 50mg & HYDROCHLOROTHIAZIDE 12.5mg TABLETS NF

OLMESARTAN

OLMESARTAN MEDOXOMIL 20mg TABLETS NF

OLMESARTAN MEDOXOMIL 40mg TABLETS NF

OLMESARTAN MEDOXOMIL 10mg TABLETS NF

PERHEXILINE

PERHEXILINE 100mg TABLETS	UNR	For the treatment of hypertrophic cardiomyopathy and heart failure in patients who still have symptoms despite maximal dose with standard therapy. For patients under Dr. Ashrafian only. MMTc, September 2013.
---------------------------	-----	---

PERINDOPRIL

PERINDOPRIL TERT-BUTYLAMINE 8mg TABLETS	Y
PERINDOPRIL ERBUMINE 4mg & INDAPAMIDE 1.25mg TABLETS	NF
PERINDOPRIL TERT-BUTYLAMINE 4mg TABLETS	Y
PERINDOPRIL TERT-BUTYLAMINE 2mg TABLETS	Y

QUINAPRIL

QUINAPRIL 40MG TABLETS	NF
QUINAPRIL 20mg TABLETS	NF
QUINAPRIL 10mg TABLETS	NF
QUINAPRIL 5mg TABLETS	NF

RAMIPRIL

RAMIPRIL 5mg TABLETS	R	Restricted to patients with feeding tubes only
RAMIPRIL 1.25mg TABLETS	Y	
RAMIPRIL 2.5mg CAPSULES	Y	
RAMIPRIL 5mg CAPSULES	Y	
RAMIPRIL TITRATION PACK	Y	
RAMIPRIL 10mg CAPSULES	Y	
RAMIPRIL 1.25mg CAPSULES	Y	

SACUBITRIL

SACUBITRIL 49mg & VALSARTAN 51mg TABLETS	R	For the treatment of symptomatic chronic heart failure with reduced ejection fraction as per NICE TA388. To be initiated by the heart failure team only. MMTC, October 2016
SACUBITRIL 24mg & VALSARTAN 26mg TABLETS	R	For the treatment of symptomatic chronic heart failure with reduced ejection fraction as per NICE TA388. To be initiated by the heart failure team only. MMTC, October 2016
SACUBITRIL 97mg & VALSARTAN 103mg TABLETS	R	For the treatment of symptomatic chronic heart failure with reduced ejection fraction as per NICE TA388. To be initiated by the heart failure team only. MMTC, October 2016
TELMISARTAN		
TELMISARTAN 20mg TABLETS	NF	
TRANDOLAPRIL		
TRANDOLAPRIL 500microgram CAPSULES	NF	
TRANDOLAPRIL 2mg CAPSULES	NF	
TRANDOLAPRIL 1mg CAPSULES	NF	
VALSARTAN		
VALSARTAN 40mg CAPSULES	R	For second line use in patients who do not tolerate ACE inhibitors. For use in heart failure and in hypertension. Medicines Effectiveness, December 2006.
VALSARTAN 160mg CAPSULES	R	For second line use in patients who do not tolerate ACE inhibitors. For use in heart failure and in hypertension. Medicines Effectiveness, December 2006.
VALSARTAN 80mg CAPSULES	R	For second line use in patients who do not tolerate ACE inhibitors. For use in heart failure and in hypertension. Medicines Effectiveness, December 2006.

VALSARTAN 40mg TABLETS

R

For second line use in patients who do not tolerate ACE inhibitors. For use in heart failure and in hypertension. Medicines Effectiveness, December 2006.

VALSARTAN + HYDROCHLOROTHIAZIDE

VALSARTAN+HYDROCHLOROTHIAZIDE
80mg+12.5mg TABLETS FILM COATED

NF

02.06 Nitrates, calcium-channel blockers, and other antianginal drugs

02.06.01 Nitrates

GLYCERYL TRINITRATE

GLYCERYL TRINITRATE 400microgram/dose SPRAY 200dose Y

GLYCERYL TRINITRATE 10mg IN 10ml INJECTION Y

?Used by cardiac cath labs to prevent radial and coronary artery spasm during primary PCI procedures.

GLYCERYL TRINITRATE 400microgram/dose SPRAY 200dose Y

GLYCERYL TRINITRATE 6.4mg M/R TABLETS NF

GLYCERYL TRINITRATE 5mg 24 HRS PATCHES Y

GLYCERYL TRINITRATE 500microgram TABLETS Y

GLYCERYL TRINITRATE 2mg TABLETS M/R (BUCCAL) Y

GLYCERYL TRINITRATE 2.6mg TABLETS M/R NF

GLYCERYL TRINITRATE 10mg 24HRS PATCHES Y

GLYCERYL TRINITRATE 50mg IN 50ml INJECTION Y

GLYCERYL TRINITRATE 3mg TABLETS M/R (BUCCAL) Y

ISOSORBIDE DINITRATE

ISOSORBIDE DINITRATE 10mg TABLETS Y

ISOSORBIDE DINITRATE 20mg TABLETS Y

ISOSORBIDE DINITRATE 20mg TABLETS M/R NF

ISOSORBIDE MONONITRATE

ISOSORBIDE MONONITRATE 50mg CAPSULES M/R NF

ISOSORBIDE MONONITRATE 10mg TABLETS	Y
ISOSORBIDE MONONITRATE 20mg TABLETS	Y
ISOSORBIDE MONONITRATE 25mg CAPSULES M/R	NF
ISOSORBIDE MONONITRATE 40mg TABLETS M/R	NF
ISOSORBIDE MONONITRATE 40mg TABLETS	Y
ISOSORBIDE MONONITRATE 60mg M/R TABLETS	NF

02.06.02 Calcium Channel blockers

NIFEDIPINE

NIFEDIPINE 10mg CAPSULES (ADALAT)	Y
-----------------------------------	---

02.06.02 Calcium-channel blockers

AMLODIPINE

AMLODIPINE 5mg IN 5ml LIQUID S/F	NF
AMLODIPINE 5mg TABLETS	Y
AMLODIPINE 10mg TABLETS	Y

DILTIAZEM

DILTIAZEM 60mg TABLETS M/R (TILDIEM)	Y
DILTIAZEM 300mg CAPSULES M/R (ADIZEM XL)	Y
DILTIAZEM 200mg CAPSULES M/R (TILDIEM LA)	Y
DILTIAZEM 180mg CAPSULES M/R (ADIZEM XL)	Y
DILTIAZEM 60mg CAPSULES M/R (DILZEM SR)	NF
DILTIAZEM 180mg CAPSULES M/R (ADIZEM SR)	Y
DILTIAZEM 120mg TABLETS M/R (TILDIEM RETARD)	Y
DILTIAZEM 120mg CAPSULES XL (ADIZEM XL)	Y
DILTIAZEM 90mg CAPSULES M/R (ADIZEM SR)	Y
DILTIAZEM 90mg TABLETS M/R (TILDIEM RETARD)	Y
DILTIAZEM 120mg CAPSULES M/R (ADIZEM SR)	Y

DILTIAZEM 240mg CAPSULES M/R (ADIZEM XL)	Y
DILTIAZEM 90mg CAPSULES M/R (DILCARDIA)	NF
FAMPRIDINE	
FAMPRIDINE 10MG MR TABLETS	NF
FELODIPINE	
FELODIPINE 10mg TABLETS M/R	Y
FELODIPINE 2.5mg TABLETS M/R	Y
FELODIPINE 5mg TABLETS M/R	Y
ISRADIPINE	
ISRADIPINE 2.5mg TABLETS	NF
LACIDIPINE	
LACIDIPINE 4mg TABLETS	NF
LACIDIPINE 2mg TABLETS	NF
LERCANIDIPINE	
LERCANIDIPINE 20mg TABLETS	NF
LERCANIDIPINE 10mg TABLETS	NF
NICARDIPINE	
NICARDIPINE 20mg CAPSULES	NF
NICARDIPINE 30mg CAPSULES	NF
NICARDIPINE 45mg CAPSULES M/R	NF
NIFEDIPINE	
NIFEDIPINE 5mg CAPSULES	Y
NIFEDIPINE 20mg CAPSULES M/R (CORACTEN)	Y
NIFEDIPINE 60mg CAPSULES M/R (CORACTEN XL)	Y
NIFEDIPINE 30mg TABLETS M/R (ADALAT LA)	Y
NIFEDIPINE 30mg CAPSULES M/R (CORACTEN XL)	Y

NIFEDIPINE 20mg TABLETS M/R	Y
NIFEDIPINE 10mg TABLETS M/R	Y
NIFEDIPINE 20mg TABLETS M/R (ADALAT LA)	Y
NIFEDIPINE 10mg CAPSULES M/R (CORACTEN)	Y

NIMODIPINE

NIMODIPINE 30mg TABLETS	Y
NIMODIPINE 10mg IN 50ml INJECTION	Y

VERAPAMIL

VERAPAMIL 120mg CAPSULES M/R (UNIVER)	Y
VERAPAMIL 80mg TABLETS	Y
VERAPAMIL 40mg TABLETS	Y
VERAPAMIL 240mg TABLETS M/R	Y
VERAPAMIL 120mg TABLETS	Y
VERAPAMIL 5mg in 2ml INJECTION	Y
VERAPAMIL 40mg/5ml LIQUID SUGAR FREE 150ml	Y
VERAPAMIL 120mg TABLETS M/R (HALF SECURON)	Y

02.06.03 Other antianginal drugs

IVABRADINE

IVABRADINE 7.5mg TABLETS	R	<p>Approved for: - ANGINA: 3rd line agent following calcium channel blockers / beta-blockers (1st line agents) and isosorbide mononitrate / nicorandil (2nd line agents); - HEART FAILURE: 3rd line agent in patients intolerant of beta-blockers and ACE-I if HR is still & over 75bpm (doses of both titrated to maximum tolerated (TA267)). - CARDIAC COMPUTED TOMOGRAPHY: short regime prior the procedure. - INAPPROPRIATE SINUS TACHYCARDIA: 3rd line agent after b-blockers and calcium channel blockers. MMTc, September 2012.</p>
--------------------------	---	--

IVABRADINE 5mg TABLETS	R	Approved for: - ANGINA: 3rd line agent following calcium channel blockers / beta-blockers (1st line agents) and isosorbide mononitrate / nicorandil (2nd line agents); - HEART FAILURE: 3rd line agent in patients intolerant of beta-blockers and ACE-I if HR is still & over 75bpm (doses of both titrated to maximum tolerated (TA267)). - CARDIAC COMPUTED TOMOGRAPHY: short regime prior the procedure. - INAPPROPRIATE SINUS TACHYCARDIA: 3rd line agent after b-blockers and calcium channel blockers. MMTC, September 2012
NICORANDIL		
NICORANDIL 10mg TABLETS	Y	
NICORANDIL 20mg TABLETS	Y	
RANOLAZINE		
RANOLAZINE 750mg TABLETS M/R	R	For the treatment of chronic angina in patients who have tried at least 2 anti-anginal therapies (at adequate doses) and have on-going symptoms. Should only be initiated by cardiology consultant or consultant cardiac nurse specialist. MMTC, August 2012.
RANOLAZINE 375mg TABLET M/R	R	For the treatment of chronic angina in patients who have tried at least 2 anti-anginal therapies (at adequate doses) and have on-going symptoms. Should only be initiated by cardiology consultant or consultant cardiac nurse specialist. MMTC, August 2012.
RANOLAZINE 500mg TABLETS M/R	R	For the treatment of chronic angina in patients who have tried at least 2 anti-anginal therapies (at adequate doses) and have on-going symptoms. Should only be initiated by cardiology consultant or consultant cardiac nurse specialist. MMTC, August 2012.

NAFTIDROFURYL

NAFTIDROFURYL 100mg CAPSULES

R

For the treatment of intermittent claudication as per NICE TA223. MMTC, March 2013.

OXERUTINS

OXERUTINS 250mg CAPSULES

Y

PENTOXIFYLLINE

PENTOXIFYLLINE 400mg TABLETS M/R

R

For use by Gastroenterology Department and Liver patients only; and for the management of patients with a diagnosis of osteoradionecrosis (ORN) of the jaw.

NB:both indications are unlicensed. MMTC, April 2013.

02.07 Sympathomimetics

02.07 Drugs for cardiac arrest

ADRENALINE

ADRENALINE (EPINEPHRINE) 1:10,000units 1mg IN 10ml SYRINGE Y

02.07.00 Sympathomimetics

ADRENALINE

ADRENALINE (EPINEPHRINE) 1 in 10,000units 1mg IN 10ml INJECTION Y

02.07.01 Inotropic sympathomimetics

DOBUTAMINE

DOBUTAMINE 250mg IN 50ml INJECTION Y

DOPAMINE

DOPAMINE 200mg IN 5ml INJECTION Y

ISOPRENALINE

ISOPRENALINE SULPHATE 100micrograms IN 2ml INJECTION UNR

For use in bradycardia only. Medicines Effectiveness, July 2011.

02.07.02 Hypertention and shock

METARAMINOL

METARAMINOL 2.5mg IN 5ml INJECTION	R	For use in intermittent bolus dosing of metaraminol in anaesthetic and critical care areas and in ED resus If preparing continuous infusion, supply 5 mg in 10 mL metaraminol ampoules. Medicines Effectiveness, September 2019
METARAMINOL 5mg IN 10ml INJECTION	R	Restricted for use in critical care units and emergency departments to prepare metaraminol infusions only. For metaraminol intermittent bolus, use the 2.5 mg in 5 mL vial size if available. Medicines Effectiveness, September 2019

02.07.02 Vasoconstrictor sympathomimetics

EPHEDRINE

EPHEDRINE 30mg in 10ml PRE FILLED SYRINGE	R	
EPHEDRINE 30mg IN 1ml INJECTION	Y	

METARAMINOL

METARAMINOL 10mg in 1ml INJECTION	Y	
-----------------------------------	---	--

METARAMINOL 2.5mg IN 5ml PRE-FILLED SYRINGES	R	For ED, ICU and Theatres use only
--	---	-----------------------------------

NORADRENALINE

NORADRENALINE(Norepinephrine) 4mg IN 4ml INJECTION	Y	
--	---	--

NORADRENALINE 16mg in 50ml PRE-FILLED SYRINGE SR

NORADRENALINE 8mg IN 50ml INJECTION (VIALS)	R	Theatres and adult critical care use only. MAC, July 2010.
---	---	--

NORADRENALINE (NOREPINEPHRINE) 2mg in 2ml INJECTION	Y	
---	---	--

NORADRENALINE (as base) 16mg in 50ml INJECTION SR (vial)		Theatres and adult critical care use only. MAC, July 2010.
--	--	--

NORADRENALINE (as base) 8mg in 50ml PRE-FILLED SR SYRINGE		Theatres and adult critical care use only. MAC, July 2010.
---	--	--

OXYCODONE

OXYCODONE 10mg IN 1ml INJECTION

R

For patients allergic or who cannot tolerate morphine. Medicines Effectiveness, March 2013

Phenylephrine

PHENYLEPHRINE 500micrograms IN 10ml PRE-FILLED SYRINGE

R

For use in obstetric anaesthesia only (delivery suite and maternity theatres) MMTC, October 2019

PHENYLEPHRINE 10mg IN 1ml INJECTION

Y

2.07.00 Sympathomimetics

ADRENALINE

ADRENALINE (EPINEPHRINE) 1:10,000units 100microgram IN 1ml INJECTION

Y

ADRENALINE (EPINEPHRINE) 1 in 10,000units 0.5mg IN 5ml INJECTION

Y

02.08 Anticoagulants and protamine

HEPARIN

HEPARIN 500units in 500ml SODIUM CHLORIDE INFUSION 500ml FKB0913G

Y

02.08 Anticoagulants and protamine

ANDEXANET ALFA

ANDEXANET ALFA 200mg INJECTION

NF

AVATROMBOPAG

AVATROMBOPAG 20mg TABLETS

R

For treating severe thrombocytopenia (that is, a platelet count of below 50,000 platelets per microlitre of blood) in adults with chronic liver disease having a planned invasive procedure as per NICETA626. MMTC, June 2021

TINZAPARIN 16000units IN 0.8ml SYRINGE

TINZAPARIN 16000units IN 0.8ml SYRINGE

NF

02.08.01 Anticoagulants

ENOXAPARIN

ENOXAPARIN (INHIXA) 80mg in 0.8ml PRE FILLED SYRINGE

R

Restricted to Maternity only for VTE prophylaxis and treatment in pregnancy and the puerperium in patients who have had a minor adverse reaction to Dalteparin MMTC August 2021

ENOXAPARIN (INHIXA) 40mg in 0.4ml PRE FILLED SYRINGE	R	Restricted to Maternity only for VTE prophylaxis and treatment in pregnancy and the puerperium in patients who have had a minor adverse reaction to Dalteparin MMTC August 2021
ENOXAPARIN (INHIXA) 100mg in 1mL PRE FILLED SYRINGE	R	Restricted to Maternity only for VTE prophylaxis and treatment in pregnancy and the puerperium in patients who have had a minor adverse reaction to Dalteparin MMTC August 2021
ENOXAPARIN (INHIXA) 20mg in 0.2mL PRE FILLED SYRINGE	R	Restricted to Maternity only for VTE prophylaxis and treatment in pregnancy and the puerperium in patients who have had a minor adverse reaction to Dalteparin MMTC August 2021
ENOXAPARIN (INHIXA) 60mg in 0.6ml PRE FILLED SYRINGE	R	Restricted to Maternity only for VTE prophylaxis and treatment in pregnancy and the puerperium in patients who have had a minor adverse reaction to Dalteparin MMTC August 2021

02.08.01 Parenteral anticoagulants

ARGATROBRAN

ARGATROBRAN 50mg IN 50ml SOLUTION FOR INFUSION	R	Alternative anticoagulant for use in heparin-induced thrombocytopenia (HIT) in adults. MMTC, August 2019
--	---	---

BIVALIRUDIN

BIVALIRUDIN 250mg INJECTION	R	For use in Cardiac Catheter laboratories only, as per NICE TA230. MAC, September 2011.
-----------------------------	---	--

DALTEPARIN

DALTEPARIN SODIUM 10,000units IN 1ml INJECTION (AMPOULES)	NF	
DALTEPARIN 5,000units in 0.2ml PRE-FILLED SYRINGE TTO (10's)	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, Sept 2017
DALTEPARIN 10,000units in 4ml INJECTION VIAL	R	For use in neonates and children only to administer small doses. MMTC, June 2023

DALTEPARIN 10,000units IN 0.4ml SYRINGE	Y	
DALTEPARIN 10,000units IN 1ml SYRINGE (GRADUATED)	Y	
DALTEPARIN 12,500units IN 0.5ml SYRINGE	Y	
DALTEPARIN 15,000units IN 0.6ml SYRINGE	Y	
DALTEPARIN 18,000units IN 0.72ml SYRINGE	Y	
DALTEPARIN 5,000units IN 0.2ml SYRINGE	Y	
DALTEPARIN 2,500units IN 0.2ml SYRINGE	Y	
DALTEPARIN 7,500units IN 0.3ml SYRINGE	Y	
DALTEPARIN 7,500units in 0.3ml PRE-FILLED SYRINGE TTO (10's)	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, Sept 2017

DANAPAROID

DANAPAROID SODIUM 750units in 0.6ml INJECTION	R	For use in patients with previous heparin induced thrombocytopenia. On advice of Haematology departemnt only. Medicines Effectiveness, July 2000.
---	---	---

DEFIBROTIDE

DEFIBROTIDE 200mg INJECTION	R	For use by Haematology and Oncology (Adults and Paediatrics) for veno-occlusive disease. Medicines Effectiveness, November 2010.
-----------------------------	---	--

ENOXAPARIN

ENOXAPARIN 40mg PRE FILLED SYRINGE	NF
ENOXAPARIN 300mg in 3ml MULTIDOSE VIAL	NF
ENOXAPARIN 150mg IN 1ml PRE-FILLED SYRINGE	NF
ENOXAPARIN 60mg in 0.6ml PRE FILLED SYRINGE	NF
ENOXAPARIN 100mg in 1ml SYRINGE	NF
ENOXAPARIN 120mg PRE FILLED SYRINGE	NF
ENOXAPARIN 80mg IN 0.8ml PRE-FILLED SYRINGE	NF

ENOXAPARIN 20mg in 0.2ml SYRINGE NF

EPOPROSTENOL

EPOPROSTENOL 500microgram INJECTION R
ADULTS: For use in renal dialysis and for the treatment of pulmonary hypertension (critical care areas only) as per drug license. PAEDIATRICS: For the treatment of pulmonary hypertension in critical care areas only. Medicines Effectiveness, April 2016. Off-label use: For the optimisation of thromboprophylaxis in pancreas transplant patients in the peri- and post-operative period. MMTC, April 2016

FONDAPARINUX

FONDAPARINUX 1.5mg IN 0.3ml PRE-FILLED SYRINGE R
For Acute Coronary Syndrome and the acute treatment of DVT or PE in patients with history of HIT. For VTE prevention in patients unable to receive Low Molecular Weight Heparin. MMTC, May 2019.

FONDAPARINUX 2.5mg IN 0.5ml PRE-FILLED SYRINGE R
For Acute Coronary Syndrome and the acute treatment of DVT or PE in patients with history of HIT. For VTE prevention in patients unable to receive Low Molecular Weight Heparin. MMTC, May 2019.

FONDAPARINUX 10mg IN 0.8ml PRE-FILLED SYRINGES R
For Acute Coronary Syndrome and the acute treatment of DVT or PE in patients with history of HIT. For VTE prevention in patients unable to receive Low Molecular Weight Heparin. MMTC, May 2019.

FONDAPARINUX 7.5mg IN 0.6ml PRE-FILLED SYRINGE R
For Acute Coronary Syndrome and the acute treatment of DVT or PE in patients with history of HIT. For VTE prevention in patients unable to receive Low Molecular Weight Heparin. MMTC, May 2019.

FONDAPARINUX 5mg IN 0.4ml PREFILLED SYRINGE R

For Acute Coronary Syndrome and the acute treatment of DVT or PE in patients with history of HIT. For VTE prevention in patients unable to receive Low Molecular Weight Heparin. MMTC, May 2019.

HEPARIN

HEPARIN SODIUM 200units in 2ml FLUSHING SOLUTION (AMPOULES)	Y
HEPARIN SODIUM 1000units IN 1ml INJECTION (AMPOULES)	Y
HEPARIN SODIUM 20,000units IN 20ml INJECTION (AMPOULES)	Y
HEPARIN SODIUM 5000units in 0.2ml INJECTION (AMPOULES)	Y
HEPARIN SODIUM 5000units in 5ml INJECTION (AMPOULES)	Y
HEPARIN SODIUM 5000units in 1ml INJECTION (AMPOULES)	Y

HEPARINISED SALINE

HEPARIN SODIUM 50units in 5ml FLUSHING SOLUTION (AMPOULES)	Y
--	---

TAUROLIDINE

TAUROLIDINE / CITRATE 4% PORT & CATHETER LOCK SOLUTION 5ml	R	Locking TPN lines. MMTC, August 2014.
--	---	---------------------------------------

TINZAPARIN

TINZAPARIN 20,000iu IN 2ml VIAL	NF	
TINZAPARIN 8000units IN 0.4ml SYRINGE	NF	
TINZAPARIN 18000units IN 0.9ml SYRINGE	NF	
TINZAPARIN 1400units INJECTION SYRINGE	NF	
TINZAPARIN 12000units IN 0.6ml SYRINGE	NF	
TINZAPARIN 2500units INJECTION SYRINGE	R	For haemodialysis patients only. MAC, August 2011.
TINZAPARIN 3500units INJECTION SYRINGE	R	For haemodialysis patients only. MAC, August 2011.
TINZAPARIN 4500units INJECTION SYRINGE	R	For haemodialysis patients only. MAC, August 2011.

TRISODIUM CITRATE

TRISODIUM CITRATE 30% PRE-FILLED SYRINGE 2X3ml (CITRAFLOW)	R	Restricted to Oxford Kidney Unit for maintenance of patency of temporary and tunnelled haemodialysis/ haemofiltration lines. MMTC, December 2017
TRISODIUM CITRATE 46.7% PRE-FILLED SYRINGE 2x3ml (CITRAFLOW)	R	?Restricted to Oxford Kidney Unit for maintenance of patency of temporary and tunnelled haemodialysis/ haemofiltration lines. MMTC, December 2017 Only to be used whilst Citralock is unavailable Graham 14.06.22
TRISODIUM CITRATE 46.7% PRE-FILLED SYRINGE 2x2.5ml (D.B.M CITRA-LOCK)	R	Restricted to Oxford Kidney Unit for maintenance of patency of temporary and tunnelled haemodialysis/ haemofiltration lines. MMTC, December 2017
TRISODIUM CITRATE 30% PRE-FILLED SYRINGE 2x2.5ml (D.B.M CITRA-LOCK)	R	Restricted to Oxford Kidney Unit for maintenance of patency of temporary and tunnelled haemodialysis/ haemofiltration lines. MMTC, December 2017

02.08.02 Oral anticoagulants

ACENOCOUMAROL

ACENOCOUMAROL 1mg TABLETS Y

APIXABAN

APIXABAN 2.5mg TABLETS R

For the prevention of venous thromboembolism after total hip or knee replacement in adults as per NICE TA245; the prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation as per NICE TA275; and the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. MMTC, August 2015.

APIXABAN 5mg TABLETS R

For the prevention of venous thromboembolism after total hip or knee replacement in adults as per NICE TA245; the prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation as per NICE TA275; and the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. MMTC, August 2015.

APIXABAN 5mg TABLETS TTO	SR	For use in DVT clinic only. MMTC, May 2015.
AVATROMBOPAG		
AVATROMBOPAG 20mg TABLETS	R	For treating severe thrombocytopenia (that is, a platelet count of below 50,000 platelets per microlitre of blood) in adults with chronic liver disease having a planned invasive procedure as per NICETA626. MMTC, June 2021
AVATROMBOPAG 20mg TABLETS	R	For treatment of primary chronic immune thrombocytopenia as per NICE TA 853. MMTC April 2023
DABIGATRAN		
DABIGATRAN ETEXILATE 110mg CAPSULES	R	For the prevention of stroke and systemic embolism in atrial fibrillation as per NICE TA249, and for short term use for cardioversion / ablation. Also approved for use as per other NICE TAs following discussion with Dr. Reynolds (MMTC Chair). An individual patient NICE implementation form is required (see PPDU SharePoint). Medicines Effectiveness, August 2013.
DABIGATRAN ETEXILATE 75mg CAPSULES	R	For the prevention of stroke and systemic embolism in atrial fibrillation as per NICE TA249, and for short term use for cardioversion / ablation. Also approved for use as per other NICE TAs following discussion with Dr. Reynolds (MMTC Chair). An individual patient NICE implementation form is required (see PPDU SharePoint). Medicines Effectiveness, August 2013.

DABIGATRAN ETEXILATE 150mg CAPSULES	R	For the prevention of stroke and systemic embolism in atrial fibrillation as per NICE TA249, and for short term use for cardioversion / ablation. Also approved for use as per other NICE TAs following discussion with Dr. Reynolds (MMTC Chair). An individual patient NICE implementation form is required (see PPDU SharePoint). Medicines Effectiveness, August 2013.
EDOXABAN		
EDOXABAN 30MG TABLETS	R	For the treatment and prevention of deep vein thrombosis and pulmonary embolism as per NICE TA354; For the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation as per NICE TA355. MMTC, April 2016
EDOXABAN 60mg TABLETS	R	For the treatment and prevention of deep vein thrombosis and pulmonary embolism as per NICE TA354; For the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation as per NICE TA355. MMTC, April 2016
PENTOSAN		
PENTOSAN POLYSULFATE 100mg CAPSULES	NF	
PHENINDIONE		
PHENINDIONE 10mg TABLETS	NF	
PHENINDIONE 25mg TABLETS	Y	
RIVAROXABAN		
RIVAROXABAN 5mg/5ml LIQUID S/F (100ml)	R	For treatment of VTE and prevention of VTE recurrence in term neonates, infants and toddlers, children, and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation treatment. MMTC, July 2021

RIVAROXABAN 5mg/5ml LIQUID S/F (250ml BOTTLE)	R	For treatment of VTE and prevention of VTE recurrence in term neonates, infants and toddlers, children, and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation treatment. MMTC, July 2021
RIVAROXABAN 2.5mg TABLETS	R	For the prevention of adverse outcomes after acute management of acute coronary syndrome as per NICE TA335. And for preventing atherothrombotic events in people with peripheral artery disease as per NICE TA607,
RIVAROXABAN 10mg TABLETS TTO 7'S	UNR	For use as TTO pack for Covid-19 VTE prophylaxis in AAU and ED only Medicines Effectiveness, October 2021
RIVAROXABAN 15mg TABLETS	R	For the prevention of stroke and systemic embolism in people with atrial fibrillation as per NICE TA256; for the treatment and prevention of deep vein thrombosis and pulmonary embolism as per TA261 and TA287; and for the prevention of venous thromboembolism after total hip or total knee replacement in adults as per TA170. MMTC, July 2014
RIVAROXABAN 20mg TABLETS	R	For the prevention of stroke and systemic embolism in people with atrial fibrillation as per NICE TA256; for the treatment and prevention of deep vein thrombosis and pulmonary embolism as per TA261 and TA287; and for the prevention of venous thromboembolism after total hip or total knee replacement in adults as per TA170. MMTC, July 2014
RIVAROXABAN 10mg TABLETS	R	For the prevention of stroke and systemic embolism in people with atrial fibrillation as per NICE TA256; for the treatment and prevention of deep vein thrombosis and pulmonary embolism as per TA261 and TA287; and for the prevention of venous thromboembolism after

TINZAPARIN

TINZAPARIN 10000units IN 0.5ml SYRINGE NF

WARFARIN

WARFARIN 3mg TABLETS Y

WARFARIN 1mg/1ml LIQUID 150ml NF

WARFARIN 1mg TABLETS Y

WARFARIN 500microgram TABLETS Y

WARFARIN 5mg TABLETS Y

02.08.03 Protamine sulfate

PROTAMINE SULPHATE

PROTAMINE SULPHATE 50mg IN 5ml INJECTION Y

02.09 Antiplatelet drugs

ASPIRIN

ASPIRIN 75mg TABLETS E/C (CaPP3 STUDY) C For CaPP3 Study ONLY

02.09 Antiplatelet drugs

ASPIRIN

ASPIRIN 75mg TABLETS E/C (NF) NF

CANGRELOR

CANGRELOR 50mg INJECTION R Percutaneous Coronary Intervention (PCI) MMTC Sept 2019

DIPYRIDAMOLE

DIPYRIDAMOLE 100mg TABLETS Y

DIPYRIDAMOLE 25mg TABLETS Y

DIPYRIDAMOLE 200mg CAPSULES M/R R Prevention of occlusive vascular events as per NICE TA210. MAC, September 2010.

TIROFIBAN

TIROFIBAN 12.5mg IN 250ml SOLUTION FOR INFUSION	R	For use in cardiac cath labs (CCL) for use during PCI instead of abciximab whilst there is an ongoing supply problem. Likely switch back in March 2018. Medicines Effectiveness, October 2017
---	---	---

02.09. Myocardial ischaemia

TICAGRELOR

TICAGRELOR 90mg ORODISPERSIBLE TABLETS	R	For use in patients' with NGT only. For treatment of Acute Coronary Syndrome (ACS) as per NICE TA236 and for preventing atherothrombotic events post myocardial infarction as per NICE TA420. MMTC, August 2017
--	---	---

02.09.00 Antiplatelet drugs

ASPIRIN

ASPIRIN 75mg TABLETS DISPERSIBLE TTO 28's	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, February 2013.
---	----	--

DIPYRIDAMOLE

DIPYRIDAMOLE 200mg ASPIRIN 25mg M/R CAPSULES (ASASANTIN)	NF	
--	----	--

02.09.00 Anti-platelet drugs

ASPIRIN

ASPIRIN 500mg IN 5ml INJECTION (Provided as LYSINE ASPIRIN 900mg)	UNR	Restricted to Un-ruptured aneurysms. Medicines Effectiveness, February 2013.
---	-----	--

ASPIRIN 75mg TABLETS DISPERSIBLE	Y	
----------------------------------	---	--

CLOPIDOGREL

CLOPIDOGREL 75mg TABLETS (GENERIC)	R	For use in: - Stent patients - High risk patients with true aspirin intolerance (not GI upset) - In combination with aspirin, to cover the first 28 days after percutaneous coronary angioplasty - Patients with Acute Coronary Syndromes (ACS) as per TA80 and CG94). - Prevention of occlusive vascular events as per NICE TA210 MAC, September 2010.
------------------------------------	---	---

CLOPIDOGREL 300mg TABLETS	R	For use by cardiac wards only. Medciines Effectiveness, March 2013.
CLOPIDOGREL 1mg SACHET	NF	
PRASUGREL		
PRASUGREL 10mg TABLETS	R	Initiation is restricted to interventional cardiologists and Jan Keenan (Nurse Consultant, Cardiac Medicine).MAC 28.07.09
		Restricted for use in accordance with NICETA317. It is to be offered as an option for patients who are allergic to, or have contraindications to clopidogrel
PRASUGREL 5mg TABLETS	R	Initiation is restricted to interventional cardiologists and Jan Keenan (Nurse Consultant, Cardiac Medicine).MAC 28.07.09
		Restricted for use in accordance with NICETA317. It is to be offered as an option for patients who are allergic to, or have contraindications to clopidogrel
TICAGRELOR		
TICAGRELOR 90mg TABLETS	R	For Acute Coronary Syndrome as per NICE TA236. MMTC, November 2012.

02.10 Stable angina, acute coronary syndromes, and fibrinolysis

Emicizumab

EMICIZUMAB 150mg in 1ml INJECTION (Compassionate use)	NF	This is FOC stock for individual patient granted for compassionate use.
--	----	---

TENECTEPLASE

TENECTEPLASE 50mg (10,000units) INJECTION	R	Restricted for use in Thrombolysis for patients unable to undergo pPCI during COVID-19. MMTC, March 2020
---	---	--

02.10.02 Fibrinolytic drugs

ALTEPLASE

ALTEPLASE 2mg INJECTION	R	For treatment of occluded central access devices in renal haemodialysis only. MMTC, October 2016
ALTEPLASE 10mg INJECTION	Y	
ALTEPLASE 50mg INJECTION	Y	
ALTEPLASE 20mg INJECTION	Y	
STREPTOKINASE		
STREPTOKINASE 250,000unit INJECTION	Y	
STREPTOKINASE 1,500,000unit INJECTION	Y	
UROKINASE		
UROKINASE 25,000international units INJECTION	R	Please note this drug is being used for an unlicensed indication. See the Unlicensed Medicines Register Medicines Effectiveness, April 2011
UROKINASE 10,000international units INJECTION	R	For unblocking Hickman lines. Medicines Effectiveness, April 2011.

02.11 Antifibrinolytic drugs and haemostatics

VERASEAL FIBRIN SEALANT pre-filled syringe 10ml (free stock) NF

EMICIZUMAB

EMICIZUMAB CONVENIENCE KIT 4 (1ml syringe with needles) R

02.11 Antifibrinolytic drugs and haemostaticsgs and haemostatics

ARTISS

ARTISS FIBRIN SEALANT 10ml R For use in breast surgery. MMTC, September 2015

TISSEEL FIBRIN

TISSEEL FIBRIN SEALANT RTU 10ml Y

02.11.00 Antifibrinolytic drugs and haemostatics

APROTININ

APROTININ 500,000units in 50ml INJECTION	R	For use as per the Blood Management in Cardiothoracic Surgery Policy. To be used by CTCC or Cardiac Theatres only. MMTC, September 2023.
EMICIZUMAB		
EMICIZUMAB 105mg IN 0.7ml INJECTION	R	Restricted to Haemophilia Consultants for prophylaxis in people with congenital haemophilia A who have acquired factor VIII inhibitors, as per NHS Clinical Commissioning Policy 170067/P, and as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors as per NHSE clinical commissioning policy 170134/P MMTC October 2019
EMICIZUMAB 30mg IN 1ml INJECTION	R	Restricted to Haemophilia Consultants for prophylaxis in people with congenital haemophilia A who have acquired factor VIII inhibitors, as per NHS Clinical Commissioning Policy 170067/P, and as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors as per NHSE clinical commissioning policy 170134/P MMTC October 2019
EMICIZUMAB 150mg IN 1ml INJECTION	R	Restricted to Haemophilia Consultants for prophylaxis in people with congenital haemophilia A who have acquired factor VIII inhibitors, as per NHS Clinical Commissioning Policy 170067/P, and as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors as per NHSE clinical commissioning policy 170134/P MMTC October 2019

EMICIZUMAB 60mg IN 0.4ml INJECTION	R	Restricted to Haemophilia Consultants for prophylaxis in people with congenital haemophilia A who have acquired factor VIII inhibitors, as per NHS Clinical Commissioning Policy 170067/P, and as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors as per NHSE clinical commissioning policy 170134/P MMTc October 2019
------------------------------------	---	--

02.11.00 Tissue plasminogen activators

SPONGOSTAN

SPONGOSTAN STANDARD 7cm x 5cm x 1cm	R	For use by theatres only. Medicines Effectiveness, March 2013.
SPONGOSTAN SPECIAL 7cm x 5cm x 0.1cm	R	For use by theatres only. Medicines Effectiveness, March 2013.

TRANEXAMIC

TRANEXAMIC ACID 500mg TABLETS (TTO PACK) 60 SR

TRANEXAMIC ACID

TRANEXAMIC ACID 500mg IN 5ml INJECTION	Y	
TRANEXAMIC ACID 500mg/5ml LIQUID	SR	For the inhibition of fibrinolysis when tablets cannot be tolerated. Medicines Effectiveness, June 2017
TRANEXAMIC ACID 5% MOUTHWASH 100ml	SR	To be used by Haemophilia and MaxFax only. Medicines Effectiveness, July 2012.
TRANEXAMIC ACID 500mg TABLETS	Y	

UROKINASE

UROKINASE 100,000u	R	ONLY TO BE USED IN PLACE OF 25,000 units UROKINASE . Please note this drug is being used for an unlicensed indication. See the Unlicensed Medicines Register Medicines Effectiveness, April 2011
--------------------	---	--

02.12 Lipid-regulating drugs

02.01.01 Cardiac glycosides

ALIROCUMAB

ALIROCUMAB 75mg PRE-FILLED PEN	R	For the treatment of primary hypercholesterolaemia and mixed dyslipidaemia as per NICE TA393. MMTc, February 2017
ALIROCUMAB 150mg PRE-FILLED PEN	R	For the treatment of primary hypercholesterolaemia and mixed dyslipidaemia as per NICE TA393. MMTc, February 2017
<i>02.12.00 Fibrates</i>		
ACIPIMOX		
ACIPIMOX 250mg CAPSULES	NF	
ATORVASTATIN		
ATORVASTATIN 80mg TABLETS	Y	
ATORVASTATIN 40mg TABLETS	Y	
ATORVASTATIN 20mg TABLETS	Y	
ATORVASTATIN 10mg TABLETS	Y	
BEZAFIBRATE		
BEZAFIBRATE 400mg TABLETS M/R	Y	
BEZAFIBRATE 200mg TABLETS	Y	
CIPROFIBRATE		
CIPROFIBRATE 100mg TABLETS	NF	
COLESEVELAM		
COLESEVELAM 625mg TABLETS	R	For the treatment of bile acid malabsorption in patients with a true intolerance to colestyramine and colestipol following recommendation by gastroenterology only. NB: To be continued in primary care when initiated by gastroenterology only and prior approval from the OCCG Medicines Optimisation Team. MMTc, February 2015
COLESTYRAMINE		
COLESTYRAMINE 4g SACHETS	Y	
COLESTYRAMINE 4g SACHETS SUGAR FREE	Y	
COVID-19 VACCINE COMIRNATY MONOVALENT		

INCLISIRAN 284mg in 1.5ml PRE FILLED SYRINGE	R	For treatment of primary hypercholesterolaemia or mixed dyslipidaemia as per NICE TA733. To be prescribed ONLY in OUH lipid clinic only. MMTC, December 2023
EZETIMIBE		
EZETIMIBE 10mg TABLETS	R	For the treatment of primary (heterozygous familial or non familial) hypercholesterolaemia as per NICE TA385. MMTC, August 2017
FENOFIBRATE		
FENOFIBRATE 200mg CAPSULES micronised	R	Restricted to use in endocrinology for slowing progression of diabetic retinopathy. MMTC, February 2019
FENOFIBRATE 160mg TABLETS	R	1st line therapy for patients with extreme hypertriglyceridaemia. 2nd line therapy as adjunct to a statin in combined hyperlipidaemia. MMTC, January 2015.
FENOFIBRATE 67mg CAPSULES (MICRONISED)	NF	
FENOFIBRATE MICRO 267mg CAPSULES (micronised)	R	Restricted to use in endocrinology for slowing progression of diabetic retinopathy. MMTC, February 2019
FLUVASTATIN		
FLUVASTATIN 80mg TABLETS XL	NF	
FLUVASTATIN 40mg CAPSULES	NF	
FLUVASTATIN 20mg CAPSULES	NF	
GEMFIBROZIL		
GEMFIBROZIL 300mg CAPSULES	R	For use by Transplant patients only. Medicines Effectiveness, August 2001
GEMFIBROZIL 300mg CAPSULES	R	For use by Transplant patients only. Medicines Effectiveness, August 2001.
NICOTINIC ACID		

NICOTINIC ACID 1g TABLETS M/R NF

PRAVASTATIN

PRAVASTATIN 20mg TABLETS R For patients who require treatment with a statin but cannot take simvastatin/atorvastatin due to interactions. Medicines Effectiveness, December 2009.

PRAVASTATIN 10mg TABLETS R For patients who require treatment with a statin but cannot take simvastatin/atorvastatin due to interactions. Medicines Effectiveness, December 2009.

PRAVASTATIN 40mg TABLETS R For patients who require treatment with a statin but cannot take simvastatin/atorvastatin due to interactions. Medicines Effectiveness, December 2009.

ROSUVASTATIN

ROSUVASTATIN 20mg TABLETS NF

ROSUVASTATIN 40mg TABLETS NF

ROSUVASTATIN 10mg TABLETS NF

ROSUVASTATIN 5mg TABLETS NF

SIMVASTATIN

SIMVASTATIN 10mg TABLETS Y

SIMVASTATIN 20mg TABLETS Y

SIMVASTATIN 40mg TABLETS Y

02.12.00 Lipid-regulating drugs

EVOLOCUMAB

EVOLOCUMAB 140MG IN 1ML PRE-FILLED PEN R For the treatment of primary hypercholesterolaemia and mixed dyslipidaemia as per NICE TA394. MMTTC, February 2017

02.13 Local sclerosants

02.13 Local sclerosants

SODIUM TETRADECYL

SODIUM TETRADECYL (STD) 1% (20mg in 2ml) INJECTION 2ml Y

SODIUM TETRADECYL (STD) 3% INJECTION 5ml Y

02.14 Drugs affecting the ductus arteriosus

02.14 Drugs affecting the ductus arteriosus

IBUPROFEN

IBUPROFEN 10mg in 2ml INJECTION (PEDEA)	R	For use by SCBU only (FOR CLOSURE OF DUCTUS ARTERIOSUS IN NEONATES). Medicines Effectiveness, January 2010.
IBUPROFEN 10mg in 2ml INJECTION (PEDEA)	UNR	For use by SCBU only. Medicines Effectiveness, January 2010.

03 Respiratory system

Tezepelumab

TEZEPELUMAB 210mg in 1.91ml INJECTION (PFS)	R	For treatment of severe asthma as per NICE TA880. MMTC, September 2023
TEZEPELUMAB 210mg in 1.91ml PRE-FILLED PEN (TEZSPIRE)	R	For treatment of severe asthma as per NICE TA880. MMTC, September 2023

03.01 Bronchodilators

03.01.00 Bronchodilators

SALBUTAMOL

SALBUTAMOL 4mg TABLETS	Y	
SALBUTAMOL 5mg NEBULES	Y	

03.01.01 Adrenoceptor agonists

EPHEDRINE

EPHEDRINE 30mg TABLETS	Y	
------------------------	---	--

FORMOTEROL

FORMOTEROL 12microgram EASYHALER CFC FREE 120dose	R	For the treatment of moderate COPD as per inhaled maintenance treatments of COPD MIL. MMTC, April 2017
FORMOTEROL 12microgram/dose TURBOHALER 60dose	R	For initiation by Respiratory clinicians only. Medicines Effectiveness Team, November 2000.

FORMOTEROL 6microgram/dose TURBOHALER 60dose	R	For initiation by Respiratory clinicians only. Medicines Effectiveness Team, November 2000.
FORMOTEROL 12mcg/dose INHALER 100 DOSES	R	For initiation by Respiratory clinicians only. Medicines Effectiveness Team, March 2011

INDACATEROL

INDACATEROL 300micrograms INHALATION POWDER (HARD CAPSULE) with BREEZHALER	NF
INDACTEROL 150micrograms INHALATION POWDER (HARD CAPSULE) with BREEZHALER	NF

SALBUTAMOL

SALBUTAMOL 100microgram/dose INHALER (200dose) (CFC FREE)	Y	
SALBUTAMOL 2mg/5ml LIQUID S/F	Y	
SALBUTAMOL 100microgram EASIBREATH (200dose)	R	For initiation by Respiratory clinicians only.. Medicines Effectiveness, March 2001.
SALBUTAMOL 100microgram/DOSE INHALER (CFC FREE) TTO PACK 200DOSE	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.
SALBUTAMOL 2.5mg NEBULES (20)	Y	
SALBUTAMOL 200microgram ACCUHALER (60 dose)	NF	
SALBUTAMOL 500microgram in 1ml INJECTION	Y	
SALBUTAMOL 5mg IN 5ml INJECTION	Y	

SALMETEROL

SALMETEROL 25microgram/dose INHALER (120dose)	Y	
SALMETEROL 50microgram/dose ACCUHALER 60 dose	R	For patients unable to use the evohaler. To be initiated by Respiratory clinicians only. Medicines Effectiveness, November 2004.

TERBUTALINE

TERBUTALINE 2.5mg in 5ml INJECTION	Y
TERBUTALINE 500microgram in 1ml INJECTION	Y

TERBUTALINE 500microgram/dose TURBOHALER (100 dose)	R	For the Chest Unit only. Medicines Effectiveness, March 2001
TERBUTALINE 5mg in 2ml RESPULES	Y	
<i>03.01.02 Antimuscarinic bronchodilators</i>		
ACLIDINIUM		
ACLIDINIUM 322microgram INHALER	R	For COPD patients who cannot tolerate tiotropium. For initiation by Respiratory clinicians in out-patient clinics only. MMTC, May 2013.
ACLIDINIUM 340microgram / FORMOTEROL 12microgram INHALER (60dose)	R	For the treatment of COPD. Initiation by respiratory consultants only. MMTC, August 2015.
GLYCOPYRRONIUM		
GLYCOPYRRONIUM 44microgram INHALER & CAPSULES FOR INHALER	NF	
IPRATROPIUM		
IPRATROPIUM 500microgram in 2ml RESP SOLUTIONY (2ml vial)		
IPRATROPIUM 20microgram/dose INHALER TTO PK (200 DOSE)	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.
IPRATROPIUM 20microgram/dose INHALER (200dose)	Y	
IPRATROPIUM 250microgram in 1ml RESP SOLUTIONY (1ml vial)		
TIOTROPIUM		
TIOTROPIUM 18micrograms INHALATION CAPSULES (30)	R	For initiation by Respiratory clinicians only. Medicines Effectiveness, November 2004.
TIOTROPIUM 2.5microgram RESPIMAT INHALER	R	For patients unable to use Handihaler®. For initiation by Respiratory clinicians only. MMTC, September 2008.
TIOTROPIUM 18micrograms CAPSULES (WITH HANDIHALER)	R	For initiation by Respiratory clinicians only. Medicines Effectiveness, November 2004.
UMECLIDIUM		

UMECLIDINIUM 55microgram DRY POWDER INHALER
30dose

R For the treatment of moderate
COPD as per inhaled
maintenance treatments of
COPD MIL. MMTTC, April 2017

03.01.03 Theophylline

AMINOPHYLLINE

AMINOPHYLLINE 250mg in 10ml INJECTION Y

AMINOPHYLLINE 225mg TABLETS M/R Y

AMINOPHYLLINE 350mg TABLETS M/R Y
(PHYLLOCONTIN)

THEOPHYLLINE

THEOPHYLLINE 300mg TABLETS M/R (UNIPHYLLIN) Y

THEOPHYLLINE 200mg TABLETS M/R (UNIPHYLLIN) Y

THEOPHYLLINE 400mg TABLETS M/R (UNIPHYLLIN) Y

03.01.04 Compound bronchodilator preparations

BUDESONIDE

BUDESONIDE 200mcg FORMOTEROL 6mcg Y
INHALER (Symbicort 200/6) 120dose

For the treatment of very severe
COPD as per MIL. MMTTC, April
2017

GLYCOPYRRONIUM

GLYCOPYRRONIUM 7.2mcg / FORMOTEROL 5mcg / Y
BUDESONIDE 160mcg INHALER 120dose (TRIXEO)

GLYCOPYRRONIUM 7.2mcg / FORMOTEROL 5mcg Y
INHALER 120dose (BEVESPI)

INDACATEROL

INDACATEROL 85microgram & GLYCOPYRRONIUM NF
43microgram INHALATION POWDER (HARD

OLODATEROL

OLODATEROL 2.5microgram / dose INHALER R
(RESPIMAT with 60 dose CARTRIDGE)

For the treatment of moderate
COPD as per MIL. MMTTC, April
2017

SALBUTAMOL

SALBUTAMOL 2mg TABLETS Y

SALBUTAMOL 100micrograms EASYHALER (200 R
dose)

For the treatment of moderate
COPD as per inhaled
maintenance treatments of
COPD MIL. MMTTC, April 2017

TIOTROPIUM

TIOTROPIUM 10microgram INHALATION CAPSULES NF
with ZONDA INHALER (30cap pack)

TIOTROPIUM + OLODATEROL

TIOTROPIUM/OLODATEROL 2.5mcg +2.5mcg/PUFF INHALER R For the treatment of moderate COPD as per inhaled maintenance treatments of COPD MIL. MMTc, April 2017

UMECLIDINIUM

UMECLIDINIUM 55micrograms / VILANTEROL 22micrograms INHALER R For the treatment of moderate COPD as per inhaled maintenance treatments of COPD MIL. MMTc, April 2017

03.01.05 Peak flow meters, inhaler devices and nebulisers

AEROCHAMBER

AEROCHAMBER PLUS WITH ADULT MASK R For continuation or following recommendation by respiratory medicine only. Medicines Effectiveness, May 2016

AEROCHAMBER PLUS WITH ADULT MOUTHPIECE Y

AEROCHAMBER PLUS with INFANT MASK Y

AEROCHAMBER PLUS WITH CHILD MASK Y

PEAK FLOW METER

PEAK FLOW METER STANDARD Y

PEAK FLOW METER - LOW Y

VOLUMATIC

VOLUMATIC SPACER PAEDIATRIC Y

03.02 Corticosteroids

03.01.00 Bronchodilators

BECLOMETASONE

BECLOMETASONE 200microgram INHALER (200dose) CFC FREE Y

BECLOMETASONE 50microgram BA-AUTO INHALER (200dose) CFC FREE R For initiation by Respiratory clinicians only. Medicines Effectiveness, January 2008.

BECLOMETASONE 100microgram INHALER (200dose) CFC FREE Y

BECLOMETASONE 250microgram INHALER (200dose) CFC FREE Y

BECLOMETASONE 100microgram EASI-BREATHE INHALER CFC FREE	R	For initiation by Respiratory clinicians only. Medicines Effectiveness, January 2008.
BECLOMETASONE 100microgram BA-AUTO INHALER (200dose) CFC FREE		For initiation by Respiratory clinicians only. Medicines Effectiveness, January 2008.
BECLOMETASONE 50microgram EASI-BREATHE INHALER CFC FREE 200dose	R	For initiation by Respiratory clinicians only. Medicines Effectiveness, January 2008.
BECLOMETASONE 50microgram INHALER (200dose) CFC FREE	Y	
BUDESONIDE		
BUDESONIDE 100mcg FORMOTEREL 6mcg TURBOHALER (Symbicort 100/6)	R	For initiation by Respiratory clinicians only. Medicines Effectiveness, August 2010.
BUDESONIDE 100microgram TURBOHALER DRY POWDER 200 DOSE	R	For the maintenance management of asthma in adults as per MIL. MMTTC, December 2017
FLUTICASONE		
FLUTICASONE 100microgram ACCUHALER (60 dose)	NF	
FLUTICASONE / SALMETEROL 100microgram/50microgram ACCUHALER	R	For patients unable to use the evohaler. To be initiated by Respiratory clinicians only. Medicines Effectiveness, November 2004.
FLUTICASONE 2mg IN 2ml NEBULES	NF	
FLUTICASONE + SALMETEROL		
FLUTICASONE / SALMETEROL 500microgram/50microgram ACCUHALER	R	For patients unable to use the evohaler. To be initiated by Respiratory clinicians only. Medicines Effectiveness, November 2004.
FLUTICASONE / SALMETEROL 125microgram/25microgram EVOHALER 120dose	R	To be initiated by Respiratory clinicians only. Medicines Effectiveness, November 2004.
FLUTICASONE / SALMETEROL 50microgram/25microgram EVOHALER 120dose	R	To be initiated by Respiratory clinicians only. Medicines Effectiveness, November 2004.
MOMETASONE		
MOMETASONE FUROATE 400microgram DRY POWDER INHALER (30 DOSE)	NF	

03.02.00 Corticosteroids

BECLOMETASONE

BECLOMETASONE 200mcg DRY POWDER INHALER (EASYHALER) NF

BECLOMETASONE / FORMOTEROL 200micrograms / 6micrograms INHALER 120dose

For the maintenance management of asthma in adults as per MIL. MMTC, December 2017

BECLOMETASONE / FORMOTEROL 200micrograms / 6micrograms DRY POWDER INHALER 120dose

For the maintenance management of asthma in adults as per MIL. MMTC, December 2017

BECLOMETASONE 100microgram CLICKHALER (200 dose) NF

BECLOMETASONE/ FORMOTEROL 100micrograms/6micrograms DRY POWDER INHALER R

For the maintenance management of asthma in adults as per MIL. MMTC, December 2017

BECLOMETASONE + GLYCOPYRRONIUM +

BECLOMETASONE 87micrograms / GLYCOPYRRONIUM 5micrograms / FORMOTEROL R

For the treatment of COPD. To be initiation by Respiratory clinicians only. MMTC, March 2018

BECLOMETHASONE + FORMOTEROL

BECLOMETHASONE/FORMOTEROL 100micrgrams/6micrograms INHALER R

For the treatment of: - COPD as per MILV10N7 Guidelines for the inhaled maintenance treatments of COPD; - For the maintenance management of asthma in adults as per MIL. MMTC, December 2017

BUDESONIDE

BUDESONIDE 160MCG FORMOTEROL 4,5MCG INHALER 120DOSE (DUORESP) NF

BUDESONIDE 1mg ORODISPERSIBLE TABLETS R

For inducing remission of eosinophilic oesophagitis for up to 12 weeks in adults as per NICE TA720. MMTC, January 2022

BUDESONIDE 0.5mg in 2ml RESPULES Y

BUDESONIDE 200mcg FORMOTEROL 6mcg TURBOHALER (Symbicort 200/6)	R	For the treatment of: - COPD as per MILV10N7 Guidelines for the inhaled maintenance treatments of COPD; - For the maintenance management of asthma in adults as per MIL. MMTc, December 2017
BUDESONIDE 200microgram/dose 100dose TURBOHALER	R	For initiation by Respiratory clinicians only. Medicines Effectiveness, August 2010.
BUDESONIDE 400mcg FORMOTEREL 12mcg TURBOHALER (Symbicort 400/12)	R	For the maintenance management of asthma in adults as per MIL. MMTc, December 2017
BUDESONIDE 400microgram/dose 50dose TURBOHALER	R	For initiation by Respiratory clinicians only. Medicines Effectiveness, August 2010.
BUDESONIDE 1mg in 2ml RESPULES	Y	
BUDESONIDE 320mcg FORMOTEROL 9mcg INHALER 60dose (Duoresp)	NF	
FLUTICASONE		
FLUTICASONE FUROATE 184micrograms / VILANTEROL 22micrograms INHALER	R	For the maintenance management of asthma in adults as per MIL. MMTc, December 2017
FLUTICASONE 250microgram EVOHALER (120dose)	Y	
FLUTICASONE 250microgram/dose 60 doses ACCUHALER	R	For patients unable to use the evohaler. To be initiated by Respiratory clinicians only. Medicines Effectiveness, August 2010
FLUTICASONE 125microgram EVOHALER (120dose)	Y	
FLUTICASONE 500microgram/dose 60 dose ACCUHALER	R	For patients unable to use the evohaler. To be initiated by Respiratory clinicians only. Medicines Effectiveness, August 2010.
FLUTICASONE 50microgram EVOHALER (120dose)	Y	

FLUTICASONONE 92micrograms / VILANTEROL 22micrograms INHALER	R	For the treatment of: - COPD as per MILV10N7 Guidelines for the inhaled maintenance treatments of COPD; - For the maintenance management of asthma in adults as per MIL. MMTTC, December 2017
FLUTICASONONE / FORMOTEROL 125micrograms/5micrograms INHALER	NF	
FLUTICASONONE + FORMOTEROL		
FLUTICASONONE / FORMOTEROL 50micrograms/5micrograms INHALER	NF	
FLUTICASONONE / FORMOTEROL 250micrograms/10micrograms INHALER	NF	
FLUTICASONONE + SALMETEROL		
FLUTICASONONE / SALMETEROL 500microgram / 50microgram INHALER 60dose (AIRFLUSAL)	R	For patients unable to use the evohaler. To be initiated by Respiratory clinicians only. Medicines Effectiveness, November 2004.
FLUTICASONONE / SALMETEROL 250microgram/50microgram ACCUHALER	R	For patients unable to use the evohaler. To be initiated by Respiratory clinicians only. Medicines Effectiveness, November 2004.
FLUTICASONONE / SALMETEROL 250micrograms/25microgram EVOHALER 120dose	R	To be initiated by Respiratory clinicians only. Medicines Effectiveness, November 2004.
FLUTICASONONE + UMECLIDINIUM + VILANTEROL		
FLUTICASONONE 92micrograms / UMECLIDINIUM 55micrograms / VILANTEROL 22micrograms INHALER	R	For the treatment of COPD. To be initiation by Respiratory clinicians only. MMTTC, March 2018
SALMETEROL + FLUTICASONONE		
SALMETEROL 25micrograms / FLUTICASONONE 250micrograms INHALER (AIRFLUSAL)	R	To be initiated by Respiratory clinicians only. Medicines Effectiveness, November 2004.
SALMETEROL 25micrograms / FLUTICASONONE 125micrograms INHALER (AIRFLUSAL)	R	To be initiated by Respiratory clinicians only. Medicines Effectiveness, November 2004.

03.03 Cromoglicate and related therapy, leukotriene receptor antagonists, and phosphodiesterase type-4

03.03.00 Cromoglicate and related therapy, leukotriene receptor antagonists, and phosphodiesterase

BENRALIZUMAB

BENRALIZUMAB 30mg PRE FILLED PEN	R	Restricted for use in severe eosinophilic asthma as per NICE TA565. MMTC, April 2019
BENRALIZUMAB 30mg IN 1ml PRE-FILLED SYRINGE NF (COMPASSIONATE USE)		
CICLESONIDE		
CICLESONIDE MULTIDOSE INHALER 80MCG	R	For the maintenance management of asthma in adults as per MIL. MMTC, December 2017
CICLESONIDE 160microgram INHALER (60 dose)	NF	
MONTELUKAST		
MONTELUKAST 4mg GRANULES	R	For prophylaxis of asthma in paediatric patients only. To be initiated by Respiratory clinicians only. Medicines Effectiveness, March 2001.
MONTELUKAST 5mg CHEWABLE TABLETS	R	For prophylaxis of asthma in paediatric patients only. To be initiated by Respiratory clinicians only. Medicines Effectiveness, March 2001.
MONTELUKAST 10mg TABLETS	R	For prophylaxis of asthma. To be initiated by Respiratory clinicians only. Medicines Effectiveness, March 2001.
MONTELUKAST 4mg CHEWABLE TABLETS	R	For prophylaxis of asthma in paediatric patients unable to manage montelukast chewable tablets. To be initiated by Respiratory clinicians only. MMTC, January 2013.
NEDOCROMIL		
NEDOCROMIL 2mg/dose INHALER	NF	
ROFLUMILAST		
ROFLUMILAST 500microgram TABLETS	R	For the treatment of chronic obstructive pulmonary disease as per NICE TA461. NB: please note shared care arrangements with primary care. MMTC, August 2017
SODIUM CROMOGLICATE		
SODIUM CROMOGLICATE 5mg/dose INHALER (112dose)	NF	

03.04 Antihistamines, hyposensitisation, and allergic emergencies

Icatibant

ICATIBANT 30mg in 3ml PRE FILLED SYRINGE (CELIX)	R	Restricted: For the treatment of Acute Attacks in Hereditary Angioedema as per NHS England Policy NHSCB/B09/P/b. MMTC, May 2013.
--	---	--

03.04.00 Antihistamines, hyposensitisation, and allergic emergencies

ADRENALINE

ADRENALINE (EPINEPHRINE) 0.3mg PEN (EPIPEN - Pk2)		TWO strengths of EpiPen available, please ensure you select the CORRECT one. AE 19.09.08
---	--	--

ADRENALINE (EPINEPHRINE) 1 in 1000units 5mg IN 5ml INJECTION	Y	
--	---	--

RESLIZUMAB

RESLIZUMAB 100mg IN 1ml INJECTION	R	For treatment of severe eosinophilic asthma as per NICE TA479. MMTC, January 2018
RESLIZUMAB 25mg IN 2.5ml INJECTION	R	For treatment of severe eosinophilic asthma as per NICE TA479. MMTC, January 2018

03.04.01 Antihistamines

ACRIVASTIN

ACRIVASTIN 8mg CAPSULES	NF	
-------------------------	----	--

ALIMEMAZINE

ALIMEMAZINE FORTE 30mg/5ml LIQUID	Y	
-----------------------------------	---	--

ALIMEMAZINE 7.5mg/5ml LIQUID	Y	
------------------------------	---	--

ALIMEMAZINE 10mg TABLETS	Y	
--------------------------	---	--

BEE VENOM

BEE VENOM 100; 1,000; 10,000; 100,000 SQ-units/ml INJECTION (4 VIAL INITIAL PACK - ALUTARD)	Y	
---	---	--

BILASTINE

BILASTINE 20MG TABLETS	NF	
------------------------	----	--

CETIRIZINE

CETIRIZINE 5mg/5ml LIQUID	Y	
---------------------------	---	--

CETIRIZINE 10mg TABLETS	Y	
CHLORPHENAMINE		
CHLORPHENAMINE 4mg TABLETS	Y	
CHLORPHENAMINE 10mg IN 1ml INJECTION	Y	
CHLORPHENAMINE 2mg/5ml LIQUID	Y	
CHLORPHENAMINE 4mg TABLETS TTO 28's	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, February 2013.
CLEMASTINE		
CLEMASTINE 1mg TABLETS	NF	
CYPROHEPTADINE		
CYPROHEPTADINE 4mg TABLETS	R	For use as part of paediatric oncology anti-emetic policy. Medicines Effectiveness, February 2013.
DARUNAVIR		
LEVOCETIRIZINE HYDROCHLORIDE 2.5mg/5ml LIQUID	NF	
DIPHENHYDRAMINE		
DIPHENHYDRAMINE 25mg TABLETS	NF	
FEXOFENADINE		
FEXOFENADINE 30mg TABLETS	R	For use by the ENT department only. Formulary options are cetirizine and loratadine. Medicines Effectiveness, March 2013.
FEXOFENADINE 180mg TABLETS	R	For use by the ENT department only. Formulary options are cetirizine and loratadine. Medicines Effectiveness, March 2013.
FEXOFENADINE 120mg TABLETS	R	For use by the ENT department only. Formulary options are cetirizine and loratadine. Medicines Effectiveness, March 2013.
House dust mite		
ACARIZAX TABS (ACARIZAX 30 TABLET PACK)	R	Restricted for use by Immunology Only.

HYDROXYZINE

HYDROXYZINE 10mg TABLETS Y

HYDROXYZINE 25mg TABLETS Y

KETOTIFEN

KETOTIFEN 1mg TABLETS NF

LORATADINE

LORATADINE 10mg TABLETS Y

LORATADINE 5mg/5ml LIQUID Y

MIZOLASTINE

MIZOLASTINE 10mg TABLETS M/R NF

OLOPATADINE

OLOPATADINE 1mg/ml EYE DROPS TTO PACK 5ml SR

PROMETHAZINE

PROMETHAZINE 5mg/5ml LIQUID Y

PROMETHAZINE 25mg TABLETS Y

PROMETHAZINE 10mg TABLETS Y

PROMETHAZINE 25mg IN 1ml INJECTION Y

TERFENADINE

TERFENADINE 60mg TABLETS NF

Tree pollen

ITULAZAX TABS (ITULAZAX 30 TABLET PACK) R For Immunology Use ONLY

03.04.02 Allergen Immunotherapy

BEE VENOM

BEE VENOM MAINTENANCE 100,000 SQ-units/ml INJECTION (ALUTARD) Y For the treatment of bee and wasp venom allergy as per NICE TA246. February 2012

DAP CLAVULANIC

DAP CLAVULANIC DIAGNOSTIC TEST 5mg/20mg INJECTION (18 PACK) UNR For use by Immunology. Medicines Effectiveness, March 2013.

DAP PENICILLIN

DAP PENICILLINS DIAGNOSTIC TEST 0.04mg/0.5mg UNR
INJECTION (6 PACK)

For use by Immunology.
Medicines Effectiveness, March
2013.

GRASS and TREE POLLEN EXTRACT

GRASS and TREE POLLEN EXTRACT INJECTION R

For use by
Dermatology/Immunology only.
Medicines Effectiveness, March
2013.

GRASS POLLEN EXTRACT

GRASS POLLEN EXTRACT 75,000 UNITS TABLETS 30

R For treatment of allergic rhinitis
in paediatrics (initiated by allergy
team) only. MMTC November
2018

MEPOLIZUMAB

MEPOLIZUMAB 100mg IN 10ml INJECTION R

For the treatment of refractory
eosinophilic asthma in adults (as
per NICE TA431) and children
over 6 years old (as per NHSE
commissioning statement
170001/P). MMTC, March 2019

MEPOLIZUMAB 100mg PRE FILLED PEN R

For the treatment of refractory
eosinophilic asthma in adults (as
per NICE TA431) and children
over 6 years old (as per NHSE
commissioning statement
170001/P). MMTC, March 2019

OMALIZUMAB

OMALIZUMAB 150mg IN 1.2ml PRE-FILLED SYRINGE
(COMPASSIONATE USE)

NF For Treatment of Patients with
Chronic Spontaneous Urticaria
(CSU) only. Medicines
Effectiveness, May 2015.

OMALIZUMAB 150mg IN 1.2ml PRE-FILLED SYRINGE R

For the treatment of severe
persistent allergic asthma as per
NICE TA133 (Respiratory
Consultants only), and for
patients with previously treated
chronic spontaneous urticarial as
per NICE TA339 (Immunology
Consultants only). MMTC, May
2015.

OMALIZUMAB 75mg in 0.5ml PRE-FILLED SYRINGE	R	For the treatment of severe persistent allergic asthma as per NICE TA133 (Respiratory Consultants only), and for patients with previously treated chronic spontaneous urticarial as per NICE TA339 (Immunology Consultants only). MMTc, May 2015.
---	---	---

WASP VENOM

WASP VENOM MAINTENANCE 100,000 SQ-units/ml INJECTION (ALUTARD)	Y	For the treatment of bee and wasp venom allergy as per NICE TA246. February 2012
--	---	--

WASP VENOM 100; 1,000; 10,000; 100,000 SQ-units/ml INJECTION (4 VIAL INITIAL PACK - ALUTARD)	Y	
--	---	--

03.04.03 Allergic emergencies

ADRENALINE

ADRENALINE (EPINEPHRINE) 150microgram PRE FILLED PEN	R	Ordered as a substitute for EpiPen Junior during shortage. Medicines Effectiveness. October 2018
--	---	--

ADRENALINE (EPINEPHRINE) 300microgram PRE-FILLED PEN (JEXT)	R	For use in areas who usually use EpiPen 0.3mg auto-injector whilst there is a supply problem ongoing. Medicines Effectiveness, April 2018
---	---	---

ADRENALINE (EPINEPHRINE) 1 in 1000units 10mg IN 10ml INJECTION	Y	
--	---	--

ADRENALINE (EPINEPHRINE) 0.3mg PEN (EPIPEN)	Y	
---	---	--

ADRENALINE (EPINEPHRINE) 1 in 1000 1mg in 1ml SYRINGE (ANAPHYLAXIS)	Y	
---	---	--

ADRENALINE (EPINEPHRINE) 0.15mg PEN (EPIPEN)	Y	
--	---	--

ADRENALINE (EPINEPHRINE) 1 in 1000 (1mg in 1ml) INJECTION	Y	
---	---	--

C1 ESTERASE

C1 ESTERASE INHIBITOR 1500international units INJECTION (BERINERT)	R	For the Treatment of Acute Attacks in Hereditary Angioedema as per NHSE Policy Statement NHSCB/B09/P/b. NB: long-term prophylaxis requires an IFR. MMTc, June 2013
--	---	--

C1 ESTERASE INHIBITOR TIM 500units	R	For the Treatment of Acute Attacks in Hereditary Angioedema as per NHSE Policy Statement NHSCB/B09/P/b. NB: long-term prophylaxis requires an IFR. MMTc, June 2013.
C1 ESTERASE INHIBITOR 500units INJECTION (CINRYZE) with administration set	R	For the Treatment of Acute Attacks in Hereditary Angioedema as per NHSE Policy Statement NHSCB/B09/P/b. NB: long-term prophylaxis requires an IFR. MMTc, June 2013.

CONESTAT ALFA

CONESTAT ALFA 2100units INJECTION	R	
-----------------------------------	---	--

EPIPEN

EPIPEN TRAINER	Y	
----------------	---	--

ICATIBANT

ICATIBANT 30mg IN 3ml PRE-FILLED SYRINGE	NF	For the treatment of Acute Attacks in Hereditary Angioedema as per NHS England Policy NHSCB/B09/P/b. MMTc, May 2013.
--	----	--

03.05 Respiratory stimulants and pulmonary surfactants

03.05.01 Respiratory stimulants

CAFFEINE

CAFFEINE CITRATE 20mg in 1ml (CAFFEINE BASE 10mg/ml) INJECTION	R	Restricted to apnoea in neonates and infants. Medicines Effectiveness, July 2011
--	---	--

DOXAPRAM

DOXAPRAM 100mg IN 5ml INJECTION	Y	For use in resuscitation of patients in COVID areas and theatres during COVID-19.
---------------------------------	---	---

03.05.02 Pulmonary surfactants

PORACTANT

PORACTANT ALFA 120mg IN 1.5ml endotracheopulmonary suspension vials	R	For the treatment and prophylaxis of neonatal respiratory distress syndrome. MAC, May 2010.
---	---	---

PORACTANT ALFA 240mg IN 3ml endotracheopulmonary suspension vials	R	For the treatment and prophylaxis of neonatal respiratory distress syndrome. MAC, May 2010.
---	---	---

03.07 Mucolytics

03.07.00 Mucolytics

CARBOCISTEINE

CARBOCISTEINE 250mg/5ml LIQUID

R

For use as per NICE guidelines in patients with swallowing difficulties or feeding tube only. Medicines Effectiveness, December 2004.

CARBOCISTEINE 375mg CAPSULES

R

For use as per NICE guidelines. Medicines Effectiveness, December 2004.

DORNASE ALFA

DORNASE ALFA 2.5mg (2500units) IN 2.5ml NEBULISER SOLUTION

R

For cystic fibrosis patients with associated spirometric monometric monitoring; and for loculated empyema (unlicensed indication - to be used under direction from Dr Naj Rahman only, Pleural Consultant). Medicines Effectiveness, September 2013.

IVACAFTOR

IVACAFTOR 150mg TABLETS (COMPASSIONATE SUPPLY)

NF

For the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene.

MMTC, January 2013

MANNITOL

MANNITOL (BIDA PACK) 40mg CAPULES + INHALER R

For the treatment of cystic fibrosis as per NICE TA266. FOR TRIAL DOSES ONLY. MMTC, April 2013.

SODIUM CHLORIDE

SODIUM CHLORIDE 7% NEBULES

R

For CF and bronchiectasis patients only on Geoffrey Harris Ward (CH) or Melanies (JR). WARNING - High Strength Product Do NOT issue as ward stock - issue to individually named patients only. MMTC, September 2010.

03.09 Cough preparations

03.09.00 Cough preparations

SIMPLE LINCTUS

SIMPLE LINCTUS SUGAR FREE 200ml Y

03.10 Systemic nasal decongestants

03.10.00 Systemic nasal decongestants

PSEUDOEPHEDRINE

PSEUDOEPHEDRINE 30mg/5ml LIQUID Y

03.11 Antifibrotics

03.11.00 Antifibrotics

PIRFENIDONE

PIRFENIDONE 267mg CAPSULES R For treating idiopathic pulmonary fibrosis as per NICE TA504. MMTC, February 2018

PIRFENIDONE 267mg CAPSULES (2 WEEK INITIATION PACK) R For treating idiopathic pulmonary fibrosis as per NICE TA504. MMTC, February 2018

03.11.00 Antifibrotics

NINTEDANIB

NINTEDANIB 150mg CAPSULES R OFEV Brand only - For the treatment of idiopathic pulmonary fibrosis as per NICE TA379. MMTC, March 2016

NINTEDANIB 100mg CAPSULES R OFEV Brand only -For the treatment of idiopathic pulmonary fibrosis as per NICE TA379. MMTC, March 2016

04 Central nervous system

04.01 Hypnotics and anxiolytics

04.01 Hypnotics and anxiolytics

Melatonin

MELATONIN 5mg/5ml LIQUID (MARTINDALE) SR For use prior to EEGs, auditory brainstem response (ABR) testing and sleep management in paediatric patients only. MMTC, June 2023

MELATONIN 5mg TABLETS M/R R For management of sleep disturbance in children age 2 years and over as per sleep management shared care protocol criteria. MMTC, December 2023

MELATONIN 1mg TABLETS M/R	R	For management of sleep disturbance in children age 2 years and over as per sleep management shared care protocol criteria. MMTC, December 2023
Nitrazepam		
NITRAZEPAM 2.5mg/5ml LIQUID	NF	For established patients only. Medicines Effectiveness, February 2013.
TELOTRISTAT		
TELOTRISTAT 250 MG TABLETS	NF	
<i>04.01.00 Antihypertensives</i>		
CLONIDINE		
CLONIDINE 750micrograms in 50ml PRE-FILLED SYRINGES	SR	For sedation in critical care areas, Medicines Effectiveness January 2021
<i>04.01.01 Hypnotics</i>		
CHLORAL		
CHLORAL HYDRATE 25mg SUPPOSITORIES	SR	For the sedation of paediatrics prior painless procedures. Medicines Effectiveness, May 2017
CHLORAL HYDRATE 50mg SUPPOSITORIES	SR	For the sedation of paediatrics prior painless procedures. Medicines Effectiveness, May 2017
CHLORAL HYDRATE 500mg/5ml LIQUID	SR	Until licensed version available again
CLOMETHIAZOLE		
CLOMETHIAZOLE 192mg CAPSULES	R	For sedation only. NOT to be used for acute alcohol withdrawal. Medicines Effectiveness, August 2001.
CLOMETHIAZOLE 250mg/5ml LIQUID	R	For sedation only. NOT to be used for acute alcohol withdrawal. Medicines Effectiveness, August 2001.
FLURAZEPAM		
FLURAZEPAM 15mg CAPSULES	NF	
LOPRAZOLAM		

LOPRAZOLAM 1mg TABLETS	NF	
MELATONIN		
MELATONIN 2mg TABLETS M/R	R	For sleep management in paediatric patients only. MMTC, March 2016
NITRAZEPAM		
NITRAZEPAM 5mg TABLETS	Y	
SODIUM OXYBATE		
SODIUM OXYBATE 500mg/ml LIQUID 180ml	R	For use by Consultant Neurologists only following an IFR approval from OCCG. Prescription must be on sodium oxybate-specific form. Medicines Effectiveness, March 2013.
TEMAZEPAM		
TEMAZEPAM 10mg/5ml LIQUID S/F	Y	
TEMAZEPAM 10mg TABLETS	Y	
TRICLOFOS SODIUM		
TRICLOFOS SODIUM 500mg/5ml LIQUID	NF	
ZOLPIDEM		
ZOLPIDEM 10MG TABLETS	NF	
ZOLPIDEM TARTRATE 5mg TABLETS	NF	
ZOPICLONE		
ZOPICLONE 7.5mg TABLETS	Y	
ZOPICLONE 3.75mg TABLETS	Y	
<i>04.01.02 Anxiolytics</i>		
ALCOHOL		
ALCOHOL ABSOLUTE 5ml INJECTION	Y	
ALCOHOL ABSOLUTE 2ml INJECTION	Y	
BUSPIRONE		
BUSPIRONE 5mg TABLETS	NF	
CHLORDIAZEPOXIDE		

CHLORDIAZEPOXIDE 10mg CAPSULES Y

CHLORDIAZEPOXIDE 5mg CAPSULES Y

CLORAZEPATE

CLORAZEPATE DIPOTASSIUM 15mg CAPSULES NF

DIAZEPAM

DIAZEPAM 10mg IN 2ml INJECTION Y

DIAZEPAM 10mg RECTAL TUBES Y

DIAZEPAM 2mg/5ml LIQUID Y

DIAZEPAM 5mg TABLETS Y

DIAZEPAM 10mg TABLETS Y

DIAZEPAM 2mg TABLETS Y

LORAZEPAM

LORAZEPAM 4mg IN 1ml INJECTION Y

LORAZEPAM 1mg TABLETS Y

OXAZEPAM

OXAZEPAM 10mg TABLETS NF

04.01.03 Barbiturates

AMYLOBARBITONE

AMYLOBARBITONE SODIUM (AMOBARBITAL SODIUM) 500mg INJECTION UNR Restricted for Wada intra arterial testing only. Medicines Effectiveness. May 2018

MEPROBAMATE

MEPROBAMATE 400mg TABLETS NF

4.01.02 Anxiolytics

LORAZEPAM

LORAZEPAM 2.5mg TABLETS NF

04.02 Drugs used in psychoses and related disorders

04.02 Drugs used in psychoses and related disorders

NORADRENALINE

NORADRENALINE 4mg IN 50ml INJECTION (VIALS) Y

04.02.00 Drugs used in psychoses and related disorders

ELTROMBOBAG

ELTROMBOBAG 75mg TABLETS	R	For treating chronic immune (idiopathic) thrombocytopenic purpura as per NICE TA293. (Also included under Medicines for Children Policy) available for paediatrics. MMTC August 2019
--------------------------	---	--

04.02.01 Antipsychotic drugs

AMISULPRIDE

AMISULPRIDE 200mg TABLETS	R	For continuation of therapy as per the Mental Health Trust. Medicines Effectiveness, July 2012.
---------------------------	---	---

AMISULPRIDE 500mg/5ml LIQUID	NF
------------------------------	----

AMISULPRIDE 50mg TABLETS	R	For continuation of therapy as per the Mental Health Trust. Medicines Effectiveness, July 2012.
--------------------------	---	---

ARIPIRAZOLE

ARIPIRAZOLE 1mg/ml ORAL SOLUTION 150ml	NF
--	----

ARIPIRAZOLE 15mg TABLETS ORODISPERSIBLE	NF
---	----

ARIPIRAZOLE 10mg TABLETS	R	For continuation of therapy as per the Mental Health Trust. MMTC, November 2013.
--------------------------	---	--

ARIPIRAZOLE 5mg TABLETS	R	For continuation of therapy as per the Mental Health Trust. MMTC, November 2013.
-------------------------	---	--

ARIPIRAZOLE 15mg TABLETS	R	For continuation of therapy as per the Mental Health Trust. MMTC, November 2013.
--------------------------	---	--

Asenapine

ASENAPINE 10MG SUBLINGUAL TABLETS	NF
-----------------------------------	----

CHLORPROMAZINE

CHLORPROMAZINE 50mg TABLETS	Y
-----------------------------	---

CHLORPROMAZINE 100mg TABLETS	Y
------------------------------	---

CHLORPROMAZINE 25mg TABLETS	Y
-----------------------------	---

CHLORPROMAZINE 25mg/5ml LIQUID	Y	
CLOZAPINE		
CLOZAPINE 100mg TABLETS (SCORED)	NF	For no-charge label of OH stock only. Not for ordering. Medicines Effectiveness April 2019
CLOZAPINE 25mg TABLETS (SCORED)	NF	For relabelling purposes only. Never to be ordered for OUH
FLUPENTIXOL		
FLUPENTIXOL 3MG TABLETS	NF	
HALOPERIDOL		
HALOPERIDOL 5mg IN 1ml INJECTION	Y	
HALOPERIDOL 5mg TABLETS	Y	
HALOPERIDOL 10mg/5ml LIQUID	Y	
HALOPERIDOL 1.5mg TABLETS	Y	
Levomepromazine		
LEVOMEPRMAZINE HYDROCHLORIDE 25mg in 5ml ORAL SOLUTION SF		R Only to be used if Levomepromazine 25mg tablets are unavailable.
LEVOMEPRMAZINE 25mg TABLETS	Y	
LEVOMEPRMAZINE 25mg IN 1ml INJECTION	Y	
LURASIDONE		
LURASIDONE 37mg TABLETS	NF	
LURASIDONE 74mg TABLETS	NF	
OLANZAPINE		
OLANZAPINE 10mg in 2ml INJECTION	R	For NBM patients who cannot tolerate haloperidol. MAC, May 2011.
OLANZAPINE 10mg TABLETS	Y	
OLANZAPINE 2.5mg TABLETS	Y	
OLANZAPINE 5mg TABLETS	Y	

OLANZAPINE ORODISPERSIBLE 10mg TABLETS	R	For palliative or end of life care patients with swallowing difficulties and for patients with feeding tubes only. MMTC, June 2014.
OLANZAPINE ORODISPERSIBLE 15mg TABLETS	R	For palliative or end of life care patients with swallowing difficulties and for patients with feeding tubes only. MMTC, June 2014.
OLANZAPINE ORODISPERSIBLE 5mg TABLETS	R	For palliative or end of life care patients with swallowing difficulties and for patients with feeding tubes only. MMTC, June 2014.
OLANZAPINE 15mg TABLETS	Y	
PALIPERIDONE		
PALIPERIDONE 100mg INJECTION PRE-FILLED SYRINGE	NF	
PALIPERIDONE 50mg INJECTION PRE-FILLED SYRINGE	NF	
PERICYAZINE		
PERICYAZINE 10mg/5ml SYRUP	NF	
PERICYAZINE 2.5mg TABLETS	NF	
PROMAZINE		
PROMAZINE 25mg/5ml LIQUID 150ml	NF	
PROMAZINE 25mg TABLETS	NF	
QUETIAPINE		
QUETIAPINE 200mg MR TABLETS	NF	
QUETIAPINE 100mg TABLETS	R	For use by or on recommendation from a Consultant in Mental Health only and for continuation of therapy. Medicines Effectiveness, April 2007.
QUETIAPINE 150mg TABLETS	R	For use by or on recommendation from a Consultant in Mental Health only and for continuation of therapy. Medicines Effectiveness, April 2007.

QUETIAPINE 200mg TABLETS	R	For use by or on recommendation from a Consultant in Mental Health only and for continuation of therapy. Medicines Effectiveness, April 2007.
QUETIAPINE 25mg TABLETS	R	For use by or on recommendation from a Consultant in Mental Health only and for continuation of therapy. Medicines Effectiveness, April 2007.
QUETIAPINE 300mg TABLETS M/R	NF	
QUETIAPINE 50mg TABLETS M/R	NF	
QUETIAPINE 300mg TABLET	R	For use by or on recommendation from a Consultant in Mental Health only and for continuation of therapy. Medicines Effectiveness, April 2007.
RISPERIDONE		
RISPERIDONE 2mg ORODISPERSIBLE TABLETS	NF	
RISPERIDONE 1mg TABLETS	Y	
RISPERIDONE 2mg TABLETS	Y	
RISPERIDONE 500microgram ORODISPERSIBLE TABLETS	NF	
RISPERIDONE 3mg TABLETS	Y	
RISPERIDONE 500microgram TABLETS	Y	
RISPERIDONE 5mg/5ml LIQUID	Y	
SULPIRIDE		
SULPIRIDE 200mg TABLETS	R	For use by or on the recommendation of a Consultant in Mental Health only. Medicines Effectiveness, June 2007.
SULPIRIDE 200mg/5ml LIQUID	R	For use by or on the recommendation of a Consultant in Mental Health only. Medicines Effectiveness, June 2007.

SULPIRIDE 400mg TABLETS

R

For use by or on the recommendation of a Consultant in Mental Health only. Medicines Effectiveness, June 2007.

TRIFLUOPERAZINE

TRIFLUOPERAZINE 5mg TABLETS

Y

TRIFLUOPERAZINE 10mg CAPSULES M/R

Y

TRIFLUOPERAZINE 15mg CAPSULES M/R

Y

TRIFLUOPERAZINE 1mg TABLETS

Y

TRIFLUOPERAZINE 1mg/5ml LIQUID 200ml

Y

TRIFLUOPERAZINE 5mg/5ml LIQUID 150ml

Y

ZUCLOPENTHIXOL

ZUCLOPENTHIXOL ACETATE 50mg IN 1ml INJECTION NF

ZUCLOPENTHIXOL 10mg TABLETS

Y

ZUCLOPENTHIXOL 2mg TABLETS

Y

04.02.01 Antipsychotic drugs > Second-generation antipsychotic drugs

ARIPIRAZOLE

ARIPIRAZOLE 7.5mg IN 1ml INJECTION

NF

04.02.01 Antipsychotics

OLANZAPINE

OLANZAPINE 210mg PR INJECTION

NF

04.02.02 Antipsychotic depot injections

FLUPENTIXOL

FLUPENTIXOL DECANOATE 20mg in 1ml INJECTION NF

HALOPERIDOL

HALOPERIDOL DECANOATE 50mg IN 1ml INJECTION NF

HALOPERIDOL DECANOATE 100mg IN 1ml INJECTION NF

OLANZAPINE

OLANZAPINE 7.5mg TABLETS

Y

PALIPERIDONE

PALIPERIDONE 263mg INJECTION PRE-FILLED SYRINGE	NF
PALIPERIDONE 75mg INJECTION PRE-FILLED SYRINGE	NF
PALIPERIDONE 150mg INJECTION PRE-FILLED SYRINGE	NF

RISPERIDONE

RISPERIDONE 25mg DEPOT INJECTION	NF
RISPERIDONE 37.5mg DEPOT INJECTION	NF
RISPERIDONE 50mg DEPOT INJECTION	NF

ZUCLOPENTHIXOL

ZUCLOPENTHIXOL DECANOATE 200mg in 1ml INJECTION	NF
ZUCLOPENTHIXOL DECANOATE 500mg IN 1ml INJECTION	NF

04.02.03 Antidepressant drugs

VALPROIC ACID

VALPROIC ACID 500mg TABLETS E/C	R	For use by or on the recommendation of a Consultant Mental Health only and for continuation of therapy. Medicines Effectiveness, February 2008
VALPROIC ACID 250mg TABLETS E/C	R	For use by or on the recommendation of a Consultant Mental Health only and for continuation of therapy. Medicines Effectiveness, February 2008.

04.02.03 Antimanic drugs

LITHIUM

LITHIUM CARBONATE 250mg TABLETS (CAMCOLIT)	R	For continuation therapy or initiation following advice of a psychiatrist only. Medicines Effectiveness, December 2010.
LITHIUM CARBONATE 400mg M/R TABLETS (PRIADEL)	R	For continuation therapy or initiation following advice of a psychiatrist only. Medicines Effectiveness, December 2010.
LITHIUM CITRATE 5.4mmol/5ml LIQUID (Li-Liquid)	R	For continuation therapy or initiation following advice of a psychiatrist only. Medicines Effectiveness, December 2010.

LITHIUM CARBONATE 200mg MR TABLETS (PRIADEL)	R	For continuation therapy or initiation following advice of a psychiatrist only. Medicines Effectiveness, December 2010.
LITHIUM CARBONATE (LISKONUM) 450mg M/R TABLETS	NF	
LITHIUM CARBONATE 400mg M/R TABLETS (CAMCOLIT)	R	For continuation therapy or initiation following advice of a psychiatrist only. Medicines Effectiveness, December 2010.

04.02.03 Drugs used for mania and hypomania

LITHIUM

LITHIUM CITRATE 520mg/5ml LIQUID	NF	
----------------------------------	----	--

04.08.01 Control of epilepsy

PHENYTOIN

PHENYTOIN 50mg TABLETS	UNR	Restricted for established patients during supply problem
------------------------	-----	---

04.08.01 Control of the epileps

TOPIRAMATE

TOPIRAMATE 50mg/5ml ORAL SUSPENSION	NF	
-------------------------------------	----	--

04.08.01 Control of the epilepsies

Brivaracetam

BRIVARACETAM 25MG TABLETS	R	For the treatment of drug resistant partial onset seizures (3rd line option). For initiation by neurologists only. MMTC, January 2017
---------------------------	---	---

SAFINAMIDE

SAFINAMIDE 100mg TABLETS	NF	
--------------------------	----	--

04.02 Epilepsy and other seizure disorders

04.02.00 Antiepileptics

FENFLURAMINE

FENFLURAMINE 2.2mg/ml ORAL SOLUTION 120ml	R	?For treatment of seizures associated with Dravet syndrome in people aged 2 years and older as per NICE TA808. MMTC, December 2022
---	---	--

04.03 Antidepressant drugs

04.03.01 Tricyclic and related antidepressant drugs

TRIMIPRAMINE

TRIMIPRAMINE 25mg TABLETS	R	For continuation of therapy or initiation by psychological medicine only. MMTC, October 2016
TRIMIPRAMINE 10mg TABLETS	R	For continuation of therapy or initiation by psychological medicine only. MMTC, October 2016
<i>04.03.01 Tricyclic and related antidepressant drugs</i>		
AMITRIPTYLINE		
AMITRIPTYLINE 50mg TABLETS	Y	
AMITRIPTYLINE 25mg/5ml LIQUID S/F	Y	
AMITRIPTYLINE 25mg TABLETS	Y	
AMITRIPTYLINE 10mg TABLETS	Y	
CLOMIPRAMINE		
CLOMIPRAMINE 10mg CAPSULES	R	For continuation of therapy or initiation by psychological medicine only. MMTC, October 2016
CLOMIPRAMINE 25mg CAPSULES	R	For continuation of therapy or initiation by psychological medicine only. MMTC, October 2016
CLOMIPRAMINE 50mg CAPSULES	R	For continuation of therapy or initiation by psychological medicine only. MMTC, October 2016
DOSULEPIN		
DOSULEPIN 75mg TABLETS	R	For continuation of therapy or initiation by psychological medicine only. MMTC, October 2016
DOSULEPIN 25mg CAPSULES	R	For continuation of therapy or initiation by psychological medicine only. MMTC, October 2016
DOXEPIN		
DOXEPIN 25mg CAPSULES	R	For continuation of therapy or initiation by psychological medicine only. MMTC, October 2016

IMIPRAMINE

IMIPRAMINE 25mg TABLETS	R	For continuation of therapy or initiation by psychological medicine only. MMTTC, October 2016
IMIPRAMINE 25mg/5ml LIQUID SUGAR FREE	R	For continuation of therapy or initiation by psychological medicine only. MMTTC, October 2016
IMIPRAMINE 10mg TABLETS	R	For continuation of therapy or initiation by psychological medicine only. MMTTC, October 2016

LOFEPRAMINE

LOFEPRAMINE 70mg TABLETS	Y
LOFEPRAMINE 70mg/5ml LIQUID	Y

METHYLPHENIDATE

METHYLPHENIDATE 27mg M/R TABLETS	NICE	Approved for use as per NICE TA only. An individual patient NICE implementation form is required (see PPDU SharePoint). Medicines Effectiveness, March 2013
----------------------------------	------	---

MIANSERIN

MIANSERIN 10mg TABLETS	Y
------------------------	---

MOTIVAL

MOTIVAL TABLETS (NF)	NF
----------------------	----

NORTRIPTYLINE

NORTRIPTYLINE 25mg TABLETS	Y
NORTRIPTYLINE 10mg TABLETS	Y

TRAZODONE

TRAZODONE 50mg/5ml LIQUID	NF
TRAZODONE 100mg CAPSULES	Y
TRAZODONE 50mg CAPSULES	Y

TRIMIPRAMINE

TRIMIPRAMINE 50mg CAPSULES	R	For continuation of therapy or initiation by psychological medicine only. MMTTC, October 2016
TRIPTAFEN		
TRIPTAFEN 25mg/2mg TABLETS	NF	
<i>04.03.02 Monoamine-oxidase inhibitors</i>		
ISOCARBOXAZID		
ISOCARBOXAZID 10mg TABLETS	NF	
MOCLOBEMIDE		
MOCLOBEMIDE 150mg TABLETS	R	For use by Consultant Psychiatrist only. Medicines Effectiveness, March 2013.
PHENELZINE		
PHENELZINE 15mg TABLETS	Y	
TRANLYCYPROMINE		
TRANLYCYPROMINE 10mg TABLETS	Y	
<i>04.03.03 Selective serotonin re-uptake inhibitors</i>		
CITALOPRAM		
CITALOPRAM 40mg/ml ORAL DROPS 15ml	Y	
CITALOPRAM 10mg TABLETS	Y	
CITALOPRAM 20mg TABLETS	Y	
ESCITALOPRAM		
ESCITALOPRAM 5mg TABLETS	NF	
ESCITALOPRAM 10mg TABLETS	NF	
ESCITALOPRAM 20mg TABLETS	NF	
Paroxetine		
PAROXETINE 10mg TABLETS	Y	
PAROXETINE 20mg TABLETS	Y	
PAROXETINE 10mg/5ml LIQUID SUGAR FREE	Y	
PAROXETINE 30mg TABLETS	Y	

SERTRALINE

SERTRALINE 100mg TABLETS Y

SERTRALINE 50mg TABLETS Y

04.03.04 Other antidepressant drugs

AGOMELATINE

AGOMELATINE 25mg TABLETS NF

DULOXETINE

DULOXETINE 20mg CAPSULES NF

DULOXETINE 40mg CAPSULES NF

DULOXETINE 30mg CAPSULES R For painful diabetic neuropathy following the recommendation by a Pain or Diabetes specialist. MMTC, July 2013.

DULOXETINE 60mg CAPSULES R For painful diabetic neuropathy following the recommendation by a Pain or Diabetes specialist. MMTC, July 2013.

FLUOXETINE

FLUOXETINE 20mg/5ml LIQUID Y

FLUOXETINE 20mg CAPSULES Y

FLUPENTIXOL

FLUPENTIXOL DECANOATE 200MG/ML SOLUTION FOR INJECTION NF

FLUPENTIXOL DECANOATE 100mg in 1ml INJECTION NF

FLUPENTIXOL 500microgram TABLETS Y

FLUPENTIXOL 1mg TABLETS Y

FLUPHENAZINE

FLUPHENAZINE HYDROCHLORIDE 1mg TABLETS Y

FLUVOXAMINE

FLUVOXAMINE 50mg TABLETS NF

MIRTAZAPINE

MIRTAZAPINE 45mg TABLETS	R	For use in established patients, as per MILV3N1 Initiating antidepressants for the treatment of depression in adults in hospital or on the recommendation by psychogeriatricians or psychiatrists only. MMTC,
MIRTAZAPINE 15mg ORODISPERSIBLE TABLETS	R	Restricted to patients with swallowing difficulties or feeding-tubes. For use in established patients, as per MILV3N1 Initiating antidepressants for the treatment of depression in adults in hospital or on the recommendation by psychogeriatricians or psychiatrists only. MMTC, October 2017
MIRTAZAPINE 15mg TABLETS	R	For use in established patients, as per MILV3N1 Initiating antidepressants for the treatment of depression in adults in hospital or on the recommendation by psychogeriatricians or psychiatrists only. MMTC,
MIRTAZAPINE 30mg ORODISPERSIBLE TABLETS	R	Restricted to patients with swallowing difficulties or feeding-tubes. For use in established patients, as per MILV3N1 Initiating antidepressants for the treatment of depression in adults in hospital or on the recommendation by psychogeriatricians or psychiatrists only. MMTC, October 2017
MIRTAZAPINE 30mg TABLETS	R	For use in established patients, as per MILV3N1 Initiating antidepressants for the treatment of depression in adults in hospital or on the recommendation by psychogeriatricians or psychiatrists only. MMTC,

MIRTAZAPINE 45mg ORODISPERSIBLE TABLETS	R	Restricted to patients with swallowing difficulties or feeding-tubes. For use in established patients, as per MILV3N1 Initiating antidepressants for the treatment of depression in adults in hospital or on the recommendation by psychogeriatricians or psychiatrists only. MMTC, October 2017
MIRTAZAPINE 75mg/5ml LIQUID 66ml	NF	
TRYPTOPHAN		
TRYPTOPHAN 500mg TABLETS	NF	
VENLAFAXINE		
VENLAFAXINE 75mg TABLETS	R	For initiation by a psychiatrist or a psychogeriatrician only. Medicines Effectiveness, December 2002.
VENLAFAXINE 150mg CAPSULES XL	R	For initiation by a psychiatrist or a psychogeriatrician only. Medicines Effectiveness, December 2002.
VENLAFAXINE 37.5mg TABLETS M/R	R	For initiation by a psychiatrist or a psychogeriatrician only. Medicines Effectiveness, December 2002.
VENLAFAXINE 75mg CAPSULES XL	R	For initiation by a psychiatrist or a psychogeriatrician only. Medicines Effectiveness, December 2002.
VENLAFAXINE 37.5mg TABLETS	R	For initiation by a psychiatrist or a psychogeriatrician only. Medicines Effectiveness, December 2002.
VORTIOXETINE		
VORTIOXETINE 5mg TABLETS	R	Approved for continuation of treatment for major depressive episodes in adults as per NICE TA367 MMTC, December 2018

040302 Attention deficit hyperactivity disorder drugs

METHYLPHENIDATE

METHYLPHENIDATE 36mg TABLETS M/R (XAGGITIN) NF

Noradrenaline reuptake inhibitors

ATOMOXETINE

ATOMOXETINE 10mg CAPSULES NF

ATOMOXETINE 20mg/5ml ORAL SOLUTION (3 x 100ml) NF

04.04 CNS stimulants and drugs used for attention deficit hyperactivity disorder

Lisdexamfetamine

LISDEXAMFETAMINE 40mg CAPSULES NF

04.04 CNS stimulants and drugs used for attention deficit hyperactivity disorder

DEXAMFETAMINE

DEXAMFETAMINE 5mg TABLETS NF

DEXAMFETAMINE 5mg TABLETS NF

LISDEXAMFETAMINE

LISDEXAMFETAMINE 50mg CAPSULES NF To be prescribed at Oxford Health NHS Foundation Trust only.

METHYLPHENIDATE

METHYLPHENIDATE 5mg TABLETS R For treatment of children over 5 years with ADHD as per NICE guideline NG87
MMTC, February 2021

METHYLPHENIDATE MR 10MG CAPSULES R For treatment of children over 5 years with ADHD as per NICE guideline NG87
MMTC, February 2021
For treatment of children over 5 years with ADHD as per NICE guideline NG87
MMTC, February 2021
For treatment of children over 5 years with ADHD as per NICE guideline NG87
MMTC, February 2021

METHYLPHENIDATE 20mg TABLETS R For treatment of children over 5 years with ADHD as per NICE guideline NG87
MMTC, February 2021

METHYLPHENIDATE 10mg TABLETS R For treatment of children over 5 years with ADHD as per NICE guideline NG87
MMTC, February 2021

METHYLPHENIDATE MR 20mg CAPSULES	R	For treatment of children over 5 years with ADHD as per NICE guideline NG87 MMTC, February 2021
METHYLPHENIDATE 30mg M/R CAPSULES	R	For treatment of children over 5 years with ADHD as per NICE guideline NG87 MMTC, February 2021
METHYLPHENIDATE 36mg TABLETS M/R	NF	
METHYLPHENIDATE 18mg TABLETS M/R	R	For treatment of children over 5 years with ADHD as per NICE guideline NG87 MMTC, February 2021

04.04.00 CNS stimulants and drugs used for attention deficit hyperactivity disorder

MODAFINIL

MODAFINIL 100mg TABLETS	R	Patients with proven diagnosis of narcolepsy Medicines Advisory Committee, September 2010.
-------------------------	---	--

RIOCIGUAT

RIOCIGUAT 1.5MG TABLETS	NF	
-------------------------	----	--

04.04.00 Noradrenaline reuptake inhibitors

REBOXETINE

REBOXETINE 4mg TABLETS	NF	
------------------------	----	--

4.04 CNS stimulants and drugs used for attention deficit hyperactivity disorder

CAFFEINE

CAFFEINE CITRATE 20mg/ml (100mg/5ml) LIQUID	Y	
---	---	--

LISDEXAMFETAMINE

LISDEXAMFETAMINE 20mg CAPSULES	NF	
LISDEXAMFETAMINE 30mg CAPSULES	NF	

METHYLPHENIDATE

METHYLPHENIDATE 5mg CAPSULES M/R	R	For treatment of children over 5 years with ADHD as per NICE guideline NG87 MMTC, February 2021
----------------------------------	---	--

Noradrenaline reuptake inhibitors

ATOMOXETINE

ATOMOXETINE 18mg CAPSULES	NF	
---------------------------	----	--

04.05 Drugs used in the treatment of obesity

04.05.01 Anti-obesity drugs acting on the gastro-intestinal tract

ORLISTAT

ORLISTAT 120mg CAPSULES NF

04.05.02 Centrally acting appetite suppressants

FENFLURAMINE

FENFLURAMINE 2.2mg/ml ORAL SOLUTION 120ml NF Requires overlabelling
(FREE OF CHARGE)

04.06 Drugs used in nausea and vertigo

Prochlorperazine

PROCHLORPERAZINE 3mg BUCCAL TABLETS Y

04.02.00 Drugs used in psychoses and related disorders

NETUPITANT + PALONOSETRON

NETUPITANT 300mg / PALONOSETRON NF
500microgram CAPSULES

04.02.01 Antipsychotic drugs

PROCHLORPERAZINE

PROCHLORPERAZINE 3mg BUCCAL TABLETS Y

04.06 Drugs used in nausea and vertigo

PROCHLORPERAZINE

PROCHLORPERAZINE 12.5mg IN 1ml INJECTION Y

PROCHLORPERAZINE 5mg TABLETS Y

04.06.00 Antimuscarinics

HYOSCINE HIDROBROMIDE

HYOSCINE 1.5mg PATCHES R For excess secretions. Medicines
Effectiveness, March 2010.

04.06.00 Drugs used in nausea and vertigo

PETHIDINE

PETHIDINE 50mg TABLETS NF

04.06.00 Nausea and labyrinth disorders

APREPITANT

APREPITANT 125mg & 80mg CAPSULES 3 DAY PACK	R	To prevent nausea and vomiting associated with highly emetogenic chemotherapy not responding to standard antiemetic therapy. It may be used as first line in: a) Head and Neck patients receiving 2 cycles neoadjuvant CF; b) Sarcoma patients receiving highly emetic chemotherapy. NB: its use in children is off-label (approved by MMTC). And for use in primary prophylaxis of CINV during COVID-19 pandemic
APREPITANT 80mg CAPSULES	R	To prevent nausea and vomiting associated with highly emetogenic chemotherapy not responding to standard antiemetic therapy. It may be used as first line in: a) Head and Neck patients receiving 2 cycles neoadjuvant CF; b) Sarcoma patients receiving highly emetic chemotherapy. THIS PACK SIZE IS FOR SMALL PAEDIATRIC PATIENTS ONLY. NB: its use in children is off-label (approved by MMTC). MMTC, May 2014.
BETAHISTINE		
BETAHISTINE 8mg TABLETS	Y	
BETAHISTINE 16mg TABLETS	Y	
CINNARIZINE		
CINNARIZINE 15mg TABLETS	Y	
CINNARIZINE + DIMENHYDRINATE		
CINNARIZINE+DIMENHYDRINATE 20mg/40mg TABLETS	NF	
CYCLIZINE		
CYCLIZINE 50mg IN 1ml INJECTION	Y	
CYCLIZINE 50mg IN 1ml INJECTION	Y	
CYCLIZINE 50mg TABLETS TTO (50)	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, February 2013.
CYCLIZINE 50mg TABLETS	Y	

DOMPERIDONE

DOMPERIDONE 5mg/5ml LIQUID Y

DOMPERIDONE 10mg TABLETS Y

DROPERIDOL

DROPERIDOL 5mg in 2ml INJECTION Y

GRANISETRON

GRANISETRON 3.1MG/24HR PATCHES NF

IVEMEND

FOSAPREPITANT 150mg INJECTION 10ml VIAL R For NBM patients to prevent nausea and vomiting associated with highly emetogenic chemotherapy not responding to standard antiemetic therapy. MAC, December 2011.

Ketotifen

KETOTIFEN 1mg in 5ml LIQUID SUGAR FREE NF

Metoclopramide

METOCLOPRAMIDE 10mg IN 2ml INJECTION Y

METOCLOPRAMIDE 10mg TABLETS TTO 9s SR For areas allowed to keep TTO packs Medicines Effectiveness, March 2013.

METOCLOPRAMIDE 10mg TABLETS TTO (28) SR For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.

METOCLOPRAMIDE 10mg TABLETS Y

METOCLOPRAMIDE 10mg IN 2ml INJECTION Y

METOCLOPRAMIDE 5mg/5ml LIQUID Y

NABILONE

NABILONE 1mg CAPSULES NF

Ondansetron

ONDANSETRON 4mg IN 2ml INJECTION Y

ONDANSETRON 8mg IN 4ml INJECTION Y

ONDANSETRON 4mg MELTS	R	For paediatrics and patients with swallowing difficulties only. Medicines Effectiveness, November 2013.
ONDANSETRON 8mg TABLETS TTO (10)	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.
ONDANSETRON 8mg TABLETS	Y	
ONDANSETRON 8mg IN 4ml INJECTION	Y	
ONDANSETRON 4mg/5ml LIQUID SUGAR FREE	R	For small doses in only. Medicines Effectiveness, November 2013.
ONDANSETRON 4mg TABLETS	Y	
ONDANSETRON 4mg IN 2ml INJECTION	Y	

PALONOSETRON

PALONOSETRON 500microgram CAPSULE	NF	
-----------------------------------	----	--

04.07.02 Opioid analgesics

BUPRENORPHINE

BUPRENORPHINE 2mg ORAL LYOPHILISATE TABLETS	NF	
---	----	--

DIHYDROCODEINE

DIHYDROCODEINE 30MG TABLETS TTO 14'S	SR	TTO pack restricted for use by Maternity only. Medicines Effectiveness, January 2020
--------------------------------------	----	--

OXYCODONE

OXYCODONE 50mg IN 50ml INJECTION VIAL	SR	For adult PCA use only, Medicines Effectiveness November 2019
---------------------------------------	----	---

15.02 Anaesthesia

HYOSCINE HYDROBROMIDE

HYOSCINE HYDROBROMIDE 300microgram TABLETS	Y	
--	---	--

Palonosetron

PALONOSETRON 250microgram in 5ml INJECTION	NF	
--	----	--

04.07 Analgesics

04.06 .00 Non-opioid Pain

Paracetamol

PARACETAMOL 500mg SOLUBLE TABLETS	Y	
<i>04.06.00 Opiod</i>		
TRAMADOL		
TRAMADOL 50mg CAPSULES	Y	
<i>04.06.00 Opiod drugs</i>		
Co-codamol		
CO-CODAMOL 8mg/500mg EFFERVESCENT TABLETS	Y	
<i>04.06.00 opioid Pain</i>		
Codeine		
CODEINE PHOSPHATE 30mg TABLETS TTO 28's	SR	
<i>04.07.00 Analgesics</i>		
BUPIVACAINE		
BUPIVACAINE 0.25% INFUSION BAGS 250ml	SR	For analgesia in adult and paediatric surgery. Medicines Effectiveness, February 2013.
BUPIVACAINE + FENTANYL		
BUPIVACAINE 0.1% & FENTANYL 2microgram/ml IN SOD CHLOR 0.9% 250ml	R	For epidural analgesia in Maternity, adult and paediatric surgery. Medicines Effectiveness, March 2013.
Levobupivacaine		
LEVOBUPIVACAINE 0.125% (125mg in 100ml) INJECTION 100ml	R	
LEVOBUPIVACAINE 0.125% (250mg in 200ml) INFUSION BAG	R	
LEVOBUPIVACAINE + FENTANYL		
LEVOBUPIVACAINE 0.1% & FENTANYL 2mcg/ml IN SOD CHLORIDE 0.9% EPIDURAL INFUSION 250ml	UNR	For use in maternity areas only. All other areas to use bupivacaine & fentanyl mixtures only at the moment.
LEVOBUPIVACAINE 0.1% & FENTANYL 5micrograms/ml in SOD CHLORIDE 0.9% 250ml	SR	For post-op epidural analgesia. Medicines Effectiveness, December 2013.
LEVOBUPIVACAINE 0.1% & FENTANYL 4micrograms/ml in SOD CHLORIDE 0.9% 500ml	SR	For epidural analgesia in adult and paediatric surgery. Medicines Effectiveness, March 2013.
<i>04.07.01 Non-opioid analgesics and compound analgesic preparations</i>		
ASPIRIN		

ASPIRIN 300mg TABLETS TTO PACK 32	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, February 2013.
ASPIRIN DISPERSIBLE 300mg TABLETS	Y	
ASPIRIN 150mg SUPPOSITORIES	R	Restricted for use in acute stroke or other emergency antiplatelet Rx in patients with unsafe swallow. Medicines Effectiveness, September 2015
ASPIRIN 300mg SUPPOSITORIES	R	Restricted for use in acute stroke or other emergency antiplatelet Rx in patients with unsafe swallow. Medicines Effectiveness, September 2015
CO-CODAMOL		
CO-CODAMOL 30/500mg TABLETS EFFERVESCENT	Y	
CO-CODAMOL 8/500mg TABLETS EFFERVESCENT	Y	
CO-CODAMOL 30/500mg TABLETS	NF	
CO-CODAMOL 8/500mg TABLETS	Y	
CO-DYDRAMOL		
CO-DYDRAMOL 10/500mg TABLETS	NF	
NEFOPAM		
NEFOPAM HYDROCHLORIDE 30mg TABLETS	Y	
Paracetamol		
PARACETAMOL 100mg IN 10ml PAEDIATRIC INJECTION	R	Restricted to neonates and infants under 10kg, for children over 10 kg use 50ml vials. MMTC, May 2020
PARACETAMOL 250mg SUPPOSITORIES	R	
PARACETAMOL SOLUBLE 500mg TABLETS	Y	
PARACETAMOL 250mg/5ml LIQUID	Y	
PARACETAMOL 120mg/5ml LIQUID (sugar free)	Y	

PARACETAMOL 30mg SUPPOSITORIES	R	Paracetamol suppositories are considerably more expensive than oral and injectable preparations. The rectal route should only be used in patients with no oral/ enteral route or absorption and in whom the provision of intravenous access is impossible or inappropriate. Medicines Effectiveness, June 2009.
PARACETAMOL 125mg SUPPOSITORIES	R	Paracetamol suppositories are considerably more expensive than oral and injectable preparations. The rectal route should only be used in patients with no oral/ enteral route or absorption and in whom the provision of intravenous access is impossible or inappropriate. Medicines Effectiveness, June 2009.
PARACETAMOL 500mg IN 50ml INFUSION	R	For patients requiring pain relief but who have no reliable enteral route of administration. The infusion is considerably more expensive than oral preparations and owing to its 100% bioavailability there may be a higher risk of toxicity in organ impairment. Stop any inappropriate use as per recommended on the Therapeutic Substitution MIL. Medicines Effectiveness, June 2009.
PARACETAMOL 500mg SUPPOSITORIES	R	Paracetamol suppositories are considerably more expensive than oral and injectable preparations. The rectal route should only be used in patients with no oral/ enteral route or absorption and in whom the provision of intravenous access is impossible or inappropriate. Medicines Effectiveness, June 2009.
PARACETAMOL 500mg TABLETS	R	For use in MDS (Nomad) boxes only. PPDU, November 2011.
PARACETAMOL SOLUBLE 500mg TABLET TTO 24's	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.

PARACETAMOL 120mg SACHETS (12)	R	For Oxfordshire ambulance service only. Medicines Effectiveness, March 2013.
PARACETAMOL 1000mg IN 100ml INFUSION	R	For patients requiring pain relief but who have no reliable enteral route of administration. The infusion is considerably more expensive than oral preparations and owing to its 100% bioavailability there may be a higher risk of toxicity in organ impairment. Stop any inappropriate use as per recommended on the Therapeutic Substitution MIL. Medicines Effectiveness, June 2009.
PARACETAMOL 60mg SUPPOSITORIES	R	Paracetamol suppositories are considerably more expensive than oral and injectable preparations. The rectal route should only be used in patients with no oral/ enteral route or absorption and in whom the provision of intravenous access is impossible or inappropriate. Medicines Effectiveness, June 2009.
PARACETAMOL 500mg TABLETS TTO 32's	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.
PARACETAMOL 500mg TABLETS	Y	
TRAMADOL		
TRAMADOL 50mg CAPSULES	Y	
TRAMADOL 50mg DISPERSIBLE TABLETS	R	For patients with swallowing difficulties or feeding tubes only. Medicines Effectiveness, March 2013.

04.07.02 Opioid analgesics

BUPIVACAINE 100mg, CLONIDINE 20mg & MORPHINE SNF SULPHATE (Preservative free) 900mg in 45mL

BUPRENORPHINE

BUPRENORPHINE 52.5microgram/hour PATCHES	R	Restricted to use for pain relief in patients with renal impairment on recommendation of Palliative care or Pain team only. MMTC, April 2019
BUPRENORPHINE 15microgram/hour PATCHES	R	Restricted to use for pain relief in patients with renal impairment on recommendation of Palliative care or Pain team only. MMTC, April 2019
BUPRENORPHINE 35microgram/hour PATCHES	R	Restricted to use for pain relief in patients with renal impairment on recommendation of Palliative care or Pain team only. MMTC, April 2019
BUPRENORPHINE 20microgram/hour PATCHES (WEEKLY)	R	Restricted to use for pain relief in patients with renal impairment on recommendation of Palliative care or Pain team only. MMTC, April 2019
BUPRENORPHINE 70microgram/hour PATCH	R	Restricted to use for pain relief in patients with renal impairment on recommendation of Palliative care or Pain team only. MMTC, April 2019
BUPRENORPHINE 200microgram SUBLINGUAL TABLETS	NF	For continuation of treatment of opioid dependence only. Medicines Effectiveness, March 2010.
BUPRENORPHINE 5microgram/hour PATCHES (WEEKLY)	R	Restricted to use for pain relief in patients with renal impairment on recommendation of Palliative care or Pain team only. MMTC, April 2019
BUPRENORPHINE 10microgram/hour PATCHES (WEEKLY)	R	Restricted to use for pain relief in patients with renal impairment on recommendation of Palliative care or Pain team only. MMTC, April 2019
CODEINE		
CODEINE PHOSPHATE 15mg/5ml LIQUID S/F	R	For use when codeine 25mg in 5mL oral solution is unavailable in patients who require medication administration via enteral tubes. Medicines Effectiveness, January 2019

CODEINE PHOSPHATE

CODEINE PHOSPHATE 10mg SUPPOSITORIES	R	For paediatric use only. Medicines Effectiveness, August 2000.
CODEINE PHOSPHATE 30mg SUPPOSITORIES	R	For NBM patients only. Medicines Effectiveness, March 2013.
CODEINE PHOSPHATE 30mg TABLETS	Y	
CODEINE PHOSPHATE 3mg SUPPOSITORIES (1g mould size) (12)	R	For paediatric use only. Medicines Effectiveness, December 2003.
CODEINE PHOSPHATE 5mg SUPPOSITORIES	Y	
CODEINE PHOSPHATE 15mg TABLETS	Y	
CODEINE PHOSPHATE 25mg/5ml LIQUID	Y	
DIAMORPHINE		
DIAMORPHINE 100mg INJECTION	Y	
DIAMORPHINE 600mg IN SODIUM CHLORIDE 0.9% 250ml RESERVOIR (CADD-LEGACY PCA MODEL	SR	For patient S.A.E. (Haematology) only. Medicines Effectiveness, March 2013.
DIAMORPHINE 10mg TABLETS	NF	
DIAMORPHINE 30mg INJECTION	Y	
DIAMORPHINE 5mg INJECTION	Y	
DIAMORPHINE 500mg INJECTION	Y	
DIAMORPHINE 10mg INJECTION	Y	
DIAMORPHINE 650mg IN SODIUM CHLORIDE 0.9% 250ml RESERVOIR (CADD-LEGACY PCA MODEL	SR	For patient S.A.E. (Haematology) only. Medicines Effectiveness, March 2013.
DICONAL		
DICONAL TABLETS	NF	
DIHYDROCODEINE		
DIHYDROCODEINE 60mg TABLETS M/R	NF	
DIHYDROCODEINE 30mg TABLETS	Y	

DIHYDROCODEINE 120mg TABLETS M/R NF

FENTANYL

FENTANYL 50micrograms/DOSE NASAL SPRAY (6-DOSE)	R	For the treatment of acute pain in children in palliative care of Helen House. It would be used in teenage patients receiving end of life care where oral morphine is too slow or not effective for breakthrough pain. MMTC, March 2018
FENTANYL 50micrograms/DOSE NASAL SPRAY (10-DOSE)	R	For the treatment of acute pain in children in palliative care under the care of Helen House. It would be used in teenage patients receiving end of life care where oral morphine is too slow or not effective for breakthrough pain. MMTC, March 2018
FENTANYL 37.5microgram/hour PATCHES (MATRIX)	R	?Initiation by palliative care as per MMTC
FENTANYL 600microgram SUBLINGUAL TABLETS	NF	
FENTANYL 1600microgram LOZENGES	R	For the management of breakthrough pain following recommendation by acute pain and palliative care consultants. Medicines Effectiveness, April 2017
FENTANYL 12microgram/hour PATCHES (MATRIX)	R	Initiation on advice from the Acute or Chronic Pain Teams only. Medicines Effectiveness, March 2010.
FENTANYL 1200microgram LOZENGE (3)	R	For the management of breakthrough pain following recommendation by acute pain and palliative care consultants. Medicines Effectiveness, April 2017
FENTANYL 100microgram/hour PATCHES (MATRIX)	R	Initiation on advice from the Acute or Chronic Pain Teams only. Medicines Effectiveness, March 2010.

FENTANYL 200microgram LOZENGES (30)	R	For the management of breakthrough pain following recommendation by acute pain and palliative care consultants. Medicines Effectiveness, April 2017
FENTANYL 75micrograms PATCHES (MATRIX)	R	Initiation on advice from the Acute or Chronic Pain Teams only. Medicines Effectiveness, March 2009.
FENTANYL 600microgram LOZENGES (3)	R	For the management of breakthrough pain following recommendation by acute pain and palliative care consultants. Medicines Effectiveness, April 2017
FENTANYL 50microgram/hour PATCHES (MATRIX)	R	Initiation on advice from the Acute or Chronic Pain Teams only. Medicines Effectiveness, March 2009.
FENTANYL 200microgram SUBLINGUAL TABLETS	NF	
FENTANYL 400microgram SUBLINGUAL TABLETS	NF	
FENTANYL 100microgram SUBLINGUAL TABLETS	NF	
FENTANYL 25microgram/hour PATCHES (MATRIX)	R	Initiation on advice from the Acute or Chronic Pain Teams only. Medicines Effectiveness, March 2009.
FENTANYL 200microgram LOZENGES	R	For the management of breakthrough pain following recommendation by acute pain and palliative care consultants. Medicines Effectiveness, April 2017
FENTANYL 400microgram LOZENGES	R	For the management of breakthrough pain following recommendation by acute pain and palliative care consultants. Medicines Effectiveness, April 2017
FENTANYL 800microgram LOZENGES (3)	R	For the management of breakthrough pain following recommendation by acute pain and palliative care consultants. Medicines Effectiveness, April 2017

FENTANYL 200mcg BUCCAL TABLETS	NF	
FENTANYL 400microgram LOZENGES (30)	R	For the management of breakthrough pain following recommendation by acute pain and palliative care consultants. Medicines Effectiveness, April 2017
FENTANYL 800microgram BUCCAL TABLETS	NF	
FENTANYL 600microgram BUCCAL TABLETS	NF	
HYDROMORPHONE		
HYDROMORPHONE 4mg CAPSULES MR	NF	
HYDROMORPHONE 24mg CAPSULES M/R	NF	
HYDROMORPHONE 2mg CAPSULES M/R	NF	
HYDROMORPHONE 8mg CAPSULES M/R	NF	
HYDROMORPHONE 1.3mg CAPSULES	NF	
HYDROMORPHONE 2.6mg CAPSULES	NF	
HYDROMORPHONE 16mg CAPSULES M/R	NF	
MEPTAZINOL		
MEPTAZINOL 200mg TABLETS	Y	
METHADONE		
METHADONE 5mg TABLETS	Y	
METHADONE 10mg IN 1ml INJECTION	Y	
METHADONE 50mg IN 1ml INJECTION	Y	
Morphine		
MORPHINE SULPHATE 50mg in 50ml IV INFUSION VIALS	Y	
MORPHINE SULPHATE 10mg in 10ml INJECTION	Y	
MORPHINE SULPHATE 50mg IN 50ml IV INFUSION (vials)	Y	
MORPHINE SULPHATE 10mg/5ml ORAL SOLUTION	Y	

MORPHINE SULPHATE 10mg TABLETS M/R	Y	
MORPHINE SULPHATE 10mg/5ml ORAL SOLUTION	Y	
MORPHINE SULPHATE 10mg TABLETS (SEVREDOL)	Y	
MORPHINE SULPHATE 10mg SUPPOSITORIES	Y	
MORPHINE SULPHATE 10mg IN 1ml INJECTION	Y	
MORPHINE SULPHATE 15mg SUPPOSITORIES	Y	
MORPHINE SULPHATE 15mg TABLETS M/R	Y	
MORPHINE SULPHATE 30mg CAPSULES M/R	R	For patients with swallowing difficulties. Medicines Effectiveness, June 2005.
MORPHINE SULPHATE 60mg SACHETS M/R	NF	
MORPHINE SULPHATE 90mg CAPSULES M/R	NF	
MORPHINE SULPHATE 100mg CAPSULES M/R	R	For patients with swallowing difficulties or where capsules are specified. Medicines Effectiveness, May 2005.
MORPHINE SULPHATE 1mg IN 1ml INJECTION PRESERVATIVE FREE	Y	
MORPHINE SULPHATE 30mg CAPSULES M/R	NF	
MORPHINE SULPHATE 30mg in 1ml INJECTION	Y	
MORPHINE SULPHATE 60mg TABLETS M/R	Y	
MORPHINE SULPHATE 60mg IN 2ml INJECTION	Y	
MORPHINE SULPHATE 60mg CAPSULES M/R	R	For patients with swallowing difficulties. Medicines Effectiveness, June 2005.
MORPHINE SULPHATE 100mg/5ml ORAL SOLUTION	Y	
MORPHINE SULPHATE 5mg TABLETS M/R	Y	
MORPHINE SULPHATE 10mg CAPSULES M/R	R	For patients with swallowing difficulties or where capsules are specified. Medicines Effectiveness, May 2005.

MORPHINE SULPHATE 50mg TABLETS (SEVREDOL)	Y	
MORPHINE SULPHATE 30mg TABLETS M/R	Y	
MORPHINE SULPHATE 20mg TABLETS (SEVREDOL)	Y	
MORPHINE SULPHATE 20mg SACHETS MR	NF	
MORPHINE SULPHATE 200mg CAPSULES M/R (24hr PREP)	NF	
MORPHINE SULPHATE 200mg CAPSULES M/R	R	For patients with swallowing difficulties. Medicines Effectiveness, June 2005.
MORPHINE SULPHATE 100mg IN 50ml INJECTION VIAL	Y	
MORPHINE SULPHATE 100mg TABLETS M/R	Y	
MORPHINE SULPHATE 100mg/5ml ORAL SOLUTION	Y	
MORPHINE SULPHATE 30mg SUPPOSITORIES	Y	
Morphine sulfate		
MORPHINE 5mg ORODISPERSIBLE TABLETS S/F	R	?For treatment of pain for palliative care patients and other paediatric patients with swallowing difficulties. MMTC, December 2022
MORPHINE 2.5mg ORODISPERSIBLE TABLETS S/F	R	For treatment of pain for palliative care patients and other paediatric patients with swallowing difficulties. MMTC, December 2022
MORPHINE 1mg ORODISPERSIBLE TABLETS S/F	R	For treatment of pain for palliative care patients and other paediatric patients with swallowing difficulties. MMTC, December 2022
MORPHINE 30mg ORODISPERSIBLE TABLETS S/F	R	For treatment of pain for palliative care patients and other pediatric patients with swallowing difficulties. MMTC, December 2022
MORPHINE 20mg ORODISPERSIBLE TABLETS S/F	R	For treatment of pain for palliative care patients and other pediatric patients with swallowing difficulties. MMTC, December 2022

MORPHINE 10mg ORODISPERSIBLE TABLETS S/F	R	For treatment of pain for palliative care patients and other paediatric patients with swallowing difficulties. MMTC, December 2022
OXYCODONE		
OXYCODONE 5mg/5ml LIQUID	R	For patients allergic or who cannot tolerate morphine and have swallowing difficulties. Medicines Effectiveness, March 2013
OXYCODONE 5mg TABLETS M/R	R	For patients allergic or who cannot tolerate morphine. Medicines Effectiveness, March 2013.
OXYCODONE 80mg TABLETS M/R	R	For patients allergic or who cannot tolerate morphine. Medicines Effectiveness, March 2013.
OXYCODONE 5mg CAPSULES (OXYNORM)	R	For patients allergic or who cannot tolerate morphine. Medicines Effectiveness, March 2013.
OXYCODONE 50mg/ml INJECTION	R	For high-dose syringe drivers in Sobell House ONLY for patients allergic or who cannot tolerate morphine. It should not be used for outliers in any other clinical areas. MAC, April 2012
OXYCODONE 50mg/5ml CONCENTRATE LIQUID	R	For patients allergic or who cannot tolerate morphine. Medicines Effectiveness, March 2013.
OXYCODONE 40mg TABLETS M/R	R	For patients allergic or who cannot tolerate morphine. Medicines Effectiveness, March 2013.
OXYCODONE 20mg in 2ml INJECTION	R	For patients allergic or who cannot tolerate morphine. Medicines Effectiveness, March 2013.
OXYCODONE 20mg CAPSULES (OXYNORM)	R	For patients allergic or who cannot tolerate morphine. Medicines Effectiveness, March 2013.

OXYCODONE 10mg TABLETS M/R	R	For patients allergic or who cannot tolerate morphine. Medicines Effectiveness, March 2013.
OXYCODONE 10mg CAPSULES (OXYNORM)	R	For patients allergic or who cannot tolerate morphine. Medicines Effectiveness, March 2013.
OXYCODONE 20mg TABLETS M/R	R	For patients allergic or who cannot tolerate morphine. Medicines Effectiveness, March 2013.

OXYCODONE + NALOXONE

OXYCODONE/NALOXONE 20mg/10mg TABLETS M/R NF

OXYCODONE/NALOXONE 10mg/5mg TABLETS M/R NF

OXYCODONE/NALOXONE

OXYCODONE/NALOXONE 40mg/20mg TABLETS M/R NF

PENTAZOCINE

PENTAZOCINE 50mg CAPSULES Y

TAPENTADOL

TAPENTADOL 50mg TABLETS NF

TAPENTADOL 50mg M/R TABLETS NF

TAPENTADOL 100mg M/R TABLETS NF

TRAMADOL

TRAMADOL 100mg TABLETS M/R NF

TRAMADOL 150mg CAPSULES M/R NF

TRAMADOL 200mg TABLETS M/R NF

TRAMADOL 100mg in 2ml INJECTION R For use by NOC only. For post-operative pain only. Medicines Effectiveness, April 2004.

04.07.04 Antimigraine drugs

CLONIDINE

CLONIDINE 25microgram TABLETS Y

FLUNARIZINE

FLUNARIZINE 10mg TABLETS	UNR	Last line pharmaceutical option for migraine prophylaxis. For initiation by neurologists only. MMTC, May 2015
--------------------------	-----	---

MIGRALEVE

MIGRALEVE (PINK PACK) TABLETS	Y	
-------------------------------	---	--

PIZOTIFEN

PIZOTIFEN 500microgram TABLETS	Y	
--------------------------------	---	--

PIZOTIFEN 1.5mg TABLETS	Y	
-------------------------	---	--

RIZATRIPTAN

RIZATRIPTAN 10mg ORODISPERSIBLE TABLETS	Y	
---	---	--

RIZATRIPTAN 10mg ORODISPERSIBLE TABLETS	Y	
---	---	--

SUMATRIPTAN

SUMATRIPTAN 6mg IN 0.5ml PRE FILLED SYRINGE (Pack of 2 syringes)	Y	
--	---	--

SUMATRIPTAN 100mg TABLETS	NF	
---------------------------	----	--

SUMATRIPTAN 10mg/0.1ml NASAL SPRAY	NF	
------------------------------------	----	--

SUMATRIPTAN 50mg TABLETS	NF	
--------------------------	----	--

SUMATRIPTAN 20mg/0.1ml NASAL SPRAY	NF	
------------------------------------	----	--

ZOLMITRIPTAN

ZOLMITRIPTAN 2.5mg TABLETS	NF	
----------------------------	----	--

4.07.02 Opioid analgesics

TRAMADOL

TRAMADOL 100mg IN 2ml INJECTION	R	For use by NOC only. For post-operative pain only. Medicines Effectiveness, April 2004
---------------------------------	---	--

04.08 Antiepileptic drugs

04.08.01 Contro

Cenobamate

CENOBAMATE 150mg TABLETS	R	
--------------------------	---	--

CENOBAMATE 50mg TABLETS	R	
-------------------------	---	--

CENOBAMATE 200mg TABLETS	R	
--------------------------	---	--

04.08.01 Control of epilepsy

BRIVARACETAM

BRIVARACETAM 50mg/5ml LIQUID 300ml NF

CENOBAMATE

CENOBOMATE 50mg TABLETS R ?For treatment of focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy, as per NICE TA 753. MMTC, April 2022.

CENOBAMATE 12.5mg TABLETS and 25mg TABLETS INTITATION PACK R ?For treatment of focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy, as per NICE TA 753. MMTC, April 2022.

CENOBAMATE 200mg TABLETS R ?For treatment of focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy, as per NICE TA 753. MMTC, April 2022.

CENOBAMATE 100mg TABLETS R ?For treatment of focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy, as per NICE TA 753. MMTC, April 2022.

CLONAZEPAM

CLONAZEPAM 2mg TABLETS Y

ESLICARBAZEPINE

ESLICARBAZEPINE 250mg/5ml LIQUID R

LAMOTRIGINE

LAMOTRIGINE 50mg TABLETS Y

SODIUM VALPROATE

SODIUM VALPROATE 300mg TABLETS M/R (CHRONO)	R	Restricted for initiation of treatment for: Bipolar disorder by psychological medicine; Epilepsy by neurologist or paediatric medicine. If female under 55 years, may only be on advice of Consultant Neurologist for epilepsy (not paediatric medicine) or consultant in psychological medicine. MMTC, December 2018
SODIUM VALPROATE 200mg TABLETS M/R (CHRONO)	R	Restricted for initiation of treatment for: Bipolar disorder by psychological medicine; Epilepsy by neurologist or paediatric medicine. If female under 55 years, may only be on advice of Consultant Neurologist for epilepsy (not paediatric medicine) or consultant in psychological medicine. MMTC, December 2018
SODIUM VALPROATE 200mg TABLETS E.C	R	Restricted for initiation of treatment for: Bipolar disorder by psychological medicine; Epilepsy by neurologist or paediatric medicine. If female under 55 years, may only be on advice of Consultant Neurologist for epilepsy (not paediatric medicine) or consultant in psychological medicine. MMTC, December 2018
SODIUM VALPROATE 100mg CRUSHABLE TABLETS R		Restricted for initiation of treatment for: Bipolar disorder by psychological medicine; Epilepsy by neurologist or paediatric medicine. If female under 55 years, may only be on advice of Consultant Neurologist for epilepsy (not paediatric medicine) or consultant in psychological medicine. MMTC, December 2018

SODIUM VALPROATE 500mg TABLETS M/R (CHRONO)	R	Restricted for initiation of treatment for: Bipolar disorder by psychological medicine; Epilepsy by neurologist or paediatric medicine. If female under 55 years, may only be on advice of Consultant Neurologist for epilepsy (not paediatric medicine) or consultant in psychological medicine. MMTC, December 2018
SODIUM VALPROATE 500mg TABLETS E.C	R	Restricted for initiation of treatment for: Bipolar disorder by psychological medicine; Epilepsy by neurologist or paediatric medicine. If female under 55 years, may only be on advice of Consultant Neurologist for epilepsy (not paediatric medicine) or consultant in psychological medicine. MMTC, December 2018
ZONISAMIDE		
ZONISAMIDE 100mg/5ml ORAL SUSPENSION	NF	
<i>04.08.01 Control of the epileps</i>		
Cenobamate		
CENOBAMATE 100mg TABLETS	R	
CENOBAMATE 150mg TABLETS	R	
CLONAZEPAM 500microgram		
CLONAZEPAM 500microgram TABLETS	Y	
DRONABINOL + CANNABIDIOL		
DRONABINOL 2.7mg & CANNABIDIOL 2.5mg OROMUCOSAL SPRAY	R	
PHENYTOIN		
PHENYTOIN 30mg/5ml SUSPENSION	UNR	To be used in place of the licensed product during supply problem only. Medicines Effectiveness August 2019
PHENYTOIN 30mg/5ml LIQUID	UNR	To be used in place of the licensed product during supply problem only. Medicines Effectiveness August 2019

04.08.01 Control of the epileps of epilepsy

CLONAZEPAM

CLONAZEPAM 2mg/5ml LIQUID NF

Levetiracetam

LEVETIRACETAM 250mg GRANULES S/F NF

04.08.01 Control of the epilepsies

BRIVARACETAM

BRIVARACETAM 50mg TABLETS R For the treatment of drug resistant partial onset seizures (3rd line option). For initiation by neurologists only. MMTC, January 2017

BRIVARACETAM 100mg TABLETS R For the treatment of drug resistant partial onset seizures (3rd line option). For initiation by neurologists only. MMTC, January 2017

CARBAMAZEPINE

CARBAMAZEPINE 200mg TABLETS M/R Y

CARBAMAZEPINE 250mg SUPPOSITORIES R For short-term management of epilepsy only (max 7 days) where oral route is not possible. Also, see therapeutic substitution MILV5N3 Medicines Effectiveness, September 2017

CARBAMAZEPINE 125mg SUPPOSITORIES R For short-term management of epilepsy only (max 7 days) where oral route is not possible. Also, see therapeutic substitution MILV5N3 Medicines Effectiveness, September 2017

CARBAMAZEPINE 100mg TABLETS Y

CARBAMAZEPINE 400mg TABLETS M/R Y

CARBAMAZEPINE 200mg TABLETS Y

CARBAMAZEPINE 100mg/5ml LIQUID Y

CARBAMAZEPINE 400mg TABLETS Y

CLOBAZAM

CLOBAZAM 10mg TABLETS Y

CLOBAZAM 10mg/5ml LIQUID NF

CLONAZEPAM

CLONAZEPAM 2mg TABLETS Y

DIAZEPAM

DIAZEPAM 5mg RECTAL TUBES Y

ESLICARBAZEPINE

ESLICARBAZEPINE 800mg TABLETS R For adjunctive treatment in adults as a 3rd line treatment those who have failed treatment with at least 3 drugs. MMTc, December 2016

ETHOSUXIMIDE

ETHOSUXIMIDE 250mg/5ml LIQUID R For initiation by Neurology only. Medicines Effectiveness, August 2001.

ETHOSUXIMIDE 250mg CAPSULES R For initiation by Neurology only. Medicines Effectiveness, August 2001.

GABAPENTIN

GABAPENTIN 300mg CAPSULES R For use by Neurology, pain relief and palliative care only. Medicines Effectiveness, March 2003.

GABAPENTIN 250mg/5ml ORAL SOLUTION R For treatment of epilepsy: in paediatric patients and adults who are unsuitable for capsules or have an enteral tube in situ. Medicines Effectiveness, December 2019

GABAPENTIN 100mg CAPSULES R For use by Neurology, pain relief and palliative care only. Medicines Effectiveness, March 2003.

GABAPENTIN 400mg CAPSULES R For use by Neurology, pain relief and palliative care only. Medicines Effectiveness, March 2003.

LACOSAMIDE

LACOSAMIDE 200mg in 20ml INJECTION	R	For adjunctive treatment of partial epilepsy with secondary generalisation in those with no oral access or those who are not absorbing enteral feeds / meds ONLY. Medicines Effectiveness, November 2017
LACOSAMIDE 100mg TABLETS F/C	R	For adjunctive treatment of partial epilepsy with secondary generalisation. MAC, January 2010.
LACOSAMIDE 10mg/ml SYRUP	R	For adjunctive treatment of partial epilepsy with secondary generalisation. MAC, January 2010.
LACOSAMIDE 200mg TABLETS F/C	R	For adjunctive treatment of partial epilepsy with secondary generalisation. MAC, January 2010.
LACOSAMIDE 50mg TABLET F/C	R	For adjunctive treatment of partial epilepsy with secondary generalisation. MAC, January 2010.
LAMOTRIGINE		
LAMOTRIGINE 25MG TABLETS	NF	
LAMOTRIGINE 100mg DISPERSIBLE TABLETS	Y	
LAMOTRIGINE 100mg TABLETS	Y	
LAMOTRIGINE 200mg TABLETS	Y	
LAMOTRIGINE 25mg DISPERSIBLE TABLETS	Y	
LAMOTRIGINE 25mg TABLETS	Y	
LAMOTRIGINE 5mg DISPERSIBLE TABLETS	Y	
LAMOTRIGINE 50mg TABLETS	NF	
LAMOTRIGINE 100mg TABLETS (LAMICTAL)	NF	
LEVETIRACETAM		
LEVETIRACETAM 500mg/5ml LIQUID	Y	
LEVETIRACETAM 1g TABLETS	Y	

LEVETIRACETAM 500mg TABLETS	Y
LEVETIRACETAM 500mg in 5ml INFUSION	Y
LEVETIRACETAM 250mg TABLETS	Y

OXCARBAZEPINE

OXCARBAZEPINE 300mg/5ml LIQUID	R	To be initiated by Consultant Neurologists only. For patients with swallowing difficulties or feeding tubes only. Medicines Effectiveness, March 2013.
OXCARBAZEPINE 300mg TABLETS	R	To be initiated by Consultant Neurologists only. Medicines Effectiveness, March 2013.
OXCARBAZEPINE 150mg TABLETS	R	To be initiated by Consultant Neurologists only. Medicines Effectiveness, March 2013.

PERAMPANEL

PERAMPANEL 2mg TABLETS	R	For initiation by epileptologists only as adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalisation, in patients with epilepsy aged 12 years and older. MMTC, March 2013
PERAMPANEL 4mg TABLETS	R	For initiation by epileptologists only as adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalisation, in patients with epilepsy aged 12 years and older. MMTC, March 2013
PERAMPANEL 10mg TABLETS	R	For initiation by epileptologists only as adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalisation, in patients with epilepsy aged 12 years and older. MMTC, March 2013

PERAMPANEL 12mg TABLETS	R	For initiation by epileptologists only as adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalisation, in patients with epilepsy aged 12 years and older. MMTC, March 2013.
PERAMPANEL 8mg TABLETS	R	For initiation by epileptologists only as adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalisation, in patients with epilepsy aged 12 years and older. MMTC, March 2013.
PERAMPANEL 6mg TABLETS	R	For initiation by epileptologists only as adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalisation, in patients with epilepsy aged 12 years and older. MMTC, March 2013.

PHENOBARBITAL

PHENOBARBITAL SODIUM 60mg IN 1ml INJECTION	Y	
PHENOBARBITAL 30mg TABLETS	Y	
PHENOBARBITAL BASE 50mg/5ml LIQUID (ALCOHOLSR FREE) 50ml		For paediatric use only. Medicines Effectiveness, March 2013.
PHENOBARBITAL SODIUM 200mg IN 1ml INJECTION	Y	
PHENOBARBITAL 15mg TABLETS	Y	

PHENYTOIN

PHENYTOIN 50mg CHEWABLE TABLETS	Y
PHENYTOIN SODIUM 50mg CAPSULES	Y
PHENYTOIN SODIUM 100mg CAPSULES	Y
PHENYTOIN 250mg IN 5ml INJECTION	Y
PHENYTOIN 250mg in 5ml INJECTION	Y
PHENYTOIN 30mg/5ml LIQUID	Y

PHENYTOIN 100mg TABLETS	NF
PHENYTOIN SODIUM 300mg CAPSULES	Y
PHENYTOIN SODIUM 25mg CAPSULES	Y

PREGABALIN

PREGABALIN 100mg CAPSULES	R	For adjunctive treatment of epilepsy. Initiation by Consultant Neurologist only. For neuropathic Pain following the advice form the Pain Relief Unit. Medicines Effectiveness, August 2009.
PREGABALIN 75mg CAPSULES	R	For adjunctive treatment of epilepsy. Initiation by Consultant Neurologist only. For neuropathic Pain following the advice form the Pain Relief Unit. Medicines Effectiveness, August 2009.
PREGABALIN 25mg CAPSULES	R	For adjunctive treatment of epilepsy. Initiation by Consultant Neurologist only. For neuropathic Pain following the advice form the Pain Relief Unit. Medicines Effectiveness, August 2009.
PREGABALIN 50mg CAPSULES	R	For adjunctive treatment of epilepsy. Initiation by Consultant Neurologist only. For neuropathic Pain following the advice form the Pain Relief Unit. Medicines Effectiveness, August 2009.
PREGABALIN 200mg CAPSULES	R	For adjunctive treatment of epilepsy. Initiation by Consultant Neurologist only. For neuropathic Pain following the advice form the Pain Relief Unit. Medicines Effectiveness, August 2009.
PREGABALIN 100mg/5ml LIQUID 473ml	NF	
PREGABALIN 150mg CAPSULES	R	For adjunctive treatment of epilepsy. Initiation by Consultant Neurologist only. For neuropathic Pain following the advice form the Pain Relief Unit. Medicines Effectiveness, August 2009.

PRIMIDONE

PRIMIDONE 50mg TABLETS	Y
------------------------	---

PRIMIDONE 250mg TABLETS	Y	
RUFINAMIDE		
RUFINAMIDE 200mg TABLETS	R	For use in Lennox-Gastaut Syndrome in children who do not respond to other treatment. MAC, September 2008.
RUFINAMIDE 400mg TABLETS	R	For use in Lennox-Gastaut Syndrome in children who do not respond to other treatment. MAC, September 2008.
RUFINAMIDE 40mg IN 1ml ORAL SUSPENSION 460mlR		For use in Lennox-Gastaut Syndrome in children who do not respond to other treatment. MAC. September 2008.
RUFINAMIDE 100mg TABLETS	R	For use in Lennox-Gastaut Syndrome in children who do not respond to other treatment. MAC, September 2008.
SODIUM VALPROATE		
SODIUM VALPROATE 200mg/5ml LIQUID Sugar Free	R	Restricted for initiation of treatment for: Bipolar disorder by psychological medicine; Epilepsy by neurologist or paediatric medicine. If female under 55 years, may only be on advice of Consultant Neurologist for epilepsy (not paediatric medicine) or consultant in psychological medicine. MMTC, December 2018
SODIUM VALPROATE 300mg IN 3ml INJECTION	R	Restricted for initiation of treatment for: Bipolar disorder by psychological medicine; Epilepsy by neurologist or paediatric medicine. If female under 55 years, may only be on advice of Consultant Neurologist for epilepsy (not paediatric medicine) or consultant in psychological medicine. MMTC, December 2018
SODIUM VALPROATE 1g GRANULES M/R	NF	
SODIUM VALPROATE 100mg GRANULES M/R	NF	
SODIUM VALPROATE 250mg GRANULES M/R	NF	
SODIUM VALPROATE 50mg GRANULES M/R		

SODIUM VALPROATE 50mg GRANULES M/R	NF	
STIRIPENTOL		
STIRIPENTOL 500mg SACHETS	R	For initiation by Consultant Neurologists only. Medicines Effectiveness, March 2008.
STIRIPENTOL 250mg SACHETS	R	For initiation by Consultant Neurologists only. Medicines Effectiveness, March 2008.
STIRIPENTOL 500mg CAPSULES	NF	
STIRIPENTOL 250mg CAPSULES	NF	
TIAGABINE		
TIAGABINE 5mg TABLETS	R	For use by Consultant Neurologists only. Medicines Effectiveness, December 2003.
TOPIRAMATE		
TOPIRAMATE 25mg SPRINKLE PREP CAPSULES	Y	
TOPIRAMATE 50mg TABLETS	Y	
TOPIRAMATE 100mg TABLETS	Y	
TOPIRAMATE 25mg TABLETS	Y	
TOPIRAMATE 15mg SPRINKLE PREP CAPSULES	Y	
VIGABATRIN		
VIGABATRIN 500mg SACHETS	Y	
VIGABATRIN 500mg TABLETS	Y	
ZONISAMIDE		
ZONISAMIDE 25mg CAPSULES	R	To be initiated by Consultant Neurologists only. Medicines Effectiveness, March 2008.
ZONISAMIDE 100mg CAPSULES	R	To be initiated by Consultant Neurologists only. Medicines Effectiveness, March 2008.
ZONISAMIDE 50mg CAPSULES	R	To be initiated by Consultant Neurologists only. Medicines Effectiveness, March 2008.

04.08.02 Drugs used in status epilepticus

CLONAZEPAM

CLONAZEPAM 1mg IN 1ml INJECTION (UNLICENSED FRENCH IMPORT)

UNR For use by Paediatric-Neurology, Neonatology and PITU to control seizures when other treatments failed (e.g. Phenobarbital, Phenytoin). Medicines Effectiveness, December 2013

CLONAZEPAM 1mg IN 1ml INJECTION

UNR

For use by Paediatric-Neurology, Neonatology and PITU to control seizures when other treatments failed (e.g. Phenobarbital, Phenytoin). Medicines Effectiveness, December 2013.

MIDAZOLAM

MIDAZOLAM 100mg IN 50ml PRE- FILLED SYRINGE R

For use in Critical Care Areas only during COVID-19. CTG March 2020

MIDAZOLAM 100mg IN 50ml INJECTION PRE-FILLED SYRINGE (CTASU PREP)

SR For use in Critical Care Areas during COVID only. CTG March 2020

MIDAZOLAM 7.5mg in 1.5ml PRE-FILLED BUCCAL SYRINGE R

For treatment of epileptic fits in children and for oral sedation in children undergoing stressful procedures or as a pre-med. MMTC, December 2016

MIDAZOLAM 10mg in 2ml PRE-FILLED BUCCAL SYRINGE R

For treatment of epileptic fits in children and for oral sedation in children undergoing stressful procedures or as a pre-med. MMTC, December 2016

MIDAZOLAM 2.5mg in 0.5ml PRE-FILLED BUCCAL SYRINGE R

For treatment of epileptic fits in children and for oral sedation in children undergoing stressful procedures or as a pre-med. MMTC, December 2016

MIDAZOLAM 5mg in 1ml PRE-FILLED BUCCAL SYRINGE R

For treatment of epileptic fits in children and for oral sedation in children undergoing stressful procedures or as a pre-med. MMTC, December 2016

PARALDEHYDE

PARALDEHYDE AND OLIVE OIL ENEMA 30ml Y

04.09 Drugs used in parkinsonism and related disorders

04.09.01 Dopaminergic drugs

ROPINIROLE

ROPINIROLE 2mg TABLETS	R	For initiation by a Consultant Neurologist only for the treatment of severe and persistent symptoms of Restless Leg Syndrome (RLS) and Periodic Leg Movements During Sleep (PLMS) as per APCO Shared Care Protocol and Parkinson's Disease MAC, April 2009.
------------------------	---	---

04.09.01 Dopaminergic drugs used in Parkinson's disease

AMANTADINE

AMANTADINE 100mg CAPSULES	R	For Parkinson's Disease; Adult patients with traumatic brain injury and disordered GCS or cognition. MMTc, December 2021.
AMANTADINE 50mg/5ml LIQUID	R	For Parkinson's Disease only in patients unable to use capsules. Medicines Effectiveness, January 2015.

APOMORPHINE

APOMORPHINE 2mg TABLETS	NF	
APOMORPHINE 30mg IN 3ml PEN	Y	
APOMORPHINE 30mg in 3ml PEN (FREE STARTER PACK)	Y	
APOMORPHINE 50mg in 10ml PRE-FILLED SYRINGE	Y	
APOMORPHINE 50mg in 5ml INJECTION	Y	

CABERGOLINE

CABERGOLINE 2mg TABLETS (20)	Y	
CABERGOLINE 1mg TABLETS (20)	Y	

CO-BENELDOPA

CO-BENELDOPA 12.5/50 TABLETS DISPERSIBLE (MADOPAR 62.5)	Y	
CO-BENELDOPA 50/200mg CAPSULES (MADOPAR 250)	Y	
CO-BENELDOPA 25/100 TABLETS DISPERSIBLE (MADOPAR 125)	Y	
CO-BENELDOPA 25/100 CAPSULES (MADOPAR 125)	Y	
CO-BENELDOPA 12.5/50 CAPSULES (MADOPAR 62.5)	Y	

CO-BENELDOPA 25/100 CAPSULES M/R (MADOPAR Y
CR)

CO-CARELDOPA

CO-CARELDOPA 50/200mg TABLETS M/R Y

CO-CARELDOPA 25mg/100mg TABLETS M/R Y

CO-CARELDOPA 25/250mg TABLETS Y

CO-CARELDOPA 10/100mg TABLETS Y

CO-CARELDOPA 25/100mg TABLETS Y

CO-CARELDOPA 12.5/50mg TABLETS (SINEMET
62.5) Y

Entacapone

ENTACAPONE 200mg TABLETS Y

LEVODOPA

LEVODOPA 150mg / CARBIDOPA 37.5mg /
ENTACAPONE 200mg TABLETS NF

LEVODOPA 175MG / CARBIDOPA 43.75MG /
ENTACAPONE 200MG TABLETS NF

LEVODOPA 75mg CARBIDOPA 18.75mg
ENTACAPONE 200mg TABLETS NF

LEVODOPA + CARBIDOPA + ENTACAPONE

LEVODOPA 200mg CARBIDOPA 50mg ENTACAPONE NF
200mg TABLETS

LEVODOPA 150mg CARBIDOPA 37.5mg
ENTACAPONE 200mg TABLETS NF

LEVODOPA 125mg CARBIDOPA 31.25mg
ENTACAPONE 200mg TABLETS NF

LEVODOPA 100mg CARBIDOPA 25mg ENTACAPONE NF
200mg TABLETS

LEVODOPA 50mg CARBIDOPA 12.5mg
ENTACAPONE 200mg TABLETS NF

OPICAPONE

OPICAPONE 50mg CAPSULES NF

Pramipexole

PRAMIPEXOLE 180microgram TABLETS R

PRAMIPEXOLE 3.15mg TABLETS M/R NF

PRAMIPEXOLE 350microgam TABLETS	R	For initiation by a Consultant Neurologist only. - Treatment of severe and persistent symptoms of Restless Leg Syndrome (RLS) and Periodic Leg Movements During Sleep (PLMS) as per APCO Shared Care Protocol. - Parkinson's Disease MAC, April 2009.
PRAMIPEXOLE 700microgram TABLETS	R	For initiation by a Consultant Neurologist only. - Treatment of severe and persistent symptoms of Restless Leg Syndrome (RLS) and Periodic Leg Movements During Sleep (PLMS) as per APCO Shared Care Protocol. - Parkinson's Disease MAC, April 2009.
PRAMIPEXOLE 1.57mg M/R TABLETS	NF	
PRAMIPEXOLE 88microgram TABLETS	R	For initiation by a Consultant Neurologist only. - Treatment of severe and persistent symptoms of Restless Leg Syndrome (RLS) and Periodic Leg Movements During Sleep (PLMS) as per APCO Shared Care Protocol. - Parkinson's Disease MAC, April 2009.
PRAMIPEXOLE 2.62mg TABLETS M/R	NF	
PRAMIPEXOLE 520microgram TABLETS M/R	NF	
PRAMIPEXOLE 1.05mg M/R TABLETS	NF	
PRAMIPEXOLE 260micrograms M/R TABLETS	NF	
PRAMIPEXOLE 180microgram TABLETS	R	For initiation by a Consultant Neurologist only. - Treatment of severe and persistent symptoms of Restless Leg Syndrome (RLS) and Periodic Leg Movements During Sleep (PLMS) as per APCO Shared Care Protocol. - Parkinson's Disease MAC, April 2009.
RASAGILINE		
RASAGILINE 1mg TABLETS	R	Second line to selegiline for Parkinson's Disease. Specialist initiation only. MMTC, September 2013.

ROPINIROLE

ROPINIROLE 500microgram TABLETS	R	For initiation by a Consultant Neurologist only for the treatment of severe and persistent symptoms of Restless Leg Syndrome (RLS) and Periodic Leg Movements During Sleep (PLMS) as per APCO Shared Care Protocol and Parkinson's Disease MAC, April 2009.
ROPINIROLE 1mg TABLETS	R	For initiation by a Consultant Neurologist only for the treatment of severe and persistent symptoms of Restless Leg Syndrome (RLS) and Periodic Leg Movements During Sleep (PLMS) as per APCO Shared Care Protocol and Parkinson's Disease MAC, April 2009.
ROPINIROLE 250microgram TABLETS	R	For initiation by a Consultant Neurologist only for the treatment of severe and persistent symptoms of Restless Leg Syndrome (RLS) and Periodic Leg Movements During Sleep (PLMS) as per APCO Shared Care Protocol and Parkinson's Disease MAC, April 2009.
ROPINIROLE 4mg TABLETS M/R	NF	
ROPINIROLE 5mg TABLETS	R	For initiation by a Consultant Neurologist only for the treatment of severe and persistent symptoms of Restless Leg Syndrome (RLS) and Periodic Leg Movements During Sleep (PLMS) as per APCO Shared Care Protocol and Parkinson's Disease MAC, April 2009.
ROPINIROLE 8mg TABLETS M/R	NF	
ROPINIROLE STARTER PACK	R	For initiation by a Consultant Neurologist only. - Treatment of severe and persistent symptoms of Restless Leg Syndrome (RLS) and Periodic Leg Movements During Sleep (PLMS) as per APCO Shared Care Protocol. - Parkinson's Disease MAC, April 2009.
ROPINIROLE XL 2mg TABLETS	NF	

ROPINIROLE 2mg TABLETS

R For initiation by a Consultant Neurologist only for the treatment of severe and persistent symptoms of Restless Leg Syndrome (RLS) and Periodic Leg Movements During Sleep (PLMS) as per APCO Shared Care Protocol and Parkinson's Disease MAC, April 2009.

ROTIGOTINE

ROTIGOTINE 4mg per 24hour PATCHES

R For patients with Parkinson's or Restless Legs Syndrome who get insufficient response or cannot tolerate ropinirole, or patients who are unable to take their usual oral therapy (i.e.: nil by mouth, where NG access is not possible or appropriate) - Revert to the patient's usual oral therapy when the patient recovers the ability to swallow. MMTC, May 2013.

ROTIGOTINE 6mg per 24hour PATCHES

R For patients with Parkinson's or Restless Legs Syndrome who get insufficient response or cannot tolerate ropinirole, or patients who are unable to take their usual oral therapy (i.e.: nil by mouth, where NG access is not possible or appropriate) - Revert to the patient's usual oral therapy when the patient recovers the ability to swallow. MMTC, May 2013.

ROTIGOTINE 8mg per 24hour PATCHES

R For patients with Parkinson's or Restless Legs Syndrome who get insufficient response or cannot tolerate ropinirole, or patients who are unable to take their usual oral therapy (i.e.: nil by mouth, where NG access is not possible or appropriate) - Revert to the patient's usual oral therapy when the patient recovers the ability to swallow. MMTC, May 2013.

ROTIGOTINE 2mg per 24hour PATCHES	R	For patients with Parkinson's or Restless Legs Syndrome who get insufficient response or cannot tolerate ropinirole, or patients who are unable to take their usual oral therapy (i.e.: nil by mouth, where NG access is not possible or appropriate) - Revert to the patient's usual oral therapy when the patient recovers the ability to swallow. MMTC, May 2013.
-----------------------------------	---	--

ROTIGOTINE 1mg per 24hour PATCHES	R	For patients with Parkinson's or Restless Legs Syndrome who get insufficient response or cannot tolerate ropinirole, or patients who are unable to take their usual oral therapy (i.e.: nil by mouth, where NG access is not possible or appropriate) - Revert to the patient's usual oral therapy when the patient recovers the ability to swallow. MMTC, May 2013.
-----------------------------------	---	--

SELEGILINE

SELEGILINE 5mg TABLETS	Y
SELEGILINE 10mg TABLETS	Y
SELEGILINE 1.25mg ORODISPERSIBLE TABLETS	NF

04.09.02 Antimuscarinic drugs used in parkinsonism

PROCYCLIDINE

PROCYCLIDINE 5mg IN 5ml LIQUID (SUGAR FREE)	Y
PROCYCLIDINE 5mg TABLETS	Y
PROCYCLIDINE 10mg IN 2ml INJECTION	Y

TRIHEXYPHENIDYL

TRIHEXYPHENIDYL 2mg TABLETS	Y
TRIHEXYPHENIDYL 5mg TABLETS	Y

04.09.03 Drugs used in essential tremor, chorea, tics, and related disorders

BOTULINUM

BOTULINUM A TOXIN 200units INJECTION (BOTOX)	R	As per NICE TA260. For other indications, see botulinum toxin table. Medicines Effectiveness, July 2009.
BOTULINUM A TOXIN 50units INJECTION (BOTOX)	R	As per NICE TA260. For other indications, see botulinum toxin table. Medicines Effectiveness, July 2009.
BOTULINUM A TOXIN 100units INJECTION (XEOMIN)	R	As per NICE TA260. For other indications, see botulinum toxin table. Medicines Effectiveness, July 2009.
BOTULINUM TOXIN		
BOTULINUM A TOXIN 300units INJECTION (DYSPORT)	R	As per NICE TA260. For other indications, see botulinum toxin table. Medicines Effectiveness, July 2009.
BOTULINUM A TOXIN 100units INJECTION (BOTOX)	R	As per NICE TA260. For other indications, see botulinum toxin table. Medicines Effectiveness, July 2009.
BOTULINUM A TOXIN 500units INJECTION (DYSPORT)	R	As per NICE TA260. For other indications, see botulinum toxin table. Medicines Effectiveness, July 2009.
BOTULINUM A TOXIN 50units INJECTION (XEOMIN)	R	As per NICE TA260. For other indications, see botulinum toxin table. Medicines Effectiveness, July 2009.
BOTULINUM TOXIN TYPE B 10,000 units in 2ml INJECTION	NF	
PIRACETAM		
PIRACETAM 1.2g TABLETS	Y	
PIRACETAM 333.3mg/ml LIQUID	Y	
PIRACETAM 800mg TABLETS	Y	
RILUZOLE		

RILUZOLE 50mg TABLETS F/C

R

For Amyotrophic lateral sclerosis (ALS) form of Motor Neurone Disease (MND) as per NICE TA20. Should only be initiated by Consultant Neurologists with expertise in the management of MND. Medicines Effectiveness, February 2005.

TAFAMIDIS

TAFAMIDIS 61mg CAPSULES (FREE OF CHARGE SUPPLY)

NF

TETRABENAZINE

TETRABENAZINE 25mg TABLETS

Y

04.09.03 Torsion dystonias and other involuntary movements

Pitolisant

PITOLISANT 4.5mg TABLETS

NF

PITOLISANT 18mg TABLETS

NF

RILUZOLE

RILUZOLE 25mg/5ml ORAL SUSPENSION

R

For Amyotrophic lateral sclerosis (ALS) form of Motor Neurone Disease (MND) as per NICE TA20. In patients who have difficulty swallowing. Should only be initiated by Consultant Neurologists with expertise in the management of MND. MMTTC, August 2022

Tofersen

TOFERSEN (BIIB067) 100mg in 15ml INTRATHECAL INJECTION (COMPASSIONATE USE)

UNR

Approved June 2023 - Early access scheme for amyotrophic lateral sclerosis.

04.10 Drugs used in substance dependence

04.10 Drugs used in substance dependence

ACAMPROSATE

ACAMPROSATE 333mg TABLETS E.C

R

For Gastroenterology use on a consultant request only. Medicines Effectiveness, February 2013.

04.10.00 Drugs used in substance dependence

BUPROPION

BUPROPION 150mg TABLETS M/R

NF

DISULFIRAM

DISULFIRAM 200mg TABLETS	Y	
<i>04.10.00 Smoking cessation</i>		
NICOTINE		
NICOTINE 2mg CHEWING GUM	R	Smoking cessation for pregnant and postpartum women until discharged from midwifery care. MMTC, Nov 2023
<i>04.10.00 Substance Dependence</i>		
BUPRENORPHINE		
BUPRENORPHINE 8MG ORAL LYOPHILISATE TABLETS	NF	Espranor is not interchangeable with other buprenorphine product
BUPRENORPHINE 8mg ORAL LYOPHILISATE TABLETS	NF	Espranor is not interchangeable with other buprenorphine product
METHADONE		
METHADONE 1mg/1ml LIQUID S/F	Y	
NALMEFENE		
NALMEFENE 18mg TABLETS	R	Nalmefene is an option for reducing alcohol consumption, for people with alcohol dependence, as per NICE TA325. MMTC, August 2018
<i>15.01 General anaesthesia</i>		
BUPRENORPHINE		
BUPRENORPHINE 2mg SUBLINGUAL TABLETS	R	For continuation of treatment of opioid dependence only. Medicines Effectiveness, March 2010.
BUPRENORPHINE 400microgram SUBLINGUAL TABLETS	R	For continuation of treatment of opioid dependence only. Medicines Effectiveness, March 2010.
BUPRENORPHINE 8mg SUBLINGUAL TABLETS	R	For continuation of treatment of opioid dependence only. Medicines Effectiveness, March 2010.
LOFEXIDINE		
LOFEXIDINE 200micrograms TABLETS F/C	NF	
METHADONE		
METHADONE 10mg/ml LIQUID	Y	

NALTREXONE

NALTREXONE 50mg TABLETS	R	For Hepatology use in treatment of pruritus due to cholestatic liver disease only. NOT for Opioid dependence. Medicines Effectiveness, November 2004.
-------------------------	---	---

4.10.00 Smoking c

NICOTINE

NICOTINE 1.5mg MINI LOZENGE SUGAR FREE (3x20)	R	For use as per MIL Nicotine Replacement Therapy (NRT) for Smoking Cessation. MMTC, May 2017
NICOTINE 15mg/16hours PATCHES (NICORETTE INVISI PATCH)	NF	As per NRT Medicines Information Leaflet. Medicines Effectiveness, February 2013.
NICOTINE 1mg/ DOSE MOUTHSPRAY 13.2ml (NICORETTE QUICKMIST)	R	Smoking cessation for pregnant and postpartum women until discharged from midwifery care. MMTC, Nov 2023
NICORETTE 4mg MINI LOZENGE SUGAR FREE (60)	R	As per NRT Medicines Information Leaflet. Medicines Effectiveness, February 2013.
NICOTINE 15mg INHALATOR STARTER PACK	R	As per NRT Medicines Information Leaflet. Medicines Effectiveness, February 2013.
NICOTINE 15mg INHALATOR REFILL PACK (36)	R	As per NRT Medicines Information Leaflet. Medicines Effectiveness, February 2013.

VARENICLINE

VARENICLINE 11 x 500mcg & 14 x 1mg TABLETS	R	For continuation of therapy started in community only, as per NICE TA123. MMTC, April 2013.
--	---	---

4.10.00 Smoking cessation

NICOTINE

NICOTINE 10mg/16hours PATCHES (NICORETTE)	NF	
NICOTINE 4mg CHEWING GUM	R	Smoking cessation for pregnant and postpartum women until discharged from midwifery care. MMTC, Nov 2023

NICOTINE 2mg MICROTABS	R	?Smoking cessation for pregnant and postpartum women until discharged from midwifery care. MMTC, Nov 2023
------------------------	---	---

NICOTINE 25mg/16hours PATCHES (NICORETTE INVISI PATCH)	NF	Use 24 hour patches and remove after 16 hours as per NRT MIL. MMTC, September 2018
--	----	--

NIQUITIN

NICOTINE 21mg/24hours TRANSDERMAL PATCHES (NIQUITIN CQ)	R	As per NRT Medicines Information Leaflet. Medicines Effectiveness, February 2013.
---	---	---

NICOTINE 7mg/24hours TRANSDERMAL PATCHES (NIQUITIN CQ)	R	As per NRT Medicines Information Leaflet. Medicines Effectiveness, February 2013
--	---	--

NICOTINE 14mg/24hours TRANSDERMAL PATCHES (NIQUITIN CQ)	R	As per NRT Medicines Information Leaflet. Medicines Effectiveness, February 2013.
---	---	---

VARENICLINE

VARENICLINE 1mg TABLETS	R	For continuation of therapy started in community only, as per NICE TA123. MMTC, April 2013.
-------------------------	---	---

04.11 Drugs for dementia

04.1.00 drugs for dementia

GLYCERIN

GLYCERIN BP INJECTION 5ml	SR	To be used by Neuro-Radiology for the treatment of trigeminal neuralgia Medicines Effectiveness Jan '24
---------------------------	----	---

04.11 Drugs for dementia

DONEPEZIL

DONEPEZIL 5mg TABLETS	R	For the management of managing mild to moderate Alzheimer's disease as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the care of patients with dementia (i.e. psychiatrists including those specializing in learning disability, neurologists, and physicians specializing in the care of older people). MMTC, March 2017
-----------------------	---	---

GALANTAMINE

GALANTAMINE 12mg TABLETS

R For the management of managing mild to moderate Alzheimer's disease as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the care of patients with dementia (i.e. psychiatrists including those specializing in learning disability, neurologists, and physicians specializing in the care of older people). MMTC, March 2017

GALANTAMINE 24mg CAPSULES M/R

R For the management of managing mild to moderate Alzheimer's disease as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the care of patients with dementia (i.e. psychiatrists including those specializing in learning disability, neurologists, and physicians specializing in the care of older people). MMTC, March 2017

GALANTAMINE 8mg CAPSULE M/R

R For the management of managing mild to moderate Alzheimer's disease as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the care of patients with dementia (i.e. psychiatrists including those specializing in learning disability, neurologists, and physicians specializing in the care of older people). MMTC, March 2017

GALANTAMINE 16mg CAPSULES M/R

R

For the management of managing mild to moderate Alzheimer's disease as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the care of patients with dementia (i.e. psychiatrists including those specializing in learning disability, neurologists, and physicians specializing in the care of older people). MMTC, March 2017

MEMANTINE

MEMANTINE TABLET INITIATION PACK

R

For the management of managing mild to moderate Alzheimer's disease in those who cannot take acetylcholinesterase (AChE) inhibitor as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the Memory Clinic only. MMTC,

MEMANTINE HYDROCHLORIDE 10mg TABLETS

R

For the management of managing mild to moderate Alzheimer's disease in those who cannot take acetylcholinesterase (AChE) inhibitor as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the Memory Clinic only. MMTC,

MEMANTINE 10mg/ml ORAL DROPS

R

For the management of managing mild to moderate Alzheimer's disease in those who cannot take acetylcholinesterase (AChE) inhibitor as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the Memory Clinic only. MMTC,

RIVASTIGMINE

RIVASTIGMINE 10mg in 5ml LIQUID 120ml	R	For patients with swallowing difficulties or feeding tubes. For the management of managing mild to moderate Alzheimer's disease as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the care of patients with dementia (i.e. psychiatrists including those specializing in learning disability, neurologists, and physicians specializing in the care of older people). MMTTC, March 2017
RIVASTIGMINE 4.5mg CAPSULES	R	For the management of managing mild to moderate Alzheimer's disease as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the care of patients with dementia (i.e. psychiatrists including those specializing in learning disability, neurologists, and physicians specializing in the care of older people). MMTTC, March 2017
RIVASTIGMINE 4.6mg/24hr TRANSDERMAL PATCHES	R	Patches are restricted strictly for those unable to swallow. For the management of managing mild to moderate Alzheimer's disease as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the care of patients with dementia (i.e. psychiatrists including those specializing in learning disability, neurologists, and physicians specializing in the care of older people). MMTTC, March 2017

RIVASTIGMINE 9.5mg/24h TRANSDERMAL PATCH	R	Patches are restricted strictly for those unable to swallow. For the management of managing mild to moderate Alzheimer's disease as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the care of patients with dementia (i.e. psychiatrists including those specializing in learning disability, neurologists, and physicians specializing in the care of older people). MMTC, March 2017
RIVASTIGMINE 3mg CAPSULES	R	For the management of managing mild to moderate Alzheimer's disease as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the care of patients with dementia (i.e. psychiatrists including those specializing in learning disability, neurologists, and physicians specializing in the care of older people). MMTC, March 2017
RIVASTIGMINE 13.3mg/24hr TRANSDERMAL PATCHES	R	For the management of managing mild to moderate Alzheimer's disease as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the care of patients with dementia (i.e. psychiatrists including those specializing in learning disability, neurologists, and physicians specializing in the care of older people). MMTC, March 2017

04.11.00 Anticholinesterases

DONEPEZIL

DONEPEZIL 10mg TABLETS

R For the management of managing mild to moderate Alzheimer's disease as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the care of patients with dementia (i.e. psychiatrists including those specializing in learning disability, neurologists, and physicians specializing in the care of older people). MMTC, March 2017

04.11.00 Drugs for dementia

RIVASTIGMINE

RIVASTIGMINE 1.5mg CAPSULES

R For the management of managing mild to moderate Alzheimer's disease as per NICE TA217 and the Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia. To be initiated by specialists in the care of patients with dementia (i.e. psychiatrists including those specializing in learning disability, neurologists, and physicians specializing in the care of older people). MMTC, March 2017

05 Infections

05.01 Antibacterial drugs

05.00.00 Infections

LEVOFLOXACIN

LEVOFLOXACIN 500mg IN 100ml INJECTION

R For treatment of HAP and sepsis CAP in severe penicillin allergy patients. MMTC, November 2023.

MEROPENEM + VABORBACTAM

MEROPENEM 1g / VABORBACTAM 1g INJECTION

R For treatment of Gram negative multi-drug-resistant infections on advice of Micro/ID only. ASG, January 2020

05.01 01 Penicillins

PIPERACILLIN + TAZOBACTAM

PIPERACILLIN/TAZOBACTAM 2.25g INJECTION

R

05.01 Antibacterial drugs

PHENOXYMETHYLPENICILLIN

PHENOXYMETHYLPENICILLIN 250mg/5ml LIQUID 100ml Y

05.01.00 Antibacterial drugs

Atropine

ATROPINE 500microgram IN 5ml INJECTION PRE-FILLED SYRINGE R For use during Covid-19 only. MMTC, March 2020

CO-TRIMOXAZOLE

CO-TRIMOXAZOLE 480mg IN 5ml INJECTION UNR Please check patient being discharged on IV antibiotics is staying within Oxfordshire and thus have a postcode starting with 'OX'. (As per instruction from Ted Baker Medical Director Sep 11).

05.01.00 Antibiotic

BEDAQUILINE

BEDAQUILINE 100mg TABLETS R Pulmonary multidrug-resistant tuberculosis (MDR-TB) Approved ASG and MMTC Aug 2015

CEFIDEROCOL

CEFIDEROCOL 1g INJECTION R For treatment of multi-drug resistance gram-negative organisms on the advice/recommendation of Micro/ID only. MMTC February 2021

CLARITHROMYCIN

CLARITHROMYCIN 125mg/5ml LIQUID TTO 70ml SR

DAPTOMYCIN

DAPTOMYCIN 500mg INFUSION R For use following Micro/ID recommendation for treatment of MRSA or VRE when alternatives (eg vancomycin, teicoplanin or linezolid) are contraindicated or there is resistance to these drugs. MMTC, June 2013. Please check patient being discharged on IV antibiotics is staying within Oxfordshire and thus have a postcode starting with 'OX'. (As per instruction from Ted Baker Medical Director Sep 11).

DAPTOMYCIN 350mg INFUSION	R	For treatment of MRSA or VRE when alternatives (eg vancomycin, teicoplanin or linezolid) are contraindicated or there is resistance to these drugs. MMTC, June 2013.
FLUCLOXACILLIN		
FLUCLOXACILLIN 250mg/5ml LIQUID TTO 100ml	UNR	
PROCAINE PENICILLIN		
PROCAINE PENICILLIN 1.2million units INJECTION	UNR	This antimicrobial requires prescribing by: - Genito-urinary medicine consultant or registrar. This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
<i>05.01.00 Antibiotics</i>		
CEFTOLOZANE		
CEFTOLOZANE 1g & TAZOBACTAM 500mg INJECTION	R	For the treatment of: -hospital acquired pneumonia -intra-abdominal infections -sepsis - UTI For initiation following recommendation by Micro/ID only. MMTC, April 2017
<i>05.01.01 Penicillins</i>		
AMOXICILLIN		
AMOXICILLIN 500mg INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
AMOXICILLIN 500mg CAPSULES	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

AMOXICILLIN 500mg CAPSULES TTO 15's	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
AMOXICILLIN 125mg/5ml LIQUID 100ml	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
AMOXICILLIN 125mg/5ml SUGAR FREE LIQUID TTO 100ml	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
AMOXICILLIN 250mg CAPSULES	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
AMOXICILLIN 3g SACHET S/F	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
AMOXICILLIN 250mg/5ml LIQUID SUGAR FREE TTO 100ml	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

AMOXICILLIN 250mg CAPSULES TTO 15's	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
AMOXICILLIN 250mg/5ml LIQUID 100ml	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
AZTREONAM		
AZTREONAM 1g INJECTION	R	For use by the Respiratory Unit (adult and children) only. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
BENZYL PENICILLIN		
BENZYL PENICILLIN 1.2g INJECTION	Y	
BENZYL PENICILLIN 600mg INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CO-AMOXICLAV		
CO-AMOXICLAV 500/125mg TABLETS TTO 21's	Y	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

CO-AMOXICLAV 125/31mg/5ml LIQUID SUGAR FREE TTO 100ml		SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CO-AMOXICLAV 1000/200 (1.2g) INJECTION amoxicillin 1g & clavulanic acid 200mg	Y		As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CO-AMOXICLAV DUO 400/57 LIQUID 70ml		NF	
CO-AMOXICLAV 500/125mg TABLETS	Y		As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CO-AMOXICLAV 500/100 (600mg) INJECTION amoxicillin 500mg & clavulanic acid 100mg (600mg)	Y		As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CO-AMOXICLAV 250/62 in 5ml LIQUID SUGAR FREE TTO 100ml		SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CO-AMOXICLAV 250/62 in 5ml LIQUID SUGAR FREE 100ml	Y		As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

CO-AMOXICLAV 125/31 in 5ml (Paed) LIQUID S/F 100ml	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
FLUCLOXACILLIN		
FLUCLOXACILLIN 500mg CAPSULES TTO 28's	R	FOR AREAS ALLOWED TO DISPENSE TTO PACKS
FLUCLOXACILLIN 1g INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
FLUCLOXACILLIN 125mg/5ml LIQUID TTO 100ml	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
FLUCLOXACILLIN 125mg/5ml LIQUID 100ml	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
FLUCLOXACILLIN 500mg INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

FLUCLOXACILLIN 500mg CAPSULES	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
-------------------------------	---	---

FLUCLOXACILLIN 250mg/5ml LIQUID 100ml	Y	
---------------------------------------	---	--

FLUCLOXACILLIN 250mg CAPSULES	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
-------------------------------	---	---

PHENOXYMETHYLPENICILLIN

PHENOXYMETHYLPENICILLIN 250mg/5ml LIQUID S/F 100ml TTO PACK	Y	For areas allowed to keep TTO packs only
---	---	--

PHENOXYMETHYLPENICILLIN 250mg TABLETS TTO 28's	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar. - Paediatric ID consultant or registrar. Antimicrobials Steering Group, January 2012.
--	----	--

PHENOXYMETHYLPENICILLIN 250mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
---------------------------------------	---	---

PHENOXYMETHYLPENICILLIN 125mg/5ml LIQUID 100ml	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
--	---	---

PIPERACILLIN + TAZOBACTAM

PIPERACILLIN/TAZOBACTAM 4.5g INJECTION	R	This antimicrobial is approved for: Neutropenic fever empirical treatment (with gentamicin) It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar ASG Jan 2009.
--	---	---

PIVMECILLINAM

PIVMECILLINAM 200mg TABLETS	R	Used as an alternative option for treatment of non-severe lower UTI in female (non-pregnant) and male patients, where susceptibility tests have shown resistance to other formulary antibiotics. MMTC, June 2013.
-----------------------------	---	---

TEMOCILLIN

TEMOCILLIN 1g INJECTION	R	This antimicrobial requires approval/prescribing by: - Cystic Fibrosis consultants (adults). It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
-------------------------	---	---

05.01.02 Cephalosporins, carbapenems and other beta-lactams

CEFALEXIN

CEFALEXIN 250mg/5ml LIQUID TTO 100ml	UNR	
--------------------------------------	-----	--

CEFTAZIDIME

CEFTAZIDIME 2g / AVIBACTAM 0.5g INJECTION	R	For MDR gram negative organisms following recommendation by Micro/ID only. MMTC, June 2017
---	---	--

CEFTRIAZONE

CEFTRIAXONE 1g INJECTION

R This antimicrobial is approved for: Bacterial meningitis:- empirical treatment (+/- amoxicillin);- prophylaxis of meningococcal meningitis in pregnant women 2nd-line treatment of severe infections /surgical prophylaxis (after co-amoxiclav iv). It is also available following approval/prescribing by: Microbiology/ID consultant or registrar Paediatric ID consultant or registrar. NB: Avoid in neonates and infants under 3 months gestational age. ASG Jan 2009

05.01.02 Cephalosporins, carbapenems and other beta-lactams

BENZYL PENICILLIN

BENZYL PENICILLIN 600mg INJECTION

Y

CEFAZOLIN

CEFAZOLIN 1g INJECTION

R

For the second line treatment of MSSA, For surgical prophylaxis and for treatment of skin and soft tissue infections, also available following approval/prescribing by:
- Microbiology/ID consultant or registrar
MMTC June 2021

CEFOXITIN

CEFOXITIN 1g INJECTION

R

For the treatment of non-tuberculous mycobacteria (NTM) in adult patients with cystic fibrosis. MMTC, July 2010

CEFTAZIDIME

CEFTAZIDIME 2g INJECTION

R

This antimicrobial requires prescribing by: Respiratory consultant or registrar (adults and paediatrics Treatment of neurosurgical infections. Or approval/prescribing by: - Microbiology/ID consultant or registrar. - Paediatric ID consultant or registrar. ASG, January 2009.

CEFUROXIME

CEFUROXIME 250mg INJECTION	R	This antimicrobial requires prescribing by: - Paediatric consultant or registrar It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar . Antimicrobial Steering Group, January 2012
----------------------------	---	---

CEFUROXIME 250mg INJECTION	R	
----------------------------	---	--

CEFUROXIME 50mg INTERCAMERAL INJECTION VIAL	R	For cataract surgery only. MMTC, July 2014.
---	---	---

05.01.02 Cephalosporins, carbapenems, and other beta-lactams

AZTREONAM

AZTREONAM 2g INJECTION	R	For use by the Respiratory Unit (adult and children) only. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
------------------------	---	---

CEFACLOR

CEFACLOR 125mg/5ml LIQUID	NF	
---------------------------	----	--

CEFALEXIN

CEFALEXIN 125mg/5ml LIQUID 100ml S/F	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
--------------------------------------	---	---

CEFALEXIN 500mg CAPSULES	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
--------------------------	---	---

CEFALEXIN 250mg/5ml LIQUID 100ml	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CEFALEXIN 250mg CAPSULES	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CEFALEXIN 500mg CAPSULES TTO 21's	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CEFAZOLIN		
CEFAZOLIN 2g INJECTION	R	For the second line treatment of MSSA, For surgical prophylaxis and for treatment of skin and soft tissue infections, also available following approval/prescribing by: - Microbiology/ID consultant or registrar. MMTc June 2021
CEFEPIME		
CEFEPIME 2g INJECTION	R	For treatment of Gram-negative bacterial infections with MDR in adults. This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant only. ASG, September 2019
CEFIXIME		
CEFIXIME 200MG TABLETS	R	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, June 2014.
CEFOTAXIME		

CEFOTAXIME 500mg INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CEFTAROLINE FOSAMIL		
CEFTAROLINE FOSAMIL (AS ACETATE) 600MG INJECTION	R	For the treatment of complicated skin infections in adults, including MRSA. This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant only. ASG, September 2019 For the treatment of complicated skin infections in adults, including MRSA. This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant only. ASG, September 2019
Ceftazidime		
CEFTAZIDIME 2g INJECTION	R	This antimicrobial requires prescribing by: - Respiratory Unit (adult and children) - Neurosciences (empirical treatment of neurosurgical infections). It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012. Please check patient being discharged on IV antibiotics is staying within Oxfordshire and thus have a postcode starting with 'OX'.
CEFTAZIDIME 1g INJECTION	Y	

CEFTAZIDIME 500mg INJECTION	R	This antimicrobial requires prescribing by: - Respiratory Unit (adult and children) - Neurosciences (empirical treatment of neurosurgical infections). It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CEFTRIAZONE		
CEFTRIAZONE 2g INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012
CEFTRIAZONE 250mg INJECTION	Y	
CEFTRIAZONE 1g INJECTION	Y	
CEFTRIAZONE 250mg INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CEFUROXIME		
CEFUROXIME 750mg INJECTION	R	Only for Surgical prophylaxis in Adults as per Trust Guidelines or when recommended by Micro / ID. MMTC August 2019
CEFUROXIME 250mg INJECTION	R	This antimicrobial requires prescribing by: - Paediatric consultant or registrar It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar Antimicrobials Steering Group, January 2012.

ERTAPENEM

ERTAPENEM 1g INJECTION	R	For home or outpatient IV therapy following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2009.
IMIPENEM		
IMIPENEM 500mg / CILASTIN 500mg / RELEBACTAM 250mg INJECTION	R	For treatment of resistance gram negative bacteria as 3rd line treatment ONLY on advice of Micro/ID. MMTC, July 2021
IMIPENEM / CILASTATIN 500mg INJECTION (20ml vials)	R	Approved for Treatment of non-tuberculous mycobacteria (NTM) in adult patients with cystic fibrosis. Or approval/prescribing by CF consultants. MAC, March 2011
MEROPENEM		
MEROPENEM 1g INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
MEROPENEM 500mg INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
OFLOXACIN		
OFLOXACIN 200MG/100ML INJECTION	NF	
TICARCILLIN		
TICARCILLIN 3g / CLAVULANIC ACID 200mg INJECTION	R	This antimicrobial requires approval/prescribing by: - Cystic Fibrosis consultants (adults). It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

05.01.03 Tetracycline

DOXYCYCLINE

DOXYCYCLINE HYCLATE 100mg IN 5ml INJECTION UNR For the treatment of rickettsia, legionella and following recommendation by Micro/ID where the oral route is not appropriate. All use must have Micro/ID approval. MMTC, August 2017 For intralesional sclerotherapy of lymphatic malformations in adults for use in JR Interventional Radiology MMTC, October 2021 (review date: April 2022)

DOXYCYCLINE 100mg CAPSULES TTO 14s (Unlicensed) SR For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by:
- Microbiology/ID consultant or registrar
- Paediatric ID consultant or registrar
Antimicrobials Steering Group, January 2012

05.01.03 Tetracyclines

DEMECLOCYCLINE

DEMECLOCYCLINE 150mg CAPSULES Y

DOXYCYCLINE

DOXYCYCLINE 100mg CAPSULES TTO 14's SR For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by:
- Microbiology/ID consultant or registrar
- Paediatric ID consultant or registrar
Antimicrobials Steering Group, January 2012.

DOXYCYCLINE 50mg CAPSULES Y As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by:
- Microbiology/ID consultant or registrar
- Paediatric ID consultant or registrar
Antimicrobials Steering Group, January 2012.

DOXYCYCLINE 100mg CAPSULES	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
DOXYCYCLINE 100mg CAPSULES TTO 28's	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
DOXYCYCLINE 100mg DISPERSIBLE TABLETS	Y	Patients with feeding tubes or swallowing difficulties only. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
Eravacycline		
ERAVACYCLINE 100mg INJECTION	NF	
LYMECYCLINE		
LYMECYCLINE 408mg CAPSULES	R	For continuation of treatment of Bullous pemphigoid and other rarer immunobullous diseases in patients under the care of dermatology only. Initiation of treatment should be completed by GP. MMTc, January 2017
MINOCYCLINE		
MINOCYCLINE 50mg TABLETS	R	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

MINOCYCLINE 100mg CAPSULES M/R	R	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
MINOCYCLINE 100mg TABLETS	R	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
OXYTETRACYCLINE		
OXYTETRACYCLINE 250mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
TETRACYCLINE		
TETRACYCLINE 250mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
TIGECYCLINE		
TIGECYCLINE 50mg INJECTION	R	For treatment of non-tuberculous mycobacteria (NTM) in adult patients with cystic fibrosis. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

05.01.04 Aminoglycosides

AMIKACIN

AMIKACIN PAED 100mg IN 2ml INJECTION	R	For the treatment of Non-Tuberculosis Mycobacterium infections in CF patients and MDRTB. This antimicrobial requires prescribing by: - Respiratory Unit (adult and children) It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
AMIKACIN 500mg in 2ml INJECTION	R	For the treatment of Non-Tuberculosis Mycobacterium infections in CF patients and MDRTB. This antimicrobial requires prescribing by: - Respiratory Unit (adult and children) It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
Amikacin liposomal		
AMIKACIN LIPOSOMAL 590mg NEBULISER VIALS WITH DEVICE	R	For the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex refractory to current treatment options (adults and post pubescent children) ?as per NHSE policy 221007P. MMTc, September 2023
GENTAMICIN		
GENTAMICIN 80mg IN 2ml INJECTION (AMPOULES)	Y	
GENTAMICIN INTRATHECAL 5mg in 1ml INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

GENTAMICIN 20mg in 2ml Paediatric INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
GENTAMICIN 80mg in 2ml INJECTION (AMPOULES)	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
TOBRAMYCIN		
TOBRAMYCIN 80mg in 2ml INJECTION	R	This antimicrobial requires prescribing by: - Respiratory Unit (adult + paediatric) consultant or registrar It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar. Antimicrobials Steering Group.
TOBRAMYCIN 300mg IN 5ml NEBULISER SOLUTION	R	This antimicrobial requires prescribing by:- Respiratory Unit (adult + paediatric) consultant or registrar It is also available following approval/prescribing by:- Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar ASG Jan 2009
TOBRAMYCIN 300mg IN 4ml NEBULISER SOLUTION	NF	This antimicrobial requires prescribing by: - Respiratory Unit (adult + paediatric) consultant or registrar It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

05.01.05 Macrolides

AZITHROMYCIN

AZITHROMYCIN 500mg TABLETS	R	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar. - Respiratory consultants for the treatment of COPD, CF and Bronchiectasis Antimicrobials Steering Group, November 2019.
AZITHROMYCIN 250mg TABLETS	R	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar. - Respiratory consultants for the treatment of COPD, CF and Bronchiectasis Antimicrobials Steering Group, November 2019.
AZITHROMYCIN 200mg/5ml LIQUID 30ml	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012
AZITHROMYCIN 250MG TABLETS TTO PK 8	SR	For OSHS use only
AZITHROMYCIN 250mg CAPSULES	NF	RESTRICTED: For use by Chest consultants; Gynaecology consultants and on Micro/ID recommendation only 'Bunmi 2007
AZITHROMYCIN 200mg/5ml LIQUID 15ml	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

Clarithromycin

CLARITHROMYCIN 500mg INJECTION	Y	Please check patient being discharged on IV antibiotics is staying within Oxfordshire and thus have a postcode starting with 'OX'. (As per instruction from Ted Baker Medical Director Sep 11).
CLARITHROMYCIN 500mg INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CLARITHROMYCIN 250mg/5ml LIQUID 70ml	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CLARITHROMYCIN 500mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CLARITHROMYCIN 500mg TABLETS TTO 14's	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CLARITHROMYCIN 250mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

CLARITHROMYCIN 125mg/5ml PAED LIQUID 70ml	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
ERYTHROMYCIN		
ERYTHROMYCIN 250mg/5ml LIQUID 100ml	R	For pregnant women and for ITU as a prokinetic agent. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, July 2011
ERYTHROMYCIN 125mg/5ml LIQUID 100ml	R	For pregnant women and for ITU as a prokinetic agent. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, July 2011
ERYTHROMYCIN 500mg/5ml LIQUID 100ml	R	For pregnant women and for ITU as a prokinetic agent. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, July 2011
ERYTHROMYCIN 250mg TABLETS E/C	R	For pregnant women and for ITU as a prokinetic agent. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, July 2011

ERYTHROMYCIN LACTOBIONATE 1g INJECTION	R	For pregnant women and for ITU as a prokinetic agent. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, July 2011
PAROMYCIN		
PAROMOMYCIN 250mg CAPSULES	UNR	For the treatment of diarrhoea caused by Giardia, Cryptosporidium and E. histolytica where standard treatment has failed as recommended by Micro / ID. MMTC, August 2019
<i>05.01.05 Mecillinams</i>		
AZITHROMYCIN		
HC AZITHROMYCIN 250MG TABLETS	R	
<i>05.01.06 Clindamycin</i>		
CLINDAMYCIN		
CLINDAMYCIN 150mg CAPSULES	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CLINDAMYCIN 600mg IN 4ml INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CLINDAMYCIN 75mg CAPSULES	NF	
CLINDAMYCIN 150mg CAPSULES	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

CLINDAMYCIN 300mg IN 2ml INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
------------------------------------	---	---

CLINDAMYCIN + BENZOYL PEROXIDE

CLINDAMYCIN 1% & BENZOYL PEROXIDE 5% GEL 60g	NF
---	----

05.01.07 Some other antibacterials

CHLORAMPHENICOL

CHLORAMPHENICOL 250mg CAPSULES	R	This antimicrobial requires prescribing by: - Respiratory Unit (adult and paediatric) consultant or registrar It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
--------------------------------	---	--

CHLORAMPHENICOL 1g INJECTION	R	2nd-line empirical treatment of bacterial meningitis (severe penicillin allergy). It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
------------------------------	---	---

COLISTIMETHATE

COLISTIMETHATE 125mg CAPSULES FOR INHALATION (TEST DOSE)	R	For treating pseudomonas lung infections in cystic fibrosis patients as per NICE TA276. MMTc, June 2013.
--	---	--

COLOMYCIN

COLOMYCIN 500,000units (0.5mu) INJECTION	NF
--	----

COLISTIMETHATE	R	This antimicrobial requires prescribing by: - Respiratory Unit (adult and children) - Neurosciences (empirical treatment of neurosurgical infections) It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar NB: only the injection is stocked (it can be given IV and can be nebulised). Antimicrobials Steering Group, January 2012.
COLOMYCIN 2,000,000units (2million units) INJECTION	R	This antimicrobial requires prescribing by: - Respiratory Unit (adult and children) - Neurosciences (empirical treatment of neurosurgical infections) It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar NB: only the injection is stocked (it can be given IV and can be nebulised). Antimicrobials Steering Group, January 2012.
DALBAVANCIN		
DALBAVANCIN 500mg INJECTION	R	For treatment of gram positive bacterial infection in people who inject drugs, for whom other options have failed and oral options are not appropriate, on advice of Micro/ID only. MMTC, April 2021
FIDAXOMICIN		
FIDAXOMICIN 200mg TABLETS	R	For recurrent Clostridium difficile infection. This antimicrobial requires prescribing by: - Micro/ID consultant. Antimicrobials Steering Group, January 2014.
FOSFOMYCIN		
FOSFOMYCIN 3g SACHETS	R	For the treatment of extended spectrum beta-lactamases (ESBL) UTIs resistant to other formulary antimicrobials, following ID/Microbiology recommendation only. ASG, 2013.

FOSFOMYCIN 4g INJECTION	R	For multi-resistant pseudomonas aeruginosa infection of the lung in cystic fibrosis. This antimicrobial requires prescribing by: Respiratory Unit Consultant or Microbiologist; Microbiology/ID consultant or registrar. MMTC, January 2015.
LINEZOLID		
LINEZOLID 600mg TABLETS	R	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
LINEZOLID 600mg in 300ml INJECTION	R	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
LINEZOLID 100mg/5ml ORAL SUSPENSION	R	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
ORITAVANCIN		
ORITAVANCIN 400mg INJECTION	R	
PRISTINAMYCIN		
PRISTINAMYCIN 500mg TABLETS	UNR	For staphylococcal infection or multi resistant organisms. This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
RIFAXIMIN		
RIFAXIMIN 200mg TABLETS	NF	

RIFAXIMIN 550mg TABLETS	R	For preventing episodes of overt hepatic encephalopathy as per NICE TA337. MMTTC, November 2015
SODIUM FUSIDATE		
FUSIDIC ACID 250mg/5ml LIQUID	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
SODIUM FUSIDATE 250mg TABLETS	R	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
TEDIZOLID		
TEDIZOLID 200mg TABLETS	NF	
TEICOPLANIN		
TEICOPLANIN 200mg INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
TEICOPLANIN 400mg INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
VANCOMYCIN		
VANCOMYCIN 1g INJECTION	Y	
VANCOMYCIN 500mg INJECTION	Y	

VANCOMYCIN INTRATHECAL 20mg in 4ml INJECTION (STERILE WRAPPED PRE FILLED SYRINGE)		UNR For CSF infection. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar.- Paediatric ID consultant or registrar. Antimicrobials Steering Group, January 2018
VANCOMYCIN 500mg INJECTION	Y	
VANCOMYCIN 125mg CAPSULES	R	For Clostridium difficile infection (CDI) or following Microbiology advice. Medicines Effectiveness, April 2014.

05.01.08 Sulfonamides and trimethoprim

Co-trimoxazole

CO-TRIMOXAZOLE 240mg/5ml PAED LIQUID (UNLICENSED IMPORT)	UNR	
CO-TRIMOXAZOLE 480mg in 5ml INJECTION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CO-TRIMOXAZOLE 480mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CO-TRIMOXAZOLE 480mg TABLETS TTO (28)	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CO-TRIMOXAZOLE 480mg/5ml ADULT LIQUID	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

CO-TRIMOXAZOLE 240mg/5ml PAED LIQUID	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
--------------------------------------	---	---

SULFADIAZINE

SULFADIAZINE 500mg TABLETS	R	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
----------------------------	---	--

TRIMETHOPRIM

TRIMETHOPRIM 100mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
----------------------------	---	---

TRIMETHOPRIM 200mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
----------------------------	---	---

TRIMETHOPRIM 50mg/5ml LIQUID	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
------------------------------	---	---

05.01.09 Antituberculosis drugs

AMINOSALICYLIC ACID

AMINOSALICYLIC ACID 4g GRANULES	UNR	For use by Infectious Diseases physicians use in multi resistant TB only. Medicines Effectiveness, May 2002.
---------------------------------	-----	--

CAPREOMYCIN

CAPREOMYCIN 1g INJECTION	R	Restricted to Micro / ID consultant initiated for MDRTB. MMTC, June 2012.
CYCLOSERINE		
CYCLOSERINE 250mg PULVULES	R	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
Delamanid		
DELAMANID 50mg TABLETS	R	As per NHSE commissioning policy 201203P
ETHAMBUTOL		
ETHAMBUTOL 1g in 10ml INJECTION	UNR	This antimicrobial is approved for: TB treatment It is also available following approval/prescribing by: Microbiology/ID consultant or registrar Paediatric ID consultant or registrar NB: tablets are the preferred formulation ASG Jan 2009
ETHAMBUTOL 100mg TABLETS	R	This antimicrobial is approved for: - TB treatment It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar ASG, January 2009.
ETHAMBUTOL 400mg TABLETS	R	This antimicrobial is approved for: - TB treatment It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar ASG, January 2009.
ISONIAZID		
ISONIAZID 50mg/5ml LIQUID	SR	This antimicrobial is approved for: TB prophylaxis in immunosuppressed patients/TB treatment It is also available following approval/prescribing by: Microbiology/ID consultant or registrar Paediatric ID consultant or registrar ASG Jan 2009

ISONIAZID 50mg/5ml LIQUID	SR	This antimicrobial is approved for: TB prophylaxis in immunosuppressed patients/TB treatment It is also available following approval/prescribing by: Microbiology/ID consultant or registrar Paediatric ID consultant or registrar ASG, January 2009
ISONIAZID 50mg TABLETS	R	For TB prophylaxis in immunosuppressed patients OR mycobacterial infections. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2009.
ISONIAZID 50mg IN 2ml INJECTION	UNR	For TB prophylaxis in immunosuppressed patients OR mycobacterial infections. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2009.
ISONIAZID 100mg TABLETS	R	For TB prophylaxis in immunosuppressed patients OR mycobacterial infections. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2009.
PROTIONAMIDE		
PROTIONAMIDE 250mg TABLETS	UNR	For Multi Drug Resistant TB. This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

PYRAZINAMIDE

PYRAZINAMIDE 500mg TABLETS	R	For mycobacterial infections. This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
RIFABUTIN		
RIFABUTIN 150mg CAPSULES	R	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
RIFAMPICIN		
RIFAMPICIN 600mg INFUSION	R	This antimicrobial is approved for: -Mycobacterial infections - Prophylaxis of meningococcal meningitis (single agent) It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
RIFAMPICIN 300mg CAPSULES	R	This antimicrobial is approved for: -Mycobacterial infections - Prophylaxis of meningococcal meningitis (single agent) It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
RIFAMPICIN 150mg CAPSULES	R	This antimicrobial is approved for: -Mycobacterial infections - Prophylaxis of meningococcal meningitis (single agent) It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

RIFAMPICIN 100mg/5ml LIQUID

R This antimicrobial is approved for: -Mycobacterial infections - Prophylaxis of meningococcal meningitis (single agent) It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

RIFAMPICIN + ISONIAZID

RIFAMPICIN 150mg + ISONIAZID 100mg TABLETS

R For mycobacterial infections. This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

RIFAMPICIN 300mg + ISONIAZID 150mg TABLETS

R For mycobacterial infections. This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

RIFAMPICIN + ISONIAZID + PYRIZINAMIDE

RIFAMPICIN 120mg + ISONIAZID 50mg + PYRAZINAMIDE 300mg TABLETS

R For mycobacterial infections. This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

05.01.10 Antileprotic drugs

CLOFAZIMINE

CLOFAZIMINE 100mg CAPSULES

UNR RESTRICTED for use by infectious diseases wards only

CLOFAZIMINE 50mg CAPSULES

UNR This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

DAPSONE

DAPSONE 50mg TABLETS	R	For PCP prophylaxis in immunosuppressed patients This antimicrobial requires approval/prescribing by: - Dermatology (adults and paediatrics) - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
<i>05.01.11 Metronidazole and tinidazole</i>		
Delafloxacin		
DELAFLOXACIN 450mg TABLETS	R	
DELAFLOXACIN 300mg INJECTION	R	
Metronidazole		
METRONIDAZOLE 400mg TABLETS TTO 14'S	SR	For use as a TTO pack on GUM only. Medicines Effectiveness, August 2023
METRONIDAZOLE 400mg TABLETS TTO 6'S	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, April 2015
METRONIDAZOLE 200mg/5ml LIQUID	R	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
METRONIDAZOLE 400mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
METRONIDAZOLE 400mg TABLETS TTO 21's	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

METRONIDAZOLE 400mg TABLETS TTO 10's	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
METRONIDAZOLE 200mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
METRONIDAZOLE 500mg SUPPOSITORIES	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
METRONIDAZOLE 1g SUPPOSITORIES	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
METRONIDAZOLE 500mg in 100ml INFUSION ECOFLAC PLUS (429626)	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
TINIDAZOLE		
TINIDAZOLE 500mg TABLETS	UNR	This antimicrobial requires approval or prescribing by: Microbiology/ID consultant or registrar.- Paediatric ID consultant or registrar.Do not dispense this medicine unless the relevant approval has been obtained. Medicines Effectiveness. February 2009.

CEFUROXIME

CEFUROXIME 1.5g INJECTION

R Only for Surgical prophylaxis in Adults as per Trust Guidelines or when recommended by Micro / ID. MMTC August 2019

CIPROFLOXACIN

CIPROFLOXACIN 500mg TABLETS

Y As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by:
- Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar

CIPROFLOXACIN 500mg TABLETS TTO PACK 10'S SR

CIPROFLOXACIN 250mg TABLETS

Y As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by:
- Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar .
Antimicrobials Steering Group, January 2012.

CIPROFLOXACIN 250mg TABLETS

Y As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by:
- Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar
Antimicrobials Steering Group, January 2012.

CIPROFLOXACIN 100mg TABLETS

Y As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by:
- Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar
Antimicrobials Steering Group, January 2012.

CIPROFLOXACIN 250mg/5ml LIQUID 100ml	R	For small paediatric doses or patients intolerant of tablets dispersed in water only. Disperse tablets in water to give via feeding tube or for patients with swallowing difficulties. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CIPROFLOXACIN 500mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CIPROFLOXACIN 400mg IN 200ml INJECTION	R	For NBM or not absorbing patients only. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CIPROFLOXACIN 200mg in 100ml INJECTION	R	For NBM or not absorbing patients only. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CIPROFLOXACIN 500mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

CIPROFLOXACIN 750mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CIPROFLOXACIN 500mg TABLETS TTO 4'S	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, April 2015.
LEVOFLOXACIN		
LEVOFLOXACIN 250mg TABLETS	R	Restricted for the treatment of Helicobacter Pylori infection as a 2nd-line treatment where there is a history of penicillin allergy (non-severe and severe). Also restricted for prophylaxis in Myeloma patients. It is also available following approval/prescribing by: Microbiology/ID consultant or registrar Paediatric ID consultant
LEVOFLOXACIN 500mg TABLETS	R	Restricted for the treatment of Helicobacter Pylori infection as a 2nd-line treatment where there is a history of penicillin allergy (non-severe and severe). Also restricted for prophylaxis in Myeloma patients. It is also available following approval/prescribing by: Microbiology/ID consultant or registrar Paediatric ID consultant
LEVOFLOXACIN 250mg TABLETS	R	Antimicrobials Steering Group, January 2012
MOXIFLOXACIN		
MOXIFLOXACIN 400mg TABLETS	R	3rd-line treatment of LRTIs (severe penicillin allergy - per adult empirical treatment guide). It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

MOXIFLOXACIN 400mg in 250ml INJECTION	R	For nil-by-mouth or not absorbing patients only. 3rd-line treatment of LRTIs (severe penicillin allergy - per adult empirical treatment guide). It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
---------------------------------------	---	--

NORFLOXACIN

NORFLOXACIN 400mg TABLETS	NF	
---------------------------	----	--

OFLOXACIN

OFLOXACIN 200mg TABLETS	R	For use by Infectious Diseases and Genito-urinary Medicine only. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar; - Paediatric ID consultant or registrar. Antimicrobials Steering Group, January 2012
-------------------------	---	--

05.01.13 Urinary-tract infections

METHENAMINE

METHENAMINE HIPPURATE 1g TABLETS	R	For treatment of recurrent UTI prophylaxis on initiation by micro/ID ONLY. MMTC, January 2023
----------------------------------	---	---

NITROFURANTOIN

NITROFURANTOIN 100MG CAPSULES M/R	NF	Please put out of use after this order
-----------------------------------	----	--

NITROFURANTOIN 25mg/5ml LIQUID	NF	
--------------------------------	----	--

NITROFURANTOIN 100mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
------------------------------	---	---

NITROFURANTOIN 50mg CAPSULES	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
------------------------------	---	---

NITROFURANTOIN 50mg CAPSULES TTO 12'S	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by:- Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
---------------------------------------	----	---

5.01.07 Some other antibacterials

Vancomycin

VANCOMYCIN 1g INJECTION	Y	
-------------------------	---	--

VANCOMYCIN HYDROCHLORIDE 125mg / 5mL LIQUID 150ml	UNR	For Clostridium difficile infection (CDI) in patients with swallowing difficulties or feeding tubes as per MicroGuide. MMTc, October 2018
---	-----	---

05.01 Bacterial infection

05.01.01 Antibacterials

BENZATHINE BENZYL PENICILLIN

BENZATHINE BENZYL PENICILLIN 2.4million units INJECTION	R	For the treatment of early and latent Syphilis. For use by Genito-Urinary Medicine only. It is also available following approval/prescribing by:- Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar. Antimicrobials Steering Group, January 2012
---	---	---

05.02 Antifungal drugs

05.02 Bacterial infections

AMPHOTERICIN

AMPHOTERICIN 50mg INJECTION (FUNGIZONE)	R	Restricted for intravitreal use in Eye Theatres only. ASG, November 2018
---	---	---

AMPHOTERICIN LIPOSOMAL 50mg INJECTION (AMBISOME)	R	4th-line treatment of possible fungal infection in febrile neutropaenia patient. (Haematology/Oncology (adult and paediatric) - consultant only. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
FLUCONAZOLE		
FLUCONAZOLE 150mg CAPSULES TTO 1's	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
FLUCONAZOLE 50mg in 5ml LIQUID	R	For small paediatric doses or patients with feeding tubes only. Disperse the contents of capsules in water for patients with swallowing difficulties. As per OUH Antimicrobial Guidelines. NB: for oral thrush, use nystatin mouthwash instead. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
FLUCONAZOLE 50mg CAPSULES	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
FLUCONAZOLE 150mg CAPSULES	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

FLUCONAZOLE 200mg in 5ml LIQUID	R	For small paediatric doses or patients with feeding tubes only. Disperse the contents of capsules in water for patients with swallowing difficulties. As per OUH Antimicrobial Guidelines. NB: for oral thrush, use nystatin mouthwash instead. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
FLUCONAZOLE 50mg CAPSULES TTO 7's	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
FLUCONAZOLE 50mg in 25ml INJECTION	R	Strictly restricted for nil-by-mouth or not absorbing patients. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2009.
FLUCONAZOLE 200mg in 100ml INFUSION	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
FLUCONAZOLE 200mg CAPSULES	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

FLUCYTOSINE

FLUCYTOSINE 500mg TABLETS

UNR This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

ITRACONAZOLE

ITRACONAZOLE 100mg CAPSULES

R This antimicrobial requires prescribing by: Haematology/oncology (adult and paediatric) Or approval/prescribing by: Microbiology/ID consultant or registrar Paediatric ID consultant or registrar ASG Jan 2009

ITRACONAZOLE 50mg/5ml LIQUID 150ml

R This antimicrobial requires prescribing by: - Haematology/oncology (adult and paediatric) - Respiratory consultant It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2009.

ITRACONAZOLE 100mg CAPSULES

R This antimicrobial requires prescribing by: - Haematology/oncology (adult and paediatric) - Respiratory consultant It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2009.

NYSTATIN

NYSTATIN 500,000international units TABLETS

NF

POSACONAZOL

POSACONAZOLE 300mg VIALS

R Restricted for prophylaxis and treatment of invasive fungal infections in adult haematology patients where the oral route is unavailable or impaired. MMTG, August 2017

POSACONAZOLE

POSACONAZOLE 100mg TABLETS E/C	R	For the treatment of invasive fungal infection refractory to fluconazole / voriconazole, following approval/prescribing by:- Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar. For prophylaxis of invasive fungal infections in Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia, following approval/prescribing by:- Haematology/Oncology consultant or registrar. MMTC, January 2014
POSACONAZOLE 200mg/5ml SUSPENSION 105mls	R	Prophylaxis of invasive fungal infections in Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia. MMTC, August 2013.
TERBINAFINE		
TERBINAFINE 250mg TABLETS	R	This antimicrobial requires prescribing by: - Dermatology (adult + paediatric) consultant or registrar It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
VORICONAZOLE		
VORICONAZOLE 200mg INJECTION VIAL (UNLICENSED)	UNR	This antimicrobial requires prescribing by: - Oncology/Haematology (adult + paediatric) consultant or registrar as per Febrile Neutropenia protocol. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

VORICONAZOLE 50mg TABLETS	R	This antimicrobial requires prescribing by: - Oncology/Haematology (adult + paediatric) consultant or registrar as per Febrile Neutropenia protocol. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
VORICONAZOLE 200mg/5ml ORAL SOLUTION 70ml	R	This antimicrobial requires prescribing by: - Oncology/Haematology (adult + paediatric) consultant or registrar as per Febrile Neutropenia protocol. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
VORICONAZOLE 200mg TABLETS	R	This antimicrobial requires prescribing by: - Oncology/Haematology (adult + paediatric) consultant or registrar as per Febrile Neutropenia protocol. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
VORICONAZOLE 200mg INJECTION	R	This antimicrobial requires prescribing by: - Oncology/Haematology (adult + paediatric) consultant or registrar as per Febrile Neutropenia protocol. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

05.02.00 Antifungal drugs

GRISEOFULVIN

GRISEOFULVIN 125mg TABLETS

R This antimicrobial requires prescribing by: - Dermatology (adult and paediatric) consultant or registrar It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

05.02.01 Triazole antifungals

ISAVUCONAZOLE

ISAVUCONAZOLE 200mg INJECTION

R For the treatment resistant fungal infections or if intolerant to alternatives (amphotericin, voriconazole, posiconazole). All use must be approved by Micro/ID and any off-label use requires an IFR. MMTc, January 2017

ISAVUCONAZOLE 100mg CAPSULES

R For the treatment resistant fungal infections or if intolerant to alternatives (amphotericin, voriconazole, posiconazole). All use must be approved by Micro/ID and any off-label use requires an IFR. MMTc, January 2017

05.02.04 Echinocandin antifungals

CASPOFUNGIN

CASPOFUNGIN ACETATE 70mg INJECTION

R For treatment of proven or suspected invasive fungal disease in adults and paediatrics when: initiated by consultant haematologist/oncologist, or, following approval by ID/Micro consultant/registrar. ASG, September 2019ASG, March 2019

CASPOFUNGIN ACETATE 50mg INJECTION

R For treatment of proven or suspected invasive fungal disease in adults and paediatrics when: initiated by consultant haematologist/oncologist, or, following approval by ID/Micro consultant/registrar. ASG, September 2019ASG, March 2019

MICAFUNGIN

MICAFUNGIN 100mg INJECTION	R	This antimicrobial requires prescribing by:- Transplant consultant or registrar - prophylaxis at induction (single dose); - Haematology/Oncology (adult and paediatrics; consultant initiation only); - for the treatment of severe fungal infection, 3rd-line treatment of possible fungal infections in febrile neutropenia patients. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar; - Paediatric ID consultant or registrar. Antimicrobials Steering Group,
----------------------------	---	--

MICAFUNGIN 50mg INJECTION	R	This antimicrobial requires prescribing by:- Transplant consultant or registrar - prophylaxis at induction (single dose); - Haematology/Oncology (adult and paediatrics; consultant initiation only); - for the treatment of severe fungal infection, 3rd-line treatment of possible fungal infections in febrile neutropenia patients. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar; - Paediatric ID consultant or registrar. Antimicrobials Steering Group,
---------------------------	---	--

05.03 Antiviral drugs

Aciclovir

ACICLOVIR 400mg TABLETS TTO 56s	SR	For use as a TTO pack on GUM only. Medicines Effectiveness, August 2023
---------------------------------	----	---

Baloxavir

BALOXAVIR 40mg TABLETS (RECOVERY TRIAL)	R	For use in the RECOVERY Trial only. EudraCT: 2020-000113-21 ME 19.12.23
---	---	---

Bulevirtide

BULEVIRTIDE 100mg/ml INJECTION (PROCEDURE PACK)	R	For treatment of Chronic hepatitis D in adults with compensated liver disease as per NICE TA896. MMTc, December 2023
--	---	--

BULEVIRTIDE 2mg INJECTION	R	For treatment of chronic hepatitis D in adults with compensated liver disease as per NICE TA896. MMTC, December 2023
---------------------------	---	--

GANCICLOVIR

GANCICLOVIR 500mg INJECTION	NF	
-----------------------------	----	--

INDINAVIR

INDINAVIR 400mg CAPSULES	NF	
--------------------------	----	--

Oseltamivir

OSELTAMIVIR 75mg CAPSULES (RECOVERY TRIAL) C		For use in the RECOVERY Trial only. EudraCT: 2020-000113-21 ME 19.12.23
--	--	---

OSELTAMIVIR 30mg/5ml LIQUID 65ml (RECOVERY TRIAL) C		For use in the RECOVERY Trial only. EudraCT: 2020-000113-21 ME 19.12.23
---	--	---

Raltegravir

RALTEGRAVIR 100mg CHEWABLE TABLETS	R	For treatment of post exposure prophylaxis or treatment of HIV in paediatric patients. For use/recommended by paed ID/ID/OSHS only. MMTC Oct 2017.
------------------------------------	---	--

05.03 Antiviral drugs

FOSCARNET

FOSCARNET 6g in 250ml INFUSION	R	For the treatment of acute retinal necrosis only. MMTC, January 2016
--------------------------------	---	--

05.03.00 Antiviral drugs

GANCICLOVIR

GANCICLOVIR 500mg in 100ml SODIUM CHLORIDE 0.9% INFUSION (EMERGENCY BAG) SR		For emergency use only- see procedure on sharepoint site (Clinical/Baxter). Pharmacist to calculate exact volume to be administered to deliver prescribed dose. If stock expires book out to Transplant/Haematology/Critical Care PPDU, November 2011.
---	--	--

05.03.01 HIV infecti

EFAVIRENZ

EFAVIRENZ 100mg CAPSULES	R	For use by Infectious Diseases and Genito-urinary Medicine only. Medicines Effectiveness, October 2007
EFAVIRENZ 50mg CAPSULES	R	For use by Infectious Diseases and Genito-urinary Medicine only. Medicines Effectiveness, October 2007.
<i>05.03.01 HIV infection</i>		
ABACAVIR		
ABACAVIR 100mg/5ml LIQUID	R	For use by Infectious Diseases and Genito-urinary Medicine only. Medicines Effectiveness, Jul 1999.
ABACAVIR 300mg TABLETS	R	For use by Infectious Diseases and Genito-urinary Medicine only. Medicines Effectiveness, Jul 1999.
ABACAVIR + LAMIVUDINE		
ABACAVIR 600mg & LAMIVUDINE 300mg (KIVEXA) TABLETS	R	For use by Infectious Diseases and Genito-Urinary Medicine only. Medicines Effectiveness, August 2006.
COBICISTAT + ELVITEGRAVIR + EMTRICITABINE		
COBICISTAT / ELVITEGRAVIR / EMTRICITABINE / TENOFOVIR DISOPROXIL	R	For use by Infectious Diseases and Genito-urinary Medicine only. Restricted to patients who require a reduced pill burden and who are unsuitable for/intolerant of first line therapies. MMTC, July 2016
DARUNAVIR		
DARUNAVIR 500mg/5ml LIQUID	R	Patients with feeding tubes or swallowing difficulties only. For use by Infectious Diseases and Genito-urinary Medicine only. Medicines Effectiveness, February 2012.
DARUNAVIR 800mg TABLETS	R	For use by Infectious Diseases and Genito-urinary Medicine only. Medicines Effectiveness, February 2012
DARUNAVIR + COBICISTAT		

DARUNAVIR 800mg / COBICISTAT 150mg TABLETS	R	For use by Infectious Diseases and Genito-urinary Medicine only. Restricted for patients with tablet burden related adherence issues. MMTC, July 2016
DOLUTEGRAVIR		
DOLUTEGRAVIR / RILPIVIRINE 50mg/25mg TABLETS	R	For treatment of HIV-1 infection in line with NHSE/1806. MMTC October 2020
DOLUTEGRAVIR 50mg/ LAMIVUDINE 300mg TABLETS	R	For treatment of HIV. MMTC, August 2020
DORAVIRINE		
DORAVIRINE 100mg TABLETS	R	For treatment of HIV-1 infection as per NHS England commissioning policy 190137P. To be initiated following discussion in a HIV MDT only. MMTC March 2021
DORAVIRINE + LAMIVUDINE + TENOFOVIR		
DORAVIRINE 100mg / LAMIVUDINE 300mg / TENOFOVIR DISOPROXIL 245mg TABLETS	R	For treatment of HIV-1 infection as per NHS England commissioning policy 190137P. To be initiated following discussion in a HIV MDT only. MMTC March 2021
EFAVIRENZ		
EFAVIRENZ 200mg CAPSULES	R	For use by Infectious Diseases and Genito-urinary Medicine only. Medicines Effectiveness, October 2007.
EFAVIRENZ + EMTRICITABINE + TENOFOVIR		
EFAVIRENZ 600mg,EMTRICITABINE 200mg,TENOFOVIR DISOPROXIL 245mg TABLETS	R	For use by Infectious Diseases and Genito-urinary Medicine only. Medicines Effectiveness, May 2008.
EMTRICITABINE + TENOFOVIR		
TENOFOVIR 245mg & EMTRICITABINE 200mg TABLETS (TRUVADA)	R	For use by Infectious Diseases and Genito-urinary Medicine only. Antiretroviral Formulary Group, May 2010
ETRAVIRINE		

ETRAVIRINE 100mg TABLETS	R	For use by Infectious Diseases and Genito-urinary Medicine consultants only. To be initiated only after discussion of case by a group consisting of a minimum of 3 consultants, 1 HIV pharmacist and with virology input. Antiretroviral Formulary
ETRAVIRINE 200mg TABLETS	R	Use by Infectious Diseases consultants only. To be initiated only after discussion of case by a group consisting of a minimum of 3 consultants, 1 HIV pharmacist and with virology input. Antiretroviral Formulary
LAMIVUDINE + ZIDOVUDINE		
ZIDOVUDINE 300mg / LAMIVUDINE 150mg TABLETS	R	For use by Infectious Diseases and Genito-urinary Medicine only. Medicines Effectiveness, Jul 1999.
MARAVIROC		
MARAVIROC 300mg TABLETS	R	For use by Infectious Diseases and Genito-urinary Medicine only. Medicines Effectiveness, January 2009
NEVIRAPINE		
NEVIRAPINE 50mg TABLETS M/R	R	For use by infectious disease only. Medicines Effectiveness, February 2013
NEVIRAPINE 100mg TABLETS M/R	R	For use by infectious disease only. Medicines Effectiveness, February 2013
NEVIRAPINE 400mg TABLETS S/R	R	Only use if SR specified. For all other 400mg doses use 2 x 200mg tablets. Infectious Diseases only. Medicines Effectiveness, February 2013.
RALTEGRAVIR		
RALTEGRAVIR 600mg TABLETS	R	For the treatment of HIV-1 and post exposure prophylaxis (PEP) in patients requiring a once daily regime. For use by Infectious Diseases and Genito-urinary Medicine only. MMTc, March 2018

RILPIVIRINE

RILPIVIRINE 25mg TABLETS	R	2nd line treatment for HIV. Initiation restricted to ID / Paed ID / GUM. MMTC, August 2012
RITONAVIR		
RITONAVIR 100mg SACHETS	R	Restricted to Micro / ID / Paed ID / OSHS initiation. Medicines Effectiveness, July 2016
TENOFOVIR		
TENOFOVIR 245mg TABLETS	NF	
TENOFOVIR 123mg TABLETS	R	Restricted to Paed ID / Micro / ID / OSHS. Medicines Effectiveness, October 2016
TENOFOVIR 33mg/g ORAL GRANULES (60g)	R	Restricted use by Hepatologist Consultants for Hepatitis B treatment as per NICE TA173 and ID / Paed ID / GU prescribers for HIV. Medicines Effectiveness, January 2015
TENOFOVIR DISOPROXIL 245mg TABLETS	R	This antimicrobial requires approval/prescribing by: - Hepatologist Consultants for oral Hepatitis B treatment as per NICE TA173. - ID / Paed ID / GU prescribers for HIV. Medicines Effectiveness, January 2009.
TENOFOVIR + EMTRICITABINE + RILPIVIRINE		
TENOFOVIR 245mg / EMTRICITABINE 200mg / RILPIVIRINE 25mg F/C TABLETS	R	For use by Infectious Diseases and Genito-urinary Medicine only. Antiretroviral Formulary Group, May 2010
TIPRANAVIR		
TIPRANAVIR 250mg CAPSULES	R	For use by Infectious Diseases and Genito-urinary Medicine consultants only. To be initiated only after discussion of case by a group consisting of a minimum of 3 consultants, 1 HIV pharmacist and with virology input. Antiretroviral Formulary
<i>05.03.01 HIV infections</i>		
EMTRICITABINE		
EMTRICITABINE 200mg & TENOFOVIR ALAFENAMIDE 25mg TABLETS	R	For treatment of HIV 1 in adults and adolescents as per NHSE policy 16043/P. MMTC, June 2017

EMTRICITABINE 200mg & TENOFOVIR ALAFENAMIDE 10mg TABLETS	R	For treatment of HIV 1 in adults and adolescents as per NHSE policy 16043/P. MMTC, June 2017
RALTEGRAVIR		
RALTEGRAVIR 25mg CHEWABLE TABLETS	R	For treatment of post exposure prophylaxis or treatment of HIV in paediatric patients. For use/ recommended by Paeds ID / ID / OSHS only. MMTC, October 2017
Tenofovir+Cobicistat+ELVITEGRAVIR+EMTRICITABI		
TENOFOVIR ALAFENAMIDE 10mg / EMTRICITABINE 200mg / COBICISTAT 150mg / ELVITEGRAVIR 150mg		For the management of HIV in those where tenofovir disoproxil containing regimens are contraindicated due to renal or osteoporosis, or where an abacavir based regimen is clinically inappropriate. To be initiated by Infectious Diseases or GUM consultants in line with NHSE policy F03/P/a. MMTC, March 2017
<i>05.03.03 Viral hepatitis</i>		
CIDOFOVIR		
CIDOFOVIR 375mg in 5ml INJECTION	NF	See RESI file for further info Requires approval or prescribing by: - Microbiology/ID consultant or registrar. - Paediatric ID consultant or registrar Do not dispense this medicine unless the relevant approval has been obtained. Carlos, February 2009. Please check patient being discharged on IV antibiotics is staying within Oxfordshire and thus have a postcode starting with 'OX'. (As per instruction from Ted Baker Medical Director Sep 11).
ELBASVIR		
ELBASVIR 50mg & GRAZOPREVIR 100mg TABLETS	R	For the treatment of chronic hepatitis C as per NICE TA413. MMTC, May 2017
RIBAVIRIN		
RIBAVIRIN 200mg CAPSULES	R	?For use by Consultant Hepatologist for oral Hepatitis treatment as per TA75, TA106 and TA200. MAC, April 2003

SIMEPREVIR

SIMEPREVIR 150mg CAPSULES

NICE Approved for use as per NICE TA only. An individual patient NICE implementation form is required (see PPDU SharePoint).
Medicines Effectiveness, March 2015

SOFOSBUVIR

SOFOSBUVIR 400mg TABLETS

R For the treatment of hepatitis C as per TA330 and NHS England policy B07/P/a. Initiation by a hepatologist only. MMTC, January 2016

SOFOSBUVIR + LEDIPASIVIR

SOFOSBUVIR 400mg / LEDIPASIVIR 90mg TABLETS R
(Licensed stock)

For the treatment of hepatitis C as per TA363 and NHS England policy B07/P/a. Initiation by a hepatologist only. MMTC, January 2016

SOFOSBUVIR + VELPATASVIR

SOFOSBUVIR 400mg & VELPATASVIR 100mg TABLETS

R For the treatment of chronic hepatitis C as per NICE TA430. MMTC, May 2017

05.03.05 Respiratory syncytial virus

RIBAVIRIN

RIBAVIRIN 200mg TABLETS

R For use by Consultant Hepatologist for oral Hepatitis treatment as per TA75, TA106 and TA200. MAC, April 2003

15.03.00 Antiviral drugs

ACICLOVIR

ACICLOVIR 500mg INJECTION

Y Please check patient being discharged on IV antibiotics is staying within Oxfordshire and thus have a postcode starting with 'OX'. (As per instruction from Ted Baker Medical Director Sep 11).

ACICLOVIR 250mg INJECTION

Y

ACICLOVIR 250mg POWDER FOR INJECTION	R	Please check patient being discharged on IV antibiotics is staying within Oxfordshire and thus have a postcode starting with 'OX'. (As per instruction from Ted Baker Medical Director Sep 11).
ACICLOVIR 400mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
ACICLOVIR 200mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
ACICLOVIR 800mg TABLETS	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
ACICLOVIR 200mg/5ml LIQUID	R	For patients who cannot tolerate dispersible tablets or if these are not available. Use DISPERSIBLE TABLETS for children and patients with swallowing difficulties or feeding tubes (dispersible tablets are more cost-effective than the liquid and they are also preferable for tubes, as the liquid preps are really viscous). As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

ATAZANAVIR + COBICISTAT

ATAZANAVIR 300mg / COBICISTAT 150mg TABLETS NF

DARUNAVIR + COBICISTAT + EMTRICITABINE +

DARUNAVIR 800mg / COBICISTAT 150mg / R
EMTRICITABINE 200mg / TENOFOVIR ALAFENAMIDE

For treatment of HIV 1 in adults and adolescents as per NHSE policy 16043/P and NHSE policy F03/P/b.
MMTC, May 2019

DIDANOSINE

DIDANOSINE 250mg CAPSULES E.C NF

DIDANOSINE 200mg CAPSULES E.C NF

DIDANOSINE 400mg CAPSULES E.C. NF

EFAVIRENZ

EFAVIRENZ 30mg/ml SOLUTION R

For use by Infectious Diseases and Genito-urinary Medicine only. Medicines Effectiveness, October 2007.

EMTRICITABINE

BICTEGRAVIR 50mg/ EMTRICITABINE 200mg/ R
TENOFOVIR ALAFENAMIDE 25mg TABLETS

For treatment of HIV. MMTC May 2020

ENTECAVIR

ENTECAVIR 500microgram TABLETS R

Restricted use by Hepatologist Consultants for oral Hepatitis B treatment as per TA153. MAC, February 2009.

ENTECAVIR 1mg TABLETS R

Restricted use by Hepatologist Consultants for oral Hepatitis B treatment as per TA153. MAC, February 2009.

FAMCICLOVIR

FAMCICLOVIR 500mg TABLETS R

This antimicrobial requires approval or prescribing by: Microbiology/ID consultant or registrar.- Paediatric ID consultant or registrar. Do not dispense this medicine unless the relevant approval has been obtained. Medicines Effectiveness, February 2009

FAMCICLOVIR 250mg TABLETS	R	This antimicrobial requires approval or prescribing by: Microbiology/ID consultant or registrar.- Paediatric ID consultant or registrar. Do not dispense this medicine unless the relevant approval has been obtained. Medicines Effectiveness, February 2009
FAMCICLOVIR 250mg TABLETS	R	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
GLECAPREVIR		
GLECAPREVIR 100mg / PIBRENTASVIR 40mg TABLETS	R	For the treatment chronic hepatitis C in adults as per NICE TA499
INDINAVIR		
INDINAVIR 200mg CAPSULES	NF	
LAMIVUDINE		
LAMIVUDINE 50mg/5ml LIQUID 240ml	R	For viral hepatitis or HIV treatment. It is also available following approval/prescribing by: - ID consultant or registrar Antimicrobials Steering Group, January 2009.
LAMIVUDINE 100mg TABLETS FILM COATED	R	For viral hepatitis or HIV treatment. It is also available following approval/prescribing by: - ID consultant or registrar Antimicrobials Steering Group, January 2009.
LAMIVUDINE 150mg TABLETS	R	For viral hepatitis or HIV treatment. It is also available following approval/prescribing by: - ID consultant or registrar Antimicrobials Steering Group, January 2009.
LETERMOVIR		
LETERMOVIR 240mg TABLETS	R	For preventing Cytomegalovirus disease after a stem cell transplant as per NICE TA591 only. MMTC August 2019

LETERMOVIR 240mg/12ml SOLUTION FOR INFUSION
VIALS

R For preventing Cytomegalovirus disease after a stem cell transplant as per NICE TA591 only MMTC August 2019

LOPINAVER + RITONAVIR

LOPINAVER 400mg / RITONAVIR 100mg in 5ml ORAL SOLUTION 60ml

R For use by Infectious Diseases and Genito-urinary Medicine only. Medicines Effectiveness, February 2012

LOPINAVER 200mg / RITONAVIR 50mg TABLETS

R For use by Infectious Diseases and Genito-urinary Medicine only. Medicines Effectiveness, February 2012

MARAVIROC

MARAVIROC 150mg TABLETS

R For use by Infectious Diseases and Genito-urinary Medicine only. Medicines Effectiveness, January 2009.

NELFINAVIR

NELFINAVIR 250mg TABLETS

NF

NEVIRAPINE

NEVIRAPINE 50mg/5ml LIQUID

R Infectious Diseases only. Medicines Effectiveness, February 2013.

NEVIRAPINE 200mg TABLETS

R Infectious Diseases only. Medicines Effectiveness, February 2013.

OSELTAMIVIR

OSELTAMIVIR 75mg CAPSULES

R For influenza prophylaxis as per NICE TA158 and for influenza treatment only when national threshold is reached (per DoH guideline) as per TA168. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

PALIVIZUMAB

PALIVIZUMAB 100mg INJECTION	R	for passive immunisation against Respiratory Syncytial Virus (RSV) in at-risk infants as per the Green Book criteria MMTC, Oct 2023
RIBAVIRIN		
RIBAVIRIN 1.2g in 12ml INJECTION	UNR	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
RIBAVIRIN 200mg TABLETS (COPEGUS)	R	For use by Consultant Hepatologist for oral Hepatitis treatment as per TA75, TA106 and TA200. MAC, April 2003.
STAVUDINE		
STAVUDINE 40mg CAPSULES	NF	
STAVUDINE 1mg/ml SUSPENSION	NF	
STAVUDINE 30mg CAPSULES	NF	
STAVUDINE 20mg CAPSULES	NF	
TENOFOVIR ALAFENAMIDE + EMTRICITABINE +		
TENOFOVIR ALAFENAMIDE 25mg / EMTRICITABINE 200mg / RILPIVIRINE 25mg TABLETS (ODEFSEY)	R	For treatment of HIV 1 in adults and adolescents as per NHSE policy 16043/P. To be initiated by Infectious Diseases or Sexual Health HIV consultant only. MMTC, June 2017
TENOFOVIR DISOPROXIL/EMTRICITABINE		
TENOFOVIR DISOPROXIL 245mg / EMTRICITABINE 200mg TABLETS TTO (30)	SR	For pre-exposure prophylaxis of HIV infection. Provided by OSHS or ID. MMTC October 2020
VALACICLOVIR		
VALACICLOVIR 500mg TABLETS	R	For prophylaxis of CMV disease post-transplant (Transplant Unit consultant or registrar only). It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

VALGANCICLOVIR

VALGANCICLOVIR 450mg TABLETS

R For prophylaxis of CMV disease post-transplant (Transplant Unit consultant or registrar only). It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

ZANAMIVIR

ZANAMIVIR 200mg IN 20ml SOLUTION FOR INFUSION

R For the treatment of influenza in critically ill patients unable to receive enteral or inhaled antivirals as per PHE guidance. MMTC, October 2019

ZANAMIVIR 5mg/BLISTER DISKHALER + 5 DISKS

R For influenza prophylaxis as per NICE TA158 and for influenza treatment only when national threshold is reached (per DoH guideline) as per TA168. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

ZIDOVUDINE

ZIDOVUDINE 10mg/ml 20ml INJECTION

R For infectious diseases use only. Medicines Effectiveness, February 2013.

ZIDOVUDINE 10mg/1ml SYRUP

R For infectious diseases use only. Medicines Effectiveness, February 2013.

5.03.00 Antiviral drugs

ACICLOVIR

ACICLOVIR 250mg in 10ml SOLUTION FOR INJECTION

Y As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

ACICLOVIR 500mg in 20ml SOLUTION FOR INJECTION

Y As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by:
- Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar
Antimicrobials Steering Group, January 2012.

ACICLOVIR 200mg TABLETS - CANSAT PK TTO (25) SR

For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by:
- Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar
Antimicrobials Steering Group, January 2012.

ATAZANAVIR

ATAZANAVIR 200mg CAPSULES

R

For use by Infectious Diseases and Genito-urinary Medicine only. ARV, June 2016

ATAZANAVIR 300mg CAPSULES

R

For use by Infectious Diseases and Genito-urinary Medicine only. ARV, June 2016

DARUNAVIR

DARUNAVIR 600mg TABLETS

R

For use by Infectious Diseases and Genito-urinary Medicine only. The 600mg tablets can ONLY be initiated after discussion of case by a group consisting of a minimum of 3 consultants, 1 HIV pharmacist and with virology input. Medicines Effectiveness, February 2012.

OSELTAMIVIR

OSELTAMIVIR 45mg CAPSULES

R

For influenza prophylaxis as per NICE TA158 and for influenza treatment only when national threshold is reached (per DoH guideline) as per TA168. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar
Antimicrobials Steering Group, January 2012.

OSELTAMIVIR 30mg in 5ml LIQUID 65ml	R	For influenza prophylaxis as per NICE TA158 and for influenza treatment only when national threshold is reached (per DoH guideline) as per TA168. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
OSELTAMIVIR 30mg CAPSULES	R	For influenza prophylaxis as per NICE TA158 and for influenza treatment only when national threshold is reached (per DoH guideline) as per TA168. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
PALIVIZUMAB		
PALIVIZUMAB 50mg INJECTION	R	for passive immunisation against Respiratory Syncytial Virus (RSV) in at-risk infants as per the Green Book criteria MMTc, Oct 2023
RALTEGRAVIR		
RALTEGRAVIR 400mg TABLETS	R	For use by Infectious Diseases and Genito-urinary Medicine only. Medicines Effectiveness, February 2012
RIBAVIRIN		
RIBAVIRIN 200mg/5ml LIQUID	R	For small paediatric doses (for continuation of therapy) as per NICE TA300. MMTc, January 2014.
RITONAVIR		
RITONAVIR 100mg TABLETS	R	For use by Infectious Diseases and Genito-urinary Medicine only. Only in combination with a Protease Inhibitor. Antiretroviral Formulary Group, May 2010.
SAQUINAVIR		
SAQUINAVIR 500mg TABLETS	NF	

VALACICLOVIR

VALACICLOVIR 500mg TABLETS

R For prophylaxis of CMV disease post-transplant (Transplant Unit consultant or registrar only). It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

VALGANCICLOVIR

VALGANCICLOVIR 250mg/5ml LIQUID 100ml

R For patients with swallowing difficulties or feeding tubes. For prophylaxis of CMV disease post-transplant (Transplant Unit consultant or registrar only). It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

ZIDOVUDINE

ZIDOVUDINE 250mg CAPSULES

R For infectious diseases use only. Medicines Effectiveness, February 2013.

ZIDOVUDINE 100mg CAPSULES

R For infectious diseases use only. Medicines Effectiveness, February 2013.

05.04 Antiprotozoal drugs

05.04.00 Antiprotozoal drugs

NITAZOXANIDE

NITAZOXANIDE 500mg TABLETS

UNR For the treatment of Cryptosporidia, resistant giardia and Amoebiasis where standard treatment has failed as recommended by Micro / ID MMTC, August 2019

05.04.01 Antimalarials

ARTEMETHER + LUMEFANTRINE

RIAMET 20mg/120mg TABLETS	R	For the treatment of malaria. This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
ARTESUNATE		
ARTESUNATE 60mg INJECTION	UNR	For severe falciparum malaria. MAC, November 2008
CHLOROQUINE		
CHLOROQUINE SULPHATE 50mg/5ml (base) LIQUID	R	For paediatric patients, patients with swallowing difficulties or feeding tubes, for treatment of malaria. This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
MEFLOQUINE		
MEFLOQUINE 250mg TABLETS	NF	
PIPERAQUINE PHOSPHATE		
PIPERAQUINE PHOSPHATE 320mg / ARTENIMOL 40mg (EURATESIM)	NF	
PRIMAQUINE		
PRIMAQUINE PHOSPHATE 7.5mg TABLETS	UNR	For treatment of malaria. This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
PROGUANIL		
PROGUANIL 100mg TABLETS	NF	
PROGUANIL + ATOVAQUONE		
PROGUANIL 100mg / ATOVAQUONE 250mg TABLETS	R	For the treatment of malaria. ASG, August 2015.
PYRIMETHAMINE		

PYRIMETHAMINE 25mg TABLETS

R

This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

QUININE

QUININE DIHYDROCHLORIDE 300mg IN 1ml INJECTION complicated

UNR For the treatment of

falciparum malaria (second line after artesunate IV). This antimicrobial requires approval/prescribing by: Microbiology/ID consultant or registrar; Paediatric ID consultant or registrar. Antimicrobials Steering Group, January 2012.

05.04.02 Amoebicides

DILOXANIDE

DILOXANIDE FUROATE 500mg TABLETS

R

This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

05.04.04 Antigiardial drugs

CHLOROQUINE

CHLOROQUINE PHOSPHATE 250mg TABLETS

R

For treatment of malaria This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

MEPACRINE

MEPACRINE 100mg TABLETS

SR

For the treatment of Giardia unresponsive to first and second line treatment. This antimicrobial requires approval or prescribing by: Microbiology/ID consultant or registrar. MMTG, February 2017

05.04.05 Leishmaniacides

SODIUM STIBOGLUCONATE

SODIUM STIBOGLUCONATE 100ml INJECTION	R	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
---------------------------------------	---	---

05.04.07 Drugs for toxoplasmosis

SPIRAMYCIN

SPIRAMYCIN 500mg (1.5mu) TABLETS	UNR	Prevention of vertical transmission of toxoplasmosis in pregnancy [Unlicensed product]
----------------------------------	-----	--

05.04.08 Drugs for pneumocystis pneumonia

ATOVAQUONE

ATOVAQUONE 750MG/5ML SUSPENSION	R	This antimicrobial requires approval or prescribing by: - Microbiology/ID consultant or registrar. - Paediatric ID consultant or registrar .Antimicrobials Steering Group, January 2012.
---------------------------------	---	--

ATOVAQUONE 750mg/5ml SUSPENSION	R	This antimicrobial requires approval or prescribing by: - Microbiology/ID consultant or registrar. - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
---------------------------------	---	---

05.05 Anthelmintics

05.05.01 Drugs for threadworms

MEBENDAZOLE

MEBENDAZOLE 100mg/5ml LIQUID	R	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
------------------------------	---	---

MEBENDAZOLE 100mg TABLETS	R	This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
---------------------------	---	---

05.05.03 Drugs for tapeworm infections

ALBENDAZOLE

ALBENDAZOLE 400mg TABLETS

UNR This antimicrobial requires approval or prescribing by: - Microbiology/ID consultant or registrar. - Paediatric ID consultant or registrar. Antimicrobials Steering Group, January 2012

05.05.05 Schistosomicides

PRAZIQUANTEL

PRAZIQUANTEL 600mg TABLETS

UNR For schistosomiasis or hydatid cyst. This antimicrobial requires approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

05.05.06 Filaricides

IVERMECTIN

IVERMECTIN 3mg TABLETS

UNR For scabies, filariasis and strongyloides. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2009.

05.05.08 Drugs for strongyloidiasis

ALBENDAZOLE

ALBENDAZOLE 400mg TABLETS

UNR This antimicrobial requires approval or prescribing by: - Microbiology/ID consultant or registrar. - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

5.03 Antiviral drugs

05.03.00 Antiviral drugs

Remdesivir

REMDESIVIR 100mg POWDER FOR INJECTION

NF For treatment of COVID-19 patients in hospitalised patients (ages 12 and older). For treatment of COVID-19 in the community as 3rd line treatment. MMTC, February 2022 Amended to NF following negative NICE appraisal. DAVID 1.6.23

15.03.00 Antiviral drugs

EFAVIRENZ

EFAVIRENZ 600mg TABLETS R

5.3 Antiviral drugs

05.03.01 HIV infection

DOLUTEGRAVIR

DOLUTEGRAVIR 50mg & ABACAVIR 600mg & LAMIVUDINE 300mg TABLETS (TRIUMEQ) R For initiation by Infectious Diseases / Paediatric Infectious Diseases / GUM only. ARVFG, May 2015.

DOLUTEGRAVIR 50mg TABLETS R For initiation by Infectious Diseases / Paediatric Infectious Diseases / GUM only. MMTTC, May 2015.

ENTECAVIR

ENTECAVIR 50microgram/ml ORAL SOLUTION R Restricted use by Hepatologist Consultants for oral Hepatitis B treatment as per TA153. MAC, February 2009.

06 Endocrine system

06.01 Drugs used in diabetes

06.01.00 Diabetes Mellitus and hypoglycaemia

Semaglutide

SEMAGLUTIDE 14mg TABLETS NF

SEMAGLUTIDE 250microgram (1.34mg IN 1ml) INJECTION PRE-FILLED PEN R

SEMAGLUTIDE 500micrograms per dose (2mg in 1.5ml) PRE-FILLED PEN R

SEMAGLUTIDE 1mg per dose (4mg in 3ml) PRE-FILLED PEN R

SEMAGLUTIDE 3mg TABLETS NF

SEMAGLUTIDE 0.5mg PREFILLED PEN R Restricted for use in paediatric patients during shortage of Semaglutide ME 21.11.23

SEMAGLUTIDE 250micrograms PRE-FILLED PEN (WEGOVY) R ?Restricted to paediatric use ONLY during supply shortage. 12/12/23

06.01.00 Drugs used in diabetes

GLUCOSE

GLUCOSE 40% GEL (GLUCOGEL) 25g Y

06.01.01 Insulins

CLICKSTAR

CLICKSTAR PEN DEVICE R For continuation only. Medicines Effectiveness, December 2010.

GLUCOSE

GLUCOSE TABLETS R For use in Hypo Boxes. Medicines Effectiveness, November 2003.

HUMAPEN

HUMAPEN SAVVIO GREEN R For use with 'Lilly' insulin ('Humalog' or 'Humulin') 3-ml cartridges. Suitable for use with 'BD' insulin pen needles. Medicines Effectiveness, October 2017

INSULIN

INSULIN FIASP 100 UNITS/ML CARTRIDGE 3ML R For continuation of therapy and following recommendation by the Specialist Diabetes team only. MMTC, June 2017

INSULIN TRESIBA 100units/ml DISPOSABLE PEN 3ml R Restricted to use in patients with multiple episodes of hypoglycaemia over 12 months and for those with repeated admissions for DKA. Initiation following diabetologist recommendation only. MMTC, July 2015

INSULIN TRESIBA 200units/ml DISPOSABLE PEN 3ML NF

INSULIN FIASP 100units/ml VIAL R For continuation of therapy and following recommendation by the Specialist Diabetes team only. MMTC, June 2017

INSULIN ISOPHANE 100units/ml PRE FILLED PEN 3mlNF

INSULIN APIDRA 100units/ml CARTRIDGE 3ml R Restricted for continuation of therapy only. This will be ordered in for individual patients. Use solostar device if patient doesn't have pen with them. MMTC, January 2016

INSULIN DEGLUDEC 100units/ml CARTRIDGE 3ml	R	Restricted to use in patients with multiple episodes of hypoglycaemia over 12 months and for those with repeated admissions for DKA. Initiation following diabetologist recommendation only. MMTC, July 2015
INSULIN TOUJEO (SOLOSTAR) 300units / ml PRE-FILLED PEN 1.5ml	R	Restricted for continuation of therapy or initiation by diabetologist only. MMTC, January 2016
INSULIN ASPART 100units/ml PRE-FILLED PEN PEN 3ml (NOVORAPID FLEXTOUCH)	NF	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN ABASAGLAR (KWIKPEN) 100units/ml DISPOSABLE PEN 3ml	R	For continuation of therapy and following recommendation by the Specialist Diabetes team only. MMTC, June 2017
INSULIN FIASP 100units/ml FLEXTOUCH PRE-FILLED PEN 3ml	R	For continuation of therapy and following recommendation by the Specialist Diabetes team only. MMTC, June 2017
INSULIN NOVORAPID 100units/ml PUMPCART 1.6ml	R	Restricted for continuation of therapy and diabetologists or diabetes specialist nurse recommendation only. MMTC, January 2016
INSULIN HUMULIN S 100units/ml VIAL 10ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN HYPURIN PORCINE 30/70 MIX 100units/ml VIAL 10ml	Y	
INSULIN NOVOMIX 30 100units/ml DISPOSABLE PEN 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN NOVORAPID 100units/ml CARTRIDGE 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN INSULATARD 100units/ml DISPOSABLE PEN 3ml (INNOLET)	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007

INSULIN INSUMAN COMB 25/75 SOLOSTAR 3ml PRE- FILLED PEN	NF	
INSULIN INSULATARD 100units/ml VIAL 10ml	Y	
INSULIN NOVOMIX 30 100units/ml CARTRIDGE 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN HYPURIN PORCINE NEUTRAL 100units/ml VIAL 10ml	Y	
INSULIN LEVEMIR 100units/ml DISPOSABLE PEN (INNOLET) 3ml	NF	
INSULIN LEVEMIR 100units/ml DISPOSABLE FLEXPEN 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN LEVEMIR 100units/ml CARTRIDGE 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN INSULATARD 100units/ml CARTRIDGES 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN LANTUS 100units/ml VIAL 10ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN LANTUS 100units/ml DISPOSABLE PEN 3ml (SOLOSTAR)	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN LANTUS 100units/ml CARTRIDGE 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN HYPURIN PORCINE ISOPHANE 100units/ml VIAL 10ml	Y	
INSULIN HUMALOG MIX 50 (KWIKPEN) 100units/ml DISPOSABLE PEN 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN ACTRAPID 100units/ml VIAL 10ml	Y	

INSULIN HUMULIN I (KWIKPEN) 100units/ml DISPOSABLE PEN 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN HUMALOG (KWIKPEN) 100units/ml DISPOSABLE PEN 3ml	R	Restricted for continuation of therapy and diabetologists or diabetes specialist nurse recommendation only. MMTC, January 2016
INSULIN HUMALOG 100units/ml VIAL 10ml	R	Restricted for continuation of therapy and diabetologists or diabetes specialist nurse recommendation only. MMTC, January 2016
INSULIN HUMALOG MIX 25 (KWIKPEN) 100units/ml DISPOSABLE PEN 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN HUMALOG 100units/ml CARTRIDGE 3ml	R	Restricted for continuation of therapy and diabetologists or diabetes specialist nurse recommendation only. MMTC, January 2016
INSULIN HUMALOG MIX 25 100units/ml VIAL 10ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN HUMULIN M3 100units/ml VIAL 10ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN HUMALOG MIX 50 100units/ml CARTRIDGE 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN HUMAN SOLUBLE 50units IN 50ml PRE- FILLED SYRINGE	SR	For patients requiring a Variable Rate Intravenous Insulin Infusion as per MIL Vol. 6 No. 7. Medicines Effectiveness, March 2011.
INSULIN HUMULIN I 100units/ml CARTRIDGES 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN NOVORAPID 100units/ml VIAL 10ml	Y	

INSULIN NOVORAPID 100units/ml DISPOSABLE PEN 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN HUMULIN I 100units/ml VIAL 10ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN HUMULIN M3 (KWIKPEN) 100units/ml DISPOSABLE PEN 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN HUMULIN M3 100units/ml CARTRIDGE 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN HUMALOG MIX 25 100units/ml CARTRIDGE 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007
INSULIN HUMULIN S 100units/ml CARTRIDGES 3ml	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007.

INSULIN ABASAGLAR

INSULIN ABASAGLAR 100 UNITS/ML CARTRIDGES 3ML	R	For continuation of therapy and following recommendation by the Specialist Diabetes team only. MMTC, June 2017
---	---	--

INSULIN GLULISINE

INSULIN APIDRA 100units/ml DISPOSABLE PEN 3ml	R	Restricted for continuation of therapy only. MMTC, January 2016
---	---	---

NOVOPEN

NOVOPEN 4 PEN DEVICE	R	For continuation only. Medicines Effectiveness, December 2010.
----------------------	---	--

06.01.02 Antidiabetic drugs

ALOGLIPTIN

ALOGLIPTIN 12.5mg TABLETS	R	For the management of type 2 diabetes following recommendation by diabetologist only as per NICE guideline NG28. Alogliptin is considered the 1st line dipeptidylpeptidase-4 inhibitor at the OUHFT.MMTC , March 2017
---------------------------	---	---

06.01.02 Drugs used in diabetes

CANAGLIFLOZIN

CANAGLIFLOZIN 300mg TABLETS	R	For the treatment of type 2 diabetes as per NICE TA315 & NICE TA390. MMTC, November 2016.
-----------------------------	---	---

DULAGLUTIDE

DULAGLUTIDE 1.5mg IN 0.5ml PRE-FILLED PEN	NF	
---	----	--

06.01.02 Antidiabetic drugs

ACARBOSE

ACARBOSE 50mg TABLETS	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007.
-----------------------	---	--

ACARBOSE 100mg TABLETS	R	For established patients and diabetologists or diabetes specialist nurse recommendation only. MMTC, July 2007.
------------------------	---	--

ALOGLIPTIN

ALOGLIPTIN 6.25mg TABLETS	R	For the management of type 2 diabetes following recommendation by diabetologist only as per NICE guideline NG28. MMTC, March 2017
---------------------------	---	---

ALOGLIPTIN 25mg TABLETS	R	For the management of type 2 diabetes following recommendation by diabetologist only as per NICE guideline NG28. MMTC, March 2017
-------------------------	---	---

CANAGLIFLOZIN

CANAGLIFLOZIN 100mg TABLETS	R	For the treatment of type 2 diabetes as per NICE TA315 & NICE TA390. MMTC, November 2016.
-----------------------------	---	---

DAPAGLIFLOZIN

DAPAGLIFLOZIN 5mg TABLETS	R	For the treatment of type 2 diabetes as per NICE TA288, TA390 and TA418, For treatment of heart failure as per NICE TA679. MMTc, March 2021
DAPAGLIFLOZIN 10mg TABLETS	R	For the treatment of type 2 diabetes as per NICE TA288, TA390 and TA418, For treatment of heart failure as per NICE TA679. MMTc, March 2021
DULAGLUTIDE		
DULAGLUTIDE 0.75mg IN 0.5ml PRE-FILLED PEN	NF	
EMPAGLIFLOZIN		
EMPAGLIFLOZIN 25mg TABLETS	R	For the treatment of type 2 diabetes as per NICE TA336. NICE TA390. MMTc, November 2016
EMPAGLIFLOZIN 10mg TABLETS	R	For the treatment of type 2 diabetes as per NICE TA336 & NICE TA390. MMTc, November 2016.
EXENATIDE		
EXENATIDE 5microgram INJECTION	R	Initiated by diabetology consultants as per NICE TA248. Medicines Effectiveness, October 2007.
EXENATIDE 2mg INJECTION MR	NF	
EXENATIDE 10microgram INJECTION	R	Initiated by diabetology consultants as per NICE TA248. Medicines Effectiveness, October 2007.
GALVUS		
VILDAGLIPTIN 50mg TABLETS	NF	
GLICLAZIDE		
GLICLAZIDE 30mg TABLETS M/R	NF	
GLICLAZIDE 80mg TABLETS	Y	
GLIMEPIRIDE		
GLIMEPIRIDE 4mg TABLETS	NF	

GLIMEPIRIDE 1mg TABLETS	NF	
GLIMEPIRIDE 3mg TABLETS	NF	
GLIMEPIRIDE 2mg TABLETS	NF	
INSULIN GLULISINE		
INSULIN APIDRA 100units/ml VIAL 10ml	NF	
LINAGLIPTIN		
LINAGLIPTIN 5mg TABLETS F/C	R	For the management of type 2 diabetes in those with renal impairment following recommendation by diabetologist only. Linagliptin is also available for use as per the Oxford Heart Centre diabetes management protocol. MMTC, August 2016
LIRAGLUTIDE		
LIRAGLUTIDE 6mg in 1ml PRE-FILLED PEN	R	?For weight management in obese teenagers as 3rd line treatment. MMTC, October 2022
LIRAGLUTIDE 6mg in 1ml PRE-FILLED PEN	R	For the management of type 2 diabetes following recommendation by diabetologist only as per NICE guideline NG28. MMTC, March 2017
LIXISENATIDE		
LIXISENATIDE 20microgram PRE-FILLED PEN	R	For the management of type 2 diabetes following recommendation by diabetologist only as per NICE guideline NG28. MMTC, March 2017
METFORMIN		
METFORMIN 750mg TABLETS M/R	R	For continuation of therapy in any patient who has a proven GI intolerance to standard release preparation. MMTC July 2022
METFORMIN 500mg TABLETS M/R	R	For continuation of therapy in any patient who has a proven GI intolerance to standard release preparation. MMTC July 2022

METFORMIN 500mg/5ml LIQUID	R	For patients with feeding tubes only. Tablets can be crushed and dispersed in water for patients swallowing difficulties. Medicines Effectiveness, April
METFORMIN 850mg TABLETS	Y	
METFORMIN 500mg TABLETS	Y	
METFORMIN 500mg SACHETS (POWDER FOR ORAL SOLUTION)	NF	
NATEGLINIDE		
NATEGLINIDE 60mg TABLETS (NF)	NF	
NATEGLINIDE 120mg TABLETS (NF)	NF	
ONGLYZA		
SAXAGLIPTIN 5mg TABLETS	NF	
SAXAGLIPTIN 2.5mg TABLETS	NF	
PIOGLITAZONE		
PIOGLITAZONE 30mg TABLETS	Y	
PIOGLITAZONE 15mg TABLETS	Y	
REPAGLINIDE		
REPAGLINIDE 500microgram TABLETS	R	For use by Diabetologists only. Medicines Effectiveness, December 2008.
REPAGLINIDE 2mg TABLETS	R	For use by Diabetologists only. Medicines Effectiveness, December 2008.
REPAGLINIDE 1mg TABLETS	R	For use by Diabetologists only. Medicines Effectiveness, December 2008.
SITAGLIPTIN		
SITAGLIPTIN 100mg TABLETS	R	For the management of type 2 diabetes following recommendation by diabetologist only as per NICE guideline NG28. MMTc, March 2017

SITAGLIPTIN 25mg TABLETS	R	For the management of type 2 diabetes following recommendation by diabetologist only as per NICE guideline NG28. MMTC, March 2017
SITAGLIPTIN 50mg TABLETS	R	For the management of type 2 diabetes following recommendation by diabetologist only as per NICE guideline NG28. MMTC, March 2017
TETRACOSACTIDE		
GLIPIZIDE 5mg TABLETS	Y	
TOLBUTAMIDE		
TOLBUTAMIDE 500mg TABLETS	Y	
<i>06.01.02 Thyroid and antithyroid drugs</i>		
GLICLAZIDE		
GLICLAZIDE 40MG TABLETS	NF	
<i>06.01.04 Treatment of hypoglycaemia</i>		
DIAZOXIDE		
DIAZOXIDE 50mg TABLETS	Y	
GLUCAGON		
GLUCAGON NOVO 1mg INJECTION	Y	
<i>06.01.06 Diagnostic and monitoring devices for diabetes</i>		
URISTIX		
URISTIX	Y	
<i>06.01.06 Diagnostic and monitoring devices for diabetes mellitus</i>		
KETODIASTIX		
KETODIASTIX	Y	
TEST STRIPS		
KETOSTIX	Y	
BM-ACCUTEST (50)	Y	
MEDISENSE PRECISION Xceed PRO KETONE STRIPS (50)	R	For in-patient use only. Not for discharge. Medicines Effectiveness, February 2012.
ONE TOUCH ULTRA REAGENT STRIPS (50)	NF	

MEDISENSE GLUCOSE & KETONE TEST SOLUTION Y

MEDISENSE FREESTYLE OPTIUM H KETONE STRIPS (10) R For areas not converted to XCEED. Medicines Effectiveness, February 2012.

MEDISENSE FREESTYLE OPTIUM GLUCOSE STRIPS (50) R For use on discharge only. Medicines Effectiveness, February 2012.

06.01.06 Drugs affecting bone metabolism

BLOOD GLUCOSE TEST STRIPS

BLOOD GLUCOSE TEST STRIPS - FREESTYLE PRECISION PRO (100) R For in-patient use only. Not for discharge. Medicines Effectiveness, February 2012.

06.02 Thyroid and antithyroid drugs

06.02.00 Thyroid and antithyroid drugs

SOFOSBUVIR + VELPATASVIR + VOXILAPREVIR

SOFOSBUVIR 400MG / VELPATASVIR 100MG / VOXILAPREVIR 100MG TABLETS R For use as per NICE TA507 for treating chronic hepatitis C. MMTC, July 2018

06.02.01 Thyroid hormones

LEVOTHYROXINE SODIUM 200microgram in 1ml INJECTION NF

LEVOTHYROXINE

LEVOTHYROXINE 100microgram/5ml LIQUID NF

LEVOTHYROXINE 100microgram TABLETS Y

LEVOTHYROXINE 25microgram TABLETS Y

LEVOTHYROXINE 50microgram TABLETS Y

LIOTHYRONINE

LIOTHYRONINE 20microgram TABLETS R Restricted to initiation by consultant endocrinologists for hypothyroidism and consultant oncologists for adjuvant treatment of thyroid cancer. MMTC, November 2019

LIOTHYRONINE 5microgram TABLETS	R	Restricted to initiation by consultant endocrinologists for hypothyroidism and consultant oncologists for adjuvant treatment of thyroid cancer. MMTC, November 2019
LIOTHYRONINE 5microgram CAPSULES	R	
LIOTHYRONINE 20microgram INJECTION	R	Restricted to initiation by consultant endocrinologists treatment of myxoedema coma only. MMTC, November 2020
Potassium iodide		
POTASSIUM IODIDE 65mg TABLETS (UNLICENSED)	UNR	
POTASSIUM IODIDE 65mg TABLETS	UNR	For use with MIBG treatment Medicines Effectiveness May 2019
TRIIODOTHYROACETIC ACID		
TRIIODOTHYROACETIC ACID 350micrograms TABLETS	UNR	For Thyroid hormone resistance syndrome. Medicines Effectiveness, April 2015
<i>06.02.02 Antithyroid drugs</i>		
CARBIMAZOLE		
CARBIMAZOLE 5mg TABLETS	Y	
CARBIMAZOLE 20mg TABLETS	Y	
ETELCALCETIDE		
ETELCALCETIDE 2.5mg IN 0.5ml INJECTION	R	For the treatment of secondary hyperparathyroidism as per NICE TA448. MMTC, November 2017
ETELCALCETIDE 10mg IN 2ml INJECTION	R	For the treatment of secondary hyperparathyroidism as per NICE TA448. MMTC, November 2017
ETELCALCETIDE 5mg IN 1ml INJECTION	R	For the treatment of secondary hyperparathyroidism as per NICE TA448. MMTC, November 2017
IODINE		
IODINE AQUEOUS ORAL SOLUTION (LUGOLS) 500ml (HUDDERSFIELD)	SR	For theatres use only. Medicines Effectiveness, April 2014
POTASSIUM IODATE		

POTASSIUM IODATE 85mg TABLETS	R	For use by Radiology/X-ray only. Medicines Effectiveness, July 2011.
-------------------------------	---	--

POTASSIUM IODIDE

POTASSIUM IODIDE 65mg TABLETS	R	For use with MIBG treatment Medicines Effectiveness May 2019
-------------------------------	---	--

PROPYLTHIOURACIL

PROPYLTHIOURACIL 50mg TABLETS	Y	
-------------------------------	---	--

06.03 Corticosteroids

06.03.01 Replacement therapy

FLUDROCORTISONE

FLUDROCORTISONE ACETATE 100microgram TABLETS	Y	
--	---	--

06.03.02 Glucocorticoid therapy

BETAMETHASONE

BETAMETHASONE 4mg IN 1ml INJECTION	R	To prevent respiratory distress in premature babies. Medicines Effectiveness, June 2011.
------------------------------------	---	--

BETAMETHASONE SOLUBLE 500microgram TABLETS	Y	
--	---	--

Deflazacort

DEFLAZACORT 6mg TABLETS	NF	
-------------------------	----	--

DEXAMETHASONE

DEXAMETHASONE 2mg/5ml LIQUID S/F	Y	
----------------------------------	---	--

DEXAMETHASONE INTRACAMERAL 3.3mg/ml AMPOULE PRESERVATIVE FREE	UNR	For off-label intra-cameral use in Glaucoma surgery with laser ECP, and cataract surgery with iris manipulation only. MMTC, October 2018
---	-----	--

DEXAMETHASONE PHOSPHATE 8mg IN 2ml INJECTION	Y	
--	---	--

DEXAMETHASONE 500microgram TABLETS	Y	
------------------------------------	---	--

DEXAMETHASONE 2mg TABLETS TTO (50)	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.
------------------------------------	----	---

DEXAMETHASONE PHOSPHATE 4mg IN 1ml INJECTION	Y	
--	---	--

DEXAMETHASONE 2mg TABLETS	Y	
---------------------------	---	--

DEXAMETHASONE 2mg/5ml LIQUID SF	Y	
Hydrocortisone		
HYDROCORTISONE 10mg SOLUBLE TABLETS	NF	
HYDROCORTISONE 5mg TABLETS	NF	
HYDROCORTISONE 5mg/5ml LIQUID	R	For use in paediatrics only. Medicines Effectiveness June 2015
HYDROCORTISONE SOD PHOSPHATE 100mg in 1ml INJECTION	Y	
HYDROCORTISONE SOD SUCCINATE 100mg INJECTION	Y	
HYDROCORTISONE 20mg TABLETS	Y	
HYDROCORTISONE 10mg TABLETS	Y	
HYDROCORTISONE SOD SUCCINATE 100mg INJECTION TTO PACK	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, January 2015.
METHYLPREDNISOLONE		
METHYLPREDNISOLONE ACETATE 80mg in 2ml INJECTION DEPOT	Y	
METHYLPREDNISOLONE 100mg TABLETS	Y	
METHYLPREDNISOLONE ACETATE 120mg IN 3ml INJECTION DEPOT	Y	
METHYLPREDNISOLONE sodium succinate 125mg INJECTION	Y	
METHYLPREDNISOLONE sodium succinate 2g INJECTION	Y	
METHYLPREDNISOLONE 4mg TABLETS	Y	
METHYLPREDNISOLONE sodium succinate 40mg INJECTION	Y	
METHYLPREDNISOLONE sodium succinate 500mg INJECTION	Y	
METHYLPREDNISOLONE sodium succinate 1g INJECTION	Y	
METHYLPREDNISOLONE ACETATE 40mg IN 1ml INJECTION DEPOT	Y	
PREDNISOLONE		
PREDNISOLONE 50mg in 5ml LIQUID	NF	

PREDNISOLONE 20mg TABLETS	Y	
PREDNISOLONE 25mg TABLETS	Y	
PREDNISOLONE E.C 5mg TABLETS	NF	
PREDNISOLONE 5mg SOLUBLE TABLETS	NF	
PREDNISOLONE 5mg TABLETS	Y	
PREDNISOLONE 5mg TABLET TTO 28's	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.
PREDNISOLONE 1mg TABLETS	Y	
PREDNISOLONE 2.5mg TABLETS E/C	NF	

TRIAMCINOLONE

TRIAMCINOLONE 40mg in 1ml INJECTION	Y	
-------------------------------------	---	--

06.04 Endocrine system

06.04.03 Endocrine system

Oxandrolone

OXANDROLONE 2.5mg TABLETS	UNR	For prophylaxis of Hereditary Angioedema in immunology only. MMTC, June 2020 MMTC, June 2020
---------------------------	-----	--

06.04 Sex hormones

06.04 Sex hormones

TESTOSTERONE

TESTOSTERONE 16.2mg/G GEL 88g	NF	
TESTOSTERONE 40.5mg/2.5g GEL SACHETS 30's	R	

06.04.01 Female sex hormones and their modulators

CLIMESSE

CLIMESSE 2mg TABLETS	NF	
----------------------	----	--

ELLESTE

ELLESTE DUET 1mg TABLETS (1X84)	NF	
---------------------------------	----	--

ELLESTE DUET

ELLESTE DUET 2mg TABLETS (1x84)	NF	
---------------------------------	----	--

ELLESTE-DUET CONTI

ELLESTE-DUET CONTI COMBINATION TABLETS	NF	
ESTRADIOL		
ESTRADIOL 25mg IMPLANTS	UNR	For use by Menopause Clinic only. Medicines Effectiveness, February 2013.
ESTRADIOL 1mg (ELLESTE SOLO) TABLETS	NF	
ESTRADIOL 2mg (ELLESTE SOLO) TABLETS	Y	NB: Only 2mg tablets available at OUH
ESTRADIOL 1mg / DYDROGESTERONE 10mg TABLETS 3X28	NF	
ESTRADIOL 100microgram PATCHES (EVOREL)	Y	
ESTRADIOL 1mg & NORETHISTERONE 500microgram TABLETS 3X28	NF	
ESTRADIOL 1mg GEL SACHETS (SANDRENA)	Y	
ESTRADIOL 1mg TABLETS (PROGYNOVA)	Y	
ESTRADIOL 1mg/DYDROGESTERONE 5mg TABLETS 3x28	NF	
ESTRADIOL 25microgram PATCHES (EVOREL)	Y	
ESTRADIOL 2mg TABLETS (ZUMENON)	NF	
ESTRADIOL 40micrograms/24hr PATCHES	NF	
ESTRADIOL 50mg PELLETS	UNR	For use by Menopause Clinic only. Medicines Effectiveness, February 2013.
ESTRADIOL 50microgram PATCHES (EVOREL)	Y	
ESTRADIOL 80microgram/24hr PATCHES	NF	
ESTRADIOL PATCHES 80 (FEMATRIX)	NF	
ESTRADIOL 2mg TABLETS (PROGYNOVA)	Y	
OESTROGENS CONJUGATED 300microgram TABLETS (3X28)	NF	
ESTRADIOL VALERATE / MEDROXYPROGETERONE ACETATE 1mg/2.5mg TABLETS PK84	NF	
ESTROGEL		
ESTROGEL 80g GEL	NF	

ESTROPIPATE

ESTROPIPATE 1.5mg TABLETS NF

ETHINYLESTRADIOL

ETHINYLESTRADIOL 50microgram TABLETS Y

ETHINYLESTRADIOL 10microgram TABLETS Y

ETHINYLESTRADIOL 1mg TABLETS Y

EVOREL

EVOREL CONTI PATCHES (8 PATCHES) NF

KLIOFEM

KLIOFEM (Estradiol 2mg Norethisterone 1mg)
TABLETS (3x28) NF

MEDROXYPROGESTERONE

MEDROXYPROGESTERONE 10mg TABLETS Y

MEDROXYPROGESTERONE 2.5mg TABLETS Y

MEDROXYPROGESTERONE 5mg TABLETS Y

MEDROXYPROGESTERONE 10mg TABLETS Y

NORETHISTERONE

NORETHISTERONE 1mg TABLETS (MICRONOR
HRT) Y

NORETHISTERONE 5mg TABLETS Y

NUVELLE

NUVELLE TABLETS (28) Y

NUVELLE CONTINUOUS TABLETS NF

OESTROGENS CONJUGATED

OESTROGENS CONJUGATED 1.25mg TABLET
(Premarin) Y

OESTROGENS CONJUGATED 625microgram
TABLET (Premarin) Y

PREMIQUE

PREMIQUE 5mg TABLETS NF

PROGESTERONE

PROGESTERONE 50mg in 1ml INJECTION Y

PROGESTERONE (MICRONISED) 100mg CAPSULES NF
(UTROGESTAN)

PROGESTERONE 200mg PESSARIES	R	For use on the IVF unit. Also, for the prevention of preterm labour [off-label] until 34 weeks gestation, and for prevention of miscarriage in patients who have had two or more miscarriages [Off-Label]. MMTC, September 2021
------------------------------	---	--

PROGESTERONE 400mg PESSARIES	R	For use on the IVF unit. Also, for the prevention of preterm labour [off-label] until 34 weeks gestation, and for prevention of miscarriage in patients who have had two or more miscarriages [Off-Label]. MMTC, September 2021
------------------------------	---	--

PROGESTERONE 100mg in 2ml INJECTION	Y	
-------------------------------------	---	--

RALOXIFENE

RALOXIFENE 60mg TABLETS	NICE	Approved for use as per NICE TA only. An individual patient NICE implementation form is required (see PPDU SharePoint). Medicines Effectiveness, February 2013.
-------------------------	------	--

TIBOLONE

TIBOLONE 2.5mg TABLETS	Y	
------------------------	---	--

06.04.02 Male sex hormones and antagonists

DIHYDROTESTOSTERONE

DIHYDROTESTOSTERONE 2.5% TOPICAL GEL 80g	UNR	For patients with microphallus. Medicines Effectiveness, February 2013.
--	-----	--

FINASTERIDE

FINASTERIDE 5mg TABLETS	Y	
-------------------------	---	--

MESTEROLONE

MESTEROLONE 25mg TABLETS	Y	
--------------------------	---	--

TESTOSTERONE

TESTOSTERONE 2% GEL 60g	R	For use in patients with gender dysphoria under gender dysphoria clinic. MMTC, June 2021
TESTOSTERONE UNDECANOATE 1g in 4ml INJECTION (oily)	R	To be used by OCDEM for the treatment of hypogonadism in line with the Shared Care Protocol for testosterone replacement therapy. MAC, November 2011.
TESTOSTERONE 5mg PATCHES	NF	
TESTOSTERONE 40mg CAPSULES	Y	
TESTOSTERONE 250mg in 1ml INJECTION	Y	

06.04.03 Anabolic steroids

STANOZOLOL

STANOZOLOL 2mg TABLETS	UNR	For the treatment of patients with hereditary angioedema when danazol is ineffective or inappropriate. MAC, December 2010.
------------------------	-----	--

06.05 Hypothalamic and pituitary hormones and anti-oestrogens

06.04.01 Female sex hormones and their modulators

SOMATROPIN

SOMATROPIN 10mg in 1.5ml PRE-FILLED PEN (FLEXPRO)	R	
SOMATROPIN 15mg IN 1.5ml PRE-FILLED PEN (FLEXPRO)	R	
SOMATROPIN 2mg PRE-FILLED SYRINGE (GENOTROPIN-MINIQUICK)	R	For continuation of therapy only Medicines Effectiveness, March 2013.

06.05.01 Hypothalamic and anterior pituitary hormones and anti-oestrogens

CHORIOGONADOTROPIN

CHORIOGONADOTROPIN ALFA 250microgram (6,500international units) PRE-FILLED PEN	R	Restricted for use by Fertility and Endocrinology for fertility treatment. MMTC September 2018
--	---	--

CLOMIFENE

CLOMIFENE 50mg TABLETS	Y	
------------------------	---	--

CONJUGATED OESTROGENS + BAZEDOXIFENE

CONJUGATED OESTROGENS/BAZEDOXIFENE 0.45mg TABLETS m/r	R	For the treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus for whom treatment with progestin-containing therapy is inappropriate. MMTC, September 2017
CORTICOTROPIN RELEASING		
CORTICOTROPIN RELEASING HORMONE 100microgram IN 1ml INJECTION	UNR	Restricted to diagnosis of cushings disease. Medicines Effectiveness, February 2013.
FOLLITROPIN ALFA		
FOLLITROPIN ALFA 450units PEN	NF	
GONADORELIN		
GONADORELIN 100microgram INJECTION	Y	
HUMAN MENOPAUSAL GONADOTROPHIN		
HUMAN MENOPAUSAL GONADOTROPHIN 75international units INJ (MENOPUR)	R	To induce ovulation in women who have not successfully recruited a follicle using other ovulation induction methods, and in male subfertility, to treat hypogonadotropic hypogonadism to stimulate spermatogenesis. Restricted for use by Fertility and Endocrinology. MMTC July 2018
HUMAN MENOPAUSAL GONADOTROPHIN 600international units INJECTION (MENOPUR)	R	For use by Oxford Fertility Unit. Medicines Effectiveness, January 2011.
HUMAN MENOPAUSAL GONADOTROPHIN 1200international units INJECTION (MENOPUR)	R	For use by Oxford Fertility Unit. Medicines Effectiveness, January 2011.
NUTROPIN		
NUTROPIN AQ NUSPIN PRE-FILLED PEN	NF	
PEGVISOMANT		
PEGVISOMANT 10mg INJECTION	R	For the treatment of acromegaly (3rd line) as per NHS England Policy 16050/P. MMTC, January 2017
PEGVISOMANT 20mg INJECTION	R	For the treatment of acromegaly (3rd line) as per NHS England Policy 16050/P. MMTC, January 2017

PROTIRELIN

PROTIRELIN 200microgram INJECTION	UNR	For investigation of pituitary/hypothalamic hypothyroidism. Medicines Effectiveness, February 2015.
-----------------------------------	-----	---

SOMATROPIN

SOMATROPIN 0.6MG PRE-FILLED PEN (MINIQUICK)	R	For continuation of therapy and as per the OCCG Shared Care Protocol. Medicines Effectiveness, July 2016
---	---	--

SOMATROPIN 10mg/1.5ml PRE-FILLED PEN	NF	
--------------------------------------	----	--

SOMATROPIN 5mg in 1.5ml PRE-FILLED PEN (NORDITROPIN FLEXPRO)	R	For treatment of Growth failure in children as 2nd line treatment. Reserved for needle phobia in whom compliance is likely to be an issue. MMTC, March 2022.
--	---	--

SOMATROPIN 800micrograms INJECTION	R	For continuation of therapy and as per the OCCG Shared Care Protocol. Medicines Effectiveness, July 2016
------------------------------------	---	--

SOMATROPIN 15mg IN 1.5ml PRE-FILLED PEN	NF	
---	----	--

SOMATROPIN 400microgram (1.2international units) PRE-FILLED SYRINGE	R	For continuation of therapy only. Medicines Effectiveness, March 2013.
---	---	--

SOMATROPIN 5.3mg (16units) PEN REFIL CARTRIDGE	Y	
--	---	--

SOMATROPIN 200microgram (0.6units) SYRINGE	Y	
--	---	--

SOMATROPIN 5mg (15 units) in 1.5ml CARTRIDGE	NF	
--	----	--

SOMATROPIN 5mg in 1.5ml (15international units) CARTRIDGE (OMNITROPE)	Y	
---	---	--

SOMATROPIN 12mg (36units) PEN REFIL CARTRIDGE	Y	
---	---	--

SOMATROPIN 20mg (60 UNITS) IN 2.5ml INJECTION	R	For patients with proven adherence problems. Medicines Effectiveness, May 2012.
---	---	---

TETRACOSACTIDE

TETRACOSACTIDE 250microgram IN 1ml INJECTION	Y	
--	---	--

THYROTROPIN ALFA

THYROTROPIN ALFA 900micrograms INJECTION	R	For use as per thyroid cancer radioiodine treatment protocol. MMTC, October 2015.
--	---	---

06.05.01 Hypothalamic and pituitary hormones and anti-oestrogens

SOMATROPIN

SOMATROPIN 1.6mg (4.8unit) PRE-FILLED SYRINGE (MINIQUIK)		For continuation of therapy and as per the OCCG Shared Care Protocol. Medicines Effectiveness, July 2016.
--	--	---

SOMATROPIN 1.4mg (4.2unit) PRE-FILLED SYRINGE (MINIQUIK)		For continuation of therapy and as per the OCCG Shared Care Protocol. Medicines Effectiveness, July 2016.
--	--	---

SOMATROPIN 5.3mg INJECTION (GoQUICK - GENOTROPIN)	R	For continuation of therapy and as per the OCCG Shared Care Protocol. Medicines Effectiveness, July 2016.
---	---	---

SOMATROPIN 1.8mg PRE-FILLED SYRINGE (MINIQUICK)	R	For continuation of therapy and as per the OCCG Shared Care Protocol. Medicines Effectiveness, July 2016
---	---	--

SOMATROPIN 15mg IN 1.5ml (45international units) CARTRIDGE for SUREPAL (OMNITROPE)	R	For continuation of therapy and as per the OCCG Shared Care Protocol. Medicines Effectiveness, July 2016.
--	---	---

06.05.02 Posterior pituitary hormones and antagonists

ARGIPRESSIN

ARGIPRESSIN (VASOPRESSIN) 20units in 1ml INJECTION	R	Prevention of excessive blood loss during the removal of uterine fibroids OR hipotension in critical care. MAC, July 2011.
--	---	--

DESMOPRESSIN

DESMOPRESSIN 120micrograms SUBLINGUAL TABLETS	NF	
---	----	--

DESMOPRESSIN 100microgram in 1ml NASAL SOLUTION 2.5ml	Y	
---	---	--

DESMOPRESSIN 10microgram/dose NASAL SPRAY 6ml	Y	
---	---	--

DESMOPRESSIN 150microgram/DOSE NASAL SPRAY	R	For use in Haemophilia centre only. Medicines Effectiveness, November 2005.
--	---	---

DESMOPRESSIN 15microgram in 1ml INJECTION	R	For use in Haemophilia centre only. Medicines Effectiveness, November 2005.
---	---	---

DESMOPRESSIN 4microgram IN 1ml INJECTION Y

DESMOPRESSIN 100microgram TABLETS Y

SOMATROPIN

SOMATROPIN 10mg in 1.5ml (30international units) CARTRIDGE (OMNITROPE) Y

SOMATROPIN 10mg in 1.5ml INJECTION NF

SOMATROPIN 10mg in 2ml (30international Units) INJECTION (NUTROPIN AQ) NF

SOMATROPIN 15mg INJECTION NF

TERLIPRESSIN

TERLIPRESSIN 1mg in 8.5ml INJECTION Y

TERLIPRESSIN 1mg IN 5ml INJECTION (VARIQUEL) Y

TOLVAPTAN

TOLVAPTAN (JINARC) 45mg/15mg TABLETS R For the treatment of autosomal dominant polycystic kidney disease as per TA358. MMTC, November 2016

TOLVAPTAN (JINARC) 90mg/30mg TABLETS R For the treatment of autosomal dominant polycystic kidney disease as per TA358. MMTC, November 2016

TOLVAPTAN 15mg TABLETS NF

TOLVAPTAN (JINARC) 60mg/30mg TABLETS R For the treatment of autosomal dominant polycystic kidney disease as per TA358. MMTC, November 2016

6.05.01 Hypothalamic and anterior pituitary hormones and anti-oestrogens

SOMATROPIN

SOMATROPIN 4mg (12units) VIAL (ZOMACTON) R For use in needle phobic patients as requested by paediatric endocrinologist. Medicines Effectiveness, May

06.06 Drugs affecting bone metabolism

06.06.01 Calcitonin and parathyroid hormone

CALCITONIN

CALCITONIN 100international units in 1ml INJECTION NF

PAMIDRONATE

PAMIDRONATE 90mg in 10ml INJECTION Y

TERIPARATIDE

TERIPARATIDE 600mcg/2.4ML SOLUTION FOR INJECTION (CARTRIDGE) R For secondary prevention of fragility fracture in women, as per NICE TA161 following prior approval from OCCG, and men, as per NHSE commissioning statement 170064P. MMTC, May 2019

TERIPARATIDE 600mcg IN 2.4ml SOLUTION FOR INJECTION WITH PEN R For secondary prevention of fragility fracture in women, as per NICE TA161 following prior approval from OCCG, and men, as per NHSE commissioning statement 170064P. MMTC, May 2019

TERIPARATIDE 250micrograms in 1ml PEN 3ml R For secondary prevention of fragility fracture in women, as per NICE TA161 following prior approval from OCCG, and men, as per NHSE commissioning statement 170064P. MMTC, May 2019

06.06.02 Bisphosphonates and other drugs affecting bone metabolism

ALENDRONIC

ALENDRONIC ACID 70mg EFFERVESCENT TABLETSNF

ALENDRONIC ACID

ALENDRONIC ACID 70mg TABLETS Y

ALENDRONIC ACID 10mg TABLETS Y

DENOSUMAB

DENOSUMAB 120mg INJECTION R For the prevention of skeletal-related events in adults with bone metastases from solid tumours as per NICE TA265; and for the for the treatment of giant cell tumours of the bone. MMTC, April 2013.

IBANDRONIC ACID

IBANDRONIC ACID 50mg TABLETS R For the reduction of bone damage in bone metastases in breast cancer and as an adjuvant treatment of early breast cancer in post-menopausal women. MMTC,

IBANDRONIC ACID 150mg TABLET	NF	
PAMIDRONATE		
PAMIDRONATE 30mg in 10ml INJECTION	Y	
PAMIDRONATE 30mg in 2ml INJECTION	Y	
RISEDRONATE SODIUM		
RISEDRONATE 30mg TABLETS	R	Restricted to Metabolic Bone Unit at NOC only. Medicines Effectiveness, December 2011.
RISEDRONATE 35mg TABLETS	R	For patients who cannot tolerate Alendronic acid. Medicines Effectiveness, December 2011.
RISEDRONATE 5mg TABLETS	R	Restricted to NOC and established osteoporosis patients only. Medicines Effectiveness, December 2011.
SODIUM CLODRONATE		
SODIUM CLODRONATE 400mg CAPSULES	R	For use by Oncology/haematology only. Medicines Effectiveness, December 2011.
ZOLEDRONIC ACID		
ZOLEDRONIC ACID 4mg in 100ml INJECTION	R	ADULTS: For hypercalcaemia and skeletal events linked with malignancy; as an adjuvant treatment of early breast cancer in post-menopausal women And for Osteoporosis PAEDIATRICALS: For Children with Osteogenesis Imperfecta. MMTC, October 2017
ZOLEDRONIC ACID 4mg in 5ml INJECTION	NF	
ZOLEDRONIC ACID 4mg IN 5ml INJECTION	R	ADULTS: For hypercalcaemia and skeletal events linked with malignancy; as an adjuvant treatment of early breast cancer in post-menopausal women And for Osteoporosis PAEDIATRICALS: For Children with Osteogenesis Imperfecta. MMTC, October 2017

06.07 Other endocrine drugs

NAFARELIN

NAFARELIN 200microgram NASAL SPRAY (60dose) NF

06.07.01 Bromocriptine and other dopaminergic drugs

BROMOCRIPTINE

BROMOCRIPTINE 1mg TABLETS Y

BROMOCRIPTINE 2.5mg TABLETS Y

BROMOCRIPTINE 10mg CAPSULES Y

CABERGOLINE

CABERGOLINE 500microgram TABLETS (8) Y

06.07.01 Dopamine receptor agonists

QUINAGOLIDE

QUINAGOLIDE 25microgram and 50microgram TABLETS STARTER PACK NF Do NOT split this pack - always book out 6 tablets PPDU 14.03.18

QUINAGOLIDE 75microgram TABLETS NF

06.07.02 Drugs affecting gonadotrophins

Triptorelin

TRIPTORELIN 22.5mg INJECTION M/R R For precocious puberty. Initiation by Paediatric Endocrinologist only. MMTC August 2022.

TRIPTORELIN 3.75mg SYRINGE R Patients on 3 or 6 monthly gonadorelin analogues (goserelin, leuporelin or triptorelin) will receive 1-monthly injections while inpatients. NB: inform GP when next dose is due. MMTC, April 2014.

06.07.02 Gonadorelin analogues

DANAZOL

DANAZOL 100mg CAPSULES UNR

06.07.03 Metyrapone

METYRAPONE

METYRAPONE 250mg CAPSULES Y

6.04 Sex hormones

06.04.01 Female sex hormones and their modulators

ESTRADIOL

07 Obstetrics, gynaecology, and urinary-tract disorders

07.01 Drugs used in obstetrics

07.01 Drugs used in obstetrics

Alprostadiil

ALPROSTADIL 20mcg INJECTION NF

07.01.01 Bladder and urinary disorders

OXYBUTYNIN

OXYBUTYNIN 5mg TABLETS Y

07.01.01 Prostaglandins and oxytocics

ALPROSTADIL

ALPROSTADIL 10mcg INJECTION NF

CARBETOCIN

CARBETOCIN 100micrograms IN 1ml INJECTION NF

CARBOPROST

CARBOPROST 250microgram in 1ml INJECTION Y

DINOPROSTONE

DINOPROSTONE 5mg in 0.5ml INJECTION NF

DINOPROSTONE 3mg VAGINAL TABLETS R

Restricted for use in Maternity areas whilst Dinoprostone Gel is unavailable. Must be agreed by MMTC before having full Formulary approval PPDU 06.07.15

DINOPROSTONE 0.75mg in 0.75ml INJECTION Y

DINOPROSTONE 2mg VAGINAL GEL Y

ERGOMETRINE

ERGOMETRINE 500microgram in 1ml INJECTION Y

ERGOMETRINE 500microgram & OXYTOCIN 5units INJECTION Y

OXYTOCIN

OXYTOCIN 10units/ml INJECTION Y

OXYTOCIN 5units/ml injection Y

07.01.01. Prostaglandins and oxytocics

CARBOPROST

CARBOPROST 250microgram in 1ml INJECTION (UNLICENSED) UNR

Dinoprostone

DINOPROSTONE 1mg VAGINAL GEL Y

07.01.02 Mifepristone

MIFEPRISTONE

MIFEPRISTONE 200mg TABLETS (3 tabs) Y

7.01 Drugs used in obstetrics

TICAGRELOR

TICAGRELOR 60MG TABLETS R Continuation and for the preventing atherothrombotic events post myocardial infarction as per NICE TA420. MMTC, August 2017

07.02 Treatment of vaginal and vulval conditions

07.02.01 Preparations for vaginal and vulval changes

ESTRADIOL

ESTRADIOL 50micrograms/hour RING NF

ESTRADIOL 10microgram VAGINAL TABLETS NF

ESTRIOL

ESTRIOL 0.1% CREAM AND APPLICATOR 15g Y

ESTRIOL 0.01% CREAM 80g Y

07.02.02 Vaginal and vulval infections

ACETIC ACID

GLACIAL ACETIC ACID 0.94% VAGINAL JELLY NF

CLINDAMYCIN

CLINDAMYCIN 2% CREAM 40g R For use by Genito-urinary Medicine and Gynae Ward only. Medicines Effectiveness, February 2012.

CLOTRIMAZOLE

CLOTRIMAZOLE 200mg PESSARIES Y

CLOTRIMAZOLE 500mg PESSARY Y

CLOTRIMAZOLE 100mg PESSARIES Y

ECONAZOLE

ECONAZOLE NITRATE 150mg PESSARIES NF

METRONIDAZOLE

METRONIDAZOLE 0.75% VAGINAL GEL (ZIDOVAL) 40g R For use by Genito-urinary Medicine and Gynaecology only. Medicines Effectiveness, January 2013.

MICONAZOLE

MICONAZOLE 2% VAGINAL CREAM 78g R For candida resistant or refractory to fluconazole. ASG, August 2015

07.03 Contraceptives

07.03.01 Combined hormonal contraceptives

CILIQUE

CILIQUE TABLETS (3X21) R For use by Genito-urinary Medicine only. Medicines Effectiveness, August 2010.

DESOGESTREL

DESOGESTREL 75microgram TABLETS TTO PACK 84SR

DROSPIRENONE + ETHINYLESTRADIOL

DROSPIRENONE 3mg + ETHINYLESTRADIOL 30mcg TABLETS NF

ESTRADIOL

ESTRADIOL 2mg / DIENOGEST 3mg TABLETS NF

ETHINYLESTRADIOL + DESOGESTREL

GEDAREL 30/150microgram FC TABLETS (3 X 21) R For use by Genito-urinary Medicine only. MMTC, December 2011.

GEDAREL 20/150microgram TABLETS (3x21) R For use by Genito-urinary Medicine only. Medicines Effectiveness, March 2014

ETHINYLESTRADIOL + GESTODENE

FEMODENE TABLETS 21's R For use by Genito-urinary Medicine only. Medicines Effectiveness, March 2013

ETHINYLESTRADIOL + LEVONORGESTREL

MICROGYNON 30 ED 3x28	R	For use by Genito-urinary Medicine only. Medicines Effectiveness, March 2014
ETHINYLESTRADIOL 30microgram / LEVONORGESTREL 150microgram TABLETS 3X21	R	For use by Genito-urinary Medicine only. Medicines Effectiveness, March 2014
ETHINYLESTRADIOL + NORELGESTROMIN		
ETHINYLESTRADIOL 33.9mcg/24hrs & NORELGESTROMIN 203mcg/24hrs TRANSDERMAL	R	For use by Genito-urinary Medicine only. Medicines Effectiveness, March 2014
Generic Logynon tablets		
ETHINYLESTRADIOL & LEVONORGESTREL TABLETS (TRIREGOL) [MULTIPLE STRENGTHS]	NF	
LEVONORGESTREL		
LEVONORGESTREL 1500microgram TABLET	Y	
LEVONORGESTREL + ETHINYLESTRADIOL		
LEVONORGESTREL 150mcg + ETHINYLESTRADIOL 30mcg TABLETS (RIGEVIDON)	R	For use by Genito-urinary Medicine only. Medicines Effectiveness, March 2013
NORETHISTERONE		
MICRONOR TABLETS 3X28	R	For use by Gynae Day Surgery, Gynae Ward and GUM clinic. Medicines Effectiveness, November 2003.
ULIPRISTAL		
ULIPRISTAL 30mg TABLET (1)	R	For use by Genito-urinary Medicine Clinic and the Horton Orchard Health Clinic. Ella-One® is approved for use as emergency contraception for patients 72-120h post unprotected intercourse. Levonelle® will continue to be used in patients <72h post unprotected intercourse. MAC, August 2010.
ULIPRISTAL ACETATE		
ULIPRISTAL ACETATE 5MG TABLETS	NF	
<i>07.03.02 Progestogen-only contraceptives</i>		
DESOGESTREL		

CERAZETTE 75microgram TABLETS	R	Restricted to GUM clinic. Medicines Effectiveness, August 2010.
DESOGESTREL 75microgram TABLETS 3x28	R	For use by Genito-urinary Medicine; and Women's centre for post-partum contraception.

ETONOGESTREL

ETONOGESTREL 68microgram IMPLANT (NEXPLANON)	R	For use by Genito-urinary Medicine only. Medicines Effectiveness, March 2014
--	---	--

LEVONORGESTREL

LEVONORGESTREL 30microgram TABLETS pk35	R	For use by Genito-urinary Medicine only. Medicines Effectiveness, March 2014
---	---	--

LEVONORGESTREL 13.5mg INTRAUTERINE DELIVERY SYSTEM	R	For use by OSHS only. Medicines effectiveness, May 2015
--	---	---

MEDROXYPROGESTERONE

MEDROXYPROGESTERONE 150mg in 1ml INJECTION (DEPOT)	Y	
--	---	--

07.03.02 Progestogen-only contraceptives`

MEDROXYPROGESTERONE

MEDROXYPROGESTERONE 104mg in 0.65ml (subcutaneous) PRE FILLED SYRINGE	R	To be supplied as part of the post partum family planning initiative- Maternity ONLY MMTC July 2020
---	---	---

07.03.04 Contraceptive devices

LEVEONORGESTREL

LEVEONORGESTREL 19.5mg INTRAUTERINE DELIVERY DEVICE	R	For use by OSHS only. Medicines effectiveness, October 2020.
---	---	--

LEVONORGESTREL

LEVONORGESTREL 20micrograms / 24hours INTRAUTERINE DEVICE	R	For the treatment of heavy menstrual bleeding and for use as a contraceptive. MMTC, January 2018
---	---	--

LEVONORGESTREL INTRAUTERINE DEVICE	Y	
------------------------------------	---	--

07.04 Drugs for genito-urinary disorders

07.04.01 Drugs for erectile dysfunction

Sildenafil

SILDENAFIL 10mg IN 1ml ORAL SUSPENSION 122ML R

07.04.01 Drugs for urinary retention

ALFUZOSIN

ALFUZOSIN 10mg TABLETS M/R NF

ALFUZOSIN 2.5mg TABLETS NF

BETHANECHOL

BETHANECHOL CHLORIDE 10mg TABLETS Y

CARBACHOL

CARBACHOL 2mg TABLETS NF

INDORAMIN

INDORAMIN 20mg TABLETS Y

TAMSULOSIN

TAMSULOSIN HYDROCHLORIDE 400microgram
CAPSULES M/R Y

TERAZOSIN

TERAZOSIN 2mg TABLETS NF

TERAZOSIN 5mg TABLETS NF

07.04.02 Drugs for urinary frequency, enuresis, and incontinence

DARIFENACIN

DARIFENACIN HYDRBROMIDE 7.5MG TABLETS M/R NF

FESOTERODINE

FESOTERODINE 4mg TABLETS M/R NF

FESOTERODINE 8mg TABLETS M/R NF

FLAVOXATE

FLAVOXATE 200mg TABLETS Y

MIRABEGRON

MIRABEGRON 50mg TABLETS M/R R For treating symptoms of overactive bladder as per NICE TA290. MMTTC, February 2014

MIRABEGRON 25mg M/R TABLETS R For treating symptoms of overactive bladder as per NICE TA290. MMTTC, February 2014.

OXYBUTYNIN

OXYBUTYNIN 36mg (3.9mg/24hr) PATCHES	R	Only appropriate for patients unable to swallow tablets or experience severe indigestion. Medicines Effectiveness, September 2008.
OXYBUTYNIN 3mg TABLETS	Y	
OXYBUTYNIN 5mg TABLETS	Y	
OXYBUTYNIN 10mg TABLETS M/R	NF	
OXYBUTYNIN 2.5mg TABLETS	Y	
OXYBUTYNIN 5mg TABLETS M/R	NF	

PROPIVERINE

PROPIVERINE 30mg CAPSULES M/R	NF	
PROPIVERINE 15mg TABLETS	NF	

SOLIFENACIN

SOLIFENACIN 10mg TABLETS	R	For continuation of therapy only, medicines Effectiveness, June 2015.
SOLIFENACIN 5mg TABLETS	R	For continuation of therapy only, medicines Effectiveness, June 2015.

TOLTERODINE

TOLTERODINE 1mg TABLETS	R	Tolterodine 2mg standard release bd is first line for overactive bladder. If not tolerated due to side effects dose can be decreased to 1mg bd. Tolterodine 4mg modified-release is now restricted to patients who cannot tolerate standard-release tolterodine. Medicines Effectiveness, November 2015.
-------------------------	---	--

TOLTERODINE 2mg TABLETS	R	Tolterodine 2mg standard release bd is first line for overactive bladder. If not tolerated due to side effects dose can be decreased to 1mg bd. Tolterodine 4mg modified-release is now restricted to patients who cannot tolerate standard-release tolterodine. Medicines Effectiveness, November 2015.
TOLTERODINE 4mg CAPSULES M/R	R	Restricted to patients who cannot tolerate standard release Tolterodine only. Medicines Effectiveness, January 2016
TROSPIUM		
TROSPIUM CHLORIDE 60mg MR CAPSULES	NF	
TROSPIUM CHLORIDE 20mg TABLETS	NF	
<i>07.04.03 Drugs used in urological pain</i>		
POTASSIUM CITRATE		
POTASSIUM CITRATE MIXTURE BP	Y	
SODIUM CITRATE		
SODIUM CITRATE 0.3Molar LIQUID 10x30ml	Y	
<i>07.04.04 Bladder instillations and urological surgery</i>		
ALUM		
ALUM 10% BLADDER IRRIGATION 100ml	SR	For uncontrolled haematuria despite bladder irrigation due to radiotherapy only. Medicines Effectiveness, October 2017
CHLORHEXIDINE		
CHLORHEXIDINE 0.02% Bladder washout (Uro-Tainer)100ml	Y	
GEPAN		
SODIUM CHONDROITIN 0.2% BLADDER INSTILLATION 40ml (GEPAN)	NF	
GLYCINE		
DF GLYCINE 1.5% IRRIGATION BAGS 3L FKB7538T	R	
GLYCINE 1.5% IRRIGATION BAGS 3L FKB7538T	Y	
GLYCINE 1.5% FLOWFUSOR 2L	Y	

SODIUM CHLORIDE

SODIUM CHLORIDE 0.9% BLADDER IRRIGATION 50ml (For use with BCG Bladder instillation only) UNR Reconstitution pack for use with Immucst (DEG054). Medicines Effectiveness July 2012

SODIUM CHLORIDE 0.9% Bladder Irrigation 100ml Y

SODIUM CHLORIDE 0.9% Bladder Irrigation 100ml (UROTAINER M) Y

SOLUTION R

SOLUTION R BLADDER IRRIGATION (URO-TAINER TWIN 2X30ml) Y

SUBY G

SUBY G BLADDER IRRIGATION (URO-TAINER TWIN 2X30ml) Y

07.04.05 Drugs for erectile dysfunction

ALPROSTADIL

ALPROSTADIL 10microgram DUAL CHAMBER INJECTION NF

ALPROSTADIL 20microgram DUAL CHAMBER INJECTION NF

ALPROSTADIL 250microgram Appln (MUSE) NF

ALPROSTADIL 500micrograms IN 1ml INJECTION NF

APOMORPHINE

APOMORPHINE 3mg TABLETS S/L NF

AVIPTADIL & PHENTOLAMINE MESILATE

AVIPTADIL 25micrograms & PHENTOLAMINE MESILATE 2mg in 0.35ml INJECTION R Restricted for use by Endocrinology consultants and registrars in the Alexander (ED) clinic in OCDEM only. Formulary Pharmacist 03.01.2019 Charge issues to OCAD = CH OCDEM ADMIN - DELIVER TO BAGOT + DRAKE Finance code: A55360

PAPAVERINE

PAPAVERINE HCL 80mg IN 2ml INJECTION SR For use in coronary bypass surgery for graft dilatation & prevention of mammary artery spasm in cardiac theaters only. Medicines Effectiveness, January 2018

SILDENAFIL

SILDENAFIL 25mg TABLETS

R

For the treatment of:- Pulmonary Arterial Hypertension (PAH) as per the shared care arrangement with the Royal Brompton & Harefield Hospital NHSFT (RBH) - Congenital heart disease *For initiation by cardiologist only*
MMTC, December 2016

TADALAFIT

TADALAFIL 20mg TABLETS

NF

08 Malignant disease and immunosuppression

Acalabrutinib

HC ACALABRUTINIB 100mg TABLETS

R

For the treatment of previously untreated chronic lymphocytic leukaemia as per NICE TA689
MMTC, May 2021

Tepotinib

TEPOTINIB 225mg TABLETS

NICE

08 Malignant disease and immunosuppression

08 Malignant disease and immunosuppression

SOMATROPIN

SOMATROPIN 6mg in 1.03ml CARTRIDGE (FREE OF CHARGE) NF

SOMATROPIN 20mg in 2.5ml CARTRIDGE (FREE OF CHARGE) NF

08.00.00 Malignant disease and immunosuppression

BLINATUMOMAB

BLINATUMOMAB 38.5microgram POWDER FOR CONCENTRATE (FREE OF CHARGE) NF

DARATUMUMAB

DARATUMUMAB 400mg IN 20ml INJECTION (FREE OF CHARGE) NF

DARATUMUMAB 100mg IN 5ml INJECTION (FREE OF CHARGE) NF

08.01 Cytotoxic drugs

Acalabrutinib

ACALABRUTINIB 100mg TABLETS

R

For the treatment of previously untreated chronic lymphocytic leukaemia as per NICE TA689
MMTC, May 2021

Ivosidenib

IVOSIDENIB 250mg TABLETS

NICE ?For treatment of locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments as per NICE TA948. MMTC, March 2024.

Nintedanib

NINTEDANIB 100mg CAPSULES (OFEV)

R For treatment of idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted as per NICE TA864. MMTC, June 2023

NINTEDANIB 150mg CAPSULES (OFEV)

R For treatment of idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted as per NICE TA864. MMTC, June 2023

08.01 Cytotoxic drugs

ACALABRUTINIB

ACALABRUTINIB 100mg CAPSULES (FREE OF CHARGE STOCK)

NF Compassionate Use

08.01.00 Cytotoxic drugs

CALCIUM FOLINATE

CALCIUM FOLINATE 350mg in 35ml INJECTION

Y Only to be used whilst Calcium Levofolinate is unavailable. Graham 09.09.21

CALCIUM LEVOFOLINATE

CALCIUM LEVOFOLINATE 175mg in 17.5ml INJECTION Y

08.01.01 Alkylating drugs

BUSULFAN

BUSULFAN 25mg CAPSULES

NF

BUSULFAN 2mg TABLETS

Y

CALCIUM FOLINATE

CALCIUM FOLINATE 300mg IN 30ml INJECTION

Y

CALCIUM FOLINATE 50mg IN 5ml INJECTION

Y

CHLORAMBUCIL

CHLORAMBUCIL 2mg TABLETS

Y

CICLOSPORIN

CICLOSPORIN 100mg CAPSULES (VANQUORAL)	R	For use in renal transplant use only. Medicines Effectiveness, February 2017
CICLOSPORIN 50mg CAPSULES (VANQUORAL)	R	For use in renal transplant use only. Medicines Effectiveness, February 2017
CICLOSPORIN 25mg CAPSULES (VANQUORAL)	R	For use in renal transplant use only. Medicines Effectiveness, February 2017

CYCLOPHOSPHAMIDE

CYCLOPHOSPHAMIDE 50mg/5ml LIQUID 100ml	UNR	Restricted to be prescribed by consultant only, and to steroid resistant or dependant nephrotic syndrome. Medicines Effectiveness, February 2013.
CYCLOPHOSPHAMIDE 50mg TABLETS	Y	
CYCLOPHOSPHAMIDE 1000mg in 250ml SODIUM CHLORIDE 0.9% INFUSION (EMERGENCY BAG)	SR	For emergency use only- see procedure on sharepoint site (Clinical/Baxter). Pharmacist to calculate exact volume to be administered to deliver prescribed dose. If stock expires book out to Transplant/Haematology/Critical Care PPDU, November 2011.

ESTRAMUSTINE

ESTRAMUSTINE PHOSPHATE 140mg CAPSULES	NF	
---------------------------------------	----	--

LOMUSTINE

LOMUSTINE 40mg CAPSULES	R	As per PCV protocol. Medicines Effectiveness, August 2009.
LOMUSTINE 10mg CAPSULES	UNR	Restricted to being given as part of chemo regime (PNET). Medicines Effectiveness, MArch 2013.

MELPHALAN

MELPHALAN 2mg TABLETS	Y	
-----------------------	---	--

MESNA

MESNA 400mg IN 4ml INJECTION	Y	
MESNA 400mg TABLETS	Y	

MESNA 600mg TABLETS Y

MESNA 1g in 10ml INJECTION Y

08.01.02 Anthracyclines and other cytotoxic antibiotics

IDARUBICIN

IDARUBICIN 10mg CAPSULES Y

IDARUBICIN 5mg CAPSULES Y

MITOMYCIN

MITOMYCIN C 20mg INJECTION (UNLICENSED IMPORT) R

MITOMYCIN 40mg CLOSED INSTILLATION KIT FOR INTRAVESICAL USE NF

MITOMYCIN C 10mg INJECTION R

MITOMYCIN 40mg CLOSED INSTILLATION KIT FOR INTRAVESICAL USE R

For non muscle invasive bladder cancer both as a single dose immediately after TURBT of a suspected new bladder cancer and as an adjuvant treatment consisting of a weekly dose given over a six week period for those patients identified as intermediate risk of recurrence. MMTC, November 2023

08.01.03 Antimetabolites

AFATINIB

AFATINIB 30mg TABLETS R

For treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer as per NICE TA310. MMTC, September 2014.

Azacitidine

AZACITIDINE 200mg TABLETS R

?For maintenance treatment for acute myeloid leukaemia (AML) as per NICE TA827. MMTC December 2022

AZACITIDINE 300mg TABLETS R

?For maintenance treatment for acute myeloid leukaemia (AML) as per NICE TA827. MMTC December 2022

CAPECITABINE

CAPECITABINE 500mg TABLETS	R	For colorectal cancer as per NICE TA61 and TA100, for gastric cancer as per TA191, and for breast cancer as per CG81. Medicines Effectiveness, February 2013.
CAPECITABINE 150mg TABLETS	R	For colorectal cancer as per NICE TA61 and TA100, for gastric cancer as per TA191, and for breast cancer as per CG81. Medicines Effectiveness, February 2013.
CLADRIBINE		
CLADRIBINE 10mg TABLETS	R	Restricted for Multiple Sclerosis in line with NHSE Policy Medicines Effectiveness Aug 21
CLADRIBINE 10mg TABLETS	R	Restricted for Multiple Sclerosis in line with NHSE Policy Medicines Effectiveness Aug 21
CLADRIBINE 10mg TABLETS	R	Restricted for Multiple Sclerosis in line with NHSE Policy Medicines Effectiveness Aug 21
FLUDARABINE		
FLUDARABINE 10mg TABLETS	R	Fludarabine for the treatment of B-cell chronic lymphocytic leukaemia as per NICE TA29. Medicines Effectiveness, March 2013.
FLUOROURACIL		
FLUOROURACIL 5% CREAM 40g	Y	
MERCAPTOPURINE		
MERCAPTOPURINE 10mg TABLETS	UNR	For lymphatic leukaemia. Medicines Effectiveness, March 2013.
MERCAPTOPURINE 50mg TABLETS	Y	
METHOTREXATE		
METHOTREXATE 2.5mg TABLETS	NF	
METHOTREXATE 10mg in 5ml LIQUID	R	For acute lymphoblastic leukaemia. Medicines Effectiveness, March 2013

METHOTREXATE 2.5mg TABLETS	Y	See SOP for screening and dispensing methotrexate prescriptions. Medicines Effectiveness, March 2013.
----------------------------	---	---

NELARABINE

NELARABINE 5mg IN 1ml SOLUTION FOR INFUSION NF

PEMETREXED

PEMETREXED SUPPLEMENTATION PACK	UNR	For patients on pemetrexed only. Medicines Effectiveness, May 2013.
---------------------------------	-----	---

08.01.04 Vinca alkaloids and etoposide

ETOPOSIDE

ETOPOSIDE 50mg CAPSULES	Y	
-------------------------	---	--

ETOPOSIDE 100mg CAPSULES	Y	
--------------------------	---	--

MERCAPTOPURINE

MERCAPTOPURINE 100mg/5ml LIQUID 100ml !!	R	For lymphatic leukaemia. Medicines Effectiveness, March 2013.
--	---	---

VINORELBINE

VINORELBINE 20mg CAPSULES	R	For second line or later therapy for the treatment of advanced breast cancer when anthracycline based regimens have failed or are unsuitable. MAC, May 2010.
---------------------------	---	--

VINORELBINE 80mg CAPSULES	R	For second line or later therapy for the treatment of advanced breast cancer when anthracycline based regimens have failed or are unsuitable. MAC, May 2010.
---------------------------	---	--

VINORELBINE 30mg CAPSULES	R	For second line or later therapy for the treatment of advanced breast cancer when anthracycline based regimens have failed or are unsuitable. MAC, May 2010.
---------------------------	---	--

08.01.05 Other antineoplastic drugs

ABEMACICLIB

ABEMACICLIB 100mg TABLETS	R	For treatment of hormone-positive HER2-negative breast cancer as per NICE TA563 and for hormone-positive HER2-negative advanced breast cancer after endocrine therapy as per NICE TA579. MMTC, February 2020
ABEMACICLIB 50mg TABLETS	R	For treatment of hormone-positive HER2-negative breast cancer as per NICE TA563 and for hormone-positive HER2-negative advanced breast cancer after endocrine therapy as per NICE TA579. MMTC, February 2020
ABEMACICLIB 150mg TABLETS	R	For treatment of hormone-positive HER2-negative breast cancer as per NICE TA563 and for hormone-positive HER2-negative advanced breast cancer after endocrine therapy as per NICE TA579. MMTC, February 2020
ACALABRUTINIB		
ACALABRUTINIB 100mg CAPSULES (CDF STOCK)	R	Restricted for use within the Cancer Drugs Fund as an option for untreated and treated chronic lymphocytic leukaemia in adults (positive recommendation from NICE on the 18th March)
AFATINIB		
AFATINIB 40mg TABLETS	R	For treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer as per NICE TA310. MMTC, September 2014.
ALECTINIB		
ALECTINIB 150mg CAPSULES (COMPASSIONATE USE)	NF	Compassionate Use Cytotoxic
ALECTINIB 150mg CAPSULES	R	For the treatment of untreated ALK-positive advanced non-small-cell lung cancer as per NICE TA536. MMTC July 2019
ASCIMINIB		

ASCIMINIB 40mg TABLETS	NICE	For treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors as per NICE TA813. MMTC, August 2022
ASCIMINIB 20mg TABLETS	NICE	For treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors as per NICE TA813. MMTC, August 2022
ATEZOLIZUMAB		
ATEZOLIZUMAB 1200mg IN 20ml INJECTION	R	For the treatment of urothelial cancer as per NICE TA492 and NICE TA525, MMTC May 2019
Avatrombopag		
SELPERCATINIB 80mg CAPSULES	NICE	AWAITING MMTC IMPLEMENTATION.
AXITINIB		
AXITINIB 1mg TABLETS (COMPASSIONATE USE)	NF	EAMS supply only
AXITINIB 1mg TABLETS	R	For the treatment of adults with advanced renal cell carcinoma after failure of treatment with a first line tyrosine kinase inhibitor or a cytokine as per NICE TA333. MMTC, April 2017
AXITINIB 3mg TABLETS	R	For the treatment of adults with advanced renal cell carcinoma after failure of treatment with a first line tyrosine kinase inhibitor or a cytokine as per NICE TA333. MMTC, April 2017
AXITINIB 5mg TABLETS (COMPASSIONATE USE)	NF	EAMS supply only
AXITINIB 5mg TABLETS	R	For the treatment of adults with advanced renal cell carcinoma after failure of treatment with a first line tyrosine kinase inhibitor or a cytokine as per NICE TA333. MMTC, April 2017
Belzutifan		
BELZUTIFAN 40mg TABLETS (COMPASSIONATE USE)	NF	
BEVACIZUMAB		
BEVACIZUMAB 100mg INJECTION	NF	

BEVACIZUMAB 1.25mg PRE-FILLED SYRINGE 0.05ml SR

For neo-vascularisation in non wet-AMD conditions and glaucoma prior to laser treatment. And as an alternative to retinal laser treatment during COVID-19. MMTC, March 2020

BEXAROTENE

BEXAROTENE 75mg CAPSULES

R

For the treatment of cutaneous T cell lymphoma. MMTC, April 2018

BINIMETINIB

BINIMETINIB 15mg TABLETS (COMPASSIONATE USE)

NF

BINIMETINIB 15mg TABLETS

R

For treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma as per NICE TA562 MMTC July 2019

Blinatumomab

BLINATUMOMAB 38.5microgram POWDER FOR INJECTION

R

Restricted for use as per NICE TA450 (Lymphoblastic leukaemia)

BOSUTINIB

BOSUTINIB 100mg TABLETS

R

For the treatment of chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia in adults who have previously had 1 or more tyrosine kinase inhibitor and imatinib, nilotinib and dasatinib are not appropriate as per NICE TA401. MMTC, February 2017

BOSUTINIB 500mg TABLETS

R

For the treatment of chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia in adults who have previously had 1 or more tyrosine kinase inhibitor and imatinib, nilotinib and dasatinib are not appropriate as per NICE TA401. MMTC, February 2017

BOSUTINIB 100mg TABLETS (COMPASSIONATE USE) NF

BOSUTINIB 400mg TABLETS	R	For the treatment of chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia in adults who have previously had 1 or more tyrosine kinase inhibitor and imatinib, nilotinib and dasatinib are not appropriate as per NICE TA401. MMTc, February 2017
BOSUTINIB 400mg TABLETS (COMPASSIONATE USE) NF		
BRENTUXIMAB		
BRENTUXIMAB VEDOTIN 50mg INJECTION (COMPASSIONATE USE)	NF	
Brigatinib		
BRIGATINIB 90mg TABLETS	R	As per NICE TA 571 (Brigatinib for treating ALK-positive advanced NSCLC after crizotinib) and NICE TA 670 (Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor)
BRIGATINIB 30mg TABLETS	R	As per NICE TA 571 (Brigatinib for treating ALK-positive advanced NSCLC after crizotinib) and NICE TA 670 (Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor)
BRIGATINIB 180mg TABLETS	R	?As per NICE TA 571 (Brigatinib for treating ALK-positive advanced NSCLC after crizotinib) and NICE TA 670 (Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor)
CABOZANTINIB		
CABOZANTINIB 40mg TABLETS	R	For the treatment of advanced renal cell carcinoma in adults: following prior vascular endothelial growth factor-targeted therapy, as per NICE TA463; in untreated adults as per NICE TA542. MMTc May 2019

CABOZANTINIB 60mg TABLETS	R	For the treatment of advanced renal cell carcinoma in adults: following prior vascular endothelial growth factor-targeted therapy, as per NICE TA463; in untreated adults as per NICE TA542. MMTC May 2019
CABOZANTINIB 60mg TABLETS (FREE OF CHARGE NF STOCK PAEDS ONLY)		
CABOZANTINIB 140mg CAPSULES (84 x 20mg and 28R x 80mg)		For treatment of progressive medullary thyroid cancer in adults as per NICE TA516, MMTC, May 2019
CABOZANTINIB 100mg CAPSULES (28 x 20mg and 28R x 80mg)		For treatment of progressive medullary thyroid cancer in adults as per NICE TA516, MMTC, May 2019
CABOZANTINIB 40mg TABLETS (COMPASSIONATE USE)	NF	For treatment of renal cell carcinoma as per exceptional access scheme. MMTC, January 2017
CABOZANTINIB 20MG TABLETS (FREE OF CHARGE SUPPLY)	NF	
CABOZANTINIB 60mg TABLETS (COMPASSIONATE USE)	NF	For treatment of renal cell carcinoma as per patient access scheme. MMTC, January 2017
CABOZANTINIB 20mg TABLETS	R	For the treatment of advanced renal cell carcinoma in adults: following prior vascular endothelial growth factor-targeted therapy, as per NICE TA463; in untreated adults as per NICE TA542. MMTC May 2019
CABOZANTINIB 60mg CAPSULES (4 x 21 x 20mg)	R	For treatment of progressive medullary thyroid cancer in adults as per NICE TA516, MMTC, May 2019
CARBOPLATIN		
CARBOPLATIN 50mg INJECTION	R	***WHOLESALE ORDER USE ONLY*** Not for routine use in OUH.
CARFILZOMIB		
CARFILZOMIB 10mg IN 10ml INJECTION	R	For the treatment of previously treated multiple myeloma as per NICE TA457 and NICE TA657. MMTC, May 2021

CERITINIB

CERITINIB 150mg TABLETS

R For the treatment of: Advanced anaplastic lymphoma kinase positive non small cell lung cancer in adults who have had crizotinib as per NICE TA395. Untreated anaplastic lymphoma kinase (ALK) positive advanced non-small-cell lung cancer in adults as per NICE TA500. MMTC August 2018

CERITINIB 150mg CAPSULES

R For the treatment of: Advanced anaplastic lymphoma kinase positive non small cell lung cancer in adults who have had crizotinib as per NICE TA395. Untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults as per NICE TA500. MMTC August 2018

CETUXIMAB

CETUXIMAB 500mg IN 100ml INJECTION

R For the treatment of: previously untreated metastatic colorectal cancer as per NICE TA439; recurrent or metastatic squamous cell cancer of the head and neck as per NICE TA473; Squamous cell cancer of the head and neck as per NICE TA145 MMTC, June 2018

CETUXIMAB 100mg IN 20ml INJECTION

R For the treatment of: previously untreated metastatic colorectal cancer as per NICE TA439; recurrent or metastatic squamous cell cancer of the head and neck as per NICE TA473; Squamous cell cancer of the head and neck as per NICE TA145 MMTC, June 2018

CRISANTASPASE

CRISANTASPASE 10,000units INJECTION

R For patients being treated on the UKALL 2011 (Paed Haem Onc). Medicines Effectiveness, November 2013.

CRIZOTINIB

CRIZOTINIB 200mg CAPSULES	R	For the treatment of: -Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults as per NICE TA406; -Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults as per NICE TA422; For treatment of ROS1-positive advanced non-small-cell lung cancer as per NICE TA529. MMTc July 2019
CRIZOTINIB 250mg CAPSULES	R	For the treatment of: -Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults as per NICE TA406; -Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults as per NICE TA422; For treatment of ROS1-positive advanced non-small-cell lung cancer as per NICE TA529. MMTc July 2019
DASATINIB		
DASATINIB 20mg TABLETS	R	For the treatment of:- chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if they cannot have imatinib, or their disease is imatinib-resistant as per NICE TA425. - untreated chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia in adults as per NICE TA426. MMTc, April 2017
DASATINIB 100mg TABLETS	R	For the treatment of:- chronic or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if they cannot have imatinib, or their disease is imatinib-resistant as per NICE TA425; - untreated chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia in adults as per NICE TA426. MMTc, April 2017

DASATINIB 50mg TABLETS	R	For the treatment of:- chronic or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if they cannot have imatinib, or their disease is imatinib-resistant as per NICE TA425; - untreated chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia in adults as per NICE TA426. MMTC, April 2017
DASATINIB 80mg TABLETS	R	Chromosome-positive chronic myeloid leukaemia in adults, if they cannot have imatinib, or their disease is imatinib-resistant as per NICE TA425; untreated chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia in adults as per NICE TA426. MMTC, April 2017
DASATINIB 140mg TABLETS	R	For the treatment of: chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if they cannot have imatinib, or their disease is imatinib-resistant as per NICE TA425; untreated chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia in adults as per NICE TA426. MMTC, April 2017
DEXRAZOXANE		
DEXRAZOXANE 500mg INJECTION POWDER + CONCENTRATE	R	For use in anthracycline extravasation in working hours only. MMTC May 2018 MMTC May 2018
ENCORAFENIB		
ENCORAFENIB 75mg CAPSULES (COMPASSIONATE USE)	NF	
ERIBULIN		
ERIBULIN 0.44mg in 1ml INJECTION (2ml vial) *COMPASSIONATE USE ONLY*	NF	
ERLOTINIB		

ERLOTINIB 100mg TABLETS	R	For the treatment of: locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer as per NICE TA258; locally advanced or metastatic non-small-cell lung cancer as per NICE TA374. MMTC, August 2017
ERLOTINIB 150mg TABLETS	R	For the treatment of: locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer as per NICE TA258; locally advanced or metastatic non-small-cell lung cancer as per NICE TA374. MMTC, August 2017
EVEROLIMUS		
EVEROLIMUS 2.5mg TABLETS (AFINITOR) (COMPASSIONATE USE)	NF	JR Dispensary
EVEROLIMUS 10mg TABLETS (AFINITOR) (COMPASSIONATE USE)	NF	
EVEROLIMUS 5mg TABLETS (AFINITOR) (COMPASSIONATE USE)	NF	JR Dispensary
EVEROLIMUS 5mg TABLETS	NF	For the treatment of: advanced renal cell carcinoma as per NICE TA432; advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer as per NICE TA421; well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease as per NICE TA449. MMTC, August 2017
EVEROLIMUS 2.5mg TABLETS	NF	
EVEROLIMUS 10mg TABLETS	NF	For the treatment of: advanced renal cell carcinoma as per NICE TA432; advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer as per NICE TA421; well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease as per NICE TA449. MMTC, August 2017

EVEROLIMUS 2.5mg TABLETS (VOTUBIA)	R	For the treatment of Subependymal giant cell astrocytoma – tuberous sclerosis in paediatrics as per NHSE Clinical Commissioning Policy 16066/P MMTC, October 2018
EVEROLIMUS 10mg TABLETS	R	For the treatment of Subependymal giant cell astrocytoma – tuberous sclerosis in paediatrics as per NHSE Clinical Commissioning Policy 16066/P
EVEROLIMUS 5mg TABLETS (VOTUBIA)	R	For the treatment of Subependymal giant cell astrocytoma – tuberous sclerosis in paediatrics as per NHSE Clinical Commissioning Policy 16066/P MMTC, October 2018
GEFITINIB		
GEFITINIB 250mg TABLETS (CHARGEABLE STOCK - R CYCLE 3)		For locally advanced or metastatic non-small-cell lung cancer as per NICE TA192. Medicines Effectiveness, March 2013.
GEFITINIB 250mg TABLETS (FREE STOCK)	R	For locally advanced or metastatic non-small-cell lung cancer as per NICE TA192. Medicines Effectiveness, March 2013.
HYDROXYCARBAMIDE		
HYDROXYCARBAMIDE 500mg CAPSULES	R	For the treatment of sickle cell disease in paediatric patients. MMTC, October 2016
IBRUTINIB		
IBRUTINIB 280mg TABLETS	R	For the treatment of: Chronic lymphocytic leukaemia in adults as per NICE TA429. Waldenstrom's macroglobulinaemia in adults as per NICE TA491. Relapsed or refractory mantle cell lymphoma in adults as per NICE TA502. MMTC August 2018
IBRUTINIB 140mg CAPSULES	NF	

IBRUTINIB 140mg TABLETS	R	For the treatment of: Chronic lymphocytic leukaemia in adults as per NICE TA429. Waldenstrom's macroglobulinaemia in adults as per NICE TA491. Relapsed or refractory mantle cell lymphoma in adults as per NICE TA502. MMTC August 2018
IBRUTINIB 560mg TABLETS	R	For the treatment of: Chronic lymphocytic leukaemia in adults as per NICE TA429. Waldenstrom's macroglobulinaemia in adults as per NICE TA491. Relapsed or refractory mantle cell lymphoma in adults as per NICE TA502. MMTC August 2018
IBRUTINIB 560mg TABLETS (COMPASSIONATE SUPPLY MCL POST-ALLOGRAFT)	NF	COMPASSIONATE SUPPLY (mantle cell lymphoma MCL, POST-ALLOGRAFT)
IBRUTINIB 420mg TABLETS	R	For the treatment of: Chronic lymphocytic leukaemia in adults as per NICE TA429. Waldenstrom's macroglobulinaemia in adults as per NICE TA491. Relapsed or refractory mantle cell lymphoma in adults as per NICE TA502. MMTC August 2018
IDELALISIB		
IDELALISIB 150mg TABLETS	R	For the treatment of untreated chronic lymphocytic leukaemia in adults with a 17p deletion or TP53 mutation and chronic lymphocytic leukaemia in adults when the disease has been treated but has relapsed within 24 months in combination with rituximab as per NICE TA359. MMTC, April 2017
IDELALISIB 100mg TABLETS	R	For the treatment of untreated chronic lymphocytic leukaemia in adults with a 17p deletion or TP53 mutation and chronic lymphocytic leukaemia in adults when the disease has been treated but has relapsed within 24 months in combination with rituximab as per NICE TA359. MMTC, April 2017

IDEALALISIB 150mg TABLETS (COMPASSIONATE SUPPLY)	NF	
IDEALALISIB 100mg TABLETS (COMPASSIONATE SUPPLY)	NF	
IMATINIB		
IMATINIB 400mg TABLETS	NF	For the treatment of: -first-line management of metastatic gastro-intestinal stromal tumours (GISTs) as per NICE TA86 and TA209; -as adjuvant treatment for up to 3 years for adults who are at high risk of relapse after surgery of gastrointestinal stromal tumours as per NICE TA326. MMTC, April 2017. NB: Generic imatinib should be used for the treatment of chronic myeloid leukaemia as per NICE TA70 and TA426.
IMATINIB 400mg CAPSULES	NF	
IMATINIB 100mg TABLETS	R	For the treatment of: Philadelphia-chromosome-positive chronic myeloid leukaemia (CML) who initially present in the accelerated phase or with blast crisis and chronic phase in those who have not had previous treatment but have progressed to the accelerated phase or blast crisis as per NICE TA70; untreated chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia in adults as per NICE TA426; chronic graft versus host disease (GvHD) as per NHSE policy 16069/P. MMTC, August 2017
IPILIMUMAB		
IPILIMUMAB 50mg in 10ml INJECTION	R	For the treatment of: previously treated advanced (unresectable or metastatic) melanoma as per NICE TA268; previously untreated advanced (unresectable or metastatic) melanoma as per NICE TA319; advanced (unresectable or metastatic) melanoma in adults as per NICE TA400. MMTC, August 2017

IXAZOMIB

IXAZOMIB 3mg CAPSULES (COMPASSIONATE USE) NF		
IXAZOMIB 2.3mg CAPSULES (COMPASSIONATE USE)	NF	
IXAZOMIB 4mg CAPSULES (CDF/CHARGEABLE STOCK)	R	Restricted for use within the Cancer Drugs Fund as an option for treating multiple myeloma in adults as per NICE TA505 MMTc, August 2018
IXAZOMIB 3mg CAPSULES (CDF/CHARGEABLE STOCK)	R	Restricted for use within the Cancer Drugs Fund as an option for treating multiple myeloma in adults as per NICE TA505 MMTc, August 2018
IXAZOMIB 2.3mg CAPSULES (CDF/CHARGEABLE STOCK)	R	Restricted for use within the Cancer Drugs Fund as an option for treating multiple myeloma in adults as per NICE TA505 MMTc, August 2018
IXAZOMIB 4mg CAPSULES (COMPASSIONATE USE) NF		

LAROTRECTINIB

LAROTRECTINIB 100mg/5ml ORAL SOLUTION	NICE	Approved for use as per NICE TA630 only. An individual patient NICE implementation form is required (see PPDU SharePoint). Medicines Effectiveness, January 2020
LAROTRECTINIB 100mg CAPSULES	NICE	Approved for use as per NICE TA630 only. An individual patient NICE implementation form is required (see PPDU SharePoint). Medicines Effectiveness, April 2021
LAROTRECTINIB 25mg CAPSULES	NICE	Approved for use as per NICE TA630 only. An individual patient NICE implementation form is required (see PPDU SharePoint). Medicines Effectiveness, April 2021

LENVATINIB

LENVATINIB 10mg CAPSULES (LENVIMA)	R	For treatment of: advanced renal cell carcinoma in adults as per NICE TA498; thyroid cancer as per NICE TA535; advanced or unresectable hepatocellular carcinoma as per NICE TA551. MMTc May 2019
------------------------------------	---	---

LENVATINIB 4mg CAPSULES (PAEDS COMPASSIONATE USE)	NF	JR DISP
LENVATINIB 4mg CAPSULES (LENVIMA)	R	For treatment of: advanced renal cell carcinoma in adults as per NICE TA498; thyroid cancer as per NICE TA535; advanced or unresectable hepatocellular carcinoma as per NICE TA551. MMTc May 2019
LENVATINIB 10mg CAPSULES (PAEDS COMPASSIONATE USE)	NF	JR DISP
LORLATINIB		
LORLATINIB 100mg TABLETS (FREE OF CHARGE SUPPLY)	NF	
LORLATINIB 100mg TABLETS	NICE	Approved for use as per NICE TA628 only. An individual patient NICE implementation form is required (see PPDU SharePoint). Medicines Effectiveness, April 2020
LORLATINIB 25mg TABLETS	NICE	Approved for use as per NICE TA628 only. An individual patient NICE implementation form is required (see PPDU SharePoint). Medicines Effectiveness, April 2020
MIDOSTAURIN		
MIDOSTAURIN 25mg CAPSULES (COMPASSIONATE USE)	NF	
MIDOSTAURIN 25mg CAPSULES	R	For the treatment of myeloid leukaemia as per NICE TA523. MMTc NOV 2018
MITOTANE		
MITOTANE 500mg TABLETS	Y	
Mobocertinib		
MOBOCERTINIB 40mg CAPSULES	NICE	Used according to NICE TA 855.
MUPIROCIN		
PAZOPANIB 400mg TABLETS F/C (COMPASSIONATE USE - PAEDIATRICALS)	NF	JR ONLY
NERATINIB		

NERATINIB 40mg TABLETS	R	Neratinib for extended adjuvant therapy for hormone receptor positive HER2-overexpressed early breast cancer after completion of adjuvant therapy with HER2 targeted monotherapy with trastuzumab (TA612)
NILOTINIB		
NILOTINIB 150mg CAPSULES (FREE STOCK)	NF	
NILOTINIB 200mg CAPSULES	R	For the treatment of: - chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if they cannot have imatinib, or their disease is imatinib-resistant as per NICE TA425; - untreated chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia in adults as per NICE TA426. MMTC, April
NILOTINIB 150mg CAPSULES	R	For the treatment of: - chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if they cannot have imatinib, or their disease is imatinib-resistant as per NICE TA425; - untreated chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia in adults as per NICE TA426. MMTC, April
NINTEDANIB		
NINTEDANIB 100mg CAPSULES (VARGATEF BRAND)	R	For the treatment of locally advanced, metastatic or locally recurrent non small cell lung cancer of adenocarcinoma histology that has progressed after first line chemotherapy in combination with docetaxel as per NICE TA347. MMTC, April 2017
NINTEDANIB 150mg CAPSULES (VARGATEF BRAND)	R	For the treatment of locally advanced, metastatic or locally recurrent non small cell lung cancer of adenocarcinoma histology that has progressed after first line chemotherapy in combination with docetaxel as per NICE TA347. MMTC, April 2017

NIRAPARIB

NIRAPARIB 100mg CAPSULES

R

For the maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer as per NICE TA528. For maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID1680] as per NICE TA673. MMTc November 2021

NIRAPARIB 100mg CAPSULES (COMPASSIONATE USE SCHEME)

NF

For the treatment of ovarian, fallopian tube or peritoneal cancers as part of an exceptional access scheme only. All orders must be done via SharePoint. MMTc, July 2017

NIRAPARIB 100mg CAPSULES (COMPASSIONATE USE SCHEME)

NICE

For the treatment of ovarian, fallopian tube or peritoneal cancers as part of an exceptional access scheme only. All orders must be done via SharePoint. MMTc, July 2017

NIVOLUMAB

NIVOLUMAB 40mg IN 40ml INJECTION (EAMS)

NF

NIVOLUMAB 40mg in 4ml

R

For the treatment of advanced unresectable or metastatic melanoma as per NICE TA384; advanced (unresectable or metastatic) melanoma in adults as per NICE TA400; previously treated advanced renal cell carcinoma as per NICE TA417; relapsed or refractory classical Hodgkin lymphoma as per NICE TA462; Squamous non-small-cell lung cancer as per NICE TA483; Non-squamous non-small-cell lung cancer as per NICE TA484;

Squamous cell carcinoma of the head and neck as per NICE TA490; For adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease as per NICE

NIVOLUMAB 100mg IN 10ml INJECTION (EAMS)

NF

OLAPARIB

OLAPARIB 50mg CAPSULES	R	For maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy as per NICE TA381; and for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer as per NICE TA598. MMTTC, February 2020
OLAPARIB 150mg TABLETS (COMPASSIONATE USE) NF		
OLAPARIB 100mg TABLETS (COMPASSIONATE USE)	NF	
OLAPARIB 150mg TABLETS	R	For maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy as per NICE TA381; and for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer as per NICE TA598. MMTTC, February 2020
OLAPARIB 100mg TABLETS	R	For maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy as per NICE TA381; and for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer as per NICE TA598. MMTTC, February 2020
OLAPARIB 50mg CAPSULES (COMPASSIONATE USE) NF		

OSIMERTINIB

OSIMERTINIB 80mg TABLETS (COMPASSIONATE USE ONLY)	NF
OSIMERTINIB 80mg TABLETS (ORBIS FREE STOCK) NF	
OSIMERTINIB 40mg TABLETS (ORBIS FREE STOCK) NF	

OSIMERTINIB 80mg TABLETS	R	For the treatment of locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer in adults whose disease has after first-line treatment with an EGFR tyrosine kinase inhibitor as per NICE TA416. MMTc April 2017
OSIMERTINIB 40mg TABLETS	R	For the treatment of locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer in adults whose disease has after first-line treatment with an EGFR tyrosine kinase inhibitor as per NICE TA416. MMTc April 2017
PALBOCICLIB		
PALBOCICLIB 125mg TABLETS	R	Approved for the treatment of Locally advanced or Metastatic Breast cancer as per NICE TA495; and for treatment of advanced or metastatic breast cancer as per NICE TA619. MMTc, February 2020
PALBOCICLIB 125mg CAPSULES	R	Approved for the treatment of Locally advanced or Metastatic Breast cancer as per NICE TA495; and for treatment of advanced or metastatic breast cancer as per NICE TA619. MMTc, February 2020
PALBOCICLIB 100mg CAPSULES	R	Approved for the treatment of Locally advanced or Metastatic Breast cancer as per NICE TA495; and for treatment of advanced or metastatic breast cancer as per NICE TA619. MMTc, February 2020
PALBOCICLIB 75mg CAPSULES	R	Approved for the treatment of Locally advanced or Metastatic Breast cancer as per NICE TA495 MMTc, February 2019
PALBOCICLIB 100mg TABLETS	R	Approved for the treatment of Locally advanced or Metastatic Breast cancer as per NICE TA495; and for treatment of advanced or metastatic breast cancer as per NICE TA619. MMTc, February 2020

PALBOCICLIB 75mg TABLETS	R	Approved for the treatment of Locally advanced or Metastatic Breast cancer as per NICE TA495; and for treatment of advanced or metastatic breast cancer as per NICE TA619. MMTc, February 2021
PANITUMUMAB		
PANITUMUMAB 100mg IN 5ml INJECTION	R	For the treatment of previously untreated metastatic colorectal cancer as per NICE TA439. MMTc, July 2017
PANOBINOSTAT		
PANOBINOSTAT 15MG CAPSULES	R	For treatment of multiple myeloma after at least 2 previous treatments as per NICE TA380. MMTc, July 2016
PANOBINOSTAT 20mg CAPSULES	R	For treatment of multiple myeloma after at least 2 previous treatments as per NICE TA380. MMTc, July 2016
PANOBINOSTAT 20mg CAPSULES (FREE OF CHARGE)	NF	
PANOBINOSTAT 10MG CAPSULES	R	For treatment of multiple myeloma after at least 2 previous treatments as per NICE TA380. MMTc, July 2016
PAZOPANIB		
PAZOPANIB 200mg TABLETS F/C (COMPASSIONATE USE -- PAEDIATRICS)	NF	JR DISPENSARY
PAZOPANIB 200mg TABLETS F/C	R	For first-line treatment of advanced renal cell carcinoma as per NICE TA215. MAC, May 2011.
PEGASPARGINASE		
PEGASPARGINASE 3750iu IN 5ml INJECTION	R	For the treatment of acute lymphoblastic leukaemia as per NICE TA408. MMTc, July 201
PEMETREXED		

PEMETREXED 500mg INJECTION POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION	R	For the treatment of: -Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults as per NICE TA406 -Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults as per NICE TA422. MMTC, May 2017
Pemigatinib		
PEMIGATINIB 4.5mg TABLETS	NICE	
PEMIGATINIB 13.5mg TABLETS	R	For treatment of locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that has progressed after systemic therapy in adults as per NICE TA722. MMTC, March 2024.
PEMIGATINIB 4.5mg TABLETS	NF	
PEMIGATINIB 13.5mg TABLETS	NF	
PONATINIB		
PONATINIB 15mg TABLETS	R	Chronic myeloid leukaemia and acute lymphoblastic leukaemia as per NICE TA451. MMTC, September 2017
PONATINIB 45mg TABLETS	R	Chronic myeloid leukaemia and acute lymphoblastic leukaemia as per NICE TA451. MMTC, September 2017
PROCARBAZINE		
PROCARBAZINE 50mg CAPSULES	R	As per Paediatric and adults Haematology/Oncology protocols. Medicines Effectiveness, March 2013.
PROCARBAZINE 100mg/5ml LIQUID 40ml	SR	As per Paediatric and adults Haematology/Oncology protocols. Medicines Effectiveness, March 2013.
PROCARBAZINE 100mg/5ml LIQUID 25ml	SR	As per Paediatric and adults Haematology/Oncology protocols. Medicines Effectiveness, March 2013.

PROCARBAZINE 50mg CAPSULES	UNR	As per Paediatric and adults Haematology/Oncology protocols. Medicines Effectiveness, March 2013.
REGORAFENIB		
REGORAFENIB 40mg TABLETS	R	For the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours as per NICE TA488; For previously treated advanced hepatocellular carcinoma as per NICE TA555. MMTC July 2019
RIBOCICLIB		
RIBOCICLIB 200mg TABLETS	R	Approved for the treatment of Locally advanced or Metastatic Breast cancer as per NICE TA496; and for treatment of hormone receptor positive, HER2 negative advanced breast cancer as per NICE TA687. MMTC, August 2021
RUBRACA		
RUCAPARIB 200mg TABLETS	R	For maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer as per NICE TA611. MMTC, February 2020
RUXOLITINIB		
RUXOLITINIB 15mg TABLETS	R	For the treatment of disease-related splenomegaly or symptoms in adults with myelofibrosis as per NICE TA386. MMTC, July 2016
RUXOLITINIB 20mg TABLETS	R	For the treatment of disease-related splenomegaly or symptoms in adults with myelofibrosis as per NICE TA386. MMTC, July 2016
RUXOLITINIB 10mg TABLETS	R	For the treatment of disease-related splenomegaly or symptoms in adults with myelofibrosis as per NICE TA386. MMTC, July 2016

RUXOLITINIB 5mg TABLETS	R	For the treatment of disease-related splenomegaly or symptoms in adults with myelofibrosis as per NICE TA386. MMTC, July 2016
RUXOLITINIB 5mg TABLETS (FREE OF CHARGE SUPPLY)	NF	
RUXOLITINIB 15mg TABLETS (FREE OF CHARGE SUPPLY)	NF	
RUXOLITINIB 20mg TABLETS (FREE OF CHARGE SUPPLY)	NF	
RUXOLITINIB 10mg TABLETS (FREE OF CHARGE SUPPLY)	NF	
Selpercatinib		
SELPERCATINIB 40mg CAPSULES	NICE	
SORAFENIB		
SORAFENIB 200mg TABLETS	NICE	For the treatment of advanced hepatocellular carcinoma as per NICE TA474 and for treatment of thyroid cancer as per NICE TA535. MMTC, May 2019
SUNITINIB		
SUNITINIB 50mg CAPSULES	R	For treatment of: advanced and/or metastatic renal cell carcinoma as per NICE TA169; gastrointestinal stromal tumours as per TA179; well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease as per NICE TA449. MMTC, August 2017
SUNITINIB 25mg CAPSULES	R	For treatment of: advanced and/or metastatic renal cell carcinoma as per NICE TA169; gastrointestinal stromal tumours as per TA179; well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease as per NICE TA449. MMTC, August 2017

SUNITINIB 12.5mg CAPSULES	R	For treatment of: advanced and/or metastatic renal cell carcinoma as per NICE TA169; gastrointestinal stromal tumours as per TA179; well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease as per NICE TA449. MMTTC, August 2017
SUNITINIB 12.5mg CAPSULES (FIRST CYCLE - FREE STOCK)	R	For treatment of: advanced and/or metastatic renal cell carcinoma as per NICE TA169; gastrointestinal stromal tumours as per TA179; well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease as per NICE TA449. MMTTC, August 2017

TALAZOPARIB

TALAZOPARIB 1mg CAPSULES (COMPASSIONATE USE)	NF	
TALAZOPARIB 1mg CAPSULES	NICE	NICETA 10366
TALAZOPARIB 250microgram CAPSULES	NICE	NICETA 10366

TALIMOGENE LAHERPAREPVEC

TALIMOGENE LAHERPAREPVEC 10 ⁶ PFU in 1ml INJECTION	R	For the treatment of unresectable metastatic melanoma as per NICE TA410. MMTTC, October 2017
TALIMOGENE LAHERPAREPVEC 10 ⁸ PFU in 1ml INJECTION	R	For the treatment of unresectable metastatic melanoma as per NICE TA410. MMTTC, October 2017

Teduglutide

TEDUGLUTIDE 1.25mg INJECTION	R	For treatment of short bowel syndrome (SBS) in people 1 year and above as per NICE TA804. MMTTC, Feb 2024
TEDUGLUTIDE 5mg INJECTION	R	For treatment of short bowel syndrome (SBS) in people 1 year and above as per NICE TA804. MMTTC, Feb 2024

TEMOZOLAMIDE

TEMOZOLOMIDE 180mg CAPSULES	R	For the treatment of recurrent malignant glioma (brain cancer) as per NICE TA23 and NICE TA121. MMTC, June 2018 (update)
TEMOZOLOMIDE 140mg CAPSULES	R	For the treatment of recurrent malignant glioma (brain cancer) as per NICE TA23 and NICE TA121. MMTC, June 2018 (update)
TEMOZOLOMIDE		
TEMOZOLOMIDE 100mg CAPSULES	R	For the treatment of recurrent malignant glioma (brain cancer) as per NICE TA23 and NICE TA121. MMTC, June 2018 (update)
TEMOZOLOMIDE 20mg CAPSULES	R	For the treatment of recurrent malignant glioma (brain cancer) as per NICE TA23 and NICE TA121. MMTC, June 2018 (update)
TEMOZOLOMIDE 5mg CAPSULES	R	For the treatment of recurrent malignant glioma (brain cancer) as per NICE TA23 and NICE TA121. MMTC, June 2018 (update)
TEMOZOLOMIDE 250mg CAPSULES	R	For the treatment of recurrent malignant glioma (brain cancer) as per NICE TA23 and NICE TA121. MMTC, June 2018 (update)
TIVOZANIB		
TIVOZANIB 1340MCG CAPSULES	R	For treatment of renal cell carcinoma as per NICE TA512. MMTC, May 2019
TIVOZANIB 890microgram CAPSULES	R	For treatment of renal cell carcinoma as per NICE TA512. MMTC, May 2019
TOPOTECAN		
TOPOTECAN 1mg CAPSULES	R	For the treatment of relapsed small-cell lung cancer as per NICE TA184 and for the treatment of treatment of recurrent carcinoma of the cervix as per NICE TA183. MAC, May 2011

TOPOTECAN 250microgram CAPSULES	R	For the treatment of relapsed small-cell lung cancer as per NICE TA184 and for the treatment of treatment of recurrent carcinoma of the cervix as per NICE TA183. MAC, May 2011
TRAMETINIB		
TRAMETINIB 500microgram TABLETS	R	For the treatment of unresectable or metastatic melanoma in combination with Dabrafenib as per NICE TA396; For adjuvant treatment of resected BRAF V600 mutation-positive melanoma as per NICE TA544. MMTC July 2019
TRAMETINIB 2mg TABLETS	R	For the treatment of unresectable or metastatic melanoma in combination with Dabrafenib as per NICE TA396; For adjuvant treatment of resected BRAF V600 mutation-positive melanoma as per NICE TA544. MMTC July 2019
TRAMETINIB 2mg TABLETS	R	For the treatment of unresectable or metastatic melanoma in combination with Dabrafenib as per NICE TA396; For adjuvant treatment of resected BRAF V600 mutation-positive melanoma as per NICE TA544. MMTC July 2019
TRAMETINIB 500microgram TABLETS	R	For the treatment of unresectable or metastatic melanoma in combination with Dabrafenib as per NICE TA396; For adjuvant treatment of resected BRAF V600 mutation-positive melanoma as per NICE TA544. MMTC July 2019
TRAMETINIB 500microgram TABLETS (FREE OF CHARGE SUPPLY)	NF	
TRASTUZUMAB		
TRASTUZUMAB 600mg IN 5ml SUBCUTANEOUS INJECTION	R	For the treatment of advanced breast cancer as per NICE TA34, for the adjuvant treatment of early-stage HER2-positive breast cancer as per TA107, and for the treatment of HER2-positive metastatic gastric cancer a sper TA208. MMTC, December 2014

TRETINOIN

TRETINOIN 10mg CAPSULES Y

TRIFLURIDINE

TRIFLURIDINE 15mg & TIPIRACIL 6.14mg TABLETS R For the treatment of metastatic colorectal cancer as per NICE TA405. MMTC, April 2017

TRIFLURIDINE 20mg & TIPIRACIL 8.19mg TABLETS R For the treatment of metastatic colorectal cancer as per NICE TA405. MMTC, April 2017

VANDETANIB

VANDETANIB 100mg TABLETS NF

VANDETANIB 100mg TABLETS (FOC) NF

VANDETANIB 300mg TABLETS (FOC) NF

VANDETANIB 300mg TABLETS NF

VEMURAFENIB

VEMURAFENIB 240mg TABLETS R For unresectable or metastatic melanoma with the BRAF V600 mutation as per NICE TA269. MMTC, March 2013.

VENETOCLAX

VENETOCLAX 50mg TABLETS R For use in: Chronic lymphocytic leukaemia as per NICE TA487 and NICE TA56. For use with obinutuzumab for untreated chronic lymphocytic leukaemia as per NICE TA663. MMTC, November 2021

VENETOCLAX 100mg TABLETS R For use in: Chronic lymphocytic leukaemia as per NICE TA487 and NICE TA56. For use with obinutuzumab for untreated chronic lymphocytic leukaemia as per NICE TA663. MMTC, November 2021

VENETOCLAX 10mg TABLETS R For use in: Chronic lymphocytic leukaemia as per NICE TA487 and NICE TA56. For use with obinutuzumab for untreated chronic lymphocytic leukaemia as per NICE TA663. MMTC, November 2021

VENETOCLAX 100mg TABLETS	R	For use in: Chronic lymphocytic leukaemia as per NICE TA487 and NICE TA56. For use with obinutuzumab for untreated chronic lymphocytic leukaemia as per NICE TA663. MMTC, November 2021
VENETOCLAX 100mg TABLETS	R	For use in: Chronic lymphocytic leukaemia as per NICE TA487 and NICE TA56. For use with obinutuzumab for untreated chronic lymphocytic leukaemia as per NICE TA663. MMTC, November 2021
VORETIGENE NEPARVOVEC		
VORETIGENE NEPARVOVEC 5x10 ¹² VECTOR GENOMES in 1mL SUBRETINAL INJECTION	R	For treating RPE65-mediated retinal dystrophies as per NICE HST11 only. MMTC, January 2020
Zanubrutinib		
ZANUBRUTINIB 80mg CAPSULES	R	For treatment of Waldenström's macroglobulinemia in adults as per NICE TA833. MMTC, February 2023.
<i>08.01.06 Cytotoxic responsive malignancy</i>		
Afatinib		
AFATINIB 20mg TABLETS	R	For treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer as per NICE TA310. MMTC, September 2014
CALCIUM FOLINATE		
CALCIUM FOLINATE 15mg TABLETS	Y	
GILTERITINIB		
GILTERITINIB 40mg TABLETS	R	For treating relapsed or refractory FLT3-mutation-positive AML as per NICE TA642. MMTC October 2020
<i>08.02.04 Other immunomodulating drugs</i>		
DABRAFENIB		
DABRAFENIB 75mg CAPSULES (COMPASSIONATE USE PAEDIATRICALS)	NF	JR DISPENSARY
<i>8.01.01 Alkylating drugs</i>		
CALCIUM FOLINATE		

CALCIUM FOLINATE 15mg TABLETS Y

8.01.05 Other antineoplastic drugs

RUCAPARIB

RUCAPARIB 300mg TABLETS R For maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer as per NICE TA611. MMTTC, February 2020

08.02 Drugs affecting the immune response

08.02.00 Drugs affecting the immune response

ISATUXIMAB

ISATUXIMAB 500mg in 25ml SOLUTION FOR INFUSION (FREE OF CHARGE) NF

ISATUXIMAB 100mg in 5ml SOLUTION FOR INFUSION (FREE OF CHARGE) NF

MYCOPHENOLATE

MYCOPHENOLATE 500mg INJECTION NF

MYCOPHENOLATE 500mg TABLETS Y

MYCOPHENOLATE 250mg CAPSULES Y

NUSINERSEN

NUSINERSEN 12mg in 5ml INJECTION R For treatment of 5q spinal muscular atrophy as per NICE TA588

OBINUTUZUMAB

OBINUTUZUMAB 1000mg IN 40ml INJECTION R For the treatment of untreated chronic lymphocytic leukaemia as per NICE TA343; treating follicular lymphoma refractory to rituximab as per NICE TA472 and follicular lymphoma as per NICE TA513. For use with venetoclax for untreated chronic lymphocytic leukaemia as per NICE TA663, MMTTC, November 2021

OCRELIZUMAB

OCRELIZUMAB 300mg INJECTION R For the treatment of relapsing-remitting and primary progressive multiple sclerosis in adults as per NICE TA533 and NICE TA585. MMTTC, July 2021

OFATUMUMAB

OFATUMUMAB 1000mg IN 50ml INJECTION

R

For the treatment of untreated chronic lymphocytic leukaemia in combination with chlorambucil where the patient is ineligible for fludarabine based therapy and bendamustine is not suitable as per NICE TA344. MMTC, April 2017

RITUXIMAB

RITUXIMAB 500mg IN 50ml INJECTION (RIXATHON) R

For the treatment of: - Anti-neutrophil cytoplasmic - Antibody-associated vasculitis as per TA308 - Chronic lymphocytic leukaemia as for NICE TA174, TA193, and TA561- Dermatomyositis and Polymyositis as per NHSE policy 16036/P (adults) - Follicular lymphoma (first-line treatment of stage III-IV) as per TA243 - Immunoglobulin G4-related disease (IgG4-RD) as per NHSE policy 16057/P (adults). Rituximab biosimilar should be used for this indication. Myasthenia Gravis - As per NHSE policy 170084/P. For Non-Hodgkin's lymphoma as per TA137 and TA226. Also supported for use in (off label): a) acquired haemophilia associated with inhibitory antibodies; b) mantle cell lymphoma; c) marginal zone lymphoma and lymphoplasmacytic lymphoma; d) Thyroid-associated orbitopathy (dose limited to 100mg). Also approved for use without methotrexate in rheumatoid arthritis (see unlicensed medicines register). MMTC, April

RITUXIMAB 100mg IN 10ml INJECTION (RIXATHON) R

For the treatment of: - Anti-neutrophil cytoplasmic - Antibody-associated vasculitis as per TA308 - Chronic lymphocytic leukaemia as for NICE TA174, TA193, and TA561- Dermatomyositis and Polymyositis as per NHSE policy 16036/P (adults) - Follicular lymphoma (first-line treatment of stage III-IV) as per TA243 - Immunoglobulin G4-related disease (IgG4-RD) as per NHSE policy 16057/P (adults). Rituximab biosimilar should be used for this indication. Myasthenia Gravis - As per NHSE policy 170084/P. For Non-Hodgkin's lymphoma as per TA137 and TA226. Also supported for use in (off label): a) acquired haemophilia associated with inhibitory antibodies; b) mantle cell lymphoma; c) marginal zone lymphoma and lymphoplasmacytic lymphoma; d) Thyroid-associated orbitopathy (dose limited to 100mg). Also approved for use without methotrexate in rheumatoid arthritis (see unlicensed medicines register). MMTC, April

08.02.00 Malignant disease and immunosuppression

BRODALUMAB

BRODALUMAB 210mg in 1.5ml INJECTION PRE FILLED SYRINGE R

For treatment of plaque psoriasis in adults as per NICE TA511. MMTC, June 2018

08.02.00 rugs affecting the immune response

Belumosudil

BELUMOSUDIL 200mg TABLETS NF

08.02.01 Antiproliferative immunosuppressants

AZATHIOPRINE

AZATHIOPRINE 50mg/5ml LIQUID SR

For paediatric patients, patients with swallowing difficulties or feeding tubes. Medicines Effectiveness, August 2010

AZATHIOPRINE 50mg TABLETS Y

AZATHIOPRINE 25mg TABLETS Y

AZATHIOPRINE 10mg CAPSULES	SR	For patients of low body weight or those on interacting drugs as much lower azathioprine doses may be indicated. Medicines Effectiveness, July 2014.
MYCOPHENOLATE		
MYCOPHENOLATE 1g/5ml LIQUID 175ml	R	For Renal Transplant use only. Medicines Effectiveness, February 2013.
MYCOPHENOLIC ACID		
MYCOPHENOLATE SODIUM 360mg TABLETS E/C	R	For 3C Study only (Renal) Medicines Effectiveness, Oct. 2012
MYCOPHENOLATE SODIUM 180mg TABLETS E/C	R	For 3C Study only (Renal) Medicines Effectiveness, Oct. 2012
<i>08.02.02 Corticosteroids and other immunosuppressants</i>		
ANTI-THYMOCYTE IMMUNOGLOBULIN		
ANTI-THYMOCYTE IMMUNOGLOBULIN EQUINE 250mg in 5ml INJECTION	UNR	For the treatment of aplastic anaemia (adults and paediatrics). MMTC, May 2013.
ANTI-THYMOCYTE IMMUNOGLOBULIN RABBIT 25mg IN 5ml INJECTION	R	For use by Haematology (adults) and Transplant NB: Paediatrics Haematology requires preauthorisation from OCCG- Medicines Effectiveness, March 2013.
BASILIXIMAB		
BASILIXIMAB 20mg INJECTION	R	For Renal Transplant as per NICE TA85 and TA99. Medicines Effectiveness, June 2001.
BELATACEPT		
BELATACEPT 250mg INJECTION (CTASU - FOC STOCK)	NF	
CICLOSPORIN		
CICLOSPORIN 50mg CAPSULES (DEXIMUNE)	NF	
CICLOSPORIN 100mg CAPSULES (DEXIMUNE)	NF	

CICLOSPORIN 100mg/ml LIQUID (NEORAL) (50ml)	R	For use by Transplant patients with swallowing difficulties or feeding tubes only. "Ciclosporin must be prescribed by brand name only". Please ensure the patient receives the brand that has been prescribed. If no brand is specified, please query with the prescriber or screening pharmacist" Medicines Effectiveness, October 2012.
CICLOSPORIN 100mg/ml LIQUID (SANDIMMUN) (50ml)	NF	
CICLOSPORIN 10mg CAPSULES (NEORAL)	R	For use by Transplant only. "Ciclosporin / tacrolimus must be prescribed by brand name only", Please ensure the patient receives the brand that has been prescribed. If no brand is specified, please query with the prescriber or screening pharmacist" Medicines Effectiveness, October 2012.
CICLOSPORIN 50mg in 1ml INJECTION (SANDIMMUN)	R	Strictly NBM patients. "Ciclosporin must be prescribed by brand name only". Please ensure the patient receives the brand that has been prescribed. If no brand is specified, please query with the prescriber or screening pharmacist" Medicines Effectiveness, October 2012.
CICLOSPORIN 100mg CAPSULES (SANDIMMUN)	NF	
CICLOSPORIN 100mg CAPSULES (CAPIMUNE)	Y	Ciclosporin must be prescribed by brand name only. Please ensure the patient receives the brand that has been prescribed. If no brand is specified, please query with the prescriber or screening pharmacist Medicines Effectiveness, October 2012.
CICLOSPORIN 50mg CAPSULES (NEORAL)	R	For use by Transplant only. "Ciclosporin must be prescribed by brand name only". Please ensure the patient receives the brand that has been prescribed. If no brand is specified, please query with the prescriber or screening pharmacist" Medicines Effectiveness, October 2012.

CICLOSPORIN 50mg CAPSULES (CAPIMUNE)	Y	Ciclosporin must be prescribed by brand name only. Please ensure the patient receives the brand that has been prescribed. If no brand is specified, please query with the prescriber or screening pharmacist Medicines Effectiveness, October 2012.
CICLOSPORIN 25mg CAPSULES (SANDIMMUN)	NF	
CICLOSPORIN 25mg CAPSULES (NEORAL)	R	For use by Transplant only. "Ciclosporin must be prescribed by brand name only". Please ensure the patient receives the brand that has been prescribed. If no brand is specified, please query with the prescriber or screening pharmacist" Medicines Effectiveness, October 2012.
CICLOSPORIN 25mg CAPSULES (DEXIMUNE)	NF	
CICLOSPORIN 250mg in 5ml INJECTION (SANDIMMUN)	R	Strictly NBM patients. "Ciclosporin must be prescribed by brand name only". Please ensure the patient receives the brand that has been prescribed. If no brand is specified, please query with the prescriber or screening pharmacist" Medicines Effectiveness, October 2012.
CICLOSPORIN 25mg CAPSULES (CAPIMUNE)	Y	Ciclosporin must be prescribed by brand name only. Please ensure the patient receives the brand that has been prescribed. If no brand is specified, please query with the prescriber or screening pharmacist Medicines Effectiveness, October 2012.
CICLOSPORIN 100mg CAPSULES (NEORAL)	R	For use by Transplant only. "Ciclosporin must be prescribed by brand name only". Please ensure the patient receives the brand that has been prescribed. If no brand is specified, please query with the prescriber or screening pharmacist" Medicines Effectiveness, October 2012.

Imlifidase

IMIFLIDASE 11mg INJECTION	R	For desensitisation treatment before kidney transplant as per NICE TA July 2022 (MMTC, Dec 2022)
IMIFLIDASE 11mg INJECTION	R	For desensitisation treatment before kidney transplant as per NICE TA July 2022 (MMTC, Dec 2022)
SIROLIMUS		
SIROLIMUS 500microgram TABLETS	R	For Renal Transplant patients, and for autoimmune haemolytic anaemia in paediatric patients resistant to steroids. MMTC, June 2021
SIROLIMUS 2mg TABLETS	R	For Renal Transplant patients, and for autoimmune haemolytic anaemia in paediatric patients resistant to steroids. MMTC, June 2021
SIROLIMUS 1mg TABLETS	R	For Renal Transplant patients, and for autoimmune haemolytic anaemia in paediatric patients resistant to steroids. MMTC, June 2021
SIROLIMUS 5mg/5ml LIQUID	R	For Renal Transplant patients, and for autoimmune haemolytic anaemia in paediatric patients resistant to steroids. MMTC, June 2021
TACROLIMUS		
TACROLIMUS 0.75mg PROLONGED RELEASE TABLETS (ENVARUSUS)	NF	
TACROLIMUS 1mg PROLONGED RELEASE TABLETS (ENVARUSUS)	NF	Tacrolimus must be prescribed by brand name only, Please ensure the patient receives the brand that has been prescribed. If no brand is specified, please query with the prescriber or screening pharmacist Medicines Effectiveness, March 2017
TACROLIMUS 4mg PROLONGED RELEASE TABLETS (ENVARUSUS)	NF	
TACROLIMUS 0.1% OINTMENT 30g	R	For use by Dermatology in atopic dermatitis as per TA82 Medicines Effectiveness,

TACROLIMUS 0.03% OINTMENT 30g	R	For use by Dermatology in atopic dermatitis as per TA82 and for intractable perianal Crohns disease unresponsive to standard therapies. MAC June 2008
TACROLIMUS 0.5mg CAPSULES	NF	
TACROLIMUS 1mg CAPSULES	NF	
TACROLIMUS 1mg CAPSULES (ADOPORT)	Y	Tacrolimus must be prescribed by brand name only. Please ensure the patient receives the brand that has been prescribed. If no brand is specified, please query with the prescriber or screening pharmacist. Medicines Effectiveness, October 2012.
TACROLIMUS 1mg CAPSULES M/R (ADVAGRAF)	R	For use in line with the young adult/poor compliance transplant protocol at OUH transplant centre. Medicines Effectiveness April 2021
TACROLIMUS 750microgram CAPSULES (ADOPORT)	Y	
TACROLIMUS 3mg CAPSULES M/R (ADVAGRAF)	R	For use in line with the young adult/poor compliance transplant protocol at OUH transplant centre. Medicines Effectiveness April 2021
TACROLIMUS 500microgram CAPSULES (ADOPORT)	Y	Tacrolimus must be prescribed by brand name only. Please ensure the patient receives the brand that has been prescribed. If no brand is specified, please query with the prescriber or screening pharmacist. Medicines Effectiveness, October 2012.
TACROLIMUS 500microgram CAPSULES M/R (ADVAGRAF)	R	For use in line with the young adult/poor compliance transplant protocol at OUH transplant centre. Medicines Effectiveness April 2021
TACROLIMUS 5mg CAPSULES	NF	

TACROLIMUS 5mg CAPSULES (ADOPORT)	Y	Tacrolimus must be prescribed by brand name only. Please ensure the patient receives the brand that has been prescribed. If no brand is specified, please query with the prescriber or screening pharmacist. Medicines Effectiveness, October 2012.
TACROLIMUS 5mg CAPSULES M/R (ADVAGRAF)	R	For use in line with the young adult/poor compliance transplant protocol at OUH transplant centre. Medicines Effectiveness April 2021
TACROLIMUS 200microgram GRANULES	NF	
TACROLIMUS 5mg IN 1ml INJECTION	R	Strictly NBM patients. "Tacrolimus must be prescribed by brand name only". Please ensure the patient receives the brand that has been prescribed. If no brand is specified, please query with the prescriber or screening pharmacist" Medicines Effectiveness, October 2012.
TACROLIMUS 1mg GRANULES	NF	
Voclosporin		
VOCLOSPORIN 7.9mg CAPSULES	R	For treatment of active class 3 to 5 lupus nephritis as per NICE TA882. MMTc, September 2023
<i>08.02.02 Malignant disease and immunosuppression</i>		
TACROLIMUS		
TACROLIMUS 2mg SUPPOSITORIES	UNR	**Product has 90 day expiry** For treatment of chronic refractor ulcerative proctitis by consultant gastroenterologists only. MMTc, May 2019
<i>08.02.03 Anti-lymphocyte monoclonal antibodies</i>		
ALEMTUZUMAB		
ALEMTUZUMAB 30mg in 1ml INJECTION (HAEMATOLOGY)	UNR	For Haematology use only. Medicines Effectiveness, February 2013.
ALEMTUZUMAB 30mg in 1ml INJECTION (TRANSPLANT)	UNR	For Transplant use only. Medicines Effectiveness, February 2013.

ALEMTUZUMAB 12mg INJECTION	R	For the treatment of relapsing-remitting multiple sclerosis as per NICE TA312. MMTC, September 2014.
RITUXIMAB		
RITUXIMAB 500mg IN 50ml INJECTION	R	For the treatment of: - Anti-neutrophil cytoplasmic - Antibody-associated vasculitis as per TA308 - Chronic lymphocytic leukaemia as for NICE TA174,TA193, and TA561- Dermatomyositis and Polymyositis as per NHSE policy 16036/P (adults) - Follicular lymphoma (first-line treatment of stage III-IV) as per TA243 - Immunoglobulin G4-related disease (IgG4-RD) as per NHSE policy 16057/P (adults). Rituximab biosimilar should be used for this indication. Myasthenia Gravis - As per NHSE policy 170084/P. For Non-Hodgkin's lymphoma as per TA137 and TA226. Also supported for use in (off label): a) acquired haemophilia associated with inhibitory antibodies; b) mantle cell lymphoma; c) marginal zone lymphoma and lymphoplasmacytic lymphoma; d) Thyroid-associated orbitopathy (dose limited to 100mg). Also approved for use without methotrexate in rheumatoid arthritis (see unlicensed medicines register). MMTC, April
RITUXIMAB 1400mg IN 11.7ml SUBCUTANEOUS INJECTION	R	SUBCUT PREPARATION for Oncology use only. For the treatment of: - Follicular lymphoma (first-line treatment of stage III-IV) as per TA243. Also supported for use in (off label): a) mantle cell lymphoma; b) marginal zone lymphoma; c) lymphoplasmacytic lymphoma. MMTC, April 2015

RITUXIMAB 100mg IN 10ml INJECTION

R

For the treatment of: - Anti-neutrophil cytoplasmic - Antibody-associated vasculitis as per TA308 - Chronic lymphocytic leukaemia as for NICE TA174, TA193, and TA561- Dermatomyositis and Polymyositis as per NHSE policy 16036/P (adults) - Follicular lymphoma (first-line treatment of stage III-IV) as per TA243 - Immunoglobulin G4-related disease (IgG4-RD) as per NHSE policy 16057/P (adults). Rituximab biosimilar should be used for this indication. Myasthenia Gravis - As per NHSE policy 170084/P. For Non-Hodgkin's lymphoma as per TA137 and TA226. Also supported for use in (off label): a) acquired haemophilia associated with inhibitory antibodies; b) mantle cell lymphoma; c) marginal zone lymphoma and lymphoplasmacytic lymphoma; d) Thyroid-associated orbitopathy (dose limited to 100mg). Also approved for use without methotrexate in rheumatoid arthritis (see unlicensed medicines register). MMTc, April

08.02.04 Other immunomodulating drugs

DABRAFENIB

DABRAFENIB 50mg CAPSULES (COMPASSIONATE USE - PAEDIATRICS)

NF JR DISPENSARY

LENALIDOMIDE

LENALIDAMIDE 20MG CAPSULES

NF

08.02.04 Immunotherapy responsive malignancy

Lenalidomide

LENALIDOMIDE 2.5mg CAPSULES (RANBAXY)	R	For the treatment of:- multiple myeloma in people who have received at least two prior therapy NICE TA171; after treatment with bortezomib as per TA586; and in untreated multiple myeloma as per TA587 - transfusion dependent anaemia caused by low or intermediate 1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate as per NICE TA322. MMTc, September 2019
<i>08.02.04 Other immunomodulating drugs</i>		
ALDESLEUKIN		
ALDESLEUKIN 18million UNIT INJECTION	Y	
AVACOPAN		
AVACOPAN 10mg CAPSULES	R	
BCG		
BCG VACCINE 81mg BLADDER INSTILLATION	R	For bladder instillation in Urology Ward only. Medicines Effectiveness, July 2012.
BCG (BACILLUS CALMETTE-GURIN)		
BCG VACCINE 12.5mg BLADDER INSTILLATION	Y	
DABRAFENIB		
DABRAFENIB 75mg CAPSULES	R	For the treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma as per NICE TA321; unresectable or metastatic BRAF V600 mutation-positive melanoma in combination with Trametinib as per NICE TA396; For adjuvant treatment of resected BRAF V600 mutation-positive melanoma as per NICE TA544

DABRAFENIB 50mg CAPSULES	R	For the treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma as per NICE TA321; unresectable or metastatic BRAF V600 mutation-positive melanoma in combination with Trametinib as per NICE TA396; For adjuvant treatment of resected BRAF V600 mutation-positive melanoma as per NICE TA544
DIMETHYL FUMARATE		
HC DIMETHYL FUMARATE 120mg CAPSULES (HNHC)	R	For the treatment of relapsing-remitting multiple sclerosis, as per NICE TA320. MMTC, November 2014
HC DIMETHYL FUMARATE 240mg CAPSULES (HNHC)	R	For the treatment of relapsing-remitting multiple sclerosis, as per NICE TA320. MMTC, November 2014
HC TERIFLUNOMIDE 14mg TABLETS	R	For treating relapsing-remitting multiple sclerosis as per NICE TA303. MMTC, April 2014
DIMETHYL FUMERATE		
DIMETHYL FUMERATE 120mg CAPSULES	R	For the treatment of relapsing-remitting multiple sclerosis, as per NICE TA320. MMTC, November 2014.
DIMETHYL FUMERATE 240mg CAPSULES	R	For the treatment of relapsing-remitting multiple sclerosis, as per NICE TA320. MMTC, November 2014.
ENCORAFENIB		
ENCORAFENIB 75mg CAPSULES	R	For treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma as per NICE TA562 MMTC July 2019
FINGOLIMOD		
FINGOLIMOD 500microgram CAPSULES (COMPASSIONATE SUPPLY)	NF	
FINGOLIMOD 500microgram CAPSULES STARTER PACK	R	For the treatment of highly active relapsing-remitting multiple sclerosis as per NICE TA254. MMTC, September 2012.

FINGOLIMOD 500microgram CAPSULES	R	For the treatment of highly active relapsing-remitting multiple sclerosis as per NICE TA254. MMTC, September 2012.
IMATINIB		
IMATINIB 100mg TABLETS	NF	For chronic myeloid leukaemia as per NICE TA70 and TA251; and for gastrointestinal stromal tumours as per TA86 and TA209. Medicines Effectiveness, March 2013.
IMATINIB 400mg TABLETS	NF	For chronic myeloid leukaemia as per NICE TA70 and TA251; and for gastrointestinal stromal tumours as per NICE TA86 and TA209. Medicines Effectiveness, March 2013.
INTERFERON		
INTERFERON BETA-1A 6million international units (22microgram) PRE-FILLED SYRINGE	NF	
INTERFERON ALFA 6million units in 0.5ml pre-filled syringe	Y	
INTERFERON ALFA 3million units in 0.5ml pre-filled syringe	Y	
INTERFERON 4.5million international units IN 0.5ml INJECTION (ROFERON A)	Y	
Lenalidomide		
LENALIDOMIDE 15mg CAPSULES (RANBAXY)	R	For the treatment of:- multiple myeloma in people who have received at least two prior therapy NICE TA171; after treatment with bortezomib as per TA586; and in untreated multiple myeloma as per TA587 - transfusion dependent anaemia caused by low or intermediate 1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate as per NICE TA322. MMTC, September 2019
LENALIDOMIDE 2.5mg CAPSULES (REVLIMID)	NF	

LENALIDOMIDE 5mg CAPSULES (RANBAXY)	R	For the treatment of:- multiple myeloma in people who have received at least two prior therapy NICE TA171; after treatment with bortezomib as per TA586; and in untreated multiple myeloma as per TA587 - transfusion dependent anaemia caused by low or intermediate 1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate as per NICE TA322. MMTC, September 2019
LENALIDOMIDE 25mg CAPSULES	NF	
LENALIDOMIDE 5mg CAPSULES	NF	
LENALIDOMIDE 10mg CAPSULES	NF	
LENALIDOMIDE 20mg CAPSULES (RANBAXY)	R	For the treatment of:- multiple myeloma in people who have received at least two prior therapy NICE TA171; after treatment with bortezomib as per TA586; and in untreated multiple myeloma as per TA587 - transfusion dependent anaemia caused by low or intermediate 1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate as per NICE TA322. MMTC, September 2019
LENALIDOMIDE 15mg CAPSULES	NF	

LLENALIDOMIDE 10mg CAPSULES (RANBAXY)	R	For the treatment of:- multiple myeloma in people who have received at least two prior therapy NICE TA171; after treatment with bortezomib as per TA586; and in untreated multiple myeloma as per TA587 - transfusion dependent anaemia caused by low or intermediate 1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate as per NICE TA322. MMTTC, September 2019
NATALIZUMAB		
NATALIZUMAB 300mg INFUSION	R	For the treatment of adults with highly active relapsing-remitting multiple sclerosis as NICE TA 127. Medicines Effectiveness, September 2008.
OZANIMOD		
OZANIMOD 230microgram & 460microgram CAPSULES (INITIATION PACK)	R	
OZANIMOD 920microgram CAPSULES	R	
PACLITAXEL ALBUMIN		
PACLITAXEL ALBUMIN 100mg INJECTION (ABRAXANE) (COMPASSIONATE USE)	NF	
PEG INTERFERON		
PEG INTERFERON ALFA 2a 90microgram PRE FILLED SYRINGE	R	For the treatment of: Chronic Myeloproliferative disorder in young patients with MPN that require cytoreduction; Hepatitis B as per NICE TA96; Hepatitis C as per NICE TA75, TA106, TA200 and TA300. MMTTC, November 2016
PEGINTERFERON ALFA 2a 180microgram SYRINGE (PEGASYS)	R	For the treatment of hepatitis B as per NICE TA96, and for hepatitis C as per TA75, TA106, TA200 and TA300. Ensure (DEH154) Ribavirin 200mg tablets are dispensed as well. MMTTC, January 2014.

PEGINTERFERON ALFA 2a 135microgram SYRINGE (PEGASYS)	R	For the treatment of hepatitis B as per NICE TA96, and for hepatitis C as per TA75, TA106, TA200 and TA300. Ensure (DEH154) Ribavirin 200mg tablets are dispensed as well. MMTC, January 2014.
PEG INTERFERON ALFA 2b 100microgram CLEARCLICK PEN	R	For the treatment of hepatitis C as per NICE TA75, TA106, TA200 and TA300. Ensure (DEH154) Ribavirin 200mg tablets are dispensed as well. MMTC, January 2014.
POMALIDOMIDE		
POMALIDOMIDE 1mg CAPSULES (CT)	C	FOR CLINICAL TRIALS ONLY
POMALIDOMIDE 2mg CAPSULES	R	For the treatment of multiple myeloma in adults at third or subsequent relapse; that is, after 3 previous treatments including both lenalidomide and bortezomib as per NICE TA427. MMTC, April 2017
POMALIDOMIDE 3mg CAPSULES	R	For the treatment of multiple myeloma in adults at third or subsequent relapse; that is, after 3 previous treatments including both lenalidomide and bortezomib as per NICE TA427. MMTC, April 2017
POMALIDOMIDE 4mg CAPSULES	R	For the treatment of multiple myeloma in adults at third or subsequent relapse; that is, after 3 previous treatments including both lenalidomide and bortezomib as per NICE TA427. MMTC, April 2017
POMALIDOMIDE 1mg CAPSULES	R	
POMALIDOMIDE 4mg CAPSULES (FREE OF CHARGE)	NF	
Ponesimod		
PONESIMOD TABLETS INITIATION PACK (14 TABS)	R	Restricted for treatment of relapsing, remitting multiple sclerosis with active disease as per NICE TA767. MMTC, December 2022

TERIFLUNOMIDE

TERIFLUNOMIDE 14mg TABLETS	R	For treating relapsing-remitting multiple sclerosis as per NICE TA303. MMTC, April 2014.
----------------------------	---	--

THALIDOMIDE

THALIDOMIDE 50mg CAPSULES (CELGENE)	R	For chronic myeloid leukaemia as per NICE TA228. Medicines Effectiveness, March 2011.
-------------------------------------	---	---

VISMODEGIB

VISMODEGIB 150mg CAPSULES	NF	
---------------------------	----	--

08.02.04 Other immunomodulating drugs

Lenalidomide

LENALIDOMIDE 25mg CAPSULES (RANBAXY)	R	For the treatment of:- multiple myeloma in people who have received at least two prior therapy NICE TA171; after treatment with bortezomib as per TA586; and in untreated multiple myeloma as per TA587 - transfusion dependent anaemia caused by low or intermediate 1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate as per NICE TA322. MMTC, September 2019
--------------------------------------	---	--

08.02.04 Vinca alkaloids and etoposide

ENCORAFENIB

ENCORAFENIB 50mg CAPSULES	R	For treatment of unresectable or metastatic BRAF V600 mutation positive melanoma as per NICE TA562. MMTC July 2019
---------------------------	---	--

08.03 Sex hormones and hormone antagonists in malignant disease

08.03.00 Sex hormones and hormone antagonists in malignant disease

DECITABINE

DECITABINE 50mg INFUSION	NF	
--------------------------	----	--

08.03.01 Oestrogens

DIETHYLSTILBESTROL

DIETHYLSTILBESTROL 1mg TABLETS	Y	
--------------------------------	---	--

08.03.02 Progestogens

MEDROXYPROGESTERONE

MEDROXYPROGESTERONE 400mg TABLETS	Y	
MEDROXYPROGESTERONE 100mg TABLETS	Y	
MEGESTROL		
MEGESTROL ACETATE 160mg TABLETS	Y	
<i>08.03.04 Hormone antagonists</i>		
ABIRATERONE		
ABIRATERONE 500MG TABLETS	R	For castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen as per NICE TA259 and for metastatic hormone-relapsed prostate cancer before chemotherapy is indicated as per NICE TA387. MMTC, August 2016
ANASTROZOLE		
ANASTROZOLE 1mg TABLETS	R	For Oncology Consultant recommendation for adjuvant hormonal therapy of breast cancer as per NICE TA112. Medicines Effectiveness, August 2007.
APALUTAMIDE		
APALUTAMIDE 60mg TABLETS (FREE OF CHARGE STOCK)	NF	Post Titan Trial Compassionate Use - will be ordered by MacWeb portal
APALUTAMIDE 60mg TABLETS	R	For treatment of hormone-relapsed non-metastatic prostate cancer that is at high risk of metastasising in adults, as per NICE TA740. For treatment of hormone-sensitive metastatic prostate cancer in adults, as per NICE TA741. To be used ONLY alongside androgen deprivation therapy (ADT). MMTC, March 2022
BICALUTAMIDE		
BICALUTAMIDE 50mg TABLETS	R	For second line for prostate cancer. Use by Urology, Oncology and Radiotherapy only. Medicines Effectiveness, March 2013.

BICALUTAMIDE 150mg TABLETS	R	For second line for prostate cancer. Use by Urology, Oncology and Radiotherapy only. Medicines Effectiveness, March 2013.
CYPROTERONE		
CYPROTERONE 100mg TABLETS	Y	
CYPROTERONE 50mg TABLETS	Y	
DAROLUTAMIDE		
DAROLUTAMIDE 300mg TABLETS	R	For treatment of hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease as per NICE TA660 MMTC, March 2021
DEGARELIX		
DEGARELIX 80mg INJECTION	R	For the treatment of advanced hormone-dependent prostate cancer as per NICE TA404. MMTC, July 2017
DEGARELIX 120mg INJECTION	R	For the treatment of advanced hormone-dependent prostate cancer as per NICE TA404. MMTC, July 2017
ENZALUTAMIDE		
ENZALUTAMIDE 40mg TABLETS	R	For metastatic hormone relapsed prostate cancer previously treated with a docetaxel containing regimen as per NICE TA316; for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated as per NICE TA377. MMTC, April 2016
EXEMESTANE		
EXEMESTANE 25mg TABLETS	R	For Oncology Consultant recommendation for adjuvant hormonal therapy of breast cancer as per NICE TA112. Medicines Effectiveness, August 2007.
FLUTAMIDE		
FLUTAMIDE 250mg TABLETS	Y	
FULVESTRANT		

FULVESTRANT 250mg in 5ml SYRINGE	R	For treatment of breast cancer in combination with abemaciclib as per NICE TA563 and NICE TA579; for treatment of breast cancer in combination with palbociclib as per NICE TA619; and for treatment of breast cancer in combination with ribociclib as per NICE TA593. MMTC, February 2020
----------------------------------	---	---

GOSERELIN

GOSERELIN 3.6mg INJECTION	R	Patients on 3 or 6 monthly gonadorelin analogues (goserelin, leuporelin or triptorelin) will receive 1-monthly injections while inpatients. NB: inform GP when next dose is due. MMTC, April 2014.
---------------------------	---	--

GOSERELIN LA 10.8mg INJECTION	NF	
-------------------------------	----	--

LANREOTIDE

LANREOTIDE 120mg PFS AUTOGEL	R	For patients with acromegaly or neuroendocrine tumours. Prescribing by consultants familiar with the management of patients with these conditions according to a shared care protocol. Medicines Effectiveness, July 2006
------------------------------	---	---

LANREOTIDE 120mg in 0.5ml PRE FILLED SYRINGE (ADVANZ PHARMA)	R	?For patients with acromegaly or neuroendocrine tumours. Prescribing by consultants familiar with the management of patients with these conditions according to a shared care protocol. Medicines Effectiveness, July 2006
--	---	--

LANREOTIDE 60mg AUTOGEL	R	For patients with acromegaly or neuroendocrine tumours. Prescribing by consultants familiar with the management of patients with these conditions according to a shared care protocol. Medicines Effectiveness, July 2006.
-------------------------	---	--

LANREOTIDE 30mg INJECTION LA	R	For patients with acromegaly or neuroendocrine tumours. Prescribing by consultants familiar with the management of patients with these conditions according to a shared care protocol. Medicines Effectiveness, July 2006.
LANREOTIDE 90mg PFS AUTOGEL	R	For patients with acromegaly or neuroendocrine tumours. Prescribing by consultants familiar with the management of patients with these conditions according to a shared care protocol. Medicines Effectiveness, July 2006.
LETROZOLE		
LETROZOLE 2.5mg TABLETS	R	For Oncology Consultant recommendation for adjuvant hormonal therapy of breast cancer as per NICE TA112. Also approved for use as a second line, unlicensed ovulation induction treatment Restricted for use by Fertility and Endocrinology (see unlicensed medicines register).MMTC, July 2018
LEUPRORELIN		
LEUPRORELIN 11.25mg DEPOT INJECTION	R	For use in patients with gender dysphoria under gender dysphoria clinic. MMTC, June 2021
LEUPRORELIN 3.75mg SR INJECTION	R	Patients on 3 or 6 monthly gonadorelin analogues (goserelin, leuporelin or triptorelin) will receive 1-monthly injections while inpatients. NB: inform GP when next dose is due. MMTC, April 2014.
OCTREOTIDE		
OCTREOTIDE 500micrograms IN 1ml INJECTION	R	For the treatment of all licensed indication and for the treatment of severe chemotherapy induced diarrhoea (off-label) as per local guideline.MMTC, August 2017

OCTREOTIDE 100microgram IN 1ml INJECTION	R	For the treatment of all licensed indication and for the treatment of severe chemotherapy induced diarrhoea (off-label) as per local guideline. MMTC, August 2017
OCTREOTIDE 1mg in 5ml INJECTION	R	For the treatment of all licensed indication and for the treatment of severe chemotherapy induced diarrhoea (off-label) as per local guideline, and for treatment of bowel obstruction as per PCF (off-label) MMTC, November 2020
OCTREOTIDE 100micrograms in 1mL INJECTION (PRE-FILLED SYRINGES)	R	?For treatment of neuroendocrine tumours and/or acromegaly. MMTC, December 2023.
OCTREOTIDE 50micrograms in 1mL INJECTION (PRE-FILLED SYRINGES)	R	?For treatment of neuroendocrine tumours and/or acromegaly . MMTC, December 2023.
OCTREOTIDE 30mg INJECTION DEPOT (FREE SUPPLY)	R	For patients with acromegaly or Carcinoid syndrome. Prescribing by consultants familiar with the management of patients with these conditions. Octreotide LAR is administered once every month and may be a suitable alternative to multiple daily injection of octreotide; i.e. patients with acromegaly of neuroendocrine tumours (Carcinoid Syndrome). The manufacturer has agreed to provide the first dose free for patients being switched from multiple daily doses to Sandostatin LAR. Medicines Effectiveness, April 2007.

OCTREOTIDE 30mg INJECTION DEPOT

R

For patients with acromegaly or Carcinoid syndrome. Prescribing by consultants familiar with the management of patients with these conditions. Octreotide LAR is administered once every month and may be a suitable alternative to multiple daily injection of octreotide; i.e. patients with acromegaly of neuroendocrine tumours (Carcinoid Syndrome). The manufacturer has agreed to provide the first dose free for patients being switched from multiple daily doses to Sandostatin LAR.

Medicines Effectiveness, April 2007

OCTREOTIDE 20mg INJECTION DEPOT (FREE STOCK)

R

For patients with acromegaly or Carcinoid syndrome. Prescribing by consultants familiar with the management of patients with these conditions. Octreotide LAR is administered once every month and may be a suitable alternative to multiple daily injection of octreotide; i.e. patients with acromegaly of neuroendocrine tumours (Carcinoid Syndrome). The manufacturer has agreed to provide the first dose free for patients being switched from multiple daily doses to Sandostatin LAR. Medicines Effectiveness, April 2007.

OCTREOTIDE 20mg INJECTION DEPOT

R

For patients with acromegaly or Carcinoid syndrome. Prescribing by consultants familiar with the management of patients with these conditions. Octreotide LAR is administered once every month and may be a suitable alternative to multiple daily injection of octreotide; i.e. patients with acromegaly of neuroendocrine tumours (Carcinoid Syndrome). The manufacturer has agreed to provide the first dose free for patients being switched from multiple daily doses to Sandostatin LAR.

Medicines Effectiveness, April 2007

OCTREOTIDE 10mg INJECTION DEPOT (FREE SUPPLY)

R

For patients with acromegaly or Carcinoid syndrome. Prescribing by consultants familiar with the management of patients with these conditions. Octreotide LAR is administered once every month and may be a suitable alternative to multiple daily injection of octreotide; i.e. patients with acromegaly of neuroendocrine tumours (Carcinoid Syndrome). The manufacturer has agreed to provide the first dose free for patients being switched from multiple daily doses to Sandostatin LAR. Medicines Effectiveness, April 2007.

OCTREOTIDE 10mg INJECTION DEPOT	R	For patients with acromegaly or Carcinoid syndrome. Prescribing by consultants familiar with the management of patients with these conditions. Octreotide LAR is administered once every month and may be a suitable alternative to multiple daily injection of octreotide; i.e. patients with acromegaly of neuroendocrine tumours (Carcinoid Syndrome). The manufacturer has agreed to provide the first dose free for patients being switched from multiple daily doses to Sandostatin LAR.
		Medicines Effectiveness, April 2007
Pasireotide		
PASIREOTIDE 10mg INJECTION	NF	
PASIREOTIDE 600micrograms in 1mL INJECTION	NF	
PASIREOTIDE 900microgram IN 1ml INJECTION (COMPASSIONATE USE)	NF	
Relugolix + Estradiol + Norethisterone acetate		
RELUGOLIX 40mg / ESTRADIOL 1mg / NORESTHISTERONE 500microgram TABLETS	R	For treatment of moderate to severe symptoms of uterine fibroids in adults of reproductive age as per NICE TA832. MMTC, November 2023.
TAMOXIFEN		
TAMOXIFEN 20mg TABLETS	Y	Also approved for use in Hereditary Haemorrhagic Telangiectasia (see unlicensed medicines register)
TAMOXIFEN 10mg/5ml LIQUID 150ml	Y	
TAMOXIFEN 10mg TABLETS	Y	Also approved for use in Hereditary Haemorrhagic Telangiectasia (see unlicensed medicines register) MMTC June 2018
TRIPTORELIN		
TRIPTORELIN 11.25mg INJECTION MR	R	For precocious puberty. Initiation by Paediatric Endocrinologist only. Medicine Effectiveness, September 2005.

08.07 Targeted therapy responsiveness/malignancy

08.07.00 Tyrosine kinase inhibitors

TUCATINIB

TUCATINIB 150mg TABLETS

R

09 Nutrition and blood

Calcitriol

CALCITRIOL 0.25microgram CAPSULES

Y

08.01 Cytotoxic drugs

08.01.06 Cytotoxic responsive malignancy

HYDROXYCARBAMIDE

HYDROXYCARBAMIDE 500mg/5ml LIQUID

R

For the treatment of sickle cell disease in paediatric patients who are unable to swallow capsules. MMTC September 2019

09.01 Anaemias and some other blood disorders

09.01.00 Anaemias and some other blood disorders

ANAGRELIDE

ANAGRELIDE 500microgram CAPSULES

R

For second line use either after hydroxycarbamide failure or as an adjunct in those few cases where patients cannot tolerate a full dose of hydroxycarbamide. To be used by Haematology consultant only. MAC, December 2007.

DEFERRIOXAMINE

DEFERRIOXAMINE (DEFEROXAMINE) 500mg INJECTION

Y

ROMIPLOSTIM

ROMIPLOSTIM 125microgram INJECTION VIAL

R

(Medicines for Children Policy)
For the treatment of chronic immune (idiopathic) thrombocytopenic purpura, as per NICE TA 221
MMTC August 2019

09.01.01 Alkylating drugs

ROMIPLOSTIM

ROMIPLOSTIM 250microgram INJECTION	R	For the treatment of chronic immune (idiopathic) thrombocytopenic purpura as per TA221. Medicines Effectiveness, March 2013.
------------------------------------	---	--

09.01.01 Iron-deficiency anaemias

CYANOCOBALAMIN

CYANOCOBALAMIN 50microgram TABLETS	NF	
------------------------------------	----	--

FERRIC CARBOXYMALTOSE

FERRIC CARBOXYMALTOSE 500mg IN 10ml INJECTION (FERINJECT)	R	For the treatment of iron-deficiency anaemia when oral iron preparations are ineffective or cannot be used, when there is continuing blood loss, or in malabsorption. Restricted to outpatients, those attending for pre-assessment or day-case treatment, and for inpatients likely to be discharged within the next 72 hours, as per the MIL on Intravenous Iron Replacement. Medicines Effectiveness, April 2014.
---	---	--

FERRIC CARBOXYMALTOSE 100mg IN 2ml INJECTION (FERINJECT)	R	For the treatment of iron-deficiency anaemia when oral iron preparations are ineffective or cannot be used, when there is continuing blood loss, or in malabsorption. Restricted to outpatients, those attending for pre-assessment or day-case treatment, and for inpatients likely to be discharged within the next 72 hours, as per the MIL on Intravenous Iron Replacement. Medicines Effectiveness, April 2014.
--	---	--

FERRIC CARBOXYMALTOSE 1g IN 20ml INJECTION (FERINJECT)	R	For the treatment of iron-deficiency anaemia when oral iron preparations are ineffective or cannot be used, when there is continuing blood loss, or in malabsorption. Restricted to outpatients, those attending for pre-assessment or day-case treatment, and for inpatients likely to be discharged within the next 72 hours, as per the MIL on Intravenous Iron Replacement. Medicines Effectiveness, April 2014.
--	---	--

FERROUS FUMARATE

FERROUS FUMARATE 140mg/5ml LIQUID	Y	
FERROUS FUMARATE 322mg TABLETS	Y	
FERROUS FUMARATE 210mg TABLETS	Y	
FERROUS GLUCONATE		
FERROUS GLUCONATE 300mg TABLETS	NF	
FERROUS SULPHATE		
FERROUS SULPHATE 200mg TABLETS	Y	
FERROUS SULPHATE 125mg/ml ORAL DROPS 15ml	NF	
FERROUS SULPHATE 200mg TABLETS TTO'S 28	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, February 2013.
HYDROXOCOBALAMIN		
HYDROXOCOBALAMIN 1mg IN 1ml INJECTION	Y	
IRON DEXTRAN		
IRON (as iron Dextran) 500mg IN 10ml INJECTION (COSMOFER)	R	For use in Renal & Gastroenterology patients only. Medicines Effectiveness, February 2013.
IRON (as Iron Dextran) 100mg in 2ml INJECTION (COSMOFER)	R	For use in Renal & Gastroenterology patients only. Medicines Effectiveness, February 2013.
IRON ISOMALTOSIDE		
IRON (as Iron Isomaltoside) 100mg in 2ml INJECTION (DIAFER)	R	RESTRICTED for use only in haemodialysis patients. MMTC, May 2016
IRON (as Iron Isomaltoside) 500mg in 5ml INJECTION (MONOFER)	R	Restricted for treatment of anaemia in patients who cannot tolerate ferinject due to hypophosphataemia under care of Iron Deficiency Management Service, Bicester. MMTC April 2021
MAGNESIUM SULPHATE		
MAGNESIUM SULPHATE 20% (8mmol in 10ml) INJECTION 10ml	R	RESTRICTED: Delivery Suite & Observation area JR only, and HGH. PPDU 05.07.12
PREGADAY		

PREGADAY TABLETS Y

SODIUM FEREDTATE

SODIUM FEREDTATE 190mg/5ml (27.5mg IRON/5ml) LIQUID NF

09.01.02 Drugs used in megaloblastic anaemias

CYANOCOBALAMIN

CYANOCOBALAMIN 1mg IN 1ml INJECTION NF

FOLIC ACID

FOLIC ACID 5mg TABLETS Y

FOLIC ACID 2.5mg/5ml LIQUID Y

09.01.03 Drugs used in hypoplastic, haemolytic, and renal anaemias

DEFERIPRONE

DEFERIPRONE 500mg/5ml LIQUID NF

09.01.03 Drugs used in hypoplastic, haemolytic, and renal anaemias

DARBEPOETIN

DARBEPOETIN ALFA 40microgram SYRINGE R For use by the Renal Unit and as per High Cost Cancer protocol only. Medicines Effectiveness, October 2002.

DARBEPOETIN ALFA 10microgram SYRINGE R For use by the Renal Unit and as per High Cost Cancer protocol only. Medicines Effectiveness, October 2002.

DARBEPOETIN ALFA 150microgram SYRINGE R For use by the Renal Unit and as per High Cost Cancer protocol only. Medicines Effectiveness, October 2002.

DARBEPOETIN ALFA 20microgram SYRINGE R For use by the Renal Unit and as per High Cost Cancer protocol only. Medicines Effectiveness, October 2002.

DARBEPOETIN ALFA 30microgram SYRINGE R For use by the Renal Unit and as per High Cost Cancer protocol only. Medicines Effectiveness, October 2002.

DARBEPOETIN ALFA 100microgram SYRINGE R For use by the Renal Unit and as per High Cost Cancer protocol only. Medicines Effectiveness, October 2002.

DARBEPOETIN ALFA 500microgram in 1ml SYRINGE	R	For use by the Renal Unit and as per High Cost Cancer protocol only. Medicines Effectiveness, October 2002.
DARBEPOETIN ALFA 50microgram SYRINGE	R	For use by the Renal Unit and as per High Cost Cancer protocol only. Medicines Effectiveness, October 2002.
DARBEPOETIN ALFA 60microgram SYRINGE	R	For use by the Renal Unit and as per High Cost Cancer protocol only. Medicines Effectiveness, October 2002.
DARBEPOETIN ALFA 80microgram SYRINGE	R	For use by the Renal Unit and as per High Cost Cancer protocol only. Medicines Effectiveness, October 2002.
DARBEPOETIN ALFA 300microgram in 0.6ml SYRINGE	R	For use by the Renal Unit and as per High Cost Cancer protocol only. Medicines Effectiveness, October 2002.
DARBEPOETIN ALFA		
HC DARBEPOETIN ALFA 150microgram IN 0.3ml PRE-FILLED PEN	R	For use by the Renal Unit and as per High Cost Cancer protocol only. Medicines Effectiveness, October 2002
HC DARBEPOETIN ALFA 500microgram in 1ml SYRINGE	R	FOR USE BY RENAL UNIT AND AS PER HIGH COST CANCER DRUG PROTOCOL ONLY. Medicines Effectiveness, October 2002
DEFERASIROX		
DEFERASIROX 180mg FILM COATED TABLETS	R	For the treatment of iron overload for transfused and non transfused patients with chronic inherited anaemias as per NHS England Clinical Commissioning Policy 16070/P. MMTTC, November 2016
DEFERASIROX 360mg FILM COATED TABLETS	R	For the treatment of iron overload for transfused and non transfused patients with chronic inherited anaemias as per NHS England Clinical Commissioning Policy 16070/P. MMTTC, November 2016

DEFERASIROX 90mg FILM COATED TABLETS	R	For the treatment of iron overload for transfused and non transfused patients with chronic inherited anaemias as per NHS England Clinical Commissioning Policy 16070/P. MMTTC, November 2016
DEFERIPRONE		
DEFERIPRONE 500mg TABLETS	R	For use by Haematology only. Medicines Effectiveness, March 2006.
DEFERRIOXAMINE		
DEFERRIOXAMINE 2g INJECTION	Y	
ECULIZUMAB		
ECULIZUMAB 300mg IN 30ml INJECTION	R	For atypical haemolytic uraemic syndrome as per NHSE policy E03/PS(HSS)/a, and for treatment of hyperhaemolysis as per NHSE policy 1821 MMTTC, September 2014
ERYTHROPOIETIN ALFA		
ERYTHROPOIETIN ALFA 10,000 units in 1ml INJECTION	R	For use by the Renal Unit only. MMTTC, October 2014.
ERYTHROPOIETIN ALFA 4000iu IN 0.4ml PRE-FILLED SYRINGE	R	For use by the Renal Unit only. MMTTC, October 2014
ERYTHROPOIETIN ALFA 2000units IN 0.5ml SYRINGE	R	For use by the Renal Unit only. MMTTC, October 2014.
ERYTHROPOIETIN ALFA 5,000units IN 0.5ml PRE-FILLED SYRINGE	R	For use by the Renal Unit only. MMTTC, October 2014.
ERYTHROPOIETIN ALFA 3000units IN 0.3ml SYRINGE	R	For use by the Renal Unit only. MMTTC, October 2014.
ERYTHROPOIETIN ALFA 30,000units IN 0.75ml PRE-FILLED SYRINGE	R	For use by the Renal Unit only. MMTTC, October 2014.
ERYTHROPOIETIN ALFA 1000units IN 0.5ml SYRINGE	R	For use by the Renal Unit only. MMTTC, October 2014.
ERYTHROPOIETIN ALFA 40,000units IN 1ml PRE-FILLED SYRINGE	R	For use by the Renal Unit only. MMTTC, October 2014.
ERYTHROPOIETIN ALFA 8,000units IN 0.8ml PRE-FILLED SYRINGE	R	For use by the Renal Unit only. MMTTC, October 2014.

ERYTHROPOIETIN ALFA 20,000units IN 0.5ml PRE-FILLED SYRINGE R For use by the Renal Unit only. MMTC, October 2014.

ERYTHROPOIETIN ALFA 6,000units IN 0.6ml PRE-FILLED SYRINGE R For use by the Renal Unit only. MMTC, October 2014.

ERYTHROPOIETIN BETA

ERYTHROPOIETIN BETA 500international units SYRINGE Y

ERYTHROPOIETIN BETA 6,000international units SYRINGE Y

ERYTHROPOIETIN BETA 4000international units SYRINGE Y

METHOXY POLYETHYLENE GLYCOLEPOETIN BETA

METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA 50microgram PREFILLED SYRINGE R For chronic renal impairment patients who require a district nurse to administer their ESA at home, or who do not respond to Aranesp due to suspected non-compliance.. MAC, January 2009.

METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA 30microgram PREFILLED SYRINGE R For chronic renal impairment patients who require a district nurse to administer their ESA at home, or who do not respond to Aranesp due to suspected non-compliance.. MAC, January 2009.

METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA 120microgram PREFILLED SYRINGE R For chronic renal impairment patients who require a district nurse to administer their ESA at home, or who do not respond to Aranesp due to suspected non-compliance.. MAC, January 2009.

METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA 100microgram PREFILLED SYRINGE R For chronic renal impairment patients who require a district nurse to administer their ESA at home, or who do not respond to Aranesp due to suspected non-compliance.. MAC, January 2009.

METHOXY POLYETHYLENE GLYCOL-EPOTEIN BETA 75microgram PREFILLED SYRINGE R For chronic renal impairment patients who require a district nurse to administer their ESA at home, or who do not respond to Aranesp due to suspected non-compliance.. MAC, January 2009.

EPOETIN ZETA

EPOETIN ZETA 8,000units IN 0.8ml INJECTION (RETACRIT)	R	For use in renal anaemia patients on haemodialysis, MMTC March 2020
EPOETIN ZETA 2,000units IN 0.6ml INJECTION (RETACRIT)	R	For use in renal anaemia patients on haemodialysis, MMTC March 2020
EPOETIN ZETA 3,000units IN 0.9ml INJECTION (RETACRIT)	R	For use in renal anaemia patients on haemodialysis, MMTC March 2020
EPOETIN ZETA 4,000units IN 0.4ml INJECTION (RETACRIT)	R	For use in renal anaemia patients on haemodialysis, MMTC March 2020
EPOETIN ZETA 6,000units IN 0.6ml INJECTION (RETACRIT)	R	For use in renal anaemia patients on haemodialysis, MMTC March 2020
EPOETIN ZETA 5,000units IN 0.5ml INJECTION (RETACRIT)	R	For use in renal anaemia patients on haemodialysis, MMTC March 2020
EPOETIN ZETA 10,000units IN 1ml INJECTION (RETACRIT)	R	For use in renal anaemia patients on haemodialysis, MMTC March 2020

Ravulizumab

RAVULIZUMAB 1100mg (1.1g) in 11ml INJECTION (COMPASSIONATE USE)	NF	COMPASSIONATE USE ONLY
---	----	------------------------

09.01.04 Drugs used in platelet disorders

ELTROMBOPAG

ELTROMBOPAG 50mg TABLETS	R	For treating chronic immune (idiopathic) thrombocytopenic purpura as per NICE TA293. (Also included under Medicines for Children Policy) available for paediatrics. MMTC August 2019
ELTROMBOPAG 25mg TABLETS	R	For treating chronic immune (idiopathic) thrombocytopenic purpura as per NICE TA293. (Also included under Medicines for Children Policy) available for paediatrics. MMTC August 2019

09.01.06 Drugs used in neutropenia

CYANOCOBALAMIN

CYANOCOBALAMIN 1mg TABLETS	NF	
----------------------------	----	--

FILGRASTIM

FILGRASTIM 480microgram (48million unit) in 0.5ml SYRINGE Y

FILGRASTIM 300microgram (30million units) in 0.5ml SYRINGE Y

LENOGRASTIM

LENOGRASTIM 263microgram (33.6million international units) SYRINGE Y

LENOGRASTIM 105microgram (13.4million international units) SYRINGE Y

LIPEGFILGRASTIM

LIPEGFILGRASTIM 6mg in 0.6ml INJECTION (PRE FILLED SYRINGE) NF

PEGFILGRASTIM

PEGFILGRASTIM 6mg in 0.6ml PRE-FILLED SYRINGER (PELGRAZ)

?For use in paediatric populations to reduce duration and severity of neutropenia post-chemotherapy (off label use) MMTc, May 2023

PEGFILGRASTIM 6mg SYRINGE NF

PLERIXAFOR

PLERIXAFOR 24mg IN 1.2ml INJECTION VIAL R

For stem cell mobilization as per NHSE Policy B04/P/2. MMTc, January 2014.

PYRIDOXINE

PYRIDOXINE 100mg IN 2ml INJECTION UNR

For use in PHDU, SCBU and PITU for pyridoxine seizures in neonate and paediatric patients on neurologists request. Use in treatment and diagnostic - EEG. (Full resuscitation facilities MUST be available during use). Medicines Effectiveness, March 2009.

9.01.00 Anaemias and some other blood disorders

LUSUTROMBOPAG

LUSUTROMBOPAG 3mg TABLETS R

For treating severe thrombocytopenia in adults with chronic liver disease having a planned invasive procedure as per NICE TA617 MMTc, June 2021

9.01.01 Iron-deficiency anaemias

FERRIC DERISOMALTOSE

IRON (as FERRIC DERISOMALTOSE) 1,000mg in 10ml INJECTION (MONOFER)	R	Restricted for treatment of anaemia in patients who cannot tolerate ferinject due to hypophosphataemia under care of Iron Deficiency Management Service, Bicester. MMTC April 2021
--	---	--

FERROUS SULPHATE

FERROUS SULPHATE 325mg M/R TABLETS	NF
------------------------------------	----

IRON ISOMALTOSIDE

IRON (as Iron Isomaltoside) 100mg in 1ml INJECTION (MONOFER)	R	Restricted for treatment of anaemia in patients who cannot tolerate ferinject due to hypophosphataemia under care of Iron Deficiency Management Service, Bicester. MMTC April 2021
--	---	--

IRON SUCROSE

IRON SUCROSE COMPLEX 100mg IN 5ml INJECTION (VENOFER)	Y
---	---

09.02 Fluids and electrolytes

09.02.01 Oral preparation for fluid and electrolyte imbalance

ORAL REHYDRATION

ORAL REHYDRATION SALTS (ORS) BLACKCURRANT TABLETS	Y	FOR USE WHEN DIORALYTE SACHETS ARE NOT AVAILABLE
--	---	--

09.02.01 Oral preparations for fluid and electrolyte imbalance

CALCIUM RESONIUM

CALCIUM RESONIUM POWDER	Y
-------------------------	---

DIORALYTE

DIORALYTE SACHETS (BLACKCURRANT)	Y
----------------------------------	---

PATIROMER SORBITEX

PATIROMER SORBITEX CALCIUM POWDER ORAL SUSPENSION SACHETS	NF
---	----

POTASSIUM BICARBONATE

POTASSIUM BICARBONATE 500mg TABLETS EFFERVESCENT (6.5mmol Potassium)	NF
--	----

POTASSIUM CHLORIDE

POTASSIUM CHLORIDE 600mg TABLETS M/R	Y
--------------------------------------	---

POTASSIUM CHLORIDE EFFERVESCENT 12mmol TABLETS	Y
--	---

POTASSIUM CHLORIDE 5mmol/5ml LIQUID Y

POTASSIUM CHLORIDE 500mg TABLETS
EFFERVESCENT Y

SODIUM BICARBONATE

SODIUM BICARBONATE 500mg CAPSULES Y

SODIUM CHLORIDE

SODIUM CHLORIDE 5.84% (5mmol/5ml) LIQUID R For neonatal unit ward stock.
Medicines Effectiveness, October
2016

SODIUM CHLORIDE 600mg TABLETS M/R Y

09.02.02 Electrolytes and water

SODIUM CHLORIDE

POTASSIUM CHLORIDE 0.15% (10mmol) GLUCOSE UNR For routine fluid replacement in
5% SODIUM CHLORIDE 0.9% 500ml children as per local guidelines.
MMTC, December 2016

09.02.02 Parenteral preparation

DIORALYTE

DIORALYTE SACHETS (PLAIN) Y

09.02.02 Parenteral preparations for fluid and electrolyte imbalance

GELASPAN

GELASPAN 4% INFUSION 500ml Y

09.02.02 Parenteral preparations for fluid and electrolyte imbalance

Albumin human

HUMAN ALBUMIN 5% INFUSION 250ml (CTASU) C

GLUCOSE

GLUCOSE 4% & SOD CHLORIDE 0.18% 1L INFUSION Y
FE1254

DF GLUCOSE 5% 1L INFUSION (FE0064) Y

DF GLUCOSE 10% INFUSION 500ml (FKB0163G) Y

DF GLUCOSE 5% INFUSION 250ml (FE0062) Y

DF GLUCOSE 5% INFUSION 500ml (FE0063) Y

GLUCOSE 10% & SODIUM CHL 0.18% 500ml Y
INFUSION 23-62-546

GLUCOSE 10% INFUSION 500ml FE0163 Y

GLUCOSE 2.5% & SOD CHLORIDE 0.45% 500ml INF FE1023	Y	
GLUCOSE 5% INFUSION 50ml FE0086	Y	
GLUCOSE 50% INJECTION 50ml (VIALS)	Y	
GLUCOSE 50% INFUSION 500ml	Y	
GLUCOSE 20% 500ml INFUSION	Y	
GLUCOSE 5% INFUSION 500ml FE0063	Y	
GLUCOSE 5% INFUSION 250ml FE0062	Y	
GLUCOSE 5% INFUSION 1L FE0064	Y	
GLUCOSE 5% & SOD CHLORIDE 0.45% 500ml INF FKB1073G	Y	
GLUCOSE 5% INFUSION 100ml FE0087	Y	
GLUCOSE 5% & SOD CHLORIDE 0.9% 500ml INF FKE1063	Y	
GLUCOSE 20% INFUSION 100ml (VIAL)	R	For adult hypo box to be kept in all adult wards and departments. For the reversal of hypoglycaemia in adults, as per the MIL on The Management of Hypoglycaemia in Adult Inpatients. MMTTC, February 2014

MANNITOL

MANNITOL 10% INFUSION 500ml FKD5613G	Y	
MANNITOL 20% INFUSION 500ml FKD5633G	Y	

POTASSIUM CHLORIDE

POTASSIUM CHL 0.15% (10mmol) GLUCOSE 10% SOD CHL 0.18% 500ml IS336	SR	
POTASSIUM CHLORIDE 0.3% (20mmol) GLUCOSE 10% INFUSION 500ml FKB1165	SR	FOR STOCK ISSUE TO MAU/MSS ONLY. FOR ADULT DKA REGIMEN
DF POTASSIUM CHL 0.3% (40mmol) SOD CHLORIDE 0.9% 1L (FE1984)	Y	
DF POTASSIUM CHL 0.3% (40mmol) GLUCOSE 5% 1L (FE1264)	Y	
DF POTASSIUM CHL 0.15% (20mmol) SOD CHLORIDE 0.9% 1L (FE1764)	Y	

DF POTASSIUM CHL 0.15% (20mmol) GLUCOSE 5% 1L (FE1134)	Y	
POTASSIUM CHL 0.15% (20mmol) GLUC 2.5% SOD CHL 0.45% 1L 109 3156825	SR	As per the MIL: Guidelines for the Management of Hypokalaemia in Adults. Medicines Effectiveness, March 2013.
POTASSIUM CHLORIDE 20mmol IN 50ml SODIUM CHLORIDE 0.9% PRE-FILLED SYRINGE for IV	SR	Restricted as stock to authorised areas, or as per MIL/high strength potassium SOP on receipt of a prescription and CD order. Medicines Effectiveness, April 2010
POTASSIUM CHL 0.15% (10mmol) GLUC 5% SOD CHL 0.45% 500ml (GV332)	Y	
POTASSIUM CHL 0.6% (40mmol) SOD CHLORIDE 0.9% 500ml (steriflex101)	UNR	For use by NICU only. Medicines Effectiveness, July 2011.
POTASSIUM CHL 0.15% (10mmol) SOD CHLORIDE 0.9% 500ml FE1763	Y	
POTASSIUM CHL 0.3% (40mmol) GLUCOSE 5% 1L FE1264	Y	
POTASSIUM CHL 0.15% (20mmol) GLUC 4% SOD CHL 0.18% 1L FE1704	Y	
POTASSIUM CHL 0.15% (20mmol) GLUCOSE 5% 1L FE1134	Y	
POTASSIUM CHL 0.15% (20mmol) SOD CHLORIDE 0.9% 1L FE1764	Y	
POTASSIUM CHL 0.3% (40mmol) SOD CHLORIDE 0.9% 1L FE1984	Y	
POTASSIUM CHL 0.3% (20mmol) GLUC 5% SOD CHL 0.45% 500ml 1909115	SR	As per the MIL: Guidelines for the Management of Hypokalaemia in Adults. Medicines Effectiveness, March 2013.
POTASSIUM CHL 0.3% (20mmol) GLUCOSE 5% SOD CHL 0.9% 500ml (FKB2486)	SR	Restricted to diabetic patients. Medicines Effectiveness, March 2013
POTASSIUM CHL 0.3% (20mmol) SOD CHLORIDE 0.9% 500ml FE1983	Y	
POTASSIUM CHL 0.3% (40mmol) GLUC 4% SOD CHL 0.18% 1L FE1724	Y	
POTASSIUM CHL 0.6% (40mmol) GLUCOSE 5% 500ml (FKB1665)	UNR	As per the MIL: Guidelines for the Management of Hypokalaemia in Adults. Medicines Effectiveness, March 2013.

POTASSIUM CHL 0.15% (10mmol) GLUCOSE 10% 500ml FKB3737G Y

Potassium chloride + Glucose + Sodium chloride

POTASSIUM CHLORIDE 0.15% (60mmol) & GLUCOSE 2.5% & SODIUM CHLORIDE 0.45% SR ?As per MIL: guidelines for management of hypokalemia in adults

SODIUM BICARBONATE

SODIUM BICARBONATE 4.2% INJECTION 5ml UNR For treatment of metabolic acidosis and renal hyperkalaemia in paediatrics only. Medicines Effectiveness,

SODIUM BICARBONATE 4.2% INJECTION 10ml SR For treatment of metabolic acidosis and renal hyperkalaemia in paediatrics only. Medicines Effectiveness,

SODIUM BICARBONATE 8.4% INJECTION 250ml Y

SODIUM BICARBONATE 1.26% POLYFUSOR 500ml Y

SODIUM BICARBONATE 8.4% INJECTION 100ml Y

SODIUM BICARBONATE 8.4% INJECTION 10ml Y

SODIUM BICARBONATE 8.4% POLYFUSOR 200ml POLYFUSOR B Y

SODIUM CHLORIDE

SODIUM CHLORIDE 1.8% POLYFUSOR 500ml NF

SODIUM CHLORIDE 0.9% (CITRATE BUFFERED 0.3% (PH7.0)) 250ml INFUSION (OAKWAYS) R For use in elastomeric devices for ambulatory patients receiving antibiotics only. MMTC, January 2020

SODIUM CHLORIDE 0.9% (CITRATE BUFFERED 0.3% (PH7.0)) 1000ml INFUSION (OAKWAYS) UNR For use in elastomeric devices for ambulatory patients receiving antibiotics only. MMTC, January 2020

SODIUM CHLORIDE 0.9% INFUSION 100ml (STERILE WRAPPED BAGS) R To be issued as ward stock for NOC theatres ONLY, for use in ropivacaine-based LIA Medicines Effectiveness October 2018

SODIUM CHLORIDE 0.9% INTRAVENOUS INFUSION BP 2L (TERUMO BCT) R For use in Cancer Ambulatory Care only. MMTC May 2020

DF SODIUM CHLORIDE 0.9% INFUSION 100ml (FE1307) Y

COMPOUND SODIUM CHLORIDE INF 500ml (RINGERS) B2303G	R	For use by Perfusionists whilst Cardioplegia is a supply problem. Medicines Effectiveness, April 2013.
--	---	---

DF SODIUM CHLORIDE 0.9% INFUSION 500ml (FE1323)	Y
--	---

SODIUM CHLORIDE 0.9% INFUSION 500ml FE1323	Y
--	---

SODIUM CHLORIDE 0.9% INFUSION VIAFLO 100ml FE1307	Y
--	---

SODIUM CHLORIDE 0.9% INFUSION 50ml FE1306	Y
---	---

SODIUM CHLORIDE 0.45% 500ml FE1313	Y
------------------------------------	---

SODIUM CHLORIDE 0.9% 5ml INJECTION (GLASS AMPOULES)	Y
--	---

SODIUM CITRATE

SODIUM CITRATE (4% DIALYSIS) INFUSION 1500ml	R	For use on CTCC only as part of citrate haemodiafiltration. MMTc, March 2013.
--	---	---

SODIUM LACTATE

COMPOUND SODIUM LACTATE 1L INF (HARTMANN'S) FKE2324	Y
--	---

DF COMPOUND SODIUM LACTATE 500ml INF (HARTMANN'S) FKE2323	Y
--	---

DF COMPOUND SODIUM LACTATE 1L INF HARTMANN'S (FKE2324)	Y
---	---

COMPOUND SODIUM CHLORIDE INF 1L (RINGERS) FE2304	Y
---	---

COMPOUND SODIUM LACTATE 500ml INF (HARTMANN'S) FKE2323	Y
---	---

THAM

THAM 7% W/V 10ml INJECTION	Y
----------------------------	---

09.02.07 Homocystinuria drugs

BETAINE

BETAINE 1g ORAL POWDER 180g	NF
-----------------------------	----

09.03 Intravenous nutrition

NUMETA

NUMETA LIGHT PROTECTIVE COVERS 1000ml (Pack of 200)	Y	To be ordered alongside Numeta Parenteral Nutrition bags M.E September 2018
--	---	---

NUMETA G13%E PRETERM EMULSION FOR INFUSION (PARENTERAL NUTRITION)	R	Restricted for use on neonatal unit only. MMTC September 2018
<i>09.03.00 Intravenous nutrition</i>		
ADDITRACE		
ADDITRACE 10ml INJECTION	Y	
CERNEVIT		
CERNEVIT INJECTION	Y	
INTRALIPID		
INTRALIPID 20% INFUSION 500ml	R	For the treatment of local anaesthetic toxicity in accordance with the draft AAGB guidance. Medicines Effectiveness, July 2007.
SODIUM GLYCEROPHOSPHATE		
SODIUM GLYCEROPHOSPHATE 20mmol (of phosphate) in 20ml INJECTION	Y	
SYNTHAMIN		
SYNTHAMIN 14 INFUSION BAG 1L (Electrolyte-Free)	R	For use by Oncology only for patients on Dototate treatment. Medicines Effectiveness, Novemeber 2011.
VAMIN		
VAMIN 18 INFUSION BAG 1L (ELECTROLYTE FREE)	Y	
<i>09.04 Oral nutrition</i>		
<i>09.04.00 Oral nutrition</i>		
PEDITRACE		
PEDITRACE 10ml VIAL	NF	
<i>09.05 Minerals</i>		
<i>09.05.00 Minerals</i>		
MAGNESIUM GLYCEROPHOSPHATE		
MAGNESIUM GLYCEROPHOSPHATE 4mmol TABLETS	R	Second line treatment for mild asymptomatic hypomagnesaemia. MMTC, January 2015
SODIUM ACID PHOSPHATE		

PHOSPHATE (SODIUM DIHYDROGEN ACID PHOSPHATE) 1mmol/1ml ORAL LIQUID	SR	Restricted for the treatment of hypophosphataemia and prevention of bone fractures/ bone disease in neonates, infants and young children. Medicines Effectiveness, October 2010
--	----	---

09.05.01 Calcium and

CALCIUM CHLORIDE

CALCIUM 500mg TABLETS EFFERVESCENT (TUBE 19)	R	For patients with feeding tubes only. Medicines Effectiveness, May 2011.
--	---	--

09.05.01 Calcium and magnesium

CALCIUM CARBONATE

CALCICHEW 500mg TABLETS	Y	
-------------------------	---	--

CALCIUM CHLORIDE

CALCIUM CHLORIDE 150mmol in 1500ml (100mmol/1000ml) INFUSION 1500ml (CALRECIA)	R	As part of citrate based renal replacement therapy in critical care units only (ICUs and HDUs) AICU/CICU/CTCCU/NICU/PICU/P HDU. Supplied as an alternative, MMTC application required.
--	---	--

CALCIUM CHLORIDE 10mmol in 10ml INJECTION	Y	
---	---	--

CALCIUM CHLORIDE 10% SYRINGE (AURUM) 10ml	Y	
---	---	--

CALCIUM GLUCONATE

CALCIUM GLUCONATE 10% INJECTION 10ml (Plastic amp)	Y	
--	---	--

CALCIUM LACTATE

CALCIUM LACTATE 300mg TABLETS BP	NF	
----------------------------------	----	--

CINACALCET

CINACALCET 5mg CAPSULES	NF	
-------------------------	----	--

MAGNESIUM

MAGNESIUM ASPARTATE 10mmol (6.5g) SACHETS	Y	
---	---	--

MAGNESIUM SULPHATE

MAGNESIUM SULPHATE 50% (5g in 10ml) INJECTION	R	
---	---	--

MAGNESIUM SULPHATE 50% (2.5g in 5ml) INJECTION	Y	
--	---	--

MAGNESIUM SULPHATE 50% (1g IN 2ml) INJECTION Y

PHOSPHATE

PHOSPHATE SANDOZ EFFERVESCENT TABLETS Y

09.05.02 Phosphorus

CALCIUM ACETATE

CALCIUM ACETATE 950mg TABLETS (RENACET) Y

CALCIUM ACETATE 475mg TABLETS (RENACET) Y

09.05.02 Phosphorus

CALCIUM ACETATE

CALCIUM ACETATE 1g TABLETS Y

CALCIUM ACETATE 435mg & MAGNESIUM
CARBONATE HEAVY 235mg TABLETS NF

LANTHANUM

LANTHANUM CARBONATE 500mg CHEWABLE
TABLETS R

Second line to sevelamer for the control of hyperphosphataemia in patients with chronic kidney disease stage 5 who cannot tolerate calcium based phosphate binders or have pre-existing hypercalcaemia. Medicines Effectiveness, August 2007.

LANTHANUM CARBONATE 1000mg CHEWABLE
TABLETS R

Second line to sevelamer for the control of hyperphosphataemia in patients with chronic kidney disease stage 5 who cannot tolerate calcium based phosphate binders or have pre-existing hypercalcaemia. Medicines Effectiveness, August 2007.

LANTHANUM CARBONATE 750mg CHEWABLE
TABLETS R

Second line to sevelamer for the control of hyperphosphataemia in patients with chronic kidney disease stage 5 who cannot tolerate calcium based phosphate binders or have pre-existing hypercalcaemia. Medicines Effectiveness, August 2007.

LANTHANUM CARBONATE 750mg POWDER SACHETS Y

LANTHANUM CARBONATE

LANTHANUM CARBONATE 1000mg POWDER SACHETS	R	Second line to sevelamer for the control of hyperphosphataemia in patients with chronic kidney disease stage 5 who cannot tolerate calcium based phosphate binders or have pre-existing hypercalcaemia. August 2007.
---	---	--

SEVELAMER

SEVELAMER 800mg TABLETS	NF	For second or third line use as per the Renal Unit Protocol only. Medicines Effectiveness, July 2003.
-------------------------	----	---

SEVELAMER CARBONATE 800mg TABLETS	R	For second or third line use as per the Renal Unit Protocol only. Medicines Effectiveness, July 2003
-----------------------------------	---	--

SODIUM ACID PHOSPHATE

PHOSPHATE (SODIUM DIHYDROGEN ACID PHOSPHATE) 1mmol/1ml ORAL LIQUID 100ml	SR	RESTRICTED: hypophosphataemia and prevention of bone fractures/ bone disease in neonates, infants and young children.
--	----	--

09.05.03 Fluoride

SEVELAMER

SEVELAMER 2.4g SACHETS	R	For second or third line use as per the Renal Unit Protocol only in patients unable to tolerate Renagel tablets (sevelamer HCl). Medicines Effectiveness, May 2014.
------------------------	---	---

09.05.04 Zinc

ZINC SULPHATE

ZINC SULPHATE 220mg CAPSULES	Y	
ZINC SULPHATE 125mg TABLETS EFFERVESCENT	Y	

09.05.05 Selenium

SELENIUM

SELENIUM 100micrograms in 10ml INJECTION	NF	
--	----	--

SELENIUM SULFIDE

SELENIUM ACE TABLETS	NF	
----------------------	----	--

9.05.01 Calcium and ma

CALCIUM GLUCONATE

CALCIUM GLUCONATE 1g TABLETS EFFERVESCENT NF

9.05.01 Calcium and magnesium

Magnesium sulfate

MAGNESIUM SULPHATE 50% (25g IN 50ml)
(100mmol) INJECTION R

For use in critical care areas during Covid-19 only. Medicines Effectiveness, March 2020

MAGNESIUM SULPHATE

MAGNESIUM SULPHATE 20mmol IN 50ml INJECTION
PRE-FILLED SYRINGE (CTASU PREP)

SR For use on critical care areas during covid-19. Medicines Effectiveness, April 2020

09.06 Vitamins

Thiamine

THIAMINE 50mg TABLETS Y

THIAMINE 100mg TABLETS Y

THIAMINE 100mg TABLETS F

09.01.01 Iron-deficiency anaemias

VITAMIN B

VITAMIN B COMPOUND STRONG TABLETS BPC Y

09.01.06 Drugs used in neutropenia

CINACALCET

CINACALCET 30mg TABLETS R

For use by Renal for hyperparathyroidism as per NICE TA 117 only. Medicines Effectiveness, January 2007

CINACALCET 60mg TABLETS R

For use by Renal for hyperparathyroidism as per NICE TA 117 only. Medicines Effectiveness, January 2007

CINACALCET 90mg TABLETS R

For use by Renal for hyperparathyroidism as per NICE TA 117 only. Medicines Effectiveness, January 2007

Phytomenadione

PHYTOMENADIONE 2mg IN 0.2ml ORAL/IM/IV
(UNLICENSED) UNR

PHYTOMENADIONE 10mg TABLETS

UNR For reversal of elevated INR in outpatients on warfarin and the prevention of reduction in Vitamin K dependant clotting factors in maternity patients (inpatient and outpatient).
Medicines Effectiveness, January 2015

VIGRANON

VITAMIN B COMPLEX ORAL SOLUTION (VIGRANON NF B)

VITAMIN A

VITAMIN A + D CAPSULES

Y For use in CF patients only

09.06 Vitamins and analogues

Calcitriol

CALCITRIOL 0.5microgram CAPSULES

Y

09.06.0 Multivitamin preparations

FOLIC ACID

FOLIC ACID 400microgram TABLETS

Y

09.06.00 Multivitamin preparations

THIAMINE

THIAMINE 50mg TABLETS

Y

THIAMINE 100mg TABLETS

Y

TOCOPHERYL ACETATE

TOCOPHERYL 200international units GEL CAPSULES (Vitamin E)

UNR For cystic fibrosis patients and for the management of patients with a diagnosis of osteoradionecrosis (ORN) of the jaw. MMTC, April 2013.

09.06.02 Vitamin B group

BIOTIN

BIOTIN 5mg TABLETS

UNR For children with metabolic disorders. Prescribed by Paediatric Neurologists only.
Medicines Effectiveness, February 2013.

NICOTINAMIDE

NICOTINAMIDE 250mg TABLETS

UNR

For the treatment of Bullous Pemphigoid in patients under the care of dermatology. Note: this is hospital only and prescribing cannot be transferred to primary care. MMTC, February 2017

PYRIDOXAL

PYRIDOXAL 5 PHOSPHATE 50mg CAPSULES (IDIS- USA IMPORT) NF

PYRIDOXINE

PYRIDOXINE 50mg TABLETS Y

VITAMIN B+C

VITAMIN B+C HIGH POTENCY INJECTION for IV use (PABRINEX IVHP) 5ml Y

09.06.03 Vitamin C

ASCORBIC ACID

ASCORBIC ACID 100mg TABLETS Y

ASCORBIC ACID 200mg TABLETS Y

ASCORBIC ACID 500mg TABLETS Y

ASCORBIC ACID 50mg TABLETS Y

ASCORBIC ACID 500mg IN 5ml INJECTION NF

CALCIUM AND VITAMIN D

CALCIUM & ERGOCALCIFEROL TABLETS NF

09.06.04 Vitamin D

ALFACALCIDOL

ALFACALCIDOL 1microgram CAPSULES Y

ALFACALCIDOL 2microgram/1ml ORAL DROPS 10ml Y

ALFACALCIDOL 0.25microgram CAPSULES Y

ALFACALCIDOL 1microgram IN 0.5ml INJECTION Y

ALFACALCIDOL 2microgram IN 1ml INJECTION Y

CALCEOS

CALCEOS TABLETS 60 NF

CALCITRIOL

CALCITRIOL 0.25microgram CAPSULES	Y	
CALCIUM + COLECALCIFEROL		
ADCAL D3 TABLETS - TTO PK56	SR	For use by DTU only. Medicines Effectiveness, November 2015
CALCIUM AND VITAMIN D		
CALCIUM 500mg & VIT D3 440u GRANULES EFFERVESCENT 1X30	R	For use in patients unable to swallow normal chewable tabs. Medicines Effectiveness, March 2020
CALCIUM CARBONATE + COLECALCIFEROL		
ADCAL D3 SOLUBLE TABLETS	R	For patients with feeding tubes only. Medicines Effectiveness, May 2011.
ADCAL D3 TABLETS	Y	
CALCIUM CARBONATE PLUS COLECALCIFEROL 750mg / 5micrograms CAPLETS	NF	
COLECALCIFEROL		
COLECALCIFEROL 2,740international units/ml ORAL DROPS 25ml	NF	
COLECALCIFEROL 10,000units/ml ORAL DROPS 10ml	R	For the vitamin D supplementation for exclusively breastfed babies less than 34weeks. MMTC, December 2018
COLECALCIFEROL 4000units TABLETS	R	For the supplementation of vitamin D in pregnancy and breastfeeding only. NB: restricted to those unable to take 4 x 1000units. MMTC, June 2017
COLECALCIFEROL 15,000units/5ml LIQUID	R	Restricted for treatment of rickets and vitamin deficiency in children. MMTC, January 2012.
COLECALCIFEROL 800international units CAPSULES	NF	
COLECALCIFEROL 3000units/ml LIQUID	UNR	For rickets and vitamin deficiency in children. MMTC, January 2012.
COLECALCIFEROL 3200unit CAPSULES	R	To be used by fracture prevention service in accordance with OCCG Pathway for treating vitamin D deficiency. MMTC, November 2014

COLECALIFEROL

COLECALIFEROL 1000units TABLETS R For the supplementation of vitamin D in pregnancy and breastfeeding only. MMTC, June 2017

DIHYDROTACHYSTEROL

DIHYDROTACHYSTEROL 250micrograms ORAL SOLUTION NF

ERGOCALCIFEROL

ERGOCALCIFEROL 300,000units IN 1ml INJECTION Y

PYRIDOXINE

PYRIDOXINE 20mg TABLETS UNR For the prevention of peripheral neuropathy in patients on isoniazid. Medicines Effectiveness, February 2013.

TOCOPHERYL ACETATE

TOCOPHERYL ACETATE 500mg/5ml LIQUID (vitamin E) R For cystic fibrosis patients and for the management of patients with a diagnosis of osteoradionecrosis (ORN) of the jaw. MMTC, April 2013.

09.06.06 Vitamin K

MENADIOL

MENADIOL 10mg TABLETS R Reversal of elevated INR in INPATIENTS. NB: for IV doses only. Medicines Effectiveness, May 2010

PHYTOMENADIONE

PHYTOMENADIONE 10mg in 1ml INJECTION R Reversal of elevated INR in INPATIENTS. NB: for IV doses only. Medicines Effectiveness, May 2010.

PHYTOMENADIONE 10mg TABLETS UNR For reversal of elevated INR in outpatients on warfarin and the prevention of reduction in Vitamin K dependant clotting factors in maternity patients (inpatient and outpatient). Medicines Effectiveness, January 2015

PHYTOMENADIONE 2mg IN 0.2ml ORAL/IM/IV R Reversal of elevated INR in INPATIENTS. NB: for ORAL or IV doses. Medicines Effectiveness, May 2010.

VITAMIN A

VITAMIN A AND D CAPSULES	R	For use in CF patients only. Medicines Effectiveness, January 2004.
--------------------------	---	---

09.06.06 Vitamins

MULTIVITAMINS

AQUADEKS CHEWABLE TABLETS	R	For use in cystic fibrosis patients. MAC, October 2010.
---------------------------	---	---

AQUADEKS LIQUID	R	For use in cystic fibrosis patients. NB: liquid is restricted for patients unable to take the chewable tablets. Medicines Effectiveness, October 2010.
-----------------	---	--

MULTIVITAMINS AND MINERAL TABLETS (VALUPAK) Y

RENAVIT TABLETS

RENAVIT TABLETS	UNR	Restricted: For use in dialysis patients with water-soluble vitamin deficiency. MMTC October 2021
-----------------	-----	---

SANATOGEN

SANATOGEN GOLD 30	Y	
-------------------	---	--

09.06.07 Multivitamin preparations

ABIDEC

ABIDEC LIQUID 25ml	R	For vitamin D supplementation in exclusively breastfed babies less than 34 weeks. MMTC December 2017
--------------------	---	--

KETOVITE

KETOVITE TABLETS	Y	
------------------	---	--

KETOVITE LIQUID	Y	
-----------------	---	--

09.07 Bitters and tonics

09.07.00 Bitters and tonics

GENTIAN ALKALINE

GENTIAN ALKALINE MIXTURE 2 Litre	R	For use by Neurology only. Medicines Effectiveness, March 2013.
----------------------------------	---	---

09.08 Metabolic disorders

Levocarnitine

L-CARNITINE 300mg in 1ml PAEDIATRIC SOLUTION 50ml NF

09.08.00 Metabolic disorders

CARGLUMIC ACID

CARGLUMIC ACID 200mg DISPERSIBLE TABLETS NF

L-CARNITINE

L-CARNITINE 1g in 5ml INJECTION NF

L-CARNITINE 300mg IN 1ml PAED SOLUTION 20mls NF

09.08.01 Drugs used in metabolic disorders

BUROSUMAB

BUROSUMAB 20mg in 1ml INJECTION (FREE OF CHARGE) NF

Rheumatoid arthritis in adults as per NICE TA247; Giant cell arteritis in adults, as per NICE TA518; Takayasu arteritis in adults as per NHSE Clinical Commissioning Policy 16056/P

BUROSUMAB 30mg in 1ml INJECTION (FREE OF CHARGE) NF

MMTC, October 2018

CYSTAGON

MERCAPTAMINE (CYSTEAMINE) 50mg CAPSULES NF

MERCAPTAMINE (CYSTEAMINE)

MERCAPTAMINE (CYSTEAMINE) 150mg CAPSULES NF

SODIUM BENZOATE

SODIUM BENZOATE 2g in 10ml INJECTION SR

For the treatment of Urea Cycle Defects as per BIMDG adult emergency management guideline. To be initiated following discussion with Metabolic Medicine or as per patient's care plan from the national centre. MMTC, July 2016

TRIENTINE

TRIENTINE 200mg CAPSULES R

For treatment of Wilson disease as per NHSE commissioning policy 170094P, for consultant use only. MMTC, December 2023.

ZINC SULPHATE

ZINC ACETATE 50mg CAPSULES NF

09.08.01 Metabolic disorders

ARGININE

L-ARGININE HYDROCHLORIDE 5g IN 10ml (50% W/V) UNR INJECTION

For the treatment of Urea Cycle Defects as per BIMDG adult emergency management guideline. To be initiated following discussion with Metabolic Medicine or as per patient's care plan from the national centre. MMTC, July 2016

09.08.02 Acute porphyrias

HAEM ARGINATE

HAEM ARGINATE (HUMAN HEMIN) 250mg in 10ml INJECTION (4x10ml) R

For use by Haematology Consultants only. Medicines Effectiveness, August 2009.

9.01 Anaemias and some o

9.01.01 Iron-deficiency anaemias

FERROUS FUMARATE

FERROUS FUMARATE 140mg/5ml LIQUID Y

10 Musculoskeletal and joint diseases

10.01 Drugs used in rheumatic diseases and gout

MOMELOTINIB 100mg TABLETS

NICE As per NICE TA957 - for treating myelofibrosis-related splenomegaly or symptoms (only just published 20/3/24)

08.02.00 Drugs affecting the immune response

GOLIMUMAB

GOLIMUMAB 100mg PRE-FILLED PEN R

For the treatment of:
- Psoriatic arthritis as per NICE TA220;
- Rheumatoid arthritis as per TA225;
- Ankylosing spondylitis as per TA383;
- Spondyloarthritis as per NICE TA497;
- Ulcerative colitis as per NICE TA329.
MMTC, December 2018

10.01 Drugs used in rheumatic diseases and gout

DIFLUNISAL

DIFLUNISAL 250mg TABLETS

NF

ETODOLAC

ETODOLAC 600mg TABLETS M/R

R

For use by consultant rheumatologists only. Medicines Effectiveness, March 2001.

10.01.00 Drugs used in rheumatic diseases and gout

Upadacitinib

UPADACITINIB 15mg M/R TABLETS

R

For the treatment of moderate to severe active rheumatoid arthritis in adult patients as per NICE TA665. For treatment of active psoriatic arthritis after inadequate response to DMARDs as per NICE TA768. For treatment of active ankylosing spondylitis as per NICE TA829. For treatment of moderate to severe atopic dermatitis as per NICE TA814. For treatment of moderately to severely active ulcerative colitis and Chron's disease in adults and post pubescent children as per NICE TA856 and TA905. For treatment of active non-radiographic axial spondyloarthritis as per NICE TA861. For treatment of active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with 2 or more DMARDs, to be used alongside methotrexate as per NICE TA744 MMTTC, March

UPADACITINIB 15mg PR TABLETS (FOC SUPPLY)

NF

10.01.00 Drugs used in rheumatic diseases and gout

BARICITINIB

BARICITINIB 4mg TABLETS

R

For the treatment of moderate to severe rheumatoid arthritis as per NICE TA466. For initiation by consultant rheumatologists only. MMTTC, October 2017

BARICITINIB 2mg TABLETS

R

For the treatment of moderate to severe rheumatoid arthritis as per NICE TA466. For initiation by consultant rheumatologists only. MMTTC, October 2017

GOLIMUMAB

GOLIMUMAB 50mg PRE-FILLED SYRINGE

R

Strictly for those unable to use the pre-filled pen. For the treatment of:
- Psoriatic arthritis as per NICE TA220;
- Rheumatoid arthritis as per TA225;
- Ankylosing spondylitis as per TA383;
- Spondyloarthritis as per NICE TA497;
- Ulcerative colitis as per NICE TA329.
MMTC, December 2018

INFLIXIMAB

INFLIXIMAB 100mg INJECTION

R

For rheumatoid arthritis as per NICE TA130 and TA295, psoriasis as per TA134, for ulcerative colitis as per TA163 and TA329, Crohn's disease as per TA187, and psoriatic arthritis as per TA199. MMTC, June 2015.

SARILUMAB

SARILUMAB 200mg PRE-FILLED SYRINGE

R

For the treatment of moderate to severe rheumatoid arthritis as per NICE TA485. MMTC, December 2017

SARILUMAB 200mg PRE-FILLED PEN

R

For the treatment of moderate to severe rheumatoid arthritis as per NICE TA485. MMTC, December 2017

SARILUMAB 150mg PRE-FILLED PEN

R

For the treatment of moderate to severe rheumatoid arthritis as per NICE TA485. MMTC, December 2017

SARILUMAB 150mg PRE-FILLED SYRINGE

R

For the treatment of moderate to severe rheumatoid arthritis as per NICE TA485. MMTC, December 2017

TOFACITINIB

TOFACITINIB 5mg TABLETS	R	For the treatment of: Moderate to severe rheumatoid arthritis as per NICE TA480, Active psoriatic arthritis as per NICE TA543, Moderately to severely active ulcerative colitis as per NICE TA 547, Juvenile idiopathic arthritis as per NICE TA 751. For treatment of active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults as per NICE TA920 MMTC, March 2024
TOFACITINIB 10mg TABLETS	R	For the treatment of moderate to severe active ulcerative colitis as per NICE TA547. Medicines Effectiveness, May 2019
<i>10.01.00 Musculoskeletal and joint diseases</i>		
CASIRIVIMAB		
CASIRIVIMAB 300mg per 2.5mL with IMDEVIMAB 300mg per 2.5mL	R	For treatment of Covid-19 in hospitalised and non-hospitalised patients with non-omicron variant infection. MMTC,
<i>10.01.01 Non-steroidal anti-inflammatory drugs</i>		
ACEMETACIN		
ACEMETACIN 60mg CAPSULES (NF)	NF	
CELECOXIB		
CELECOXIB 200mg CAPSULES	R	For use in OA and RA as per NICE guidelines only Medicines Effectiveness, May 2004.
CELECOXIB 100mg CAPSULES	R	For use in OA and RA as per NICE guidelines only Medicines Effectiveness, May 2004.
DICLOFENAC		
DICLOFENAC 100mg TABLETS M/R	NF	
DICLOFENAC 50mg TABLETS E/C	R	For short term analgesia in A+E, Maternity and young healthy adults. Medicines Effectiveness, November 2014
DICLOFENAC 25mg TABLETS E/C	R	For short term analgesia in A+E, Maternity and young healthy adults. Medicines Effectiveness, November 2014.
DICLOFENAC PAED 12.5mg SUPPOSITORIES	Y	

DICLOFENAC 75mg IN 3ml INJECTION	Y	
DICLOFENAC 50mg SUPPOSITORIES	R	For short term analgesia in A+E, Maternity and young healthy adults. Use in patients where oral/enteral route is not suitable only. Medicines Effectiveness, November 2014.
DICLOFENAC 25mg SUPPOSITORIES	R	For short term analgesia in A+E, Maternity and young healthy adults. Use in patients where oral/enteral route is not suitable only. Medicines Effectiveness, November 2014.
DICLOFENAC 100mg SUPPOSITORIES	R	For short term analgesia in A+E, Maternity and young healthy adults. Use in patients where oral/enteral route is not suitable only. Medicines Effectiveness, November 2014.
DICLOFENAC + MISOPROSTOL		
DICLOFENAC 50mg / MISOPROSTOL 200microgram TABLETS	R	For use at NOC only. Medicines Effectiveness, August 2000.
DICLOFENAC 75mg / MISOPROSTOL 200microgram TABLETS	R	For use at NOC only. Medicines Effectiveness, August 2000.
DICLOFENAC SODIUM		
DICLOFENAC 50mg TABLETS E/C	R	For short term analgesia in A+E, Maternity and young healthy adults. Medicines Effectiveness, November 2014
ETORCOXIB		
ETORICOXIB 30mg TABLETS	R	For use in OA and RA as per NICE guidelines only. Medicines Effectiveness, May 2004. For moderate to severe pain in haemophilia patients and patients with an inherited bleeding disorder. This is an off-label indication. MMTC, June 2018

ETORICOXIB

ETORICOXIB 60mg TABLETS	R	For use in OA and RA as per NICE guidelines only. Medicines Effectiveness, May 2004. For moderate to severe pain in haemophilia patients and patients with an inherited bleeding disorder. This is an off-label indication. MMTC, June 2018
ETORICOXIB 90mg TABLETS	R	For use in OA and RA as per NICE guidelines only. Medicines Effectiveness, May 2004. For moderate to severe pain in haemophilia patients and patients with an inherited bleeding disorder. This is an off-label indication. MMTC, June 2018
FENBUFEN		
FENBUFEN 300mg TABLETS	NF	
FLURBIPROFEN		
FLURBIPROFEN 100mg TABLETS	NF	
FLURBIPROFEN 50mg TABLETS	NF	
IBUPROFEN		
IBUPROFEN 200mg TABLETS	Y	
IBUPROFEN 400mg TABLETS	Y	
IBUPROFEN 600mg TABLETS	Y	
IBUPROFEN 400mg TABLETS TTO 24's	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.
IBUPROFEN 100mg/5ml LIQUID SUGAR FREE	Y	
IBUPROFEN 600mg SACHETS	Y	
IBUPROFEN 400mg TABLETS	Y	
IBUPROFEN 800mg TABLETS M/R	R	For use by consultants only. Medicines Effectiveness, March 2001.
INDOMETACIN		
INDOMETACIN 25mg CAPSULES	Y	

INDOMETACIN 50mg CAPSULES	Y	
KETOPROFEN		
KETOPROFEN 200mg CAPSULES M/R	NF	
KETOPROFEN 100mg CAPSULES	NF	
KETOPROFEN 50mg CAPSULES	NF	
MEFENAMIC		
MEFENAMIC ACID 500mg TABLETS	Y	
MEFENAMIC ACID 250mg CAPSULES	Y	
MEFENAMIC ACID		
MEFENAMIC ACID 50MG/5ML LIQUID	NF	
MELOXICAM		
MELOXICAM 7.5mg TABLETS	R	For initiation by rheumatologist at NOC only, Medicines Effectiveness, January 2007.
NABUMETONE		
NABUMETONE 500mg TABLETS	R	For use at NOC only. Medicines Effectiveness, August 2001.
NAPROXEN		
NAPROXEN 250mg TABLETS E/C	Y	
NAPROXEN 500mg TABLETS E/C	Y	
NAPROXEN 250mg TABLETS TTO PACK (28)	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, Sept 2017
NAPROXEN 500mg TABLETS	Y	
NAPROXEN 250mg TABLETS	Y	
PIROXICAM		
PIROXICAM 10mg CAPSULES	Y	
PIROXICAM 20mg CAPSULES	Y	
SULINDAC		

SULINDAC 100mg TABLETS	R	For use by Maternity and Gynaecology only. Medicines Effectiveness, May 2001.
SULINDAC 200mg TABLETS	R	For use by Maternity and Gynaecology only. Medicines Effectiveness, May 2001.

TENOXICAM

TENOXICAM 20mg TABLETS	NF
------------------------	----

TIAPROFENIC ACID

TIAPROFENIC ACID 300mg CAPSULES M/R	NF
-------------------------------------	----

VALDECOXIB

VALDECOXIB 10mg TABLETS	NF
-------------------------	----

10.01.02 Corticosteroids

PREDNISOLONE

PREDNISOLONE ACETATE 25mg in 1ml INJECTION	Y
--	---

TRIAMCINOLONE

TRIAMCINOLONE HEXACETONIDE 20mg IN 1ml INJECTION	R	For Juvenile Idiopathic Arthritis. MMTC, June 2015
--	---	--

Triamcinolone hexacetonide

TRIAMCINOLONE HEXACETONIDE 40mg in 2ml INJECTION (UL)	UNR
---	-----

TRIAMCINOLONE HEXACETONIDE 20mg IN 1ml INJECTION	UNR
--	-----

10.01.03 Drugs for the treatment of soft-tissue disorders and topical pain relief

TOCILIZUMAB

TOCILIZUMAB 162mg in 0.9ml PRE-FILLED PEN	R	For the treatment of: Juvenile idiopathic arthritis as per NICE TA238; Rheumatoid arthritis in adults as per NICE TA247; Giant cell arteritis in adults, as per NICE TA518; Takayasu arteritis in adults as per NHSE Clinical Commissioning Policy 16056/P, and Adult Onset Still's disease (off-label) as per NHSE Policy 170056P. MMTC, December
---	---	--

10.01.03 Drugs that suppress

METHOTREXATE

METHOTREXATE 12.5mg IN 0.25ml PRE-FILLED PEN R

For NOC patients only. See SOP for screening and dispensing methotrexate prescriptions. Medicines Effectiveness, March 2013

10.01.03 Drugs that suppress the rheumatic disease process

Abatacept

ABATACEPT 125mg in 1mL PRE-FILLED PENS (ORENCIA) R

For the treatment of : rheumatoid arthritis as per NICE TA195 and TA280; Juvenile Idiopathic Arthritis as per NICE TA373. MMTC, April 2019.

ABATACEPT 250mg INFUSION R

For the treatment of : rheumatoid arthritis as per NICE TA195 and TA280; Juvenile Idiopathic Arthritis as per NICE TA373. MMTC, April 2019.

ADALIMUMAB

ADALIMUMAB 40mg IN 0.8ml INJECTION VIAL NF

ADALIMUMAB 40mg PRE-FILLED SYRINGE for INJECTION NF

For the treatment of: Ankylosing spondylitis and non-radiographic axial spondyloarthritis as per NICE TA383; Behcet's disease following recommendation by the Birmingham Centre of Excellence; Crohn's disease as per NICE TA187; Hidradenitis suppurativa as per NICE TA392; Juvenile idiopathic arthritis as per NICE TA373; Rheumatoid arthritis as per NICE TA195 and NICE TA375; Psoriasis as per NICE TA146; Psoriatic arthritis as per TA199; Ulcerative colitis as per TA329; Uveitis as per NHSE policy 170010/PS; Non-infectious Uveitis as per NICE TA460. MMTC, April 2019

APREMILAST

APREMILAST 30mg TABLETS R

For the treatment of: - chronic plaque psoriasis in adults as per NICE TA419 - active psoriatic arthritis as per NICE TA433. MMTC, April 2017

APREMILAST 10mg/20mg/30mg TABLETS (TREATMENT INITIATION PACK) R

For the treatment of: - chronic plaque psoriasis in adults as per NICE TA419 - active psoriatic arthritis as per NICE TA433. MMTC, April 2017

BELIMUMAB

BELIMUMAB 120mg INJECTION POWDER FOR RECONSTITUTION	R	For the treatment of active autoantibody-positive systemic lupus erythematosus as per NICE TA397. MMTC, October 2016
BELIMUMAB 400mg INJECTION POWDER FOR INJECTION	R	For the treatment of active autoantibody-positive systemic lupus erythematosus as per NICE TA397. MMTC, October 2016
BELIMUMAB 200mg in 1ml PRE-FILLED PEN (BENLYSTA)	R	For treatment of active autoantibody positive systemic lupus erthematosus as per NICE TA 752. MMTC, June 2022

CERTOLIZUMAB

CERTOLIZUMAB PEGOL 200mg PRE-FILLED SYRINGE	R	For the treatment of rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor as per NICE TA415. MMTC, March 2017
---	---	--

Certolizumab pegol

CERTOLIZUMAB PEGOL 200mg in 1mL PRE FILLED PEN (CIMZIA)	R	
---	---	--

Diclofenac sodium

DICLOFENAC SODIUM 25mg GASTRO RESISTANT TABLETS	R	
---	---	--

ETANERCEPT

ETANERCEPT 50mg INJECTION PRE-FILLED SYRINGE	R	For the treatment of: juvenile arthritis as per NICE TA373; psoriasis as per NICE TA103; plaque psoriasis as per NICE TA455; rheumatoid arthritis as per NICE TA375 and NICE TA195; ankylosing spondylitis as per NICE TA383; and psoriatic arthritis as per NICE TA199. MMTC, April 2019
ETANERCEPT 25mg INJECTION PRE-FILLED SYRINGE	R	For the treatment of: juvenile arthritis as per NICE TA373; psoriasis as per NICE TA103; plaque psoriasis as per NICE TA455; rheumatoid arthritis as per NICE TA375 and NICE TA195; ankylosing spondylitis as per NICE TA383; and psoriatic arthritis as per NICE TA199. MMTC, April 2019

FILGOTINIB

FILGOTINIB 200mg TABLETS

R For treating moderately to severely active ulcerative colitis as per NICE TA792. For treatment of active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with 2 or more DMARDs, alongside methotrexate as per NICE TA676. MMTc, March 2024.

GOLIMUMAB

GOLIMUMAB 50mg PRE-FILLED PEN

R For the treatment of:
- Psoriatic arthritis as per NICE TA220;
- Rheumatoid arthritis as per TA225;
- Ankylosing spondylitis as per TA383;
- Spondyloarthritis as per NICE TA497;
- Ulcerative colitis as per NICE TA329.
MMTC, December 2018

HYDROXYCHLOROQUINE

HYDROXYCHLOROQUINE 200mg TABLETS

Y

Ibuprofen

IBUPROFEN 100mg/5ml LIQUID SUGAR FREE TTO
100ml

SR

INFLIXIMAB

INFLIXIMAB 100mg INJECTION

NF

LEFLUNOMIDE

LEFLUNOMIDE 100mg TABLETS

R For use by Rheumatology at NOC only. Medicines Effectiveness, august 2001.

LEFLUNOMIDE 20mg TABLETS

R For use by Rheumatology at NOC only. Medicines Effectiveness, august 2001.

LEFLUNOMIDE 10mg TABLETS

R For use by Rheumatology at NOC only. Medicines Effectiveness, august 2001.

METHOTREXATE

METHOTREXATE 15mg IN 0.3ml PRE-FILLED PEN	R	For NOC patients only. See SOP for screening and dispensing methotrexate prescriptions. Medicines Effectiveness, March 2013.
METHOTREXATE 20mg IN 0.4ml PRE-FILLED PEN	R	For NOC patients only. See SOP for screening and dispensing methotrexate prescriptions. Medicines Effectiveness, March 2013.
METHOTREXATE 25mg IN 0.5ml PRE-FILLED PEN	R	For NOC patients only. See SOP for screening and dispensing methotrexate prescriptions. Medicines Effectiveness, March 2013.
METHOTREXATE 17.5mg in 0.35ml PRE-FILLED PEN	R	For NOC patients only. See SOP for screening and dispensing methotrexate prescriptions. Medicines Effectiveness, March 2013
METHOTREXATE 22.5mg IN 0.45ml PRE-FILLED PEN	R	For NOC patients only. See SOP for screening and dispensing methotrexate prescriptions. Medicines Effectiveness, March 2013
METHOTREXATE 7.5mg IN 0.15ml PRE-FILLED PEN	R	For NOC patients only. See SOP for screening and dispensing methotrexate prescriptions. Medicines Effectiveness, March 2013
METHOTREXATE 30mg IN 0.6ml PRE-FILLED PEN	R	For NOC patients only. See SOP for screening and dispensing methotrexate prescriptions. Medicines Effectiveness, March 2013
METHOTREXATE 10mg IN 0.2ml PRE-FILLED PEN	R	For NOC patients only. See SOP for screening and dispensing methotrexate prescriptions. Medicines Effectiveness, March 2013.

METHYLPREDNISOLONE

METHYLPREDNISOLONE 40mg & LIDOCAINE 10mg
in 1ml INJECTION DEPOT Y

PENICILLAMINE

PENICILLAMINE 125mg TABLETS Y

PENICILLAMINE 250mg TABLETS	Y	
TOCILIZUMAB		
TOCILIZUMAB 200mg in 10ml INJECTION	R	For the treatment of: Juvenile idiopathic arthritis as per NICE TA238; Rheumatoid arthritis in adults as per NICE TA247; Giant cell arteritis in adults, as per NICE TA518; Takayasu arteritis in adults as per NHSE Clinical Commissioning Policy 16056/P, and Adult Onset Still's disease (off-label) as per NHSE Policy 170056P. As first line treatment of CAR-T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older. For treatment of COVID19 in adults as per NICE TA878. MMTc, August 2023
TOCILIZUMAB 400mg in 20ml INJECTION	R	For the treatment of: Juvenile idiopathic arthritis as per NICE TA238; Rheumatoid arthritis in adults as per NICE TA247; Giant cell arteritis in adults, as per NICE TA518; Takayasu arteritis in adults as per NHSE Clinical Commissioning Policy 16056/P, and Adult Onset Still's disease (off-label) as per NHSE Policy 170056P. For treatment of COVID19 in adults as per NICE TA878. MMTc, August 2023
TOCILIZUMAB 80mg in 4ml INJECTION	R	For the treatment of: Juvenile idiopathic arthritis as per NICE TA238; Rheumatoid arthritis in adults as per NICE TA247; Giant cell arteritis in adults, as per NICE TA518; Takayasu arteritis in adults as per NHSE Clinical Commissioning Policy 16056/P, and Adult Onset Still's disease (off-label) as per NHSE Policy 170056P. For treatment of COVID 19 in adults as per NICE TA878. MMTc, August 2023
TRIAMCINOLONE		
TRIAMCINOLONE 50mg in 5ml INJECTION	Y	Licensed indications and also approved for prevention of inflammation and macular oedema post-cataract surgery MMTc July 2021

VEDOLIZUMAB

VEDOLIZUMAB 108mg/0.68ml PRE-FILLED PENS R

VEDOLIZUMAB 300mg INJECTION R

For the treatment of moderately to severely active ulcerative colitis as per TA342 and moderately to severely active Crohn's disease after prior therapy as per TA352, and for treatment of ulcerative colitis and Crohn's disease in post-pubescent adolescents in line with the NHSE medicines for children policy.
MMTC, July 2021

10.01.03 Drugs which suppress the rheumatic disease process

ADALIMUMAB

ADALIMUMAB 40mg in 0.8ml PRE-FILLED PEN (AMGEVITA) R

For the treatment of: Ankylosing spondylitis and non-radiographic axial spondyloarthritis as per NICE TA383; Behcet's disease following recommendation by the Birmingham Centre of Excellence; Crohn's disease as per NICE TA187; Hidradenitis suppurativa as per NICE TA392; Juvenile idiopathic arthritis as per NICE TA373; Rheumatoid arthritis as per NICE TA195 and NICE TA375; Psoriasis as per NICE TA146; Psoriatic arthritis as per TA199; Ulcerative colitis as per TA329; Uveitis as per NHSE policy 170010/PS; Non-infectious Uveitis as per NICE TA460.
MMTC, April 2019

ADALIMUMAB 20mg in 0.4ml PRE-FILLED SYRINGE (AMGEVITA) R

For the treatment of: Ankylosing spondylitis and non-radiographic axial spondyloarthritis as per NICE TA383; Behcet's disease following recommendation by the Birmingham Centre of Excellence; Crohn's disease as per NICE TA187; Hidradenitis suppurativa as per NICE TA392; Juvenile idiopathic arthritis as per NICE TA373; Rheumatoid arthritis as per NICE TA195 and NICE TA375; Psoriasis as per NICE TA146; Psoriatic arthritis as per TA199; Ulcerative colitis as per TA329; Uveitis as per NHSE policy 170010/PS; Non-infectious Uveitis as per NICE TA460.
MMTC, April 2019

ADALIMUMAB 40mg PRE-FILLED PEN (IMRALDI) R

For the treatment of: Ankylosing spondylitis and non-radiographic axial spondyloarthritis as per NICE TA383; Behcet's disease following recommendation by the Birmingham Centre of Excellence; Crohn's disease as per NICE TA187; Hidradenitis suppurativa as per NICE TA392; Juvenile idiopathic arthritis as per NICE TA373; Rheumatoid arthritis as per NICE TA195 and NICE TA375; Psoriasis as per NICETA146; Psoriatic arthritis as per TA199; Ulcerative colitis as per TA329; Uveitis as per NHSE policy 170010/PS; Non-infectious Uveitis as per NICE TA460. MMTTC, April 2019

ADALIMUMAB 40mg in 0.8ml PRE- FILLED SYRINGE (IMRALDI) R

For the treatment of: Ankylosing spondylitis and non-radiographic axial spondyloarthritis as per NICE TA383; Behcet's disease following recommendation by the Birmingham Centre of Excellence; Crohn's disease as per NICE TA187; Hidradenitis suppurativa as per NICE TA392; Juvenile idiopathic arthritis as per NICE TA373; Rheumatoid arthritis as per NICE TA195 and NICE TA375; Psoriasis as per NICETA146; Psoriatic arthritis as per TA199; Ulcerative colitis as per TA329; Uveitis as per NHSE policy 170010/PS; Non-infectious Uveitis as per NICE TA460. For treatment of active rheumatoid arthritis in adults, alongside methotrexate as per NICE TA715. MMTTC, March 2024.

ANAKINRA

ANAKINRA 100MG SYRINGE

R

For treatment of Juvenile Idiopathic Arthritis (JIA) as per NHSE Policy E03/PS/a and Adult Onset Still's disease as per NHSE Policy 170056P. MMTTC, December 2019

DENOSUMAB

DENOSUMAB 60mg in 1ml PRE-FILLED SYRINGE	NF	For the prevention of osteoporotic fractures in postmenopausal women as per NICE TA204. For patients unable to receive first dose by GP including non-Oxfordshire patients. MMTC July 2019
--	----	--

INFLIXIMAB

INFLIXIMAB 120mg PRE FILLED PEN	NF	Read the additional information given with this medication
---------------------------------	----	--

NIVOLUMAB

NIVOLUMAB 240mg IN 24ml INJECTION (EAMS - OSCC)	NF	
---	----	--

TOCILIZUMAB

TOCILIZUMAB 162mg PRE-FILLED SYRINGE	R	For the treatment of: Juvenile idiopathic arthritis as per NICE TA238; Rheumatoid arthritis in adults as per NICE TA247; Giant cell arteritis in adults, as per NICE TA518; Takayasu arteritis in adults as per NHSE Clinical Commissioning Policy 16056/P, and Adult Onset Still's disease (off-label) as per NHSE Policy 170056P. MMTC, December
--------------------------------------	---	--

10.01.03 Immunosuppressants

ADALIMUMAB

ADALIMUMAB 20mg IN 0.2ml PRE-FILLED SYRINGE	NF	For the treatment of: Ankylosing spondylitis and non-radiographic axial spondyloarthritis as per NICE TA383; Behcet's disease following recommendation by the Birmingham Centre of Excellence; Crohn's disease as per NICE TA187; Hidradenitis suppurativa as per NICE TA392; Juvenile idiopathic arthritis as per NICE TA373; Rheumatoid arthritis as per NICE TA195 and NICE TA375; Psoriasis as per NICE TA146; Psoriatic arthritis as per TA199; Ulcerative colitis as per TA329; Uveitis as per NHSE policy 170010/PS; Non-infectious Uveitis as per NICE TA460. MMTC, April 2019
---	----	--

10.01.04 Gout and cytotoxic-induced hyperuricaemia

ALLOPURINOL

ALLOPURINOL 100mg TABLETS	Y	
---------------------------	---	--

ALLOPURINOL 300mg TABLETS	Y	
COLCHICINE		
COLCHICINE 500microgram TABLETS	Y	
FEBUXOSTAT		
FEBUXOSTAT 120mg TABLETS	R	For the treatment of hyperuricaemia in rheumatology patients who are unable to take or intolerant to allopurinol as per NICE TA164. MAC, April 2009.
FEBUXOSTAT 80mg TABLETS	R	For the treatment of hyperuricaemia in rheumatology patients who are unable to take or intolerant to allopurinol as per NICE TA164. MAC, April 2009.
PROBENECID		
PROBENECID 500mg TABLETS	UNR	For severe gout/hyperuricaemia. Use only when Benemid is not available. Medicines Effectiveness, July 2011.
RASBURICASE		
RASBURICASE 1.5mg INJECTION	R	For use by Paediatric and Adult Heamatology/Oncology only. Medicines Effectiveness, December 2012.
RASBURICASE 7.5mg INJECTION	R	For use by Paediatric and Adult Heamatology/Oncology only. Medicines Effectiveness, December 2012.
SULFINPYRAZONE		
SULFINPYRAZONE 100mg TABLETS	Y	
<i>10.02.02 Skeletal muscle relaxants</i>		
HYALURONIC ACID		
HYALURONIC ACID 20MG INJECTION 3ml	NF	

10.01 Musculoskeletal and joint diseases

10.01.03 Drugs which suppress the rheumatic disease process

TOCILIZUMAB 162mg in 0.9ml PRE-FILLED SYRINGE (TYENNE)

NF For the treatment of: Juvenile idiopathic arthritis as per NICE TA238; Rheumatoid arthritis in adults as per NICE TA247; Giant cell arteritis in adults, as per NICE TA518; Takayasu arteritis in adults as per NHSE Clinical Commissioning Policy 16056/P, and Adult Onset Still's disease (off-label) as per NHSE Policy 170056P. MMTc, December 2019

Canakinumab

CANAKINUMAB 150mg INJECTION NF

Certolizumab

CERTOLIZUMAB PEGOL 200mg in 1ml PRE FILLED PEN (FREE OF CHARGE) F

Durvalumab

DURVALUMAB 500mg in 10ml INJECTION (FOR COMPASSIONATE USE) NF COMPASSIONATE USE FOR UPER GI To be reconstituted by Baxters GRAHAM 03.08.23

Pembrolizumab

PEMBROLIZUMAB 100mg IN 4ml SOLUTION FOR INFUSION VIAL (COMPASSIONATE USE) NF

10.02 Drugs used in neuromuscular disorders

QUININE SULPHATE

QUININE SULPHATE 300mg TABLETS Y

Risdiplam

RISDIPLAM 37.5mg/5ml LIQUID 80ml SF	R	For spinal muscular atrophy as per TA 755 Cytostatic: Solution to reconstituted in the clinical trials unit satellite laminar flow cabinet by a member of the JR dispensary team. Caution should be exercised in the handling of Evrysdi powder for oral solution. Avoid inhalation and direct contact with skin or mucous membranes with the dry powder and the constituted solution. Wear disposable gloves during constitution and while wiping the outer surface of the bottle/cap and cleaning the working surface after constitution. If contact occurs, wash thoroughly with soap and water; rinse eyes with water. Room temp storage before reconstitution. Fridge storage
-------------------------------------	---	--

10.02.01 Drugs that enhance neuromuscular transmission

EDROPHONIUM

EDROPHONIUM 150mg IN 15ml INJECTION	UNR	For use by NICU only. Medicines Effectiveness, Septemeber 2013.
-------------------------------------	-----	---

NEOSTIGMINE

NEOSTIGMINE 2.5mg IN 1ml INJECTION	Y	
------------------------------------	---	--

PYRIDOSTIGMINE

PYRIDOSTIGMINE 60mg TABLETS	Y	
-----------------------------	---	--

10.02.02 Skeletal muscle relaxants

BACLOFEN

BACLOFEN 36mg in 12ml INTRATHECAL INJECTION	SR	For use by Neurology Consultants only. Medicines Effectiveness, February 2013.
---	----	--

BACLOFEN 10mg IN 5ml INTRATHECAL INJECTION	NF	
--	----	--

BACLOFEN 30mg IN 10ml INTRATHECAL INJECTION (PRESERVATIVE FREE)	SR	For use by Neurology Consultants only. Medicines Effectiveness, February 2013.
---	----	--

BACLOFEN 50micrograms in 1ml INTRATHECAL INJECTION	R	For use by Neurology Consultants only. Medicines Effectiveness, February 2013.
--	---	--

BACLOFEN 40mg IN 20ml INTRATHECAL INJECTION	R	For use by Neurology Consultants only. Medicines Effectiveness, February 2013.
---	---	--

BACLOFEN 10mg TABLETS	Y	
BACLOFEN 5mg/5ml LIQUID	Y	
BACLOFEN 10mg in 20ml INTRATHECAL INJECTION	R	For use by Neurology Consultants only. Medicines Effectiveness, February 2013.
BACLOFEN 3mg IN 1ml INTRATHECAL INFUSION (PRES FREE) 5ml	SR	For use by Neurology Consultants only. Medicines Effectiveness, May 2016
DANTROLENE SODIUM		
DANTROLENE SODIUM 100mg CAPSULES	Y	
DANTROLENE SODIUM 25mg CAPSULES	Y	
METHOCARBAMOL		
METHOCARBAMOL 750mg TABLETS	Y	
TIZANIDINE		
TIZANIDINE 2mg TABLETS	R	For use in multiple sclerosis or in spinal cord injury/disease (second line therapy after baclofen). MAC, November 1998.
TIZANIDINE 4mg TABLETS	R	For use in multiple sclerosis or in spinal cord injury/disease (second line therapy after baclofen). MAC, November 1998.

10.03 Drugs for the treatment of soft-tissue disorders and topical pain relief

10.03.00 Drugs for the treatment of soft-tissue disorders and topical pain relief

BENZYDAMINE

BENZYDAMINE CREAM 100g (DIFFLAM) NF

10.03.00 Musculoskeletal and joint diseases

SUCROSE

SUCROSE 24% SOLUTION 2ml R For use in young infants to reduce procedural pain and distress MMTTC , July 2015

10.03.01 Enzymes

HYALURONIDASE

HYALURONIDASE 1500international units INJECTION Y

10.03.02 Rubefacients, topical NSAIDs, capsaicin, and poultices

CAPSAICIN

CAPSAICIN 0.025% CREAM 45g	NF
DICLOFENAC	
DICLOFENAC 1% EMUGEL 100g	Y
IBUPROFEN	
IBUPROFEN 100mg/5ml LIQUID	Y
IBUPROFEN 5% GEL 100g	Y
PIROXICAM	
PIROXICAM 0.5% GEL 60g	NF

11 Eye

AFLIBERCEPT

AFLIBERCEPT 3.6mg IN 0.09ml INTRAVITREAL INJECTION (PRE-FILLED SYRINGE)	R	For the treatment of:- wet-age related macular degeneration as per NICE TA294 -diabetic macular oedema as per NICE TA346 - visual impairment caused by macular oedema after branch retinal vein occlusion as per NICE TA409 - Choroidal Neovascularisation as per NICE TA 486. MMTC, February 2018
---	---	--

FLUORESCEIN

FLUORESCEIN 20% INJECTION 5ml	UNR	Restricted to angiography (eye). Medicines Effectiveness, February 2013.
-------------------------------	-----	--

HYDROXYPROPYL METHYLCELLULOSE

HYDROXYPROPYL METHYLCELLULOSE (HPMC) 2% IN BALANCED SALT 5ml VIALS	Y
--	---

Natamycin

NATAMYCIN (PIMARICIN) 5% EYE DROPS 5ml	UNR	For proven or suspected or fungal keratitis infections. Restricted to consultant ophthalmology and/or microbiology/infectious diseases physician prescribing or recommendation only. MMTC June 2018
--	-----	---

SODIUM HYALURONATE

SODIUM HYALURONATE 30mg & SOD CHONDROITIN 40mg 0.5ml INJ (VISCOAT)	Y
--	---

11.03 Anti-infective eye preparations

Chlorhexidine

CHLORHEXIDINE 0.02% EYE DROPS PRES FREE 10ml	SR	For use by Ophthalmology or on Microbiology advice only. Medicines Effectiveness, February 2003.
--	----	--

11.03.00 Anti-infective eye preparations

CHLORAMPHENICOL

CHLORAMPHENICOL 0.5% MINIMS	R	Restricted for patients with documented preservative intolerance/ allergy and to those with compromised cornea where corneal toxicity is a concern. Medicines Effectiveness, November 2016
-----------------------------	---	--

OFLOXACIN

OFLOXACIN 0.3% EYE DROPS TTO PACK 5ml	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, November 2015.
---------------------------------------	----	--

OFLOXACIN 0.3% EYE DROPS 5ml	Y	
------------------------------	---	--

11.03.01 Antibacterials

AMIKACIN

AMIKACIN 2.5% EYE DROPS (PRES FREE) 5ml	SR	To be used by Ophthalmology only - replacement for gentamicin 1.5% eye drops. Medicines Effectiveness, November 2020
---	----	--

CEFUROXIME

CEFUROXIME 5% EYE DROPS 10ml	SR	For use by Ophthalmology or on advice from Microbiology only. Medicines Effectiveness, September 2003.
------------------------------	----	--

CHLORAMPHENICOL

CHLORAMPHENICOL 1% EYE OINTMENT 4g	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
------------------------------------	---	---

CHLORAMPHENICOL 0.5% EYE DROPS TTO PACK	SR	For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CHLORAMPHENICOL 0.5% EYE DROPS 10ml	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CHLORHEXIDINE		
CHLORHEXIDINE 0.02% EYE DROPS PRES FREE 5ml	UNR	For use by Ophthalmology or on Microbiology advice only. Medicines Effectiveness, February 2003.
CIPROFLOXACIN		
CIPROFLOXACIN 0.3% EYE/EAR DROPS 5ml	Y	
CIPROFLOXACIN 0.3% EAR/EYE DROPS 5ml TTO (for use in ear(s))	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, February 2013.
FUSIDIC ACID		
FUSIDIC ACID 1% EYE DROPS 5g	Y	
GENTAMICIN		
GENTAMICIN 0.3% EYE/EAR DROPS 10ml	Y	
KETOTIFEN		
KETOTIFEN 250micrograms/ml EYE DROPS 0.4ml UNIT DOSE (preservative free)	R	For treatment of symptomatic seasonal allergic conjunctivitis in patients requiring a preservative free option. MMTC, July 2021
MOXIFLOXACIN		
MOXIFLOXACIN 0.5% EYE DROPS 5ml	NF	For treatment of microbial keratitis (first line treatment) . MMTC February 2021
PROPAMIDINE		

PROPAMIDINE 0.1% EYE DROPS 10ml

R

For the treatment of acanthamoeba infection only. Medicines Effectiveness, February 2003.

TOBRAMYCIN

TOBRAMYCIN 0.3% EYEDROPD

NF

VANCOMYCIN

VANCOMYCIN 5% EYE DROPS 5ml

SR

For use by Ophthalmology only. Medicines Effectiveness, March 2013.

11.03.03 Antivirals

ACICLOVIR

ACICLOVIR 3% EYE OINTMENT 4.5g

NF

GANCICLOVIR

GANCICLOVIR 0.15% EYE GEL 5g

R

For the treatment of Acute herpetic keratitis. MMTC, May 2019

13.10.01 Antibacterial preparations

CHLORAMPHENICOL

CHLORAMPHENICOL 0.5% MINIMS TTO (20)

SR

For areas allowed to keep TTO packs. As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by:
- Microbiology/ID consultant or registrar
- Paediatric ID consultant or registrar
Antimicrobials Steering Group, January 2012.

INDOCYANINE GREEN

INDOCYANINE GREEN 25mg IN 5ml INJECTION

R

For use as a marking agent during surgery; in patients with allergy to iodine during angiography; retinal imaging and intraocular visualisation; and for mapping of cutaneous lymphatic drainage. MMTC, June

11.04 Corticosteroids and other anti-inflammatory preparations

11.04.00 Corticosteroids and other anti-inflammatory preparations

DEXAMETHASONE

DEXAMETHASONE 0.1% EYE DROPS TTO PACK 10ml

SR

For areas allowed to keep TTO packs. Medicines Effectiveness, February 2013

PREDNISOLONE

PREDNISOLONE (FORTE) 1% EYE DROPS 5ml Y

11.04.01 Corticosteroids

FLUOCINOLONE

FLUOCINOLONE 190microgram INTRAVITREAL IMPLANT R For treatment of: diabetic macular oedema as per NICE TA301 and non-infectious uveitis as per NICE TA509. MMTC, November 2019

11.04.01 Corticosteroids

BETAMETHASONE

BETAMETHASONE 0.1% DROPS (EYE/EAR and NOSE) 10ml Y

BETAMETHASONE 0.1% & NEOMYCIN 0.5% DROPS (EYE/EAR/NOSE) 10ml Y

DEXAMETHASONE

DEXAMETHASONE 0.1% TOBRAMYCIN 0.3% EYE DROPS 5ml NF

DEXAMETHASONE 0.1% EYE DROPS TTO PACK SR For areas allowed to keep TTO packs. Medicines Effectiveness, February 2013.

DEXAMETHASONE 700microgram INTRAVITREAL IMPLANT R For macular oedema (retinal vein occlusion) - dexamethasone as per NICE TA229; Diabetic macular oedema TA349; Non-infectious uveitis as per NICE TA460. MMTC, October 2017

DEXAMETHASONE 0.1% EYE DROPS 5ml Y

FLUOROMETHOLONE

FLUOROMETHOLONE 0.1% EYE SUSPENSION 10ml Y

IOTEPREDNOL ETABONATE

LOTEPREDNOL ETABONATE 0.5% EYE DROPS 5ml NF

MAXITROL

MAXITROL EYE DROPS 5ml Y

MAXITROL EYE OINTMENT 3.5g Y

MAXITROL EYE OINTMENT TTO 3.5g SR For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.

MAXITROL EYE DROPS TTO PACK	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.
-----------------------------	----	---

PREDNISOLONE

PREDNISOLONE 1% EYE DROPS TTO PACK 10ml	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, February 2013.
---	----	--

PREDNISOLONE 0.1% PRES FREE EYE DROPS 10ml	IUNR	For ophthalmology use only. Medicines Effectiveness, April 2015.
--	------	--

PREDNISOLONE (FORTE) 1% EYE DROPS 10ml	Y	
--	---	--

PREDNISOLONE 0.5% EYE DROPS (MINIMS)	Y	
--------------------------------------	---	--

PREDNISOLONE 1% EYE DROPS PRES FREE 10ml	Y	
--	---	--

11.04.02 Other anti-inflammatory preparations

DEXAMETHASONE

DEXAMETHASONE 0.1% EYE DROPS (MINIMS)	Y	
---------------------------------------	---	--

EPINASTINE HYDROCHLORIDE

EPINASTINE HYDROCHLORIDE 500mcg/ml EYE DROPS 5ml	NF	
--	----	--

LODOXAMIDE

LODOXAMIDE 0.1% EYE DROPS 10ml	Y	
--------------------------------	---	--

NEDOCROMIL

NEDOCROMIL SODIUM 2% EYE DROPS 5ml	Y	
------------------------------------	---	--

OLOPATADINE

OLOPATADINE 1mg/ml EYE DROPS 5ml	R	For the treatment of allergic conjunctivitis in those where sodium cromoglycate is ineffective or not appropriate. MMTC, February 2018
----------------------------------	---	--

OTRIVINE-ANTISTIN

OTRIVINE-ANTISTIN EYE DROPS 10ml	NF	
----------------------------------	----	--

SODIUM CROMOGLICATE

SODIUM CROMOGLICATE 2% UNIT DOSE EYE DROPS (PRESERVATIVE FREE)	Y	
--	---	--

SODIUM CROMOGLICATE 2% EYE DROPS 13.5ml	Y	
---	---	--

11.05 Mydriatics and cycloplegics

TROPICAMIDE

TROPICAMIDE 0.2mg / PHENYLEPHRINE 3.1mg / LIDOCAINE 10mg INJECTION	R	For mydriasis and local anaesthesia in cataract surgery only. MMTC, July 2017
--	---	---

11.05.00 Mydriatics and cycloplegics

Atropine

ATROPINE 1% EYE DROPS (MINIMS) - TTO PACK (20s)	SR	For areas allowed to use TTO packs. Medicines Effectiveness.
---	----	--

ATROPINE 1% EYE DROPS (MINIMS)	Y	
--------------------------------	---	--

CYCLOPENTOLATE

CYCLOPENTOLATE 1% EYE DROPS (minims)	Y	
--------------------------------------	---	--

CYCLOPENTOLATE 0.5% EYE DROPS (MINIMS)	Y	
--	---	--

CYCLOPENTOLATE 1% EYE DROPS 5ml	Y	
---------------------------------	---	--

CYCLOPENTOLATE 0.5% EYE DROPS 5ml	Y	
-----------------------------------	---	--

CYCLOPENTOLATE 1% EYE DROPS 5ml TTO PACK	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, February 2013.
--	----	--

DORZOLAMIDE

DORZOLAMIDE 20mg/ml (0.2%) EYE DROPS PRES FREE	R	Second line carbonic anhydrase inhibitor for the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. NB: Preservative-free drops should only be used if there are documented intolerance or allergy to preservatives or there is a pre-existing ocular surface disease which is likely to be exacerbated by preservatives. MMTC, August 2017
--	---	---

PHENYLEPHRINE

PHENYLEPHRINE 2.5% EYE DROPS (MINIMS)	Y	
---------------------------------------	---	--

PHENYLEPHRINE 10% EYE DROPS (MINIMS)	Y	
--------------------------------------	---	--

TROPICAMIDE

TROPICAMIDE 0.5% EYE DROPS (MINIMS)	Y	
-------------------------------------	---	--

TROPICAMIDE 1% EYE DROPS (MINIMS) Y

11.06 Treatment of glaucoma

1.06.00 Drugs for Glucoma

LATANOPROST + TIMOLOL

LATANOPROST 50microgram/ml & TIMOLOL 5mg/ml R
UNIT DOSE EYE DROPS 0.2ml

For the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. NB: Preservative-free drops should only be used if there are documented intolerance or allergy to preservatives or there is a pre-existing ocular surface disease which is likely to be exacerbated by preservatives. MMTc, October 2019

11.06.00 Drugs for Glucoma

ACETAZOLAMIDE

ACETAZOLAMIDE 250mg CAPSULES S/R TTO 6'S SR

For areas allowed to keep TTO packs. Medicines Effectiveness, February 2013.

ACETAZOLAMIDE 250mg TABLETS Y

ACETAZOLAMIDE 500mg INJECTION Y

BETAXOLOL

BETAXOLOL 0.25% EYE DROPS 5ml Y

BETAXOLOL 0.5% EYE DROPS 5ml NF

BETAXOLOL 0.25% UNIT DOSE PRESERVATIVE FREE EYE DROPS NF

BIMATOPROST

BIMATOPROST 100micrograms/ml EYE DROPS R

Third line prostaglandin analogue for the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline.

BIMATOPROST 300microgram/ml EYE DROPS 0.4ml R
UNIT DOSE (PRES FREE)

Third line prostaglandin analogue for the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. NB: Preservative-free drops should only be used if there are documented intolerance or allergy to preservatives or there is a pre-existing ocular surface disease which is likely to be exacerbated by preservatives. MMTC, August 2017

BRIMONIDINE

BRIMONIDINE TARTRATE 0.2% (2mg/ml) EYE DROPS 5ml R

First line alpha agonist for the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. MMTC, August 2017

BRIMONIDINE + TIMOLOL

BRIMONIDINE 2mg/ml and TIMOLOL 5mg/ml EYE DROPS 5ml R

For the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. NB: Fixed dose combinations should only be used if the patient requires more than two different eye drops or compliance is an issue MMTC, August 2017

BRINZOLAMIDE

BRINZOLAMIDE 10mg/ml EYE DROPS 5ml R

First line carbonic anhydrase inhibitor for the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. MMTC, August 2017

BRINZOLAMIDE + BRIMONIDINE

BRINZOLAMIDE 10mg/ml and BRIMONIDINE 2mg/ml EYEDROPS 5ml R

For the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. Restricted to those where beta blockers are contraindicated and combination product indicated. NB: Fixed dose combinations should only be used if the patient requires more than two different eye drops or compliance is an issue MMTC, August 2017

BRINZOLAMIDE + TIMOLOL

BRINZOLAMIDE 10mg/ml and TIMOLOL 5mg/ml EYE DROPS 5ml R For the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. NB: Fixed dose combinations should only be used if the patient requires more than two different eye drops or compliance is an issue MMTC, August 2017

DORZOLAMIDE

DORZOLAMIDE 20mg/ml EYE DROPS 5ml R Second line carbonic anhydrase inhibitor for the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. MMTC, August 2017

DORZOLAMIDE 20mg/ml & TIMOLOL 5mg/ml EYE DROPS 5ml R For the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. NB: Fixed dose combinations should only be used if the patient requires more than two different eye drops or compliance is an issue MMTC, August 2017

DORZOLAMIDE 20mg/ml & TIMOLOL 5mg/ml EYE DROPS TTO 5ml SR For areas allowed to keep TTO packs. Medicines Effectiveness, February 2013.

GANFORT

BIMATOPROST/TIMOLOL 300MCG/5ML 0.4ML EYE DROPS PRESERVATIVE FREE R For the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. NB: Preservative-free drops should only be used if there are documented intolerance or allergy to preservatives or there is a pre-existing ocular surface disease which is likely to be exacerbated by preservatives. NB: Fixed dose combinations should only be used if the patient requires more than two different eye drops or compliance is an issue MMTC, August 2017

BIMATOPROST 300micrograms/ml & TIMOLOL 5mg/ml EYE DROPS 3ml	R	For the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. NB: Fixed dose combinations should only be used if the patient requires more than two different eye drops or compliance is an issue MMTC, August 2017
---	---	--

LATANOPROST

LATANOPROST 0.005% (50micrograms/ml) UNIT DOSE EYE DROPS PRES FREE	R	First line prostaglandin analogue for the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline.
--	---	--

NB: Preservative-free drops should only be used if there are documented intolerance or allergy to preservatives or there is a pre-existing ocular surface disease which is likely to be exacerbated by preservatives. MMTC, August 2017

LATANOPROST 50microgram/ml + TIMOLOL 5mg/ml EYE DROPS 2.5ml	R	This combinations is not deemed to be clinically effective. All requests should be challenged. Please see the OUH-OCCG glaucoma and ocular hypertension guideline. Medicines Effectiveness, April 2018
---	---	--

LATANOPROST 0.005% (50micrograms/ml) UNIT DOSE EYE DROPS TTO PACK	SR	
---	----	--

LATANOPROST 0.005% (50micrograms/ml) EYE DROPS 2.5ml	R	First line prostaglandin analogue for the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. MMTC, August 2017
--	---	--

LATANOPROST 0.005% (50micrograms/ml) EYE DROPS TTO 2.5ml	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.
--	----	---

LEVOBUNOLOL

LEVOBUNOLOL 0.5% UNIT DOSE EYE DROPS (PRES FREE)	Y	
--	---	--

PILOCARPINE

PILOCARPINE 2% EYE DROPS 10ml	Y	
-------------------------------	---	--

PILOCARPINE 4% EYE DROPS 10ml	Y	
-------------------------------	---	--

PILOCARPINE 2% EYE DROPS (MINIMS) (20) Y

PILOCARPINE 1% EYE DROPS 10ml Y

TAFLUPROST

TAFLUPROST 15microgram/ml EYE DROPS (SINGLE DOSE UNITS) (30) R

For the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline.

NB: Preservative-free drops should only be used if there are documented intolerance or allergy to preservatives or there is a pre-existing ocular surface disease which is likely to be exacerbated by preservatives. MMTC, August 2017

TAFLUPROST + TIMOLOL

TAFLUPROST 15micrograms/ml and TIMOLOL 5mg/ml EYEDROPS Preservative Free R

For the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. NB: Fixed dose combinations should only be used if the patient requires more than two different eye drops or compliance is an issue. MMTC, August 2017

TIMOLOL

TIMOLOL 0.5% EYE DROPS 2.5ml L.A. R

First line treatment in Infantile haemangiomas (Off-label), initiation must be on advise of dermatology team. MMTC, July 2023

TIMOLOL 0.1% EYE GEL Preservative free 30 R

First line beta blocker for the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. NB: Preservative-free drops should only be used if there are documented intolerance or allergy to preservatives or there is a pre-existing ocular surface disease which is likely to be exacerbated by preservatives. MMTC, August 2017

TIMOLOL 0.5% EYE DROPS 5ml NF

TIMOLOL 0.25% EYE DROPS 5ml	R	First line beta blocker for the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. MMTC, August 2017
TIMOLOL 0.25% EYE DROPS 2.5ml L.A.	R	Second line prostaglandin analogue for the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. MMTC, August 2017

TIMOLOL + TRAVOPROST

TRAVOPROST 40micrograms in 1ml / TIMOLOL 5mg in 1ml EYE DROPS 2.5ml	R	For the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. NB: Fixed dose combinations should only be used if the patient requires more than two different eye drops or compliance is an issue. MMTC, August 2017
---	---	---

11.06.00 Optic neuropathy

IDEBENONE

IDEBENONE 150mg TABLETS (Free of charge EAS)	R	For the treatment of Duchenne's muscular dystrophy in those patients registered on the national Exceptional Access Scheme (ExAS) only. NB: each request should be ordered on a case-by-case basis via a SharePoint request for each order and a Blueteq number. MMTC, January 2018
--	---	--

11.06.00 Retinal disorders

CARBACHOL

CARBACHOL 3.0% EYE DROPS 10ml	NF	
-------------------------------	----	--

11.07 Local anaesthetics

11.07.00 Local anaesthetics

BENOXINATE (OXYBUPROCAINE)

OXYBUPROCAINE 0.4% MINIMS	Y	
---------------------------	---	--

LIDOCAINE

LIDOCAINE 4% & FLUORESCEIN 0.25% MINIMS	Y	
---	---	--

PROXYMETACAINE

PROXYMETACAINE 0.5% EYE DROPS (MINIMS)	Y	
--	---	--

TRAVOPROST

TRAVOPROST EYE DROPS 2.5ml	R	Second line prostaglandin analogue for the treatment of glaucoma and ocular hypertension as per the OUH-OCCG treatment guideline. MMTC, August 2017
----------------------------	---	---

11.07.00.00 Local anaesthesia

LIDOCAINE

LIDOCAINE 5% & PHENYLEPHRINE 0.5% TOPICAL SOLUTION 2.5ml	Y
--	---

TETRACAINE

TETRACAINE 1% EYE DROPS (MINIMS)	Y
----------------------------------	---

15.02 Anaesthesia

TETRACAINE

TETRACAINE 0.5% EYE DROPS (MINIMS)	Y
------------------------------------	---

11.08 Miscellaneous ophthalmic preparations

Acetylcholine

ACETYLCHOLINE CHLORIDE 20mg INTRAOCULAR IRRIGATION AMPOULES	Y
---	---

11.08 Miscellaneous ophthalmic preparations

DISODIUM EDETATE

DISODIUM EDETATE 0.37% SOLUTION 20ml (PRES FREE)	SR	For Ophthalmology use only. Medicines Effectiveness, May 2013.
--	----	--

11.08.00 Miscellaneous ophthalmic pre

POLYHEXAMETHYLENE BIGUANIDE

POLYHEXAMETHYLENE BIGUANIDE 0.02% EYE DROPS	SR	For use by Ophthalmology only. Medicines Effectiveness, January 2014.
---	----	---

11.08.00 Miscellaneous ophthalmic preparations

CARMELLOSE

CARMELLOSE 1% EYE DROPS 0.4ml (30)	R	For use by Ophthalmology only. Medicines Effectiveness, March 2013.
------------------------------------	---	---

CICLOSPORIN

CICLOSPORIN 1mg/ml UNIT DOSE EYE DROPS 0.3mlR (30)		For treating dry eye disease that has not improved despite treatment with artificial tears as per NICE TA369. Initiation by consultant ophthalmologist only. MMTC, April 2016
DISODIUM EDETATE		
DISODIUM EDETATE EYE DROPS 0.37% 10ml	SR	For Ophthalmology use only. Medicines Effectiveness, May 2013.
MYDRICAINE		
MYDRICAINE No2 INJECTION	SR	For use by Ophthalmology only. Medicines Effectiveness, November 2013.
NATAMYCIN		
NATAMYCIN 5% EYE DROPS 15ml	UNR	For proven or suspected or fungal keratitis infections. Restricted to consultant ophthalmology and/or microbiology/infectious diseases physician prescribing or recommendation only. MMTC June 2019
OCRIPLASMIN		
OCRIPLASMIN 500microgram IN 0.2ml INTRAVITREALR INJECTION		For vitreomacular traction on advice of a consultant ophthalmologist in line with NICE TA297. MMTC, January 2014.
POLYHEXAMETHYLENE BIGUANIDE		
POLYHEXAMETHYLENE BIGUANIDE (POLIHEXANIDE) 0.06% EYE DROPS	SR	For use by Ophthalmology only. Medicines Effectiveness, January 2014.
Sodium acetate		
SODIUM CHLORIDE 5% EYE OINTMENT (Preservative free)	NF	
SODIUM HYALURONATE		
SODIUM HYALURONATE 0.2% EYE DROPS (PRES FREE) 10ml	Y	
SODIUM HYALURONATE 0.1% EYE DROPS (PRES FREE) 10ml	Y	
VERTEPORFIN		
VERTEPORFIN 15mg INJECTION	R	Restricted for Central Serous Chorioretinopathy, Medicines Effectiveness 2018

VISCOTEARS

CARBOMER 980 0.2% LIQUID GEL 10g Y

11.08.01 Tear deficiency, ocular lubricants and astringents

LIQUID PARAFFIN

LIQUID PARAFFIN EYE OINTMENT Y

11.08.01 Tear deficiency, ocular lubricants, and astringents

ACETYLCYSTEINE

ACETYLCYSTEINE 5% EYE DROPS 10ml Y

ARTIFICIAL TEARS

ARTIFICIAL TEARS MINIMS Y

BALANCED SALT SOLUTION

BALANCED SALT SOLUTION 15ml Y

BALANCED SALT SOLUTION 500ml Y

BALANCED SALT SOLUTION PLUS 500ml Y

CARMELLOSE

CARMELLOSE 0.5% EYE DROPS 0.4ml (30) R For use by Ophthalmology only. Medicines Effectiveness, March 2013.

CARMELLOSE SODIUM 0.5% EYE DROPS 0.4ML TTO (30) SR For areas allowed to keep TTO packs. For use by Ophthalmology only. Medicines Effectiveness, March 2013.

CARMELLOSE 0.5% GLYCERINE 1% CASTOR OIL 0.25% EYE DROPS Y

CARMELLOSE 0.5% EYE DROPS 10ml (OPTIVE) Y

CATIONORM

CATIONORM PRESERVATIVE-FREE EYE DROPS 10ml Y

HYPROMELLOSE

HYPROMELLOSE 0.3% EYE DROPS 10ml UNR

HYPROMELLOSE 0.3% EYE DROPS TTO PACK 10ml SR For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.

LACRI-LUB

LACRI-LUBE EYE OINTMENT 3.5g Y

LIQUIFILM TEARS

LIQUIFILM TEARS EYE DROPS 15ml Y

LIQUIFILM TEARS UNIT DOSE EYE DROPS (PRES FREE) Y

LUBRI TEARS

LUBRI TEARS EYE OINTMENT 5g NF

SODIUM CHLORIDE

SODIUM CHLORIDE 5% EYE DROPS 10ml Y

SODIUM CHLORIDE 5% EYE DROPS PRES FREE 10ml Y

SODIUM CHLORIDE 0.9% EYE DROPS 10ml NF

SODIUM HYALURONATE + DEXPANTHENOL

SODIUM HYALURONATE 0.1% & DEXPANTHENOL 2% EYE DROPS 10ml NF

11.08.02 Ocular diagnostic and peri-operative preparations and photodynamic treatment

APRACLONIDINE

APRACLONIDINE 0.5% EYE DROPS 5ml Y

APRACLONIDINE 1% PRESERVATIVE FREE SOLUTION Y

BROMFENAC

BROMFENAC 0.09% EYE DROPS R For post-cataract extraction in patients at high risk of developing cystoid macular oedema (CMO). MMTC, August 2013.

DICLOFENAC

DICLOFENAC 0.1% EYE DROPS (Preservative free) R For patients requiring a preservative free NSAID eye drop. For all other patients recommend changing to Ketorolac eye drops. Medicines Effectiveness, January 2001.

FLUORESCEIN

FLUORESCEIN 2% EYE DROPS (MINIMS) Y

KETOROLAC

KETOROLAC 0.5% EYE DROPS 5ml Y

KETOROLAC 0.5% EYE DROPS TTO 5ml	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.
POVIDONE IODINE		
POVIDONE IODINE 5% OPHTHALMIC SOLUTION 4x20ml	SR	For pre-op in eye theatres only, Medicines Effectiveness, August 2018
POVIDONE IODINE 5% EYE DROPS (MINIMS) 0.4ml	R	For use in EYE O/Ps only. Medicines Effectiveness, Apr 2015.
RANIBIZUMAB		
RANIBIZUMAB 1.65mg in 0.165ml (10mg/ml) PRE-FILLED SYRINGE	R	For use by Consultant Ophthalmology in patients with age related macular degeneration as per NICE TA155; and treating choroidal neovascularisation associated with pathological myopia NICE TA298. Also approved for use as per other NICE TAs following the completion of a NICE implementation form (see PPDU SharePoint). MMTC, February 2014.
SIMPLE EYE		
SIMPLE EYE OINTMENT B.P 4g	Y	
SODIUM CHLORIDE		
SODIUM CHLORIDE 0.9% EYE DROPS (MINIMS)	Y	
SODIUM HYALURONATE		
SODIUM HYALURONATE 18mg in 1ml (0.85ml) G.V INJECTION	Y	
SODIUM HYALURONATE 23mg in 1ml (0.6ml) INJECTION	Y	
SODIUM HYALURONATE 10mg in 1ml (0.55ml) INJECTION (PROVISC)	Y	
SODIUM HYALURONATE 0.18% EYE DROPS SINGLE USE 0.3ml (20sach)	R	For use by Ophthalmology only. Medicines Effectiveness, September 2006.
SODIUM HYALURONATE 10mg in 1ml (0.85ml) INJECTION	Y	

11.08.02 Ocular diagnostic and peri-operative preparations and photodynamic treatments

FLUORESCEIN

FLUORESCEIN 10% INJECTION 5ml	UNR	Restricted to angiography (eye) and confocal endomicroscopy, Fluorescent guided neurosurgery for visualisation of brain tumour and tumour vessels in adult patients. MMTC, December 2021.
FLUORESCEIN 10% INJECTION 5ml	R	Restricted to angiography (eye) and confocal endomicroscopy, Fluorescent guided neurosurgery for visualisation of brain tumour and tumour vessels in adult patients. MMTC, December 2021.

12 Ear, nose, and oropharynx

12.01 Drugs acting on the ear

Fluticasone

FLUTICASONE PROPIONATE 400micrograms NASAL R DROPS 0.4ml UNITS

For the treatment of oral mucosal diseases following recommendation by oral medicine or dermatology. Also available for use by ENT surgery. MMTC, January 2017

12.01.01 Otitis externa

ALUMINIUM ACETATE

ALUMINIUM ACETATE 13% EAR DROPS 10ml

SR For inflammation in otitis externa. Medicines Effectiveness, January 2014.

BORIC ACID

POVIDONE IODINE 1% w/w in BORIC ACID POWDER 5g

UNR For Otitis Externa. Medicines Effectiveness, March 2013.

CHLORAMPHENICOL

CHLORAMPHENICOL 5% EAR DROPS 10ml

Y As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by:
- Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.

GENTAMICIN

GENTAMICIN HC EAR DROPS 10ml

Y

LOCORTEN-VIOFORM

LOCORTEN-VIOFORM EAR DROPS 7.5ml Y

OTOMIZE EAR

OTOMIZE EAR SPRAY 5ml Y

SOFRADEX

SOFRADEX EAR/EYE DROPS 8ml TTO PACK SR For areas allowed to keep TTO packs.

SOFRADEX EAR/EYE DROPS 8ml Y

12.01.03 Removal of ear wax

OLIVE OIL

OLIVE OIL 92ml Y

SODIUM BICARBONATE

SODIUM BICARBONATE 5% EAR DROPS B.P 10ml Y

12.02 Drugs acting on the nose

12.02.00 Drugs acting on the nose

SODIUM CHLORIDE

SODIUM CHLORIDE 0.9% NASAL DROPS 10ml Y

12.02.00 Drugs for the treatment of soft-tissue disorders and topical pain relief

GLUCOSE

GLUCOSE 25% and GLYCEROL Nasal drops 30ml Y

12.02.01 Drugs used in nasal allergy

BECLOMETASONE

BECLOMETASONE AQUEOUS 50micrograms/DOSE NASAL SPRAY Y

FLUTICASONE

FLUTICASONE FUROATE 27.5microgram NASAL SPRAY NF

FLUTICASONE 50microgram AQUEOUS NASAL SPRAY NF

MOMETASONE

MOMETASONE 50microgram NASAL SPRAY R For 2nd line use after beclomethasone nasal spray. Medicines Effectiveness, January 2001.

12.02.02 Topical nasal decongestants

FLUTICASONE

FLUTICASON PROPIONATE 400microgram/0.4ml NASULES TTO 28'S	SR	For areas allowed to keep TTO packs. For initiation by chest physician only. Medicines Effectiveness, November 2004.
--	----	---

IPRATROPIUM

IPRATROPIUM BROMIDE 21microgram/dose NASAL SPRAY	Y	
---	---	--

SODIUM CHLORIDE

SODIUM CHLORIDE 0.9% NASAL SPRAY 100ml	Y	
--	---	--

TRIAMCINOLONE

TRIAMCINOLONE 55microgram NASAL SPRAY 120 DOSE	NF	
---	----	--

XYLOMETAZOLINE

XYLOMETAZOLINE 0.05% DROPS 10ml (paediatric)	Y	
--	---	--

XYLOMETAZOLINE 0.1% NASAL DROPS 10ml	Y	
--------------------------------------	---	--

XYLOMETAZOLINE 0.1% NASAL SPRAY 10ml	Y	
--------------------------------------	---	--

12.02.03 Nasal preparations for infection

MUPIROCIN

MUPIROCIN 2% NASAL OINTMENT 3g	Y	
--------------------------------	---	--

NASEPTIN

NASEPTIN NASAL CREAM 15g	Y	
--------------------------	---	--

NASEPTIN NASAL CREAM 15g TTO PACK	SR	For areas allowed to keep TTO packs. Medicines Effectiveness, March 2013.
-----------------------------------	----	---

12.02.03Nasal preparations for infection

MUPIROCIN

MUPIROCIN 2% NASAL OINTMENT TTO PACK 3g	SR	To be used in areas allowed to use TTO packs only Medicines Effectiveness, June 2021
---	----	--

12.03.01 Drugs used in nasal allergy

BUDESONIDE

BUDESONIDE 64micrograms/DOSE NASAL SPRAY 120DOSE	NF	
---	----	--

12.03 Drugs acting on the oropharynx

12.03.00 Drugs acting on the oropharynx

BIOXTRA

BIOXTRA DRY MOUTH SPRAY 50ml	R	For head and neck patients undergoing radiotherapy. Medicines Effectiveness, November 2017
MUCIN + XYLITOL		
SALIVA ORTHANA LOZENGES	NF	
<i>12.03.01 Drugs for oral ulceration and inflammation</i>		
BENZYDAMINE		
BENZYDAMINE 0.15% SPRAY 30ml	Y	
BENZYDAMINE 0.15% ORAL RINSE 300ml	Y	
CHOLINE SALICYLATE		
CHOLINE SALICYLATE 8.7% DENTAL GEL BP 15g	Y	
EPISIL		
EPISIL ORAL SPRAY 10ml (72 dose)	NF	
GELCLAIR		
GELCLAIR CONCENTRATED ORAL GEL SACHETS (21X15ml)	R	For use in Paediatric Haemato-oncology patients only. Medicines Effectiveness, September 2004.
HYDROCORTISONE		
HYDROCORTISONE SUCCINATE 2.5mg LOZENGES	Y	
ORABASE		
ORABASE ORAL PASTE 30g	Y	
<i>12.03.02 Oropharyngeal anti-infective drugs</i>		
MICONAZOLE		
MICONAZOLE 20mg/g ORAL GEL 80g	Y	
MICONAZOLE ORAL GEL 15g	Y	
NYSTATIN		
NYSTATIN 100,000international units/ml LIQUID 30ml	R	First line for the treatment of oral thrush. ASG, March 2017
<i>12.03.04 Mouthwashes, gargles, and dentifrices</i>		
CHLORHEXIDINE		

CHLORHEXIDINE 0.2% MOUTHWASH 300ml PLAIN	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
CHLORHEXIDINE MINT 0.2% MOUTHWASH 300ml	Y	As per OUH Antimicrobial Guidelines. It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
HEXETIDINE		
HEXETIDINE 0.1% MOUTHWASH 200ml	Y	
MOUTHWASH TABLETS		
MOUTHWASH TABLETS (100)	Y	
<i>12.03.05 Treatment of dry mouth</i>		
BIOXTRA		
BIOXTRA TOOTHPASTE 50ml	R	For head and neck patients undergoing radiotherapy. MMTC, July 2014.
BIOXTRA MOUTHWASH 250ml	R	For head and neck patients undergoing radiotherapy. MMTC, July 2014.
BIOXTRA ORAL GEL 40ml	R	For head and neck patients undergoing radiotherapy. MMTC, July 2014.
ORALBALANCE		
ORALBALANCE SALIVA REPLACEMENT GEL 50g	Y	
PILOCARPINE		
PILOCARPINE 5mg TABLETS	NF	
SALIVA ORTHANA		
SALIVA ORTHANA ORAL SOLUTION 50ml	Y	
SST TABLETS		
SST TABLETS	NF	

Aminolevulinic acid hydrochloride

5-AMINOLEVULINIC ACID 78mg/g GEL R

DIPHENYLCYCLOPROPENONE

DIPHENYLCYCLOPROPENONE (DCP) 2% LIQUID SR Restricted for the topical treatment of alopecia areata, viral warts and in transit melanoma metastases by dermatology only. MMTC, February 2016

DIPHENYLCYCLOPROPENONE (DCP) 0.075% LIQUID SR Restricted for the topical treatment of alopecia areata, viral warts and in transit melanoma metastases by dermatology only. MMTC, February 2016

DIPHENYLCYCLOPROPENONE (DCP) 1.5% LIQUID SR Restricted for the topical treatment of alopecia areata, viral warts and in transit melanoma metastases by dermatology only. MMTC, February 2016

DIPHENYLCYCLOPROPENONE (DCP) 1% LIQUID SR Restricted for the topical treatment of alopecia areata, viral warts and in transit melanoma metastases by dermatology only. MMTC, February 2016

DIPHENYLCYCLOPROPENONE (DCP) 0.025% LIQUID SR Restricted for the topical treatment of alopecia areata, viral warts and in transit melanoma metastases by dermatology only. MMTC, February 2016

DIPHENYLCYCLOPROPENONE (DCP) 1.25% LIQUID SR Restricted for the topical treatment of alopecia areata, viral warts and in transit melanoma metastases by dermatology only. MMTC, February 2016

DIPHENYLCYCLOPROPENONE (DCP) 0.25% LIQUID SR	Restricted for the topical treatment of alopecia areata, viral warts and in transit melanoma metastases by dermatology only. MMTC, February 2016
DIPHENYLCYCLOPROPENONE (DCP) 1.75% LIQUID SR	Restricted for the topical treatment of alopecia areata, viral warts and in transit melanoma metastases by dermatology only. MMTC, February 2016
DIPHENYLCYCLOPROPENONE (DCP) 2.5% LIQUID SR	Restricted for the topical treatment of alopecia areata, viral warts and in transit melanoma metastases by dermatology only. MMTC, February 2016
DIPHENYLCYCLOPROPENONE (DCP) 0.001% LIQUID	SR Restricted for the topical treatment of alopecia areata, viral warts and in transit melanoma metastases by dermatology only. MMTC, February 2016
DIPHENYLCYCLOPROPENONE (DCP) 0.01% LIQUID SR	Restricted for the topical treatment of alopecia areata, viral warts and in transit melanoma metastases by dermatology only. MMTC, February 2016
DIPHENYLCYCLOPROPENONE (DCP) 0.1% LIQUID SR	Restricted for the topical treatment of alopecia areata, viral warts and in transit melanoma metastases by dermatology only. MMTC, February 2016
DIPHENYLCYCLOPROPENONE (DCP) 0.75% LIQUID SR	Restricted for the topical treatment of alopecia areata, viral warts and in transit melanoma metastases by dermatology only. MMTC, February 2016
DIPHENYLCYCLOPROPENONE (DCP) 0.05% LIQUID SR	Restricted for the topical treatment of alopecia areata, viral warts and in transit melanoma metastases by dermatology only. MMTC, February 2016

DIPHENYLCYCLOPROPENONE (DCP) 0.5% LIQUID SR

Restricted for the topical treatment of alopecia areata, viral warts and in transit melanoma metastases by dermatology only. MMTTC, February 2016

POTASSIUM HYDROXIDE

POTASSIUM HYDROXIDE 20% SOLUTION 10ml Y

SULPHUR

SULPHUR 2% IN AQUEOUS CREAM 100g Y

13.00 Skin

13.00.00 Skin

PHENOL

PHENOL 89% SWAB (30) << Y

13.01 Management of skin conditions

DUPILUMAB

HC DUPILUMAB 300mg in 2ml PRE-FILLED SYRINGE R

For treatment of moderate to severe atopic dermatitis in adults as per NICE TA534 and in adolescents aged 12 to 17 years. MMTTC September 2019

13.01.00 Management of skin conditions

DUPILUMAB

DUPILUMAB 300mg in 2ml PRE-FILLED PEN (ExAS - NF
ASTHMA)

***** For Issue to Chest Clinic patients only. NOT dopd - for these patients use DHA403 *****
CW 20/2/19

DUPILUMAB 300mg IN 2ml PRE-FILLED SYRINGE R

For treatment of moderate to severe atopic dermatitis in adults as per NICE TA534 and in adolescents aged 12 to 17 years. MMTTC September 2019

DUPILUMAB 300mg in 2ml PRE-FILLED SYRINGE (SEVERE ASTHMA 7EC) NF

DUPILUMAB 300mg IN 2ml PRE-FILLED SYRINGE (COMPASSIONATE USE) NF

DUPILUMAB 300mg in 2ml PRE-FILLED PEN (SEVERE ASTHMA 7EC) NF

13.02 Emollient and barrier preparations

13.02.01 Emollients

AQUEOUS CREAM

AQUEOUS CREAM 500g	Y	
AQUEOUS CREAM 100g	Y	
ARACHIS OIL		
ARACHIS OIL 200ml	Y	
BALNEUM		
BALNEUM PLUS CREAM 500g	NF	
BALNEUM PLUS		
BALNEUM PLUS Bath Oil 500ml	Y	
CETOMACROGOL CREAM		
CETOMACROGOL CREAM BP (FORMULA A) 500g	Y	
CETRABEN CREAM		
CETRABEN CREAM 150g	Y	
DERMOL		
DERMOL 500 LOTION 500ml	R	Restricted to Dermatology only. Medicines Effectiveness, March 2013.
DERMOL 600 BATH EMOLLIENT	NF	
DIPROBASE		
DIPROBASE CREAM 50g	Y	
DIPROBASE CREAM 500g	Y	
DRAPOLENE CREAM		
DRAPOLENE CREAM 100g	Y	
E45 BATH		
E45 BATH OIL 500ml	Y	
E45 CREAM		
E45 CREAM 500g	Y	
E45 CREAM 50g	Y	
EMULSIDERM EMULSION		
EMULSIDERM EMULSION LIQUID 300ml	Y	
EMULSIFYING OINTMENT		

EMULSIFYING OINTMENT BP 500g	Y	
ENOPEN		
ENOPEN CREAM 500g	Y	
ENOPEN CREAM		
ENOPEN CREAM 50g	Y	
EPADERM		
EPADERM CREAM 500G	NF	
EPADERM OINTMENT 500g	NF	
FLAMINAL FORTE GEL		
FLAMINAL FORTE GEL 50g	R	Restricted to prescribing by and on advice of Tissue Viability Team only. MMTC October 2019
HYDROMOL		
HYDROMOL OINTMENT 500g	R	Second-line use after aqueous cream or emulsifying ointment. Medicines Effectiveness, June 2007.
HYDROMOL OINTMENT 125g	R	Second-line use after aqueous cream or emulsifying ointment. Medicines Effectiveness, June 2007.
LIQUID PARAFFIN		
ZEROBASE (LIQUID PARAFFIN) CREAM 500g	NF	
LIQUID PARAFFIN + WHITE SOFT PARAFFIN		
LIQUID PARAFFIN 50% & WHITE SOFT PARAFFIN 50% SPRAY 240ml	R	For treatment of exceptionally painful skin and children with severe eczema on Dermatology recommendation only. If the patient gets supplied 100g or more, details of the Paraffin Alert must be issued (flammable). MAC, June 2009.
LUBRICATING		
LUBRICATING JELLY STERILE 5g SACHETS (TEMP PROCUREMENT SUPPLY)	Y	
LUBRICATING JELLY		
LUBRICATING JELLY 42g (AQUAGEL)	R	Only for X-ray. Medicines Effectiveness, January 2012.

LUBRICATING JELLY 42g (OPTILUBE) Y

LUBRICATING JELLY STERILE 5g SACHETS Y

OILATUM

OILATUM EMOLLIENT 500ml Y

OILATUM PLUS BATH ADDITIVE 500ml Y

PARAFFIN

PARAFFIN YELLOW SOFT 15g (TEMP
PROCUREMENT SUPPLY) Y

PARAFFIN YELLOW SOFT 15g Y

PARAFFIN LIQUID 50% in WHITE SOFT PARAFFIN
250g Y

UNGUENTUM

UNGUENTUM CREAM 50g Y

WOOL FAT

WOOL FAT HYDROUS OINTMENT BPC 500g NF

ZINC OXIDE

ZINC & CASTOR OIL OINTMENT 500g Y

ZINC OXIDE OINTMENT Y

13.02.02 Barrier preparations

KERI LIQUID

KERI LIQUID 380ml (NF) NF

METANIUM

METANIUM OINTMENT 30g Y

SIOPEL CREAM

SIOPEL CREAM 50g Y

13.03 Topical local anaesthetics and antipruritics

13.03.00 Topical local anaesthetics and antipruritic

CROTAMITON

CROTAMITON 10% CREAM 30g Y

13.03.00 Topical local anaesthetics and antipruritics

CALAMINE

CALAMINE LOTION 200ml Y

MENTHOL

MENTHOL 1% IN AQUEOUS CREAM 100g Y

13.04 Topical corticosteroids

HYDROCORTISONE

HC HYDROCORTISONE 2.5% CREAM 15g NF

13.04.00 Topical corticosteroids

FLUTICASONE

FLUTICASONE PROPIONATE 15g CREAM Y

13.04.00 Corticosteroids

BETAMETHASONE

BETNOVATE C OINTMENT 30g Y

VIOFORM HYDROCORTISONE

VIOFORM HYDROCORTISONE OINTMENT 30g Y

13.04.00 Topical circulatory preparations

ACTISORB

ACTISORB SILVER 10.5cm X 10.5cm DRESSINGS (220) NF

13.04.00 Topical corticosteroids

HYDROCORTISONE

HYDROCORTISONE 0.5% CREAM 30g Y

13.04.00 Topical corticosteroids

BETAMETHASONE

BETNOVATE-C CREAM 30g Y

BETNOVATE-N CREAM 30g Y

BETAMETHASONE 0.1% OINTMENT 30g Y

BETAMETHASONE 0.1% CREAM 30g Y

BETAMETHASONE 0.1% SCALP APPLICATION 100ml Y

BETAMETHASONE RD 0.025% CREAM 100g Y

BETAMETHASONE RD 0.025% OINTMENT 100g Y

BETAMETHASONE 0.1% OINTMENT 100g Y

CLOTRIMAZOLE

CLOTRIMAZOLE & HYDROCORTISONE 1% CREAM 30g Y

DAKTACORT

DAKTACORT OINTMENT 30g Y

DAKTACORT CREAM 30g Y

DERMOVATE

DERMOVATE 0.05% OINTMENT 100g Y

DERMOVATE 0.05% SCALP APPLICATION 30ml Y

DERMOVATE 0.05% CREAM 30g Y

DERMOVATE 0.05% OINTMENT 30g Y

DERMOVATE 0.05% SCALP APPLICATION 100ml Y

CLOBETASOL 0.05%, NEOMYCIN 0.5% & NYSTATIN 100,000units OINTMENT 30g Y

DERMOVATE 0.05% CREAM 100g Y

DIPROSALIC

DIPROSALIC SCALP APPLICATION 100ml Y

DIPROSALIC OINTMENT 30g Y

EUMOVATE

EUMOVATE CREAM 100g Y

EUMOVATE OINTMENT 100g Y

EUMOVATE OINTMENT 30g Y

EUMOVATE CREAM 30g Y

EURAX-HYDROCORTISONE

EURAX-HYDROCORTISONE CREAM 30g Y

FLUDROXYCORTIDE

FLUDROXYCORTIDE 7.5cm X 20cm TAPE (HAELAN) Y

FLUOCINOLONE

FLUOCINOLONE ACETONIDE 0.025% GEL 30g Y

FLUOCINOLONE ACETONIDE 0.025% CREAM 30g Y

FUCIBET

FUCIBET 30g CREAM Y

FUCIDIN H

FUCIDIN H CREAM 30g Y

HYDROCORTISONE

HYDROCORTISONE 1% OINTMENT 15g Y

HYDROCORTISONE 1% CREAM 15g Y

HYDROCORTISONE BUTYRATE 0.1% LIPOCREAM 30g Y

HYDROCORTISONE 2.5% CREAM 15g NF

TIMODINE

TIMODINE CREAM 30g Y

TRIMOVATE

TRIMOVATE CREAM 30g Y

13.04.00 Topical corticosteroids

BETAMETHASONE

BETAMETHASONE 0.1% CREAM 100g Y

13.10.00 Anti-infective skin preparations

BETAMETHASONE

BETNOVATE-N OINTMENT 100g NF

BETAMETHASONE 0.1% LOTION 100ml Y

CROTAMITON

CROTAMITON 10% LOTION 100ml Y

FLUOCINOLONE

FLUOCINOLONE ACETONIDE 0.0025% CREAM 50g Y

HYDROCORTISONE

HYDROCORTISONE BUTYRATE 0.1% SCALP APPLICATION NF

LOTRIDERM CREAM

LOTRIDERM CREAM 30g

Y

TRIADCORTYL

TRIADCORTYL OINTMENT 4g

SR

For use by ENT only for otitis externa and mastoid cavity infections. MMTC, November 2013

13.05 Preparations for eczema and psoriasis

RISANKIZUMAB 360mg/2.4ML INJECTION

R

For previously treated moderately to severely active Crohn's disease as per NICE TA888. MMTC, Feb 2024

Bimekizumab

BIMEKIZUMAB 160mg/1ml SOLUTION FOR INJ PRE-FILLED SYRINGE

R

For treatment of plaque psoriasis in adults as per NICE TA723. For treatment of active ankylosing spondylitis as per NICE TA918. For treating active psoriatic arthritis as per NICE TA916. MMTC, March 2024.

BIMEKIZUMAB 160mg in 1ml PRE FILLED PEN

R

For treatment of active ankylosing spondylitis as per NICE TA918. For treating active psoriatic arthritis as per NICE TA916 MMTC March 2024

Mirikizumab

MIRIKIZUMAB 300mg in 15ml INJECTION

NICE

Risankizumab

RISANKIZUMAB 600mg INJECTION

NICE

NICE TA888 for Crohn's only, not yet been to MMTC individual use only 19/12/23

RISANKIZUMAB 600mg INJECTION

R

For previously treated moderately to severely active Crohn's disease as per TA888. MMTC, Feb 2024

Secukinumab

SECUKINUMAB 300mg in 2ml PRE FILLED PEN

R

?For treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults as per NICE TA935. MMTC, Feb 2024

13.05 Preparations for eczema and psoriasis

METHOXYPORALEN

METHOXYPORALEN 10mg TABLETS (8 MOP) UNR For use by Dermatology for PUVA treatment only. Medicines Effectiveness, March 2013.

13.05.00 Preparations for eczema an

CALCIPOTRIOL

CALCIPOTRIOL 50MCG/G WITH BETAMETHASONE 0.05% FOAM 60g R For the treatment of psoriasis following recommendation by dermatology only. MMTC, October 2017

CALCIPOTRIOL + BETAMETHASONE

CALCIPOTRIOL 50micrograms/gram & BETAMETHASONE 0.05% foam 120g R

13.05.00 Preparations for eczema and psoriasis

ACITRETIN

ACITRETIN 25mg CAPSULES Y

ACITRETIN 10mg CAPSULES Y

ALITRETINOIN

ALITRETINOIN 30mg CAPSULES R Dermatology consultants only. For the treatment of severe chronic hand eczema as per NICE TA177. MAC, February 2011.

ALITRETINOIN 10mg CAPSULES R Dermatology consultants only. For the treatment of severe chronic hand eczema as per NICE TA177. MAC, February 2011.

ALPHOSYL

ALPHOSYL SHAMPOO 125ml Y

CALCIPOTRIOL + BETAMETHASONE

CALCIPOTRIOL 0.005% / BETAMETHASONE 0.05% OINTMENT 30g NF

DIMETHYL FUMARATE

DIMETHYL FUMARATE 30MG TABLETS	R	For the treatment of: - Psoriatic arthritis as per NICE TA220; - Rheumatoid arthritis as per TA233; - Ankylosing spondylitis as per TA233; -Spondyloarthritis as per NICE TA497; -Ulcerative colitis as per NICE TA329. MMTC, December 2018
DIMETHYL FUMARATE 120mg TABLETS	R	For the treatment of moderate to severe plaque psoriasis as per NICE TA475. MMTC, December 2017
DITHRANOL		
DITHRANOL 5% in LASSARS PASTE 50g	R	For Dermatology use only. Medicines Effectiveness, January 2009.
DITHRANOL 3% IN LASSARS PASTE 50g	R	For Dermatology use only. Medicines Effectiveness, January 2009.
DITHRANOL 2% in LASSARS PASTE 100g	R	Restricted to Dermatology only. Medicines Effectiveness, January 2009.
DITHRANOL 1% in LASSARS PASTE 100g	R	Restricted to Dermatology only. Medicines Effectiveness, January 2009.
DITHRANOL 0.5% in LASSARS PASTE 100g	R	Restricted to Dermatology only. Medicines Effectiveness, January 2009.
DITHRANOL 0.25% in LASSARS PASTE 100g	R	Restricted to Dermatology only. Medicines Effectiveness, January 2009.
DITHRANOL 0.5% CREAM 50g	Y	
DITHRANOL 0.1% in LASSARS PASTE 50g	R	Restricted to Dermatology only. Medicines Effectiveness, January 2009.
DITHRANOL 0.1% CREAM 50g	Y	
DITHROCREAM		
DITHRANOL 2% CREAM 50g	Y	

DITHRANOL 1% CREAM 50g	Y	
DOVONEX		
DOVONEX 30g OINTMENT	Y	
DUPILUMAB		
DUPILUMAB 200mg in 1.14ml PRE-FILLED SYRINGE (DOPD only)	R	For treatment of moderate to severe atopic dermatitis in adults as per NICE TA534 and in adolescents aged 12 to 17 years. MMTC September 2019
EXOREX		
EXOREX LOTION 250ml	Y	
GUSELKUMAB		
GUSELKUMAB 100mg IN 1ml PRE-FILLED PEN	R	Restricted for treatment of psoriasis as per NICE TA52. MMTC September 2018
METHOXYPORALEN		
METHOXSALEN 0.005% GEL 50g	SR	For use by Dermatology for PUVA treatment only. Medicines Effectiveness, March 2013.
METHOXYPOROLEN		
METHOXYPOROLEN 20mg TABLETS (5-MOP)	UNR	For use by Dermatology for PUVA treatment only. Medicines Effectiveness, March 2013.
Mirikizumab		
MIRIKIZUMAB 100mg in 1ml PRE FILLED PENS	NICE	As per NICE TA 925
MOMETASONE		
MOMETASONE FUROATE 0.1% OINTMENT 100g	Y	
MOMETASONE FUROATE 0.1% OINTMENT 30g	Y	
PIMECROLIMUS		
PIMECROLIMUS 1% CREAM 30g	R	For moderate atopic eczema on the face and neck of children aged 2-16yrs in line with NICE TA 82. MMTC, March 2013
RISANKIZUMAB		
RISANKIZUMAB 75mg PRE-FILLED SYRINGE	R	For treatment of severe plaque psoriasis in adults as per NICE TA596. MMTC September 2019

SECUKINUMAB

SECUKINUMAB 150mg PRE-FILLED PEN	R	For treatment of: Ankylosing spondylitis TA407; Moderate to severe plaque psoriasis as per NICE TA350; Psoriatic arthritis as per NICE TA445 . MMTC, July 2017
----------------------------------	---	--

13.05.02 Preparations for psoriasis

CALCIPOTRIOL + BETAMETHASONE

CALCIPOTRIOL 0.005% / BETAMETHASONE 0.05% GEL 60g	NF
---	----

CALCITRIOL

CALCITRIOL 3microgram/g OINTMENT 100g	NF
---------------------------------------	----

13.05.03 Drugs affecting the immune response

IXEKIZUMAB

IXEKIZUMAB 80mg PRE-FILLED PEN	R	For the treatment of: Plaque psoriasis in adults as per NICE TA442 ; Psoriatic arthritis in adults as per NICE TA537 MMTC, October 2018
--------------------------------	---	---

USTEKINUMAB

USTEKINUMAB 130mg IN 26ml INJECTION VIAL	R	For treatment of moderately to severely active Crohn's disease as per NICE TA456 MMTC September 2018
USTEKINUMAB 45mg in 0.5ml PRE-FILLED SYRINGE	R	For the treatment of: - moderate to severe psoriasis, as per NICE TA180; - active psoriatic arthritis as per NICE TA340. MMTC, June 2017

13.05.03 Drugs affecting the immune response > Cytokine modulators

HC SECUKINUMAB

SECUKINUMAB 150mg PRE-FILLED SYRINGE	R	For treatment, Ankylosing spondylitis NICE TA407; Moderate to severe plaque psoriasis as per NICE TA350; Psoriatic arthritis as per NICE TA445; Moderate to severe plaque psoriasis in children and young people as per NICE TA734 MMTC, December 2021.
--------------------------------------	---	---

SECUKINUMAB

SECUKINUMAB 150mg IN 1ml PRE-FILLED PEN (FREE OF CHARGE) R

For treatment, Ankylosing spondylitis NICE TA407; Moderate to severe plaque psoriasis as per NICE TA350; Psoriatic arthritis as per NICE TA445; Moderate to severe plaque psoriasis in children and young people as per NICE TA734 MMTC, December 2021.

USTEKINUMAB

USTEKINUMAB 90mg IN 1ml PRE-FILLED SYRINGE R

For the treatment of: Moderate to severe psoriasis as per NICE TA180 Active psoriatic arthritis as per NICE TA340 Moderately to severely active Crohn's disease as per NICE TA456, and moderately to severely active ulcerative colitis in adults as per NICE TA633. MMTC, November 2020

3.05.00 Preparations for eczema and psoriasis

DIMETHYL FUMARATE

DIMETHYL FUMARATE 120mg TABLETS (SKILARENCE) R

For the treatment of moderate to severe plaque psoriasis as per NICE TA475. MMTC, December 2017

or eczema and psoriasis

COCOIS

COCONUT OIL COMPOUND SCALP APPLICATION 100g R

For use by Dermatology only. Medicines Effectiveness, March 2013.

ZINC OXIDE

ZINC & SALICYCLIC ACID PASTE 50% in WHITE SOFT PARAFFIN 100g Y

Preparations for eczema and psoriasis

MOMETASONE

MOMETASONE FUROATE 0.1% CREAM 30g Y

13.06 Acne and rosacea

13.06 Acne and rosacea

DIANETTE

DIANETTE TABLETS Y

13.06.00 Acne and rosacea

ADAPALENE + BENZOYL PEROXIDE

ADAPALENE 0.1% / BENZOYL PEROXIDE 2.5% GEL NF
45g

CLINDAMYCIN

CLINDAMYCIN 1% AQUEOUS LOTION 60ml Y

CLINDAMYCIN AQUEOUS LOTION 30ml Y

COAL TAR

CAPASAL 250ml SHAMPOO Y

ERYTHROMYCIN

ERYTHROMYCIN 4% GEL NF

ISOTRETINOIN

ISOTRETINOIN 40mg CAPSULES NF

ISOTRETINOIN 20mg CAPSULES (BEACON BRAND) Y

TRETINOIN

TRETINOIN 0.025% CREAM (RETIN-A) 60g Y

13.06.01 Topical preparations for acne

AZELAIC ACID

AZELAIC ACID 20% CREAM 30g Y

13.07 Preparations for warts and calluses

13.0.00reparations for

TRICHLOROACETIC

TRICHLOROACETIC ACID 90% SOLUTION 10ML SR

For the treatment of anogenital warts by specialist healthcare professionals in sexual health services only. Medicines Effectiveness, October 2016

13.05.00 Preparations for eczema and psoriasis

ISOTRETINOIN

ISOTRETINOIN 5mg CAPSULES (ALLIANCE-BEACON) Y

13.07.00 Preparations for warts and calluses

Imiquimod

IMIQUIMOD 5% CREAM SACHETS	UNR	Only to be use if DGI344 is unavailable? For superficial basal cell carcinoma; and GUM consultant or associate specialist initiation for patients with recalcitrant external anogenital warts. MAC, October 2007.
IMIQUIMOD 5% CREAM (12x250mg SACHETS)	R	For superficial basal cell carcinoma OR for patients with recalcitrant external anogenital warts (initiation by GUM consultants only) . MAC, October 2007.
PODOPHYLLOTOXIN		
PODOPHYLLOTOXIN 0.5% SOLUTION 3ml	Y	
PODOPHYLLOTOXIN 0.15% CREAM 5g	Y	
SALACTOL		
SALACTOL PAINT	Y	
SALATAC		
SALATAC GEL 8g	Y	
SILVER NITRATE		
SILVER NITRATE APPLICATORS 75%	Y	
<i>13.08 Sunscreens and camouflagers</i>		
<i>13.08.01 Sunscreen prepara</i>		
ANTHELIOS		
ANTHELIOS SUNCREAM SPF50+ CREAM 50ml	R	For photosensitivity from genetic disorders or photodermatosis following recommendation by Dermatology only. MMTC, October 2015
<i>13.08.01 Sunscreen preparations</i>		
DAILY FACE		
DAILY FACE SPF60 CREAM 75g	NF	
E45 SUN		
E45 SUN LOTION Spf25 150ml	Y	
METHY-5-AMINOLEVULINATE		
METHY-5-AMINOLEVULINATE 160mg/g CREAM 2g	R	For use by Dermatology for PUVA treatment only. Medicines Effectiveness, September 2008.

P20 SPF50 SUNSCREEN LOTION

P20 SPF50 SUNSCREEN LOTION SAMPLES	R	Second line sunscreen in those undergoing photodynamic therapy (PDT) only. For dermatology use only. MMTC, January 2018
------------------------------------	---	---

REFLECTANT

REFLECTANT SUNSCREEN (COFFEE) CREAM 50g	NF
---	----

SUNSENSE

SUNSENSE ULTRA SPF60 MILK (NF)	NF
--------------------------------	----

13.08.02 Camouflagers

PIGMANORM

PIGMANORM CREAM 15g	UNR	For use by Dermatology only. Medicines Effectiveness, March 2013.
---------------------	-----	---

13.09 Shampoos and other preparations for scalp and hair conditions

13.09.00 Shampoos and other preparations for scalp and hair conditions

COCOIS

COCOIS SCALP OINTMENT 100g	R	For use by Dermatology only. Medicines Effectiveness, March 2013.
----------------------------	---	---

3.09.00 Shampoos and other preparations for scalp and hair conditions

EFLORNITHINE

EFLORNITHINE 11.5% CREAM 60g	NF
------------------------------	----

SELENIUM SULFIDE

SELSUN SHAMPOO 150ml	Y
----------------------	---

13.10 Anti-infective skin preparations

13.10 Anti-infective skin preparations

DIMETICONE

DIMETICONE 4% LOTION 50ml	Y
---------------------------	---

13.10.00 Anti-infective skin preparations

BISMUTH + IODOFORM

BISMUTH & IODOFORM PASTE BPC 30g	Y
----------------------------------	---

SODIUM FUSIDATE

SODIUM FUSIDATE 2% OINTMENT 30g	Y
---------------------------------	---

13.10.01 Antibacterial preparations

FUSIDIC ACID

FUSIDIC ACID 2% CREAM 15g Y

GENTAMICIN

GENTAMICIN 0.1% CREAM 15g UNR For Tenckhoff catheter exit site infections. Medicines Effectiveness, March 2013.

METRONIDAZOLE

METRONIDAZOLE 0.75% GEL 40g (Metrogel) Y

METRONIDAZOLE 0.75% GEL 40g Y

MUPIROCIN

MUPIROCIN 2% OINTMENT 15g Y

PATCH TEST

FRAMYCETIN 20% IN 5ml FOR PATCH TEST Y

PHENOSEPT 1% IN W.S.P PATCH TEST Y

SILVER SULPHADIAZINE

SILVER SULFADIAZINE 1% CREAM 50g Y

13.10.02 Antifungal preparations

AMOROLFINE

AMOROLFINE 5% NAIL LACQUER 5ML NF

CLOTRIMAZOLE

CLOTRIMAZOLE 1% CREAM 20g Y

CLOTRIMAZOLE 1% SOLUTION 20ml Y

KETOCONAZOLE

KETOCONAZOLE 2% CREAM 30g R For seborrhoeic dermatitis and pityriasis versicolor. Medicines Effectiveness, March 2013.

KETOCONAZOLE 2% SHAMPOO 120ml Y

MICONAZOLE

MICONAZOLE POWDER 2% 20g Y

MICONAZOLE 2% CREAM 30g Y

TERBINAFINE

TERBINAFINE 1% CREAM 15g	R	This antimicrobial requires prescribing by: - Dermatology (adult + paediatric) consultant or registrar It is also available following approval/prescribing by: - Microbiology/ID consultant or registrar - Paediatric ID consultant or registrar Antimicrobials Steering Group, January 2012.
TIOCONAZOLE		
TIOCONAZOLE NAIL SOLUTION	NF	
<i>13.10.03 Antiviral preparations</i>		
ACICLOVIR		
ACICLOVIR 5% CREAM 2g	Y	
<i>13.10.04 Parasitocidal preparations</i>		
MALATHION		
MALATHION 0.5% LIQUID 150ml (DERBAC-M)	Y	
PERMETHRIN		
PERMETHRIN DERMAL CREAM 30g	Y	
PERMETHRIN 1% CREAM RINSE 59ml	Y	
PHENOTHRIN		
PHENOTHRIN 0.5% LIQUID 200ml	NF	
<i>13.10.05 Preparations for minor cuts and abrasions</i>		
HISTOACRYL		
HISTOACRYL 0.5ml TISSUE ADHESIVE CLEAR (TEMP PROCUREMENT SUPPLY)	Y	
HISTOACRYL TISSUE ADHESIVE 500mg in 0.5ml AMPOULE	Y	
HISTOACRYL TISSUE ADHESIVE BLUE 0.5ml	R	To secure paediatric epidurals. MMTC, August 2013.
MAGNESIUM SULPHATE		
MAGNESIUM SULPHATE PASTE 50g	Y	
<i>3.10.04 Parasitocidal preparations</i>		
PERMETHRIN		
PERMETHRIN 1% CREAM RINSE TWIN PACK	Y	
<i>13.11 Skin cleansers, antiseptics, and desloughing agents</i>		

DEQUALINIUM

DEQUALINIUM CHLORIDE 10mg VAGINAL TABLETS NF

HAEMOGLOBIN

HAEMOGLOBIN SPRAY 12ml (GRANULOX) NF

NORMASOL

NORMASOL SACHETS 25ml Y

13.11.00 Skin

BONNEY'S BLUE

BONNEY'S BLUE (Brilliant Green & Crystal Violet Paint UNR
10ml bottle, NON STERILE)

For marking the skin before an operation. Medicines Effectiveness, 2016.

CHLORHEXIDINE

CHLORHEXIDINE GLUCONATE 0.5%w/v in IPA CLEAR Y
SOLUTION 500ml (HIBI)

HYDROGEN PEROXIDE

HYDROGEN PEROXIDE 1% CREAM 25g R

For use by Dermatology only. Medicines Effectiveness, March 2013.

OCTENIDINE

OCTENIDINE LOTION 150ml (OCTENISAN) R

For decontamination of premature neonates where chlorhexidine cannot be used. Antimicrobials Steering Group, July 2010.

OCTENILINE

OCTENILINE IRRIGATION SOLUTION 350ml NF

TVN recommendation

POTASSIUM PERMANGANATE

POTASSIUM PERMANGANATE TABLETS Y

POVIDONE IODINE

POVIDONE IODINE ANTISEPTIC SOLUTION 500ml Y

POVIDONE IODINE ALCOHOLIC SOLUTION 500ml Y

POVIDONE IODINE 2.5% DRY POWDER SPRAY (BETADINE) 100ml Y

POVIDONE IODINE SURGICAL SCRUB 500ml Y

TISEPT

TISEPT SACHETS 25ml Y

13.11.00 Skin cleansers, antiseptics, and desloughing agents

CHLORHEXIDINE

CHLORHEXIDINE OBSTETRIC CREAM + DISPENSER Y
250ml

13.11.01 Alcohols and saline

IMS

IMS 70% SPRAY 200ml Y

13.11.02 Chlorhexidine salts

CHLORHEXIDINE

CHLORHEXIDINE GLUCONATE 1% SKIN WASH 150ml NF
(CEPTON)

TRAVASEPT

CHLORHEXIDINE ACETATE 0.015%, CETRIMIDE Y
0.15% 1L (TRAVASEPT 100) FKF7774

3.11.00 Skin cleansers, antiseptics and desloughing agents

OCTENIDINE

OCTENIDINE LOTION 500ML (OCTENISAN) R

13.12 Antiperspirants

13.12.00 Antiperspirants

GLYCOPYRRONIUM

GLYCOPYRRONIUM BROMIDE 0.05% SOLUTION IN UNR
WATER 500ml

For intractable hyperhidrosis.
Medicines Effectiveness, March
2013.

13.13 Topical circulatory preparations

13.13.00 Topical circulatory preparations

ALLEVYN

ALLEVYN LIFE 10.3cm x 10.3cm DRESSING R

Following recommendation by
Tissue Viability Team only. MAC,
October 2009.

HIRUDOID

HEPARINOID 0.3% CREAM 50g Y

PRONTOSAN

PRONTOSAN IRRIGATION SOLUTION 350ml R

Following recommendation by
the Tissue Viability team ONLY.
MAC, December 2009.

PRONTOSAN HYDROGEL

PRONTOSAN HYDROGEL WOUND GEL 50g	R	Following recommendation by the Tissue Viability team ONLY. MAC, December 2009
SORBION SANA		
SORBION SANA 12cm X 22cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
<i>13.13.08 Topical circulatory preparations</i>		
ACTIVHEAL		
ACTIV HEAL HYDROGEL 15g	Y	
BISMUTH + IODOFORM		
BISMUTH & IODOFORM GAUZE 1.25cm X 100cm (10)	Y	
GRANUFLEX		
GRANUFLEX PASTE 30g	R	Following recommendation by Tissue Viability Team MAC, October 2009.
IODOSORB		
IODOSORB OINTMENT 10g	R	Following recommendation by Tissue Viability Team. MAC, October 2009.
PURILON		
PURILON 15g GEL	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
SILICONE		
SILICONE GEL SHEET 15x12cm	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
SORBSAN		
SORBSAN PACKING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
ZINC OXIDE		
ZINC OXIDE 20% STOCKING	R	For use by Dermatology only. Medicines Effectiveness, March 2013.

14 Immunological products and vaccines

14.04 Vaccines and antisera

BCG (BACILLUS CALMETTE-GURIN)

BCG INTRADERMAL VACCINE 10 DOSE Y

DIPHTHERIA

DIPHTHERIA (adsorbed), TETANUS, PERTUSIS (Acellular), HEPATITIS B, POLIOMYELITIS and Y

DIPHTHERIA, TETANUS, PERTUSSIS (ACELLULAR, COMPONENT) AND INACTIVATED POLIOMYELITIS Y

DIPHTHERIA, TETANUS AND PERTUSSIS

Diphtheria, Tetanus, Acellular Pertussis & Inactivated Polio & ACT-HIB VACCINE PFS (Outbreak stock) R For issue to Occupational Health only. Medicines Effectiveness, Aug 2012

Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio & ACT-HIB VACCINE 0.5ml Y

DIPHTHERIA, TETANUS PERTUSSIS POLIOMYELITIS HAEMOPHILUS INFLUENZA B VACCINE Y

DIPHTHERIA, TETANUS AND POLIOMYELITIS

DIPHTHERIA, TETANUS AND POLIOMYELITIS VACCINE SYRINGE Y

FLU

FLU VACCINE NASAL SPRAY 0.2ml (FLUENZ FOR SNIFFLE STUDY) R For use by CDW only. For SNIFFLE study only. Medicines Effectiveness, October 2013.

FLU VACCINE

FLU VACCINE RECOMBINANT 0.5ml SYRINGE (FLUCELVAX TETRA) R To be aligned with EPR when decided.

HAEMOPHILLUS

HAEMOPHILLUS TYPE B + NEISSERIA MENINGITIDIS C VACCINE Y

HEPATITIS

HEPATITIS B VACCINE 40microgram IN 1ml INJECTION (FENDRIX) R For immunisation against Hepatitis B in patients with Chronic Kidney Disease in Oxford Kidney Unit. MMTc, November 2020

HEPATITIS A VACCINE 1ml SYRINGE (HAVRIX ADULT) Y

HEPATITIS A+B VACCINE SYRINGE (ADULT) 1ml Y

HEPATITIS A+B PAEDIATRIC VACCINE SYRINGE 0.5ml Y

HEPATITIS B PAEDIATRIC 0.5ml VACCINE (ENGERIX) Y

HEPATITIS B PAEDIATRIC VACCINE 5microgram in 0.5ml INJECTION (HB VAX PRO)	NF	
HEPATITIS B VACCINE 10microgram IN 1ml INJECTION (HB VAX PRO)	Y	
HEPATITIS B		
HEPATITIS B VACCINE 20microgram in 1ml PRE-FILLED SYRINGE (ENGERIX - PFS)	Y	
HEPATITIS B VACCINE		
HEPATITIS B VACCINE 40microgram IN 1ml INJECTION (HB VAX PRO)	NF	
HUMAN PAPILLOMA VIRUS VACCINE		
HUMAN PAPILLOMA VIRUS VACCINE (GARDASIL) 0.5ml PRE-FILLED SYRINGE (MSM STOCK)	R	For vaccination against Human Papillomavirus in Men who have sex with Men (MSM), as per Public Health England (PHE) guidance MMTC July 2018
INFLUENZA VACCINE ADJUVANTED QUADRIVALENT		
INFLUENZA VACCINE ADJUVANTED QUADRIVALENT 0.5ml SYRINGE (FLUAD TETRA)		R For patients' and staff members over the age of 65 years. MMTC, March 2018 WARNING - Risk of selection error due to similar flu vaccines - please check you are selecting the correct product. Medicines Effectiveness Sep 2021
MEASLES, MUMPS AND RUBELLA		
MEASLES, MUMPS AND RUBELLA VACCINE 0.5ml	Y	
MENINGOCOCCAL		
MENINGOCOCCAL GROUP B VACCINE (BEXSERO) 0.5ML	R	For use in line the Department of Health guidelines for childhood immunisation and asplenia/hyposplenia schedules. MMTC, May 2016
MENINGOCOCCAL GROUP B VACCINE 0.5ml PFS (BEXSERO) (CHARGEABLE STOCK)	Y	
MENINGOCOCCAL A,C, W135 & Y CONJUGATE VACCINE (MENVEO)	R	For preventing severe infections in patients with an absent or dysfunctional spleen as recommended on the MIL: Preventing Severe Infection in Patients with an Absent or Dysfunctional Spleen. Medicines Effectiveness, August 2012.
MENINGOCOCCAL A,C,W135&Y		

MENINGOCOCCAL A,C,W135&Y CONJUGATE VACCINE (NIMENRIX)	NF	For preventing severe infections in patients with an absent or dysfunctional splee
---	----	--

PNEUMOCOCCAL

PNEUMOCOCCAL VACCINE CONJUGATED INJECTION Y
PREVENAR 13 DOH

PNEUMOCOCCAL POLYSACCHARIDE VACCINE

PNEUMOCOCCAL POLYSACCHARIDE VACCINE 0.5ml PRE-FILLED SYRINGE	Y	Ordered in to replace pneumovax II during shortage,
--	---	---

RABIES

RABIES VACCINE (BP)	R	For use following approval by a microbiologist (Registrar or Consultant), if not available the HPA form (http://www.hpa.org.uk/topics/infectious/diseases/infectionsAZ/rabies) should be completed by microbiologist within 24 hours. Medicines Effectiveness, March 2001.
---------------------	---	---

ROTAVIRUS

ROTAVIRUS VACCINE 1.5ml PRE-FILLED ORAL SYRINGE	R	As per the National Immunisation Programme. MMTc, April 2014
---	---	--

SPECIFIC IMMUNOGLOBULIN

RABIES HUMAN IMMUNOGLOBULIN (HRIG) (NP)	UNR	
---	-----	--

VACCINE

VI CAPSULAR POLYSACCHARIDE VACCINE (TYPHIM VI)	Y	
--	---	--

RABIES VACCINE (VERORAB) - WHOLESale USE ONLY	NF	
---	----	--

HEPATITIS B 20mcg IN 1ml VACCINE PRE-FILLED SYRINGE	Y	
---	---	--

HEPATITIS A+B VACCINE SYRINGE (ADULT)	Y	
---------------------------------------	---	--

VARICELLA ZOSTER VACCINE

VARICELLA ZOSTER VACCINE (ZOSTAVAX)	NF	
-------------------------------------	----	--

VI CAPSULAR POLYSACCHARIDE

VI CAPSULAR POLYSACCHARIDE VACCINE (TYPHIM VI)	Y	
--	---	--

COVID-19 VACCINE VIDPREVTYN Beta Monovalent R
B.1.351 5micrograms /dose (Sanofi)

COVID-19 booster for patients and staff triaged into the high-risk anaphylaxis clinic who are ineligible for mRNA-based vaccinations. MMTC, October 2023

COVID-19 VACCINE COMIRNATY MONOVALENT R
Omicron XBB.1.5 30micrograms /dose (Pfizer)

COVID-19 booster for patient and staff aged 12 years and over who are eligible for a booster vaccine as per the Green book. MMTC, October 2023

HEPATITIS

HEPATITIS A VACCINE 0.5ml SYRINGE (HAVRIX Y
JUNIOR)

IMMUCOTHEL

IMMUCOTHEL 1mg INJECTION (CTASU) UNR

Measles + Mumps + Rubella vaccine

MMR VACCINE (LIVE) POWDER AND SOLVENT FOR NF
SOLUTION FOR INJECTION 0.5ML PFS

PNEUMOCOCCAL POLYSACCHARIDE

PNEUMOCOCCAL POLYSACCHARIDE VACCINE Y
0.5ml PRE-FILLED SYRINGE (PNEUMOVAX)

Rotavirus vaccine

ROTAVIRUS VACCINE 1.5ml TUBE FOR ORAL R
SUSPENSION

WHOLESALE USE ONLY

Tick-borne encephalitis vaccine

TICOVAC 0.5ML VACCINE NF

14.04.00 Vaccines and antisera

SNAKE ANTIVENOM

SNAKE ANTI-VENOM (EUROPEAN VIPER) INJECTION
(ViperaTAb)

UNR For use by A&E only

SNAKE ANTI-VENOM

SNAKE ANTI-VENOM (EUROPEAN VIPER) INJECTION
(VIPERFAV)

UNR For use in A and E only, for treatment of snake bites. Medicines Effectiveness, August 2021

14.04.14 Vaccine for smallpox

SMALLPOX VACCINE (LIVE) SUSPENSION FOR UNR
INJECTION 0.5ml (JYNNEOS)

SMALLPOX VACCIN

SMALLPOX VACCINE (LIVE) SUSPENSION for INJECTION 0.5ml	R	For vaccination of patients who meet UK HSA criteria, for use at OSHS only. MMTC July 2022
--	---	--

14.05.00 Immunoglobulins

VACCINE

VARICELLA VACCINE INJECTION 0.5ml	R	For use in NON-IMMUNE healthcare workers with patient exposure. Medicines Effectiveness, June 2017
-----------------------------------	---	--

14.05 Immunoglobulins

14.05.00 Immunoglobulins

IMMUNOGLOBULIN

IMMUNOGLOBULIN NORMAL IV 10g IN 100ml (10%) INFUSION (PANZYGA)	R	To be used strictly in accordance with the demand management protocol only. Do not substitute brands in established patients. Restricted for use by Immunology Only. Medicines Effectiveness, April 2018. Currently to be used for acute indications only AP 23.06.21
--	---	---

IMMUNOGLOBULIN SUB-CUTANEOUS 4g in 20ml INJECTION (CUVITRU)	R	To be used strictly in accordance to the 'demand management' protocol only. DO NOT substitute brands in established patients. MMTC, November 2017
---	---	---

IMMUNOGLOBULIN NORMAL IV 20g in 200ml (10%) INFUSION (INTRATECT)	R	To be used strictly in accordance with the demand management protocol only. Do not substitute brands in established patients, but use Privigen for newly initiated patients. Medicines Effectiveness, November 2016
--	---	---

IMMUNOGLOBULIN NORMAL IV 20g IN 200ml (10%) INFUSION (PANZYGA)	R	To be used strictly in accordance with the demand management protocol only. Do not substitute brands in established patients. Restricted for use by Immunology Only. Medicines Effectiveness, April 2018. Currently to be used for acute indications only AP 23.06.21
--	---	---

IMMUNOGLOBULIN NORMAL IV 5g IN 50ml (10%) INFUSION (PANZYGA)	R	To be used strictly in accordance with the demand management protocol only. Do not substitute brands in established patients. Restricted for use by Immunology Only. Medicines Effectiveness, April 2018. Currently to be used for acute indications only AP 23.06.21
IMMUNOGLOBULIN NORMAL IV 10g in 100ml (10%) INFUSION (INTRATECT)	R	To be used strictly in accordance with the demand management protocol only. Do not substitute brands in established patients, but use Privigen for newly initiated patients. Medicines Effectiveness, November 2016
IMMUNOGLOBULIN NORMAL IV 20g IN 200ml (10%) INFUSION (GAMUNEX)	R	Restricted for use by immunology ONLY. MMTC, September 2017
IMMUNOGLOBULIN SUB-CUTANEOUS 2g in 10ml INJECTION (CUVITRU)	R	To be used strictly in accordance to the 'demand management' protocol only. DO NOT substitute brands in established patients. MMTC, November 2017
IMMUNOGLOBULIN NORMAL IV 5g IN 50ml (10%) INFUSION (GAMUNEX)	R	Restricted for use by immunology ONLY. MMTC, September 2017
IMMUNOGLOBULIN NORMAL IV 10g IN 100ml (10%) INFUSION (GAMUNEX)	R	Restricted for use by immunology ONLY. MMTC, September 2017
IMMUNOGLOBULIN NORMAL		
IMMUNOGLOBULIN NORMAL IV 2.5g INF (KIOVIG)	R	To be used strictly in accordance with the demand management protocol only. Do not substitute brands in established patients, but use Privigen for newly initiated patients. Medicines Effectiveness, November 2016.
IMMUNOGLOBULIN NORMAL IV 20g INF (KIOVIG)	R	To be used strictly in accordance with the demand management protocol only. Do not substitute brands in established patients, but use Privigen for newly initiated patients. Medicines Effectiveness, November 2016.

IMMUNOGLOBULIN NORMAL IV 5g INF (KIOVIG)	R	To be used strictly in accordance with the demand management protocol only. Do not substitute brands in established patients, but use Privigen for newly initiated patients. Medicines Effectiveness, November 2016.
IMMUNOGLOBULIN NORMAL IV 10g INF (KIOVIG)	R	To be used strictly in accordance with the demand management protocol only. Do not substitute brands in established patients, but use Privigen for newly initiated patients. Medicines Effectiveness, November 2016.
IMMUNOGLOBULIN NORMAL IV 2.5g in 50ml (5%) INFR (FLEBOGAMMADIF)		To be used strictly in accordance to the “demand management” protocol only. Do not substitute brands in established patients, but use Octagam for initiated patients. Medicines Effectiveness, March 2013.
IMMUNOGLOBULIN NORMAL IV 20g in 200ml (10%) INFUSION (OCTAGAM)	R	To be used strictly in accordance to the “demand management” protocol only. Do not substitute brands in established patients, but use Octagam for initiated patients. Medicines Effectiveness, March 2013.
IMMUNOGLOBULIN NORMAL IV 20g in 200ml INFUSION (PRIVIGEN)	R	To be used strictly in accordance to the “demand management” protocol only. Do not substitute brands in established patients, but use Octagam for initiated patients. Medicines Effectiveness, March 2013.
IMMUNOGLOBULIN NORMAL IV 2g IN 20ml (10%) INFUSION (OCTAGAM)	R	To be used strictly in accordance to the “demand management” protocol only. Do not substitute brands in established patients, but use Octagam for initiated patients. Medicines Effectiveness, March 2013.
IMMUNOGLOBULIN NORMAL IV 5g in 50ml INFUSION (PRIVIGEN)	R	To be used strictly in accordance to the “demand management” protocol only. Do not substitute brands in established patients, but use Octagam for initiated patients. Medicines Effectiveness, March 2013.

IMMUNOGLOBULIN NORMAL IV 5g IN 50ml (10%) INFUSION (OCTAGAM)	R	To be used strictly in accordance to the “demand management” protocol only. Do not substitute brands in established patients, but use Octagam for initiated patients. Medicines Effectiveness, March 2013.
IMMUNOGLOBULIN NORMAL IV 5g in 100ml (5%) INF (FLEBOGAMMADIF)	R	To be used strictly in accordance to the “demand management” protocol only. Do not substitute brands in established patients, but use Octagam for initiated patients. Medicines Effectiveness, March 2013.
IMMUNOGLOBULIN NORMAL IV 2.5g in 25ml INFUSION (PRIVIGEN)	R	To be used strictly in accordance to the “demand management” protocol only. Do not substitute brands in established patients, but use Octagam for initiated patients. Medicines Effectiveness, March 2013.
IMMUNOGLOBULIN NORMAL IV 10g in 200ml (5%) INF (FLEBOGAMMADIF)	R	To be used strictly in accordance to the “demand management” protocol only. Do not substitute brands in established patients, but use Octagam for initiated patients. Medicines Effectiveness, March 2013.
IMMUNOGLOBULIN NORMAL IV 10g in 100ml INFUSION (PRIVIGEN)	R	To be used strictly in accordance to the “demand management” protocol only. Do not substitute brands in established patients, but use Octagam for initiated patients. Medicines Effectiveness, March 2013.
IMMUNOGLOBULIN NORMAL IV 10g IN 100ml (10%) INFUSION (OCTAGAM)	R	To be used strictly in accordance to the “demand management” protocol only. Do not substitute brands in established patients, but use Octagam for initiated patients. Medicines Effectiveness, March 2013.
IMMUNOGLOBULIN NORMAL IV 5g in 50ml (10%)		
IMMUNOGLOBULIN NORMAL IV 5g in 50ml (10%) INFUSION (INTRATECT)	R	To be used strictly in accordance with the demand management protocol only. Do not substitute brands in established patients, but use Privigen for newly initiated patients. Medicines Effectiveness, November 2016

IMMUNOGLOBULIN SUB-CUTANEOUS

IMMUNOGLOBULIN SUB-CUTANEOUS 8g in 40ml INJECTION (CUVITRU)	R	To be used strictly in accordance to the Demand Management Protocol only. Do not substitute brands in established patients. MMTc, November 2017
---	---	---

NORMAL IMMUNOGLOBULIN HUMAN

IMMUNOGLOBULIN SUB-CUTANEOUS 4g IN 25ml INJECTION (SUBGAM)	R	RESTRICTED to IMMUNOLOGY use only. Medicines Effectiveness, November 2004
IMMUNOGLOBULIN SUB-CUTANEOUS 2g in 12.5ml INJECTION (SUBGAM)	R	RESTRICTED to IMMUNOLOGY use only. Medicines Effectiveness, November 2004

VARICELLA

VARICELLA VACCINE (VARILRIX)	R	Immunisation should continue to be done by the GP as often as possible, but this is on the formulary as a contingency if for any reason access to the GP is likely to be delayed. MMTc August 2018
VARICELLA ZOSTER IMMUNOGLOBULIN 250mg VACC (VZIG)	UNR	Following recommendation of Microbiology only. Medicines Effectiveness, March 2013.

14.05.02 Disease-specific immunoglobulins

HEPATITIS

HEPATITIS B IMMUNOGLOBULIN 5,000international units in 100ml (HUMAN)	NF	
--	----	--

IMMUNOGLOBULIN

IMMUNOGLOBULIN SUB-CUTANEOUS 1g in 6.25ml INJECTION (SUBGAM)	R	RESTRICTED to PAEDIATRIC IMMUNOLOGY use only. Medicines Effectiveness, November 2004
--	---	--

SPECIFIC IMMUNOGLOBULIN

IMMUNOGLOBULIN ANTI-TETANUS 250units INJECTION	Y	
--	---	--

15.03.00 Antiviral drugs

INTERFERON

INTERFERON GAMMA 100microgram in 0.5ml INJECTION	Y	
--	---	--

15 Anaesthesia

10.02 Drugs used in neuromuscular disorders

10.02.02 Skeletal muscle relaxants

BACLOFEN

BACLOFEN 60mg IN 20ml INJECTION
(INTRATHECAL)

SR

For use by Neurology
Consultants only. Medicines
Effectiveness, February 2013.

15 Anaesthesia

15.01.04 Pre-op Sedation

Dexmedetomidine

DEXMEDETOMIDINE 200micrograms IN 2ml
INJECTION

R

For use as continuous sedation
in adult patients on critical care
units (400 microgram size
preferred); and procedural
sedation of paediatric patients
undergoing MRI scans under
direct supervision by an
anaesthetist. MMTC May 2020

Midazolam

MIDAZOLAM 5mg in 5ml PRE FILLED SYRINGE

R

FOR USE IN ED RESUS ONLY.
MMTC MAY 2023.

MIDAZOLAM 10mg in 5ml ORAL SOLUTION IN
SINGLE DOSE CONTAINER (ozalin)

NF

15.01 General anaesthesia

Fentanyl

FENTANYL 25microgram in 2ml PRE FILLED
SYRINGE NEONATES

SR

For use in neonates to assist
elective or semi-elective
intubation, MMTC July 2023.

Glycopyrronium bromide

GLYCOPYRRONIUM BROMIDE 2mg/5ml LIQUID 60ml
(SIALANAR)

SR For use in upper airways and
hypersalivation. Medicines
Effectiveness, March 2013.

PARECOXIB

PARECOXIB 40mg INJECTION

NF

PARECOXIB 40mg INJECTION

R

For management of pain in
palliative care patients when oral
route is not available on advice
of palliative care team. MMTC,
Feb 2024

15.01 00 Drugs for pre-med and peri operative

ATROPINE

ATROPINE SULPHATE 1mg in 5ml SYRINGE

Y

15.01 04 Sedative and analgesic peri-operative drugs

FENTANYL

FENTANYL 100micrograms in 2ML INJECTION
(UNLICENSED)

UNR Only to be ordered while there is a supply problem with the licensed product. RESTRICTED: For use in critical care areas, renal & transplant, interventional areas xray, endoscopy, cardiac cath labs, theatres, anaesthetics & recovery, A&E resus areas, Toms and Melanies. NB: fentanyl is non-formulary for other ward areas for PRN analgesia or preparation of PCAs unless advised by the acute pain team or approved by John Reynolds
MAC DEC 2010

15.01 General anaesthesia

REMIFENTANIL

REMIFENTANIL 2mg INJECTION

R ADULTS: For analgesia, sedation or as part of anaesthesia in mechanically ventilated patients on in critical care and theatres only.
PAEDIATRICALS: For analgesia and enhancement of anaesthesia in theatres only.
Medicines Effectiveness, April

REMIFENTANIL 1mg INJECTION

R ADULTS: For analgesia, sedation or as part of anaesthesia in mechanically ventilated patients on in critical care and theatres only.
PAEDIATRICALS: For analgesia and enhancement of anaesthesia in theatres only.
Medicines Effectiveness, April

REMIFENTANIL 5mg INJECTION

R ADULTS: For analgesia, sedation or as part of anaesthesia in mechanically ventilated patients on in critical care and theatres only. MMTTC, April 2016

15.01.01 Intravenous anaesthetics

ETOMIDATE

ETOMIDATE 20mg in 10ml INJECTION

Y

KETAMINE

KETAMINE (KETAMINUM) 200mg in 20ml INJECTION (VIALS)

UNR

KETAMINE 200mg IN 20ml INJECTION

Y

KETAMINE 500mg IN 10ml INJECTION (LICENSED)	Y	
PROPOFOL		
PROPOFOL 200mg IN 20ml (1%) INJECTION	Y	
PROPOFOL 1g in 100ml (1%) INJECTION	Y	
PROPOFOL 500mg IN 50ml (1%) INJECTION	Y	
THIOPENTAL		
THIOPENTAL 500mg INJECTION (without water)	Y	
THIOPENTAL 500mg IN 20ml INTRAVENEOUS PRE-FILLED SYRINGE	SR	For emergency intubation prior to cesarian section. Medicines Effectiveness, March 2013.
<i>15.01.02 Inhalational anaesthetics</i>		
DESFLURANE		
DESFLURANE 240ml	NF	
ISOFLURANE		
ISOFLURANE 250ml LIQUID	Y	
METHOXYFLURANE		
METHOXYFLURANE 999mg in 1g (99.9%) INHALATION VAPOUR 3ml	R	For use to relieve moderate to severe pain in conscious adult patients with trauma and associated pain in Emergency Departments MMTC, May 2020
SEVOFLURANE		
SEVOFLURANE 250ml <<	Y	
<i>15.01.03 Antimuscarinic drugs</i>		
ATROPINE		
ATROPINE SULPHATE 600micrograms IN 1ml INJECTION	Y	
ATROPINE SULPHATE 3mg in 10ml SYRINGE	Y	
GLYCOPYRRONIUM		
GLYCOPYRRONIUM BROMIDE 600mcg IN 3ml INJECTION	Y	
GLYCOPYRRONIUM BROMIDE		
GLYCOPYRRONIUM BROMIDE 1mg TABLETS	R	For use in upper airways and hypersalivation. Medicines Effectiveness, March 2013

GLYCOPYRRONIUM BROMIDE 200micrograms IN 1ml Y
INJECTION

HYOSCINE HYDROBROMIDE

HYOSCINE HYDROBROMIDE 400microgram in 1ml INJECTION R For Ward stock NITU and CCU (Horton) only. MAC, April 2011.

PROPOFOL

PROPOFOL 500mg IN 50ml (1%) INJECTION PRE-FILLED SYRINGE (CTASU PREP) UNR For use on critical care areas during covid-19. Medicines Effectiveness, April 2020

15.01.03 General anaesthesia

GLYCOPYRRONIUM BROMIDE

GLYCOPYRRONIUM BROMIDE 1mg/5ml LIQUID R For use in upper airways and hypersalivation. Medicines Effectiveness, March 2013.

15.01.04 Sedative and anal

Fentanyl

FENTANYL 100microgram/DOSE NASAL SPRAY (8 DOSE) NF

15.01.04 Sedative and analgesic peri-operative drugs

ALFENTANIL

ALFENTANIL 1mg IN 2ml INJECTION R Restricted for on advice of the palliative care team only. MMTC September 2018

ALFENTANIL CONCENTRATE 5mg IN 1ml INJECTION R Restricted for on advice of the palliative care team only. MMTC September 2018

DEXMEDETOMIDINE

DEXMEDETOMIDINE 400micrograms IN 4ml R Restricted for use in sedation on AICU and CICU. Initiation by ICU consultants only as per dexmedetomidine guidelines. MMTC, March 2019

FENTANYL

FENTANYL 2.5mg in 50ml PRE-FILLED SYRINGE SR

FENTANYL 500micrograms in 10ml INJECTION R For use in critical care areas, renal & transplant, interventional areas xray, endoscopy, cardiac cath labs, theatres, anaesthetics & recovery, A&E resus areas, Toms and Melanies.

FENTANYL 2.5mg in 50ml INJECTION VIAL (UNLICENSED) UNR MMTC, May 2020

FENTANYL 2.5mg in 50ml VIAL	R	Restricted to Critical Care wards only for use in continuous infusions. Medicines Effectiveness, May 2019
FENTANYL 500microgram IN 10ml INJECTION	R	For use in critical care areas, renal & transplant, interventional areas xray, endoscopy, cardiac cath labs, theatres, anaesthetics & recovery, A&E resus areas, Toms and Melanies. NB: fentanyl is non-formulary for other ward areas for PRN analgesia or preparation of PCAs unless advised by the acute pain team or approved by Dr. John Reynolds. MAC, December 2010.
FENTANYL 100microgram IN 2ml INJECTION	R	For use in critical care areas, renal & transplant, interventional areas xray, endoscopy, cardiac cath labs, theatres, anaesthetics & recovery, A&E resus areas, Toms and Melanies. NB: fentanyl is non-formulary for other ward areas for PRN analgesia or preparation of PCAs unless advised by the acute pain team or approved by Dr. John Reynolds. MAC, December 2010.
KETOROLAC		
KETOROLAC 30mg IN 1ml INJECTION	Y	
MIDAZOLAM		
MIDAZOLAM 50mg in 10ml INJECTION	R	Temporary product during shortage of normal strength. Restricted for use on Neuro Intensive Care Unit only. Medicines Effectiveness, April 2019
MIDAZOLAM 10mg IN 2ml INJECTION	R	HIGH STRENGTH product restricted to palliative care and paediatric use only. Medicines Effectiveness, July 2009.
MIDAZOLAM (BASE) 12.5mg/5ml LIQUID	SR	Pre-medication in children; and in adults with special needs undergoing dental procedures. MMTC, November 2013

MIDAZOLAM 100mg IN 50ml INJECTION 50ml VIAL	R	Restricted to adult ICU only. Medicines Effectiveness, Novemeber 2009.
MIDAZOLAM 5mg IN 5ml INJECTION	Y	
MORPHINE		
MORPHINE SULPHATE 100mg SACHETS M/R	NF	
<i>15.01.05 Neuromuscular blocking drugs</i>		
ATRACURIUM		
ATRACURIUM 50mg in 5ml INJECTION	Y	
ATRACURIUM 25mg in 2.5ml INJECTION	Y	
ATRACURIUM 250mg in 25ml INJECTION	Y	
CISATRACURIUM		
CISATRACURIUM 20mg IN 10ml INJECTION	R	For patients with proven hypersensitivity to atracurium and other curare like muscle relaxants. MAC, March 2009.
CISATRCURIUM		
CISATRCURIUM 150mg in 30ml INJECTION	NF	
EFGARTIGIMOD		
EFGARTIGIMOD ALFA 400mg in 20ml CONCENTRATE SOLUTION FOR INFUSION (FOC)	R	For treatment of patients under EAMS scheme only. MMTc Dec 2022
MIVACURIUM		
MIVACURIUM 20mg IN 10ml INJECTION	Y	
MIVACURIUM 10mg IN 5ml INJECTION	Y	
PANCURONIUM		
PANCURONIUM 4mg IN 2ml INJECTION	Y	
ROCURONIUM		
ROCURONIUM 100MG / 10ML INJECTION	Y	
ROCURONIUM 50mg IN 5ml INJECTION	Y	
Suxamethonium		

SUXAMETHONIUM 10mg in 2ml PRE FILLED SYRINGES NEONATES	SR	For use in neonates to assist elective or semi-elective intubation, MMTC July 2023.
--	----	---

SUXAMETHONIUM 100mg IN 2ml INJECTION	Y	
--------------------------------------	---	--

SUXAMETHONIUM 200mg IN 10ml INTRAVENEOUS PRE-FILLED SYRINGE	SR	For emergency intubation in obstetrics for emergency cesarian section. Medicines Effectiveness, March 2013.
---	----	---

VECURONIUM

VECURONIUM BROMIDE 10mg INJECTION	Y	
-----------------------------------	---	--

15.01.06 Drugs for reversal of neuromuscular blockade

NEOSTIGMINE

NEOSTIGMINE 2.5mg & GLYCOPYRROLATE 500microgram IN 1ml INJECTION	Y	
--	---	--

15.01.07 Antagonists for central and respiratory depression

NALOXONE

NALOXONE 400microgram in 1ml INJECTION	Y	
--	---	--

SUGAMMADEX

SUGAMMADEX 200mg IN 2ml INJECTION	R	For routine reversal of induced muscle paralysis during COVID-19 only. MMTC, April 2020
-----------------------------------	---	---

15.01.08 Drugs for malignant hyperthermia

DANTROLENE

DANTROLENE 20mg INJECTION	Y	
---------------------------	---	--

15.02 Anaesthesia

KETAMINE

KETAMINE 50mg/5ml LIQUID (SUGAR FREE)	SR	Pre-medication in children with severe behavioural issues undergoing procedures; pre-medication in children during COVID-19; and in adults with special needs undergoing dental procedures. MMTC, April 2020.
---------------------------------------	----	---

15.02 Local anaesthesia

15.02 Anaesthesia

BUPIVACAINE

BUPIVACAINE 0.5% INJECTION 10ml STERILE WRAPY		
---	--	--

BUPIVACAINE 0.25% INJECTION 10ml STERILE WRAP Y
BUPIVACAINE HEAVY 20mg IN 4ml (0.5%) INJECTION Y

EMLA CREAM

EMLA CREAM 30g SURGICAL PACK Y

ETHYL CHLORIDE

ETHYL CHLORIDE BP SPRAY 100ml Y

LIDOCAINE

LIDOCAINE 2% 40mg in 2ml INJECTION Y

LIDOCAINE 0.5% 50mg in 10ml INJECTION Y

LIDOCAINE 1% 100mg in 10ml INJECTION Y

LIDOCAINE 2% & ADRENALINE 1:80,000units 2.2ml CARTRIDGE Y

LIDOCAINE 10mg/dose SPRAY Y

LIDOCAINE 2% 400mg in 20ml INJECTION Y

LIDOCAINE 4% TOPICAL SOLUTION 25ml Y

LIDOCAINE 5% OINTMENT 15g Y

LIDOCAINE 1% 200mg in 20ml INJECTION Y

LIDOCAINE 1% 50mg in 5ml INJECTION Y

LIDOCAINE 2% 100mg in 5ml INJECTION Y

LIDOCAINE 1% 20mg in 2ml INJECTION Y

PRILOCAINE

PRILOCAINE 1% INJECTION 50ml Y

TETRACAINE

TETRACAINE GEL 1.5g Y

15.02.00 Local anaesthesia

BUPIVACAINE

BUPIVACAINE 0.5% INJECTION 10ml STERILE WRAP Y

BUPIVACAINE 0.25% INJECTION 10ml STERILE WRAP	Y	
BUPIVACAINE + FENTANYL		
BUPIVACAINE 0.1% & FENTANYL 2microgram/ml IN SOD CHLOR 0.9% 250ml (3159471)	SR	
BUPIVACAINE/CLONIDINE		
CLONIDINE 250micrograms & BUPIVACAINE 0.1% EPIDURAL BAG 250ml	SR	For pain relief in children with cerebral palsy undergoing orthopaedic surgery. MMTTC, February 2015.
EMLA CREAM		
EMLA CREAM 5g with DRESSING	Y	
LIDOCAINE		
LIDOCAINE 0.5% & ADRENALINE 1 in 200,000 INJECTION 10ml (UL)	UNR	
LIDOCAINE 1% & ADRENALINE 1 in 200,000 INJECTION 10ML	SR	For use ONLY IF DBI201 IS UNAVAILABLE.
LIDOCAINE 4% TOPICAL SOLUTION 40ml	UNR	For awake intubation procedures. Theatres only. Medicines Effectiveness, June 2013.
LIDOCAINE 5% (700mg) PATCHES	NF	
LIDOCAINE 1% & ADRENALINE 1 IN 200,000 INJECTION 20ml	R	
LIDOCAINE 1% INJECTION 20ml (For use in Eye Theatres for intraocular use only)	R	For use by Eye Theatres for intraocular use only. Medicines Effectiveness, MArch 2013.
LIDOCAINE 4% ADRENALINE 0.1% TETRACAINE 0.5% STERILE GEL 3ml (L.A.T GEL)	SR	Restricted to max fax patients with simple lacerations. MAC, July 2009.
Lidocaine + Adrenaline		
LIDOCAINE 2% & ADRENALINE 1 IN 200,000 INJECTION 20ml	Y	
MEPIVACAINE		
MEPIVACAINE 3% INJECTION 2.2ml CARTRIDGE (PLAIN)	R	For use in the fitting of intrauterine devices (off-label indication). MMTTC, June 2014.
PRILOCAINE		
PRILOCAINE 3% & OCTAPRESSIN INJECTION 2.2ml (Self-Aspirating)	Y	

PRILOCAINE 100mg IN 5ml (2%) HYPERBARIC INJECTION	R	For use in spinal anaesthesia for short procedures in the day surgery units at the Horton hospital, Churchill urology unit, NOC and Gynae theatres only. MMTc, January 2020
---	---	---

ROPIVACAINE

ROPIVACAINE 500mg in 250ml SOLUTION FOR INFUSION PRE-FILLED DEVICE (FREE SUPPLY)	R	THE 20 TRIAL UNITS WILL BE USED IN CHURCHILL HOSPITAL ONLY
--	---	--

ROPIVACAINE 75mg IN 10ml INJECTION	R	For use by the NOC theatres only. Medicines Effectiveness, May 2003.
------------------------------------	---	--

ROPIVACAINE 20mg in 10ml INJECTION	R	For use by the NOC theatres only. Medicines Effectiveness, May 2003.
------------------------------------	---	--

15.02.00 Anaesthesia

BUPIVACAINE

BUPIVACAINE 0.125% INFUSION 250ml	Y	
-----------------------------------	---	--

BUPIVACAINE 0.25% + ADRENALINE INJECTION 10ml	Y	
---	---	--

BUPIVACAINE 0.5% + ADRENALINE INJECTION 10ml	Y	
--	---	--

LIDOCAINE

LIDOCAINE 1% 100mg in 10ml INJECTION (STERILE WRAP)	Y	
---	---	--

15.02.00 Anaesthesia drugs

COCAINE

COCAINE 5% NASAL SOLUTION 4ml (colourless)	SR	For topical local anaesthesia in awake fiberoptic intubation and during ENT procedures. Medicines Effectiveness, April 2016
--	----	---

15.02.00 Drugs used for anaesthesia

COCAINE

COCAINE 25% PASTE SYRINGE 2g	Y	
------------------------------	---	--

COCAINE 5% NASAL SOLUTION 2ml (colourless)	SR	For topical local anaesthesia in awake fiberoptic intubation and during ENT procedures. Medicines Effectiveness, April 2016
--	----	---

15.02.00 Local anaesthesia

ARTICAINE

ARTICAINE & ADRENALINE 1 in 100,000 INJECTION NF
2.2ml (pk 50)

INSTILLAGEL

LIDOCAINE 2% & CHLORHEXIDINE LUBRICATING Y
GEL 6ml SYRINGE

LIDOCAINE 2% & CHLORHEXIDINE LUBRICATING Y
GEL 11ml SYRINGE

16 Emergency treatment of poisoning

ACETYLCYSTEINE

ACETYLCYSTEINE 2g in 10ml (20%) INJECTION 10ml Y

METHYLTHIONINIUM

METHYLTHIONINIUM CHLORIDE 50mg in 10ml (0.5%) Y
INJECTION

Uridine triacetate

URIDINE TRIACETATE 10g ORAL SACHETS SF UNR

other poisons

PRALIDOXIME

PRALIDOXIME CHLORIDE 1g INJECTION UNR

16.03 Drug Toxicity

16.03 Drug Toxicity

IDARUCIZUMAB

IDARUCIZUMAB 2.5g IN 50ml INJECTION R For urgent reversal of dabigatran only: (1) emergency surgery, i.e. where the surgery must be performed within the next 8 hours and (2) life-threatening or serious bleeding. MMTC, February 2016

Other poisons

HYDROXOCOBALAMIN

HYDROXOCOBALAMIN 5g INJECTION R For emergency treatment of cyanide poisoning. MMTC, April 2020

Cyananides

SODIUM THIOSULPHATE

SODIUM THIOSULPHATE 12.5g IN 50ml INJECTION R

For use as part of Cyanide Poisons Antidote Kit kept in AE. Medicines Effectiveness, March 2013

Removal and elimination

removal from the gastro-intestinal tract

ACTIVATED CHARCOAL

ACTIVATED CHARCOAL 200mg/ml LIQUID 250ml Y

23 Disinfectants

23.00 Disinfectants

23.00.00 Disinfectants

CHLORHEXIDINE

CHLORHEXIDINE 2% IN 70% IPA PINK 200ml Y

30. Injectable Contrast Media

DOTAREM

DOTAREM VIAL 10ml R

For use by MRI only. MMTC, November 2017

DOTAREM VIAL 5ml R

For use by MRI only. MMTC, November 2017

PERFLUTREN

PERFLUTREN CONTAINING LIPID MICROSPHERES R
150 microlitres IN 1ml INJECTION

Contrast for use in cardiac ECHO (cardiac out-patients) only. MMTC, September 2017

UROGRAFIN

UROGRAFIN 150 (30%) 250ml Y

UROGRAFIN 150 (30%) 500ml Y

32 Dialysis fluids

HAEMOFILTRATION

HAEMOFILTRATION (Ci-Ca K2 DIALYSATE) R
INFUSION 5L

For use on CTCC only as part of citrate haemodiafiltration. MMTC, March 2013

SODIUM CHLORIDE

DF SODIUM CHLORIDE 0.9% IRRIGATION 3L (3KB7127) UROMATIC	Y
DF SODIUM CHLORIDE 0.9% IRRIGATION BOTTLE 1L UKF7124	Y
DF SODIUM CHLORIDE 0.9% INFUSION 50ml 440732	Y
DF SODIUM CHLORIDE 0.9% IRRIGATION 3L (FKB7528T) EASYFLOW	Y

Appendix 02 Borderline substances

A02.05 Feed additives

A02.05.01 Special additives for conditions of intolerance

PROBIOTIC SACHET

PROBIOTIC SACHET (VSL#3)	NF
--------------------------	----

Appendix 05 Wound management products and elasticated garments

A05.01 Basic wound contact dressings

05.01.00 Basic wound management

HAEMOSTATIC FELT

HAEMOSTATIC FELT 3cm x 5cm DRESSING (LYOSTYPT)	Y
---	---

PARAFFIN GAUZE

PARAFFIN GAUZE 5cm x 5cm DRESSING	R	This dressing may be used by Plastics or following recommendation by Tissue Viability Team. MAC, October 2009.
PARAFFIN GAUZE 10cm x 10cm DRESSING	R	This dressing may be used by Plastics or following recommendation by Tissue Viability Team. MAC, October 2009.
PARAFFIN GAUZE 40cm x 10cm DRESSING	R	This dressing may be used by Plastics or following recommendation by Tissue Viability Team. MAC, October 2009.
PARAFFIN GAUZE 15cm x 2m DRESSING (ROLL)	R	This dressing may be used by Plastics or following recommendation by Tissue Viability Team. MAC, October 2009.

05.01.02 Absorbent dressings

KERRAMAX

KERRAMAX 10cm x 22cm DRESSING	R	Following recommendation by Tissue Viability Team. MAC, October 2009.
KERRAMAX 20cm x 22cm DRESSING	R	Following recommendation by Tissue Viability Team. MAC, October 2009.

A05.02 Advanced wound dressings

05.02.01 Hydrogel dressings

ACTIFOAM

ACTIFORM COOL 10cm X 10cm DRESSING	R	Following recommendation by Tissue Viability or Vascular only. MAC, May 2010.
ACTIFORM COOL 10cm X 15cm DRESSING	R	Following recommendation by Tissue Viability or Vascular only. MAC, May 2010.

ACTIVHEAL

ACTIV HEAL HYDROCOLLOID 15cm X 15cm DRESSING	Y
ACTIV HEAL HYDROCOLLOID 15cm X 18cm SACRAL DRESSING	Y
ACTIV HEAL HYDROCOLLOID 5cm X 7.5cm DRESSING	Y
ACTIV HEAL FOAM ADHESIVE 10cm X 10cm DRESSING	Y
ACTIV HEAL FOAM 5cm X 5cm DRESSING	Y
ACTIV HEAL HYDROCOLLOID 10cm X 10cm DRESSING	Y
ACTIV HEAL FOAM ADHESIVE 15cm X 15cm DRESSING	Y
ACTIV HEAL ALGINATE 10cm X 10cm DRESSING	Y
ACTIV HEAL FOAM ADHESIVE 12.5cm X 12.5cm DRESSING	Y
ACTIV HEAL FOAM 20cm X 20cm DRESSING	Y
ACTIV HEAL FOAM 10cm X 17.8cm DRESSING	Y
ACTIV HEAL FOAM 10cm X 10cm DRESSING	Y
ACTIV HEAL ALGINATE 5cm X 5cm DRESSING	Y
ACTIV HEAL ALGINATE 10cm X 20cm DRESSING	Y

INTRASITE

INTRASITE GEL 15g DRESSING APPLIPAK	R	For use by Plastic Out-patients (PLOP) only. Medicines Effectiveness, May 2010.
<i>05.02.02 Vapour-permeable films and membranes</i>		
OPSITE		
OPSITE SPRAY DRESSING 100ml	Y	
<i>05.02.03 Soft polymer dressings</i>		
ALLEVYN		
ALLEVYN SACRUM 17cm x 17cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
BOOT DRESSING		
BOOT DRESSING FOR MAGGOTS	Y	
HALF BOOT		
HALF BOOT DRESSING FOR MAGGOTS	Y	
MEPILEX		
MEPILEX BORDER LITE 15cm X 15cm DRESSING	R	FOLLOWING RECOMMENDATION BY TISSUE VIABILITY TEAM ONLY. MAC, OCTOBER 2009
MEPILEX LITE 10cm X 10cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
MEPILEX WITH SILICONE ADHESIVE BORDER 17cm X 20cm DRESSING	R	For use by A+E, Radiotherapy, Palliative Care and FEU, Plastics, Paediatrics OR following recommendation by Tissue Viability Team. MAC, October 2009.
MEPILEX TRANSFER 20cm X 50cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
MEPILEX LITE 15cm x 15cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
MEPILEX BORDER LITE 7.5 X 7.5cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.

MEPILEX BORDER LITE 4cm X 5cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
MEPILEX 10cm x 11cm DRESSING	R	For use by A+E, Radiotherapy, Palliative Care and FEU, Plastics, Paediatrics OR following recommendation by Tissue Viability Team. MAC, October 2009.
MEPILEX LITE 6cm X 8.5cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
MEPILEX 15cm X 16cm DRESSING	R	For use by A+E, Radiotherapy, Palliative Care and FEU, Plastics, Paediatrics OR following recommendation by Tissue Viability Team. MAC, October 2009.
SORBION SANA		
SORBION SANA 12cm X 12cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
SORBION SANA 8.5cm X 8.5cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
URGOTUL		
SOFT POLYMER DRESSING WITH SILVER 16cm x 21cm	NF	
<i>05.02.04 Hydrocolloid dressings</i>		
DUO-DERM EXTRA		
DUO-DERM EXTRA THIN 10cm x 10cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
GRANUFLEX		
GRANUFLEX BORDERED 10cm x 10cm DRESSING S156	R	Following recommendation by Tissue Viability Team MAC, October 2009.
<i>05.02.06 Alginate dressings</i>		
SORBSAN		
SORBSAN 10cm x 10cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.

SORBSAN 10cm x 20cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
SORBSAN PLUS 10cm x 15cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
SORBSAN 5cm x 5cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
SORBSAN PLUS 7.5cm x 10cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.

05.02.08 Odour absorbent dressings

CLINISORB

CLINISORB 10cm x 10cm ODOUR CONTROL DRESSING	R	Following recommendation by Tissue Viability Team or Palliative care. MAC October 2009
CLINISORB 15cm x 25cm ODOUR CONTROL DRESSING	R	Following recommendation by Tissue Viability Team or Palliative care. MAC October 2010

SORBSAN

ALGINATE DRESSING WITH ACTIVATED CARBON (SORBSAN PLUS CARBON) 15cmX20cm NF

A05.02.03 Soft polymer dressings

MEPILEX

MEPILEX WITH SILICONE ADHESIVE BORDER 7cm x 7.5cm DRESSING	R	For use by A+E, Radiotherapy, Palliative Care and FEU, Plastics, Paediatrics OR following recommendation by Tissue Viability Team. MAC, October 2009
--	---	--

A05.03 Antimicrobial dressings

05.03.01 Honey

MANUKA

ACTIVON MANUKA HONEY TULLE 10cm X 10cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, May 2010.
---	---	--

MESITRAN

MESITRAN MESH 20cm x 15cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
------------------------------------	---	--

MESITRAN MESH 10cm x 10cm DRESSING	R	Following recommendation by Tissue Viability Team only. MAC, October 2009.
------------------------------------	---	--

05.03.02 Iodine

POVIDONE IODINE

POVIDONE IODINE 5cm x 5cm DRESSINGS (Inadine)	Y
---	---

POVIDONE-IODINE

POVIDONE-IODINE 9.5cm x 9.5cm DRESSINGS (Inadine)	Y
---	---

05.03.03 Silver

ACTICOAT

ACTICOAT FLEX 3 10cm x 20cm DRESSING	NF
--------------------------------------	----

ACTISORB

ACTISORB SILVER 10.5cm X 19cm DRESSINGS (220)NF	
---	--

AQUACEL

AQUACEL AG BURN 17cm x 15cm DRESSING	R	Restricted to use in burns patients only (under Mrs Sarah Tucker). Medicines Effectiveness, January 2014
--------------------------------------	---	--

AQUACEL AG BURN 23cm x 30cm DRESSING	R	Restricted to use in burns patients only (under Mrs Sarah Tucker). Medicines Effectiveness, January 2014
--------------------------------------	---	--

AQUACEL AG BURN 13cm x 10cm DRESSING	R	Restricted to use in burns patients only (under Mrs Sarah Tucker). Medicines Effectiveness, January 2014
--------------------------------------	---	--

ATRAUMAN AG

ATRAUMAN AG 10cm X 10cm DRESSING	Y
----------------------------------	---

ATRAUMAN AG 20cm X 10cm DRESSING	Y
----------------------------------	---

ATRAUMAN AG 5cm X 5cm DRESSING	Y
--------------------------------	---

05.03.04 Other antimicrobials

SUPRASORB

SUPRASORB X + POLYHEXANIDE 14cm x 20cm DRESSINGS	R	Following recommendation by Tissue Viability Team. MAC, October 2009.
--	---	---

A05.03.01 Honey

ALGIVON

ALGIVON (DRESSING IMPREGNATED WITH MEDICAL GRADE MANUKA HONEY) 5X5cm DRESSING

R

Following recommendation by the Tissue Viability Team only. MAC, February 2010.

ALGIVON (DRESSING IMPREGNATED WITH MEDICAL GRADE MANUKA HONEY) 10X10cm

R

Following recommendation by the Tissue Viability Team only. MAC, February 2010.

A05.03 Antimicrobials

05.03.01 Honey

MANUKA

MANUKA HONEY STERILE 25g

R

Following recommendation by Tissue Viability Team only. MAC, March 2010.

A05.04 Specialised dressings

05.04.02 Silicone keloid dressings

MEPIFORM

MEPIFORM 9cm x 18cm SCAR DRESSING

NF

A05.8 Bandages preparations

05.08.09 Medicated bandages

ICHTHOPASTE

ICHTHOPASTE 7.5cm X 6m BANDAGE 120-659

Y

Unknown

PREGNANCY TEST 25million international units/ml MID-STREAM (ALERE hCG EASY)

Y

Abrocitinib

ABROCITINIB 100mg TABLETS

R

For treatment of moderate to severe atopic dermatitis as per NICE TA814. MMTc, March 2023

ABROCITINIB 200mg TABLETS

R

For treatment of moderate to severe atopic dermatitis as per NICE TA814. MMTc, March 2023

ACETAZOLAMIDE

ACETAZOLAMIDE 250mg CAPSULES M/R

Y

ACETIC ACID

	ACETIC ACID 5% SOLUTION 200ml	SR	
	ACETONE		
	ACETONE 50ml	R	Only to be used in approved areas
	Acetylcysteine		
NO	ACETYLCYSTEINE 600mg EFFERVESCENT TABLETS	C	CLINICAL TRIAL USE ONLY STOCK TO BE KEPT IN PHARMACY - SHOULD GO STRAIGHT TO CLINICAL TRIALS. FOR Ph2 INBRX SA CS USE.
	ACTICOAT		
	ACTICOAT FLEX 3 10cm X 120cm DRESSING	NF	
	Alpelisib		
	ALPELISIB 150mg TABLETS	R	For treatment of hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer as per NICE TA816. MMTC, December 2022
	ALPELISIB 200mg TABLETS	R	For treatment of hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer as per NICE TA816. MMTC, December 2022
	ALPELISIB 50mg and 200mg TABLETS (28x 50mg & 28 x200mg)	R	For treatment of hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer as per NICE TA816. MMTC, December 2022
	AMINOLEVULINIC ACID		
	5-AMINOLEVULINIC ACID 30mg/ml (1.5g) POWDER FOR ORAL SOLUTION	R	Visualisation of malignant tissue during surgery for malignant glioma. MMTC, November 2013.
	Amoxicillin		
	AMOXICILLIN 1g INJECTION	Y	
	ANTI-THYMOCYTE IMMUNOGLOBULIN		
	ANTI-THYMOCYTE IMMUNOGLOBULIN EQUINE 250mg in 5mL INJECTION	R	
	Arginine + Lysine		

L-ARGININE 25g & L-LYSINE HYDROCHLORIDE 25g R
INFUSION 1L (LYSAKARE)

ARTISS

ARTISS FIBRIN SEALANT 4ml R OUH formulary approved for use
in Breast Surgery. MMTC,
September 2015

ARTISS SEALANTS 2ml SOLUTIONS FOR SEALANT R For use in breast surgery.
MMTC, September 2015

AUTO DROP

AUTO DROP Y

Avelumab

AVELUMAB 200mg in 10ml INJECTION (Urothelial
Maintenance EAMS) NF

AZITHROMYCIN

AZITHROMYCIN 500mg INJECTION R As per OUH Antimicrobial
Guidelines. It is also available
following approval/prescribing by:
- Microbiology/ID consultant or
registrar - Paediatric ID
consultant or registrar MMTC,
April 2020.

Bambuterol

BAMBUTEROL 10mg TABLETS (3 X 10) NF

BARIUM SULPHATE

BARIUM SULPHATE 96% EZ-PAQUE POWDER R Only to be ordered for Radiology
(24x177g) Trial only

BARIUM SULPHATE LIQUID 300ml Y

BARIUM SULPHATE EZ-HD (24x340g) Y

BARIUM SULPHATE 94.6%W/W GRANULES Y

BECLOMETASONE + FORMOTEROL

<p>BECLOMETASONE 200micrograms / FORMOTEROL 6micrograms INHALER 120 dose (LUFORBEC)</p>	<p>R</p>	<p>For the management of COPD as per Maintenance Management of COPD Inhaled and Oral Therapies (Adults) guidelines and for the management of asthma as per Maintenance Management of Asthma Inhaled and Oral Therapies (adults) guidelines. To be used instead of Fostair in newly initiated patients. MMTC, December 2022</p>
<p>BECLOMETASONE 100micrograms / FORMOTEROL 6micrograms INHALER 120 dose(LUFORBEC)</p>	<p>R</p>	<p>For the management of COPD as per Maintenance Management of COPD Inhaled and Oral Therapies (Adults) guidelines and for the management of asthma as per Maintenance Management of Asthma Inhaled and Oral Therapies (adults) guidelines. To be used instead of Fostair in newly initiated patients. MMTC, December 2022</p>
<p>Beclometasone + Formoterol + Glycopyrronium</p>		
<p>BECLOMETASONE 88micrograms / GLYCOPYRRONIUM 9micrograms / FORMOTEROL</p>	<p>NF</p>	
<p>BECLOMETASONE + GLYCOPYRRONIUM +</p>		
<p>BECLOMETASONE 172micrograms/ GLYCOPYRRONIUM 9micrograms/ FORMETEROL</p>	<p>NF</p>	
<p>BEDAQUILINE</p>		
<p>BEDAQUILINE 100mg TABLETS (COMPASSIONATE USE)</p>	<p>NF</p>	
<p>Belatacept</p>		
<p>BELATACEPT 250mg INJECTION (CTASU)</p>	<p>R</p>	<p>To prevent rejection in bowel transplant patients who have demonstrable tacrolimus nephrotoxicity. MMTC, February 2013.</p>
<p>BEROTRALSTAT</p>		
<p>BEROTRALSTAT 150mg CAPSULES</p>	<p>R</p>	
<p>BEVACIZUMAB</p>		
<p>BEVACIZUMAB 100mg IN 4ml INJECTION (FREE STOCK)</p>	<p>NF</p>	
<p>BORIC ACID</p>		
<p>BORIC ACID 5g POWDER</p>	<p>UNR</p>	<p>Restricted for use in the ear Medicines Effectiveness, June 2011.</p>

BROLUCIZUMAB

BROLUCIZUMAB 120mg in 1ml PRE-FILLED SYRINGE

R For treating wet age-related macular degeneration as per NICE TA672. MMTc, May 2021

BUDESONIDE

BUDESONIDE 160microgram / FORMOTEROL 4.5micrograms INHALER 60dose NF

Cabotegravir

CABOTEGRAVIR 600mg in 3ml PROLONGED RELEASE INJECTION R

For treatment of HIV-1 infection, to be used alongside rilpivirine as per NICE TA757. MMTc, July 2022

CABOTEGRAVIR 30mg TABLETS R

CALCIUM CARBONATE

CALCIUM CARBONATE 1750mg & CALCIUM LACTATE GLUCONATE 2263mg EFFERVESCENT Y

CALCIUM PHOSPHATE

CAPHOSOL (CALCIUM PHOSPHATE SOLUTION) 15ml ORAL RINSE 2 x NF

CANNABIDIOL

CANNABIDIOL 100mg/ml LIQUID 100ml (Free of charge stock) NF

Restricted for use in paediatric patients with Dravets Syndrome and Lennox Gastaut Syndrome who are enrolled on the compassionate use scheme only. MMTc, May 2019

CANNABIDIOL 500mg/5ml LIQUID 100ml R

For the treatment of Dravet's Syndrome as per NICE TA614 and Lennox-Gastaut Syndrome as per NICE TA615. MMTc, February 2020

carboxymethylcellulose

AQUACEL AG+ 2cm x 45cm DRESSING R

AQUACEL AG+ EXTRA 10 x 10cm DRESSING R

AQUACEL AG+ EXTRA 15 x 15cm DRESSING R

AQUACEL AG+ EXTRA 5cm x 5cm DRESSINGS R

CARDIOPLEGIA

CARDIOPLEGIA STERILE CONCENTRATE 20ml R

For use by perfusionists only. Medicines Effectiveness, August 2008.

CARNOYS

CARNOYS SOLUTION 10ml SR For use in Cancer Ambulatory Care only. MMTC, May 2020

CAROB BEAN

CAROB BEAN 1% SOLUTION C Y

CASIRIVIMAB

CASIRIVIMAB 1332mg per 11.1mL with IMDEVIMAB 1332mg per 11.1ml R For treatment of Covid-19 in hospitalised and non-hospitalised patients with non-omicron variant infection. MMTC, December 2021.

CHLOR-CLEAN TABLETS

CHLOR-CLEAN TABLETS Y

CHLORHEXIDINE

CHLORHEXIDINE 0.5% in DEB PINK SPRAY 200ml (TEMP PROCUREMENT SUPPLY) R

CHLORHEXIDINE 2% IN 70% IPA 500ml (TEMP PROCUREMENT SUPPLY) UNR For skin preparation prior to surgical incision in theatres, anaesthetics and other interventional areas. Medicines Effectiveness, February 2013.

CHLORHEXIDINE GLUCONATE DENTAL GEL 1% 50g Y

CHLORHEXIDINE ACETATE 0.05% CLEAR 1L IRRIGATION BOTTLES (FKF7984) Y

CHLORHEXIDINE 0.5% in DEB PINK SPRAY 200ml Y

CHLORHEXIDINE 2% IN 70% IPA PINK 500ml UNR For skin preparation prior to surgical incision in theatres, anaesthetics and other interventional areas. Medicines Effectiveness, February 2013.

Ciclosporin

CICLOSPORIN 50mg CAPSULES (SANDIMMUN) NF

CICLOSPORIN 1mg/ml (VERKAZIA) UNIT DOSE EYE DROPS 0.3ml (120) R Severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents. MMTC, March 2021

CITRIC ACID

CITRIC ACID 1g in 10ml SACHET + SOLUTION (CARBEX) Y

Clindamycin

CLINDAMYCIN 600mg IN 4ml INJECTION	Y	
CLINDAMYCIN 300mg IN 2ml INJECTION	Y	
Clindamycin + Tretinoin		
CLINDAMYCIN 1% & TRETINOIN 0.025% GEL 30g	NF	
Clotrimazole		
CLOTRIMAZOLE 1% CREAM 50g	Y	
COCAINE		
COCAINE HYDROCHLORIDE POWDER	Y	
COCONUT OIL		
COCONUT OIL BP	R	For use by Dermatology only. Medicines Effectiveness, March 2013.
COD LIVER OIL		
COD LIVER OIL 400mg CAPSULES	UNR	For use as a marker in Radiology. Medicines Effectiveness, February 2016
Colecalciferol		
COLECALCIFEROL 20,000unit CAPSULES	R	Restricted to use for patients with significant vitamin D deficiency OR paediatric patients with cystic fibrosis under the care of Dr. Jeremy Hull. Medicines Effectiveness, February 2019
COLLATAMP G		
COLLATAMP EG 10cm x 10cm IMPLANT	NF	
COLLATAMP G 5 x 20cm IMPLANT	NF	
CRIZANLIZUMAB		
CRIZANLIZUMAB 100mg IN 10ml SOLUTION FOR INFUSION	R	For the prevention of vaso-occlusive crises in sickle cell disorders as per NICE TA743. MMTC, February 2022
CUTIMED		
CUTIMED SORBACT 4cm X 6cm DRESSING	NF	
DACOMITINIB		

DACOMITINIB 45mg TABLETS	NICE	Approved for use as per NICE TA595 only. An individual patient NICE implementation form is required (see PPDU SharePoint). Medicines Effectiveness, January 2020
--------------------------	------	---

Dapagliflozin + Metformin

DAPAGLIFLOZIN 5mg & METFORMIN 1g TABLETS	NF	
--	----	--

Daratumumab

DARATUMUMAB 400mg IN 20ml INJECTION (PAEDS FREE OF CHARGE STOCK)	NF	
--	----	--

DARATUMUMAB 100mg IN 5ml INJECTION (PAEDS FREE OF CHARGE STOCK)	NF	
---	----	--

DIAMINOPYRIDINE

3,4 DIAMINOPYRIDINE 20mg TABLETS (DURBIN)	SR	To enhance neuromuscular transmission in the treatment of Myasthenia gravis (MG), Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenia (CM). Use by Neurology only. Medicines Effectiveness, February 2013.
---	----	--

DIBOTERMIN

DIBOTERMIN ALFA 12mg VIAL (IMPLANT)	R	Bone morphogenetic protein-2 for use in spinal fusion as per NHSE Policy 16063/P. MMTC April 2018
-------------------------------------	---	---

DIHYDROXYACETONE

DIHYDROXYACETONE 30% W/V SOLUTION	Y	
-----------------------------------	---	--

DIMETHYL FUMARATE

DIMETHYL FUMARATE 0.1% PATCH TEST DOR643 5ml	Y	
--	---	--

Dinutuximab beta

DINUTUXIMAB BETA 20mg in 4.5mL INJECTION	NF	
--	----	--

Dioralyte

DIORALYTE SACHETS (BLACKCURRANT)	Y	
----------------------------------	---	--

Diroximel fumarate

DIROXIMEL FUMARATE 231mg GR CAPSULES	R	For treating relapsing remitting multiple sclerosis as per NICE TA794. MMTC, November 2022
--------------------------------------	---	--

DOTAREM

DOTAREM VIAL 20ml	R	For use by MRI only. MMTC, November 2017
DOTAREM VIALS 15ml	R	For use by MRI only. MMTC, November 2017
Dronabinol + Cannabidiol		
DRONABINOL 2.7mg & CANNABIDIOL 2.5mg OROMUCOSAL SPRAY (FOC)	R	
Dupilumab		
DUPIPILUMAB 200mg in 1.14ml PRE-FILLED PEN	R	For treatment of moderate to severe atopic dermatitis as per NICE TA 534 for adults and children from the age of 6, for treatment of severe asthma with type 2 inflammation as per NICE TA 751 for adults and children from the age of 6. MMTC, Dec 2023.
Eculizumab		
ECULIZUMAB 300mg in 30ml INJECTION (COMPASSIONATE USE)	NF	
EMICIZUMAB		
EMICIZUMAB CONVENIENCE KIT	R	To be supplied with emicizumab prescriptions
EMICIZUMAB 60mg IN 0.4ml INJECTION (COMPASSIONATE USE)	NF	
ENCORAFENIB		
ENCORAFENIB 50mg CAPSULES (COMPASSIONATE USE)	NF	
ENTRECTINIB		
ENTRECTINIB 200mg CAPSULES	R	For treatment of solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, in patients aged 12 years and older as per NICE TA644 and CDF criteria. MMTC, January 2022
Erenumab		
ERENUMAB 140mg in 1ml INJECTION PRE-FILLED PEN	R	"For Use in Neurology as per NICE TA682 MMTC, September 2021"
ERYTHROMYCIN		
E2499 ERYTHROMYCIN 1%	Y	
Eslicarbazepine		

ESLICARBAZEPINE 200mg TABLETS	R	
ESTER GUM		
ESTER GUM RESIN 20% IN WSP 5g	Y	
ETANERCEPT		
ETANERCEPT 50mg INJECTION PRE-FILLED PEN (BENEPALI)	R	
EVA		
EVA BAG 1000ml (CTASU)	Y	
EVA BAG		
EVA BAG 500ml (CTASU)	Y	
EVA BAG 250ml (CTASU)	Y	
EVEROLIMUS		
EVEROLIMUS 2.5mg TABLETS	R	For the treatment of: advanced renal cell carcinoma as per NICE TA432; advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer as per NICE TA421; well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease as per NICE TA449. MMTC, August 2017
EVEROLIMUS 5mg DISPERSIBLE TABLETS sugar free (COMPASSIONATE USE)	NF	
EVEROLIMUS 5mg TABLETS	R	For the treatment of: advanced renal cell carcinoma as per NICE TA432; advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer as per NICE TA421; well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease as per NICE TA449. MMTC, August 2017

EVEROLIMUS 10mg TABLETS	R	For the treatment of: advanced renal cell carcinoma as per NICE TA432; advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer as per NICE TA421; well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease as per NICE TA449. MMTTC, August 2017
EXTRAVASATION		
EXTRAVASATION KIT	Y	
Faricimab		
FARICIMAB 6mg in 0.05mL INTRAVITREAL INJECTION (VABYSMO)	R	??For treatment of diabetic macular oedema as per NICE TA799 and for treatment of wet age-related macular degeneration as per NICE TA800. MMTTC, Nov 2022
FEDRATINIB		
FEDRATINIB 100mg CAPSULES	R	For treatment of disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis in adults, as per NICE TA756. MMTTC, March 2022
Fidaxomicin		
FIDAXOMICIN 40mg in 1ml ORAL SUSPENSION	R	For treatment of Clostridioides Difficile infection for patients who have an NG tube or have difficulty swallowing
Filgotinib		
FILGOTINIB 100mg TABLETS	R	For treating moderately to severely active ulcerative colitis as per NICE TA792. For treatment of active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with 2 or more DMARDs, alongside methotrexate as per NICE TA676. MMTTC, March 2024.
Filgrastim		

FILGRASTIM 120microgram (12million unit) in 0.2ml SYRINGE	NF	
Flumazenil		
FLUMAZENIL 500micrograms IN 5ml INJECTION	R	
FLUMAZENIL 500microgram in 5ml INJECTION	Y	
FLUTICASONE		
FLUTICASONE 500micrograms IN 2ml NEBULES	NF	
FLUTICASONE 0.05% CREAM 30G	NF	
Fluticasone + Azelastine		
FLUTICASONE PROPIONATE 50micrograms & AZELASTINE 137micrograms NASAL SPRAY	NF	
Folinic acid		
CALCIUM FOLINATE 100mg in 10ml INJECTION	Y	
FOMEPIZOLE		
FOMEPIZOLE 1.5g IN 1.5ml INJECTION	UNR	For use after recommendation by the Poison Unit only. Medicines Effectiveness, December 2009.
FORMALDEHYDE		
FORMALDEHYDE 2% PATCH TEST (TRIAL) 8ml	Y	
FORMALDEHYDE SOLUTION BP 4% V/V IN PURIFIED WATER 50ml	UNR	For radiation proctitis. MMTC, October 2012
Fostamatinib		
FOSTAMATINIB 150mg TABLETS	R	??For treatment of refractory chronic immune thrombocytopenia as per NICE TA835. MMTC, December 2022
FOSTAMATINIB 100mg TABLETS	R	?For treatment of refractory chronic immune thrombocytopenia as per NICE TA835. MMTC, December 2022
Fremanezumab		
FREMANEZUMAB 225mg/1.5ml solution for injection pre-filled disposable devices	R	For preventing migraine in adults as per NICE TA764. MMTC, September 2022
FRUCTOSE		

FRUCTOSE POWDER 25G	SR	For Hydrogen breath test. Medicines Effectiveness, June 2015.
Galantamine		
GALANTAMINE 20mg/5mL ORAL SOLUTION	NF	
Galcanezumab		
GALCANEZUMAB 120mg/1ml solution for injection pre-filled disposable devices	R	For neurology use only as per NICE TA659. MMTTC, September 2021
Ganirelix		
GANIRELIX 250micrograms in 0.5ml PRE-FILLED SYRINGE	NF	
GASTROMIRO SOLUTION		
GASTROMIRO 300 SOLUTION 50ml	Y	
GAUZE		
KERLIX GAUZE ROLL 11.4cm X 3.7m DRESSING	NF	
Gelatin		
ISOPLEX 4% INFUSION 500ml	R	
GELOFUSINE		
GELOFUSINE INFUSION 500ml	Y	
Gentamicin		
GENTAMICIN 1.5% EYE DROPS (PRES FREE) 5ml	SR	
GLUCOMEN		
GLUCOMEN AREO SENSORS BLOOD GLUCOSE TEST STRIPS (50)	R	For use in the womens centre only. Medicines Effectiveness, February 2016.
GLUCOSE		
GLUCOSE (DEXTROSE MONOHYDRATE) POWDER 75g	UNR	Used for Glucose tolerance test during pregnancy. Medicines Effectiveness, June 2013.
GLUCOSE ANHYDROUS POWDER (LEMON) 75g	Y	
GLYCERIN		
GLYCERIN 100ml	Y	
GLYCERYL MONOTHIOGLYCOLATE		

G004 GLYCERYL MONOTHIOGLYCOLATE (GMTG) Y

GLYCOPYRROLATE

GLYCOPYRROLATE AQUEOUS SOLUTION 0.5% 50ml SR For use by Dermatology only. Medicines Effectiveness, March 2013.

GLYCOPYRROLATE 0.5% IN AQUEOUS CREAM 50g UNR For intractable hyperhidrosis. Medicines Effectiveness, March 2013.

HAEMOFILTRATION

HAEMOFILTRATION (Ci-Ca K4 DIALYSATE) INFUSION 5L R For use on CTCCU & ITU's only as part of citrate haemodiafiltration. MMTC, March 2013

HAEMOFILTRATION multiBic 0 SUBSTITUTION FLUID (NO POTASSIUM) 5L R For use on CTCC only as part of citrate haemodiafiltration. MMTC, March 2013.

HAEMOFILTRATION multiBic 4 SUBSTITUTION FLUID (20mmol POTASSIUM) 5L R For use on CTCC only as part of citrate haemodiafiltration. MMTC, March 2013.

HAEMOFILTRATION multiBic 2 SUBSTITUTION FLUID (10mmol POTASSIUM) 5L R For use on CTCC only as part of citrate haemodiafiltration. MMTC, March 2013.

HAEMOPHILLUS

HAEMOPHILLUS TYPE B + NEISSERIA MENINGITIDIS C VACCINE 0.5ml INJECTION NF

HAZ-TAB

HAZ-TAB GRANULES 500g Y

HAZ-TAB 4.5g TABLETS Y

HC HAH EMERGENCY DELIVERY FEE

HC HAH EMERGENCY DELIVERY FEE (STOP! CHECK THIS IS APPROVED) R

HEMASTIX REAGENT

HEMASTIX REAGENT STRIPS Y

HEMOSOL

HEMOSOL B0 SOLUTION FOR HAEMODIALYSIS/HEAMOFILTRATION 5L R

Heparin

HEPARIN SODIUM 5,000units IN 1litre INFUSION BAGS 1L (FKB0934G)	R	For use by neuroradiology for mechanical thrombectomies - MMTC December 2021
Herpes-Zoster		
HERPES-ZOSTER VACCINE (RECOMBINANT, ADJUVANTED) 0.5ml	NF	
HEXAMINOLEVULINATE		
HEXAMINOLEVULINATE 85mg POWDER FOR BLADDER INSTILLATION	R	For use by Urology Department only. Medicines Effectiveness, Septemeber 2008.
HIBISCRUB		
HIBISCRUB PUMP DISPENSERS	Y	
HISTOACRYL		
HISTOACRYL 0.5ml TISSUE ADHESIVE CLEAR (TEMP PROCUREMENT SUPPLY)	Y	
Human papillomavirus vaccine		
HUMAN PAPILLOMAVIRUS (GARDASIL 9) VACCINE 0.5ml pre-filled syringes	NF	
HYDROCORTISONE		
HYDROCORTISONE ACETATE 5mg/5mL LIQUID	SR	
HYDROFILM		
HYDROFILM 10cm X 15cm DRESSING	NF	
HYDROXYMETHYLPENTYLCYCLOHEXENECARBOXALDEHYDE 5% PATCH TEST		
HYDROXYMETHYLPENTYLCYCLOHEXENECARBOXALDEHYDE 5% PATCH TEST	Y	
HYDROXYPROPYL METHYLCELLULOSE		
HYDROXYPROPYLMETHYLCELLULOSE (HPMC) 2% PRE-FILLED SYRINGE 2ml	R	For use by Ophthalmology only. Medicines Effectiveness, September 2017
HYDROXYZINE		
H028 HYDROXYZINE HYDROCHLORIDE 1% PATCH TEST	Y	
IDEBENONE		
IDEBENONE 45mg TABLETS	UNR	For use by Consultant in Mitochondrial Genetics for Mitochondrial Myopathy. Medicines Effectiveness, August 2009.
ILOPROST		
ILOPROST 10microgram/ml NEBULISER SOLUTION	NF	

Imatinib

IMATINIB 400mg TABLETS	R	For the treatment of: Philadelphia-chromosome- positive chronic myeloid leukaemia (CML) who initially present in the accelerated phase or with blast crisis and chronic phase in those who have not had previous treatment but have progressed to the accelerated phase or blast crisis as per NICE TA70; untreated chronic-phase Philadelphia chromosome- positive chronic myeloid leukaemia in adults as per NICE TA426; chronic graft versus host disease (GvHD) as per NHSE policy 16069/P. MMTC, August 2017
------------------------	---	--

IMIQUIMOD

IMIQUIMOD 5% CREAM 250mg SACHETS TTO 12's	SR
---	----

IMMUNOGLOBULIN

IMMUNOGLOBULIN SUB-CUTANEOUS 4g in 20ml PRE FILLED SYRINGE (HIZENTRA)	R
--	---

IMMUNOGLOBULIN NORMAL

IMMUNOGLOBULIN 10g in 50ml INJECTION (CUVITRU)	R	
IMMUNOGLOBULIN NORMAL IV 20g in 400ml (5%) INF (FLEBOGAMMADIF)	Y	
IMMUNOGLOBULIN NORMAL IV 4g in 24ml INFUSION (CUTAQUIG)	R	
IMMUNOGLOBULIN NORMAL IV 3.3g in 20ml INFUSION (CUTAQUIG)	R	
IMMUNOGLOBULIN NORMAL IV 2g in 12ml INFUSION (CUTAQUIG)	R	
IMMUNOGLOBULIN NORMAL IV 1.65g in 10ml INFUSION (CUTAQUIG)	R	
IMMUNOGLOBULIN NORMAL IV 1g in 6ml INFUSION (CUTAQUIG)	R	
IMMUNOGLOBULIN NORMAL IV 8g in 48ml INFUSION (CUTAQUIG)	R	
IMMUNOGLOBULIN SUB-CUTANEOUS 4g IN 20ml INJECTION (HIZENTRA)	R	RESTRICTED TO IMMUNOLOGY USE ONLY.

IMS

IMS 70% POUR BOTTLES 600ml	Y
IMS 70% in DEB SPRAY 500ml	Y

Imuderm Emollient

IMUDERM EMOLLIENT 500g NF

INFACARE BABY

INFACARE BABY BATH NF

Infliximab

INFLIXIMAB 100mg INJECTION (ZESSLY) R For rheumatoid arthritis as per NICE TA130 and TA295, psoriasis as per TA134, for ulcerative colitis as per TA163 and TA329, Crohn's disease as per TA187, and psoriatic arthritis as per TA199. MMTC, June

IOHEXOL

IOMERON 350 INJECTION 200ml NF

OMNIPAQUE 350 INJECTION 500ml R For use with syringeless multidose equipment only in CT departments (JR, WW and HGH). MMTC, December 2019

OMNIPAQUE 350 INJECTION 200ml Y

OMNIPAQUE 350 INJECTION 75ml Y

IOMERON 350 INJECTION 100ml NF

IOMERON

IOMERON 350 50ml NF

IPILIMUMAB

IPILIMUMAB 50mg/10ml INJECTION (EAMS MESOTHELIOMA) NF

IPILIMUMAB 200mg in 40ml INJECTION (EAMS MESOTHELIOMA) NF

ISOCYANATE

ISOCYANATE COMPLETE SERIES I-1000 Y

KELTROL

SUSPENSION DILUENT A (XANTHAN GUM 1%) Y

KEROSENE

KEROSENE 10% IN W.S.P Y

KEROSENE 10% IN OLIVE OIL Y

KETOCONAZOLE

KETOCONAZOLE 200mg TABLETS NF

LACTIC ACID

LACTIC ACID SALICYLIC, PROPYLENE IN AQUEOUS Y
CREAM

Lenvatinib

LENVATINIB 4mg CAPSULES (KISPLYX) R For treatment of advanced renal cell carcinoma in adults. To be used with everolimus as per NICE TA498. MMTTC, August 2018

LENVATINIB 10mg CAPSULES (KISPLYX) R For treatment of advanced renal cell carcinoma in adults. To be used with everolimus as per NICE TA498. MMTTC, August 2018

Levofloxacin

LEVOFLOXACIN 5mg/ml EYE DROPS
PRESERVATIVE FREE 5ml R

LEVOFLOXACIN 5mg/ml EYE DROPS
PRESERVATIVE FREE 5ml - TTO PACK SR

LEVOSIMEDAN

LEVOSIMENDAN 12.5mg in 5ml INFUSION UNR For use by CTCCU consultant only as last line therapy in patients with cardiogenic shock or acute decompensated Heart failure. MMTTC August, 2023.

LIPIODOL ULTRA

LIPIODOL ULTRA FLUID 10ml INJECTION Y

LIQUID PARAFFIN,

LIQUID PARAFFIN, WHITE SOFT PARAFFIN &
LANOLIN EYE OINTMENT 5g R

MAGGOTS

MAGGOTS IN 4cm X 5cm BIOBAG BB100 R This dressing may be used by Vascular, Plastics or following recommendation by Tissue Viability team. MAC, October 2009.

MAGGOTS IN 12cm X 6cm BIOBAG BB300 R This dressing may be used by Vascular, Plastics or following recommendation by Tissue Viability team. MAC, October 2009

MAGGOTS IN 10cm X 10cm BIOBAG BB400	R	This dressing may be used by Vascular, Plastics or following recommendation by Tissue Viability team. MAC, October 2009.
MAGGOTS IN 5cm X 6cm BIOBAG BB200	R	This dressing may be used by Vascular, Plastics or following recommendation by Tissue Viability team. MAC, October 2009.
MAGGOTS LOOSE FULL POT (300 LARVAE)	R	This dressing may be used by Vascular, Plastics or following recommendation by Tissue Viability team. MAC, October 2009.
MAGNEVIST		
MAGNEVIST 0.04mmol in 20ml (2mmol/L) PRE-FILLED SYRINGE	R	For use as contrast enhancement in direct magnetic resonance arthrography at the NOC only. MMTc, November 2020
MANUKA		
MESITRAN HONEY OINTMENT 15g	NF	
Maribavir		
MARIBAVIR 200mg TABLETS	R	For treatment of refractory cytomegalovirus infection after hematopoietic stem cell transplant or solid organ transplant as per NICE TA860. MMTc, May 2023
MEDIHONEY		
MEDIHONEY (MANUKA HONEY) 80% WOUND GEL 20g	R	FOLLOWING RECOMMENDATION BY THE TISSUE VIABILITY TEAM ONLY. MAC OCTOBER 2009
MEDIHONEY (MANUKA HONEY) 80% WOUND GEL 10g	R	Following recommendation by the Tissue Viability Team only. MAC, October 2009.
Menotrophin		
MENOTROPHIN 150international units INJECTION (MENOPUR)	R	
MENTHOL		
MENTHOL 5% in AQUEOUS CREAM 500g	NF	
MEPITAC		

MEPITAC TAPE 2cm x 3m NF

METHACHOLINE CHLORIDE

METHACHOLINE CHLORIDE 2mg/ml INHALATION CHALLENGE SOLUTION 5ml SR

METHACHOLINE CHLORIDE 4mg/ml INHALATION CHALLENGE SOLUTION 5ml SR

METHACHOLINE CHLORIDE 16mg/ml INHALATION CHALLENGE SOLUTION 5ml SR

METHACHOLINE CHLORIDE 8mg/ml INHALATION CHALLENGE SOLUTION 5ml SR

METHACHOLINE CHLORIDE 0.125mg/ml INHALATION CHALLENGE SOLUTION 5ml SR

METHACHOLINE CHLORIDE 0.25mg/ml INHALATION CHALLENGE SOLUTION 5ml SR

METHACHOLINE CHLORIDE 32mg/ml INHALATION CHALLENGE SOLUTION 5ml SR

METHACHOLINE CHLORIDE 1mg/ml INHALATION CHALLENGE SOLUTION 5ml SR

METHACHOLINE CHLORIDE 0.0625mg/ml INHALATION CHALLENGE SOLUTION 5ml SR

METHACHOLINE CHLORIDE 0.5mg/ml INHALATION CHALLENGE SOLUTION 5ml SR

METHADONE

METHADONE 1mg IN 1ml MIXTURE NF

METHYLISOTHIGZOLINE

METHYLISOTHIGZOLINE 200parts per million PATCH TEST (TRIAL) 8ml Y

Metolazone

METOLAZONE 5mg TABLETS R

To be initiated under advice of HF team only (doctors or specialist nurses) Note this is a new licensed product and is twice as potent as previous unlicensed product.

MILTON

MILTON 2% SOLUTION 500ml Y

MINI-HAZ- TABS

HAZ-TAB 0.5g TABLETS (MINI-HAZ) Y

MO12-

MO12- METHYL-4- HYDROXYBENZOATE Y

Mogamulizumab

MOGAMULIZUMAB 20mg/5ml SOLUTION FOR INFUSION VIALS	R	For treatment of Sjzary syndrome in adults who have had at least 1 systemic treatment, as per NICE TA754. MMTTC, March 2022
Molnupiravir		
MOLNUPIRAVIR 200mg CAPSULES	R	For treatment of mild to moderate COVID-19 in non-hospitalised adults (aged 18 years and over) who can't receive nMAB. MMTTC, December 2021
MONSELS		
MONSELS SOLUTION (FERRIC SUBSULPHATE)	SR	For Haemostasis following cervical biopsy. For use by GUM and Colposcopy Only. Medicines Effectiveness, December 2017
MULTIHANCE		
MULTIHANCE INJECTION 10ml	R	Restricted to use in liver scans only. MMTTC, November 2017
MULTISTIX		
MULTISTIX 8-SG	Y	
MULTISTIX 10SG REPORT PADS	Y	
MULTISTIX 10-SG	Y	
MULTISTIX 8SG REPORT PADS	Y	
Natalizumab		
NATALIZUMAB 150mg in 1ml PRE FILLED SYRINGES	R	For the treatment of adults with highly active relapsing-remitting multiple sclerosis as NICE TA 127. MMTTC, December 2022
NIRMATRELVIR + RITONAVIR		
PF-07321332 150mg & RITONAVIR 100mg TABLETS (PAXLOVID) (pk30)	R	For treatment of COVID-19 in adults as per NICE TA878. MMTTC August, 2023
Normal immunoglobulin human		
IMMUNOGLOBULIN SUB-CUTANEOUS 2g in 10ml PRE FILLED SYRINGE (HIZENTRA)	R	
Nutryelt		
NUTRYELT INJECTION 10ml	Y	

NYSTATIN

NYSTATIN 100,000 VAGINAL TABLETS	UNR	Restricted for use in Vaginal candida resistant to standard alternatives while vaginal cream is unavailable. MMTC June 2020
----------------------------------	-----	---

OMNIPAQUE

OMNIPAQUE 140 INJECTION 200ml	Y
OMNIPAQUE 240 INJECTION 50ml	Y
OMNIPAQUE 300 INJECTION 100ml	Y
OMNIPAQUE 300 INJECTION 200ml	Y
OMNIPAQUE 300 INJECTION 50ml	Y
OMNIPAQUE 350 INJECTION 100ml	Y
OMNIPAQUE 350 INJECTION 50ml	Y
OMNIPAQUE 300 INJECTION 20ml	Y

Paravit

PARAVIT CF LIQUID 7ml	R	For treatment of Fat soluble vitamin replacement in CF patients. initiation under CF team only. MMTC, August 2021.
-----------------------	---	--

Paravit-cf capsules

PARAVIT CAPSULES	R	For treatment of Fat soluble vitamin replacement in CF patients. initiation under CF team only. MMTC, August 2021.
------------------	---	--

PATCH TEST

FERROUS SULPHATE 5% PATCH TEST ALLERGEN 2405	Y
CETYL/STEARYL ALCOHOL 20% PATCH TEST	Y
D006 - BUTYL HYDROXY TOLUENE (BHT) 2% PATCH TEST	Y
FINASTERIDE 10% PATCH TEST IN W.S.P	Y
B035 BISPHENOL F, EPOXY RESIN 0.25% PATCH TEST	Y
D049A - METHYLDIBROMO GLUTARONITRILE 0.3% PATCH TEST	Y

FINASTERIDE 1% PATCH TEST IN W.S.P	Y	
DALTEPARIN 1:10 in SODIUM CHLORIDE PATCH TEST	Y	
DIMETHYL FUMARATE 0.01% PATCH TEST DO66B 5ml	Y	
B036 1,4-BUTANEDIOL DIGLYCIDYLETHER 0.25% PATCH TEST	Y	
E1303 ALPHA-AMYL-CINNAMALDEHYDE 1% PATCH TEST	Y	
DALTEPARIN 1:100 in SODIUM CHLORIDE PATCH TEST	Y	
P013= POLYSORBATE 80 PATCH TEST	Y	
S017 SODIUM TETRACHLOROPALLADATE HYDRATE PATCH TEST	Y	
p-PHENYLENEDIAMINE 0.01% PATCH TEST (PPD)	Y	
CHLORHEXIDINE DIGLUCONATE PATCH TEST	R	For use by Dermatology/Immunology only. Medicines Effectiveness, March 2013.
PATCH TESTS		
PATCH TESTS FOR ORDERING (1)	R	
PERFLUTREN		
PERFLUTREN CONTAINING LIPID MICROSPHERES 150microlitres IN 1ml INJECTION	R	Contrast for use in cardiac ECHO (cardiac out-patients) only. MMTC, September 2017
PERITONEAL DIALYSIS FLUID		
PERITONEAL DIALYSIS FLUID 1.5% No2 2L	Y	
PHENOBARBITAL		
PHENOBARBITAL SODIUM BP	Y	
PHOXILIUM		
PHOXILIUM 1.2mmol per litre PHOSPHATE SOLUTION FOR HAEMODIALYSIS/HAEMOFILTRATION 5L	R	
PLASMALYTE		
PLASMALYTE 148 (PH 7.4) SOLUTION FOR INFUSION 1L BAGS (FKB2534)	R	For infusion as part of the priming solutions for the cardio-pulmonary bypass during cardiac surgery. MMTC February, 2022
PLASMALYTE 148 & GLUCOSE 5% SOLUTION FOR INFUSION 1L BAGS (FKE2583)	NF	

PLASMALYTE 148 (PH 7.4) SOLUTION FOR INFUSION 500ml (FKE0323)	NF	
PLASTIC TRAY		
PLASTIC ALLERGEN TRAY	Y	
PLIAZON		
PLIAZON CREAM 100ml	R	Pliazon cream free of charge for patients receiving cetuximab. Medicines Effectiveness, October 2017
Pneumococcal vaccine		
PNEUMOCOCCAL POLYSACCHARIDE CONJUGATED VACCINE 0.5ML PFS (PREVENAR 13)	R	
POTASSIUM ASCORBATE		
POTASSIUM ASCORBATE 10% EYE DROPS (PRESERVATIVE FREE) 5ml	SR	For management of chemical eye injury alongside topical steroids, antibiotics and lubricants. MMTC February 2022
POTASSIUM CHLORIDE		
POTASSIUM CHLORIDE STRONG 15% (20mmol) INJECTION 10ml	R	For use as per approved local guidelines on: - Children's areas - Silver Star - Cardiac Theatres MMTC, May 2017
POVIDONE IODINE		
POVIDONE IODINE 5% OPHTHALMIC SOLUTION 50ml	SR	For pre-op in eye theatres only, Medicines Effectiveness July 2019
PREGNANCY TEST		
PREGNANCY TEST 25million International Units/ml (ALERE hCG CASSETTE)	Y	
PRICK TEST		
PEA GREEN SKIN PRICK TEST	R	For use by Dermatology/Immunology only. Medicines Effectiveness, March 2013.
WHITE BEAN SKIN PRICK TEST	R	For use by Dermatology/Immunology only. Medicines Effectiveness, March 2013.
EGGPLANT SKIN PRICK TEST	R	
SKIN PRICK TEST SOLUTIONS (1)	R	

LONDON PLANE SKIN TEST SOLUTION 3ml	R	
POTATO SKIN PRICK TEST	R	For use by Dermatology/Immunology only. Medicines Effectiveness, March 2013.
RED OAK SKIN TEST SOLUTION 3ml	R	
COCOA SKIN PRICK TEST	R	For use by Dermatology/Immunology only. Medicines Effectiveness, March 2013.
COCONUT SKIN PRICK TEST	R	
OYSTER PRICK TEST	R	For use by Dermatology/Immunology only. Medicines Effectiveness, March 2013.
D065= DECYL GLUCOSIDE PRICK TEST	Y	
L004= LAURYL POLYGLUCOSE PRICK TEST	Y	
SOLU-PRICK-NEGATIVE CONTROL 002228 3ml	R	For use by Dermatology/Immunology only. Medicines Effectiveness, March 2013.
PRISMOCAL		
PRISMOCAL B22 SOLUTION FOR HAEMODIALYSIS/HAEMOFILTRATION 5L	R	
PRISMOCITRATE		
PRISMOCITRATE 18/0 SOLUTION FOR HAEMODIALYSIS/HAEMOFILTRATION 5L	R	
PROHANCE		
PROHANCE VIAL 20ml	R	Strictly restricted for use in those unable to have Dotarem. MMTC, November 2017
PROHANCE VIAL 15ml	R	Strictly restricted for use in those unable to have Dotarem. MMTC, November 2017
Pseudoephedrine		
PSEUDOEPHEDRINE HYDROCHLORIDE 60mg TABLETS	Y	
PYRIDOXINE		
PYRIDOXINE 100mg IN 2ml INJECTION	UNR	

RADIO-OPAQUE

RADIO-OPAQUE MARKER CAPSULES 6 CAPSULE PACK (3X2) R For use by Radiology , Paediatric Gastroenterology and Collorectal Surgery. Medicines Effectiveness, March 2013.

Raltegravir

RALTEGRAVIR 100mg SACHETS NF

RANIBIZUMAB

RANIBIZUMAB 2.3mg in 0.23ml INTRAVITREAL INJECTION R

Ravulizumab

RAVULIZUMAB 300mg in 3ml INJECTION (CTASU) R

RAVULIZUMAB 300mg in 30ml INJECTION (CTASU) NF

RAVULIZUMAB 1.1g in 11ml INJECTION (CTASU) R

RED STAINING

RED STAINING DYE FOR CHLORHEXIDINE Y

Ribavirin

RIBAVIRIN 200mg TABLETS R For use by Consultant Hepatologist for oral Hepatitis treatment as per TA75, TA106 and TA200.MAC, April 2003

Rilpivirine

RILPIVIRINE 900mg in 3ml PROLONGED RELEASE INJECTION R For treatment of HIV-1 infection, to be used alongside cabotegravir as per NICE TA 757. MMTC, July 2022

Romosozumab

ROMOSOZUMAB 105mg in 1.17ml PRE FILLED PEN (EVENITY) R For treatment of severe osteoporosis in people after menopause who are at high risk of fracture as per NICE TA791. MMTC February, 2022

Roxadustat

ROXADUSTAT 50mg TABLETS R For Symptomatic anemia in chronic kidney disease as per NICE TA807. MMTC, October 2022

ROXADUSTAT 150mg TABLETS	R	For Symptomatic anemia in chronic kidney disease as per NICE TA807. MMTC, October 2022
ROXADUSTAT 70mg TABLETS	R	For Symptomatic anemia in chronic kidney disease as per NICE TA807. MMTC, October 2022
ROXADUSTAT 100mg TABLETS	R	For Symptomatic anemia in chronic kidney disease as per NICE TA807. MMTC, October 2022
ROXADUSTAT 20mg TABLETS	R	For Symptomatic anemia in chronic kidney disease as per NICE TA807. MMTC, October 2022
Rucaparib		
RUCAPARIB 250mg TABLETS	R	"For maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer as per NICE TA611 MMTC, Feb 2020"
Rupatadine		
RUPATADINE 10mg TABLETS	NF	
SALAZOPYRIN		
SALAZOPYRIN 10% IN W.S.P PATCH TEST	Y	
Sapropterin		
SAPROPTERIN 100mg SOLUBLE TABLETS SF	NF	
SECRETIN		
SECRETIN 100international units INJECTION	UNR	For secretin-stimulated magnetic resonance cholangiopancreatography (MRCP) (unlicensed indication). Medicines Effectiveness, June 2007.
Siponimod		
SIPONIMOD 250microgram TABLETS	R	For treatment of secondary progressive Multiple Sclerosis as per NICETA656. MMTC, May 2021.

SIPONIMOD 2mg TABLETS	R	For treatment of secondary progressive Multiple Sclerosis as per NICETA656. MMTC, May 2021.
SIPONIMOD 250microgram TABLETS	R	For treatment of secondary progressive Multiple Sclerosis as per NICETA656. MMTC, May 2021.
SKIN MARKER		
SKIN MARKER PENS SM-R	Y	
Sodium chloride		
SODIUM CHLORIDE 5% INHALATION CHALLENGE SOLUTION 10ml	SR	"For use by Lung Function Lab only for Induced Sputum Testing to assess bronchial hyperresponsiveness MMTC, May 2014."
SODIUM CHLORIDE 0.9% NASAL SPRAY 50ml	Y	
SODIUM CHLORIDE 4% INHALATION CHALLENGE SOLUTION 10ml	SR	"For use by Lung Function Lab only for Induced Sputum Testing to assess bronchial hyperresponsiveness MMTC, May 2014."
SODIUM CHLORIDE 0.9% PLASTIC AMP 10ml	Y	
SODIUM CHLORIDE 0.9% PLASTIC AMP 5ml	Y	
SODIUM CHLORIDE 3% INHALATION CHALLENGE SOLUTION 10ml	SR	"For use by Lung Function Lab only for Induced Sputum Testing to assess bronchial hyperresponsiveness MMTC, May 2014."
SODIUM CHLORIDE 0.9% PLASTIC AMP 10ml	Y	
DF SODIUM CHLORIDE 0.9% INFUSION 250ml (FE1322)	Y	
DF SODIUM CHLORIDE 0.9% INFUSION 1L (FE1324)	Y	
SODIUM CHLORIDE 0.9% INFUSION 1L FKE1324TPS	Y	
SODIUM CHLORIDE 0.9% FLOWFUSOR 2L (FBP7215)	Y	

SODIUM CHLORIDE 5% BRONCHIAL SOLUTION FOR NEBULISATION 100ml		UNR For use by Lung Function Lab only for Induced Sputum Testing to assess bronchial hyperresponsiveness MMTC, May 2014.
SODIUM CHLORIDE 2.7% INTRAVENOUS INFUSION R 500ml		Restricted for the use of intracranial pressure on NICU and AICU as per Neurosciences Guideline and Severe Symptomatic Hyponatraemia as per the MIL: Guidelines for the Management of Acute Severe Symptomatic Hyponatraemia in Adults. MMTC, March 2016
SODIUM CHLORIDE 0.9% 50ml VIAL	Y	
SODIUM CHLORIDE 30% (50mmols) INJECTION 10ml	Y	
SODIUM CHLORIDE 0.9% INFUSION 250ml FE1322	Y	
SODIUM CHLORIDE 4% BRONCHIAL SOLUTION FOR NEBULISATION 100ml		UNR For use by Lung Function Lab only for Induced Sputum Testing to assess bronchial hyperresponsiveness MMTC, May 2014.
SODIUM CHLORIDE 30% (25mmol/5ml) LIQUID	UNR	Sodium Supplementation to adjust the serum levels (and sodium urine losses) in neonates, infants and in children with sodium deficiency (hyponatraemia). Medicines Effectiveness, March 2013.
SODIUM CHLORIDE 0.9% PLASTIC AMP 20ml	Y	
SODIUM CHLORIDE 0.9% PLASTIC AMP 5ml	Y	
SODIUM CHLORIDE 0.9% PLASTIC AMP 10ml	Y	
SODIUM CHLORIDE 0.9% IRRIGATION BOTTLE 1L UKF7124	Y	
SODIUM CHLORIDE 0.9% IRRIGATION BAGS 1L (FKB7525T) EASIFLOW	Y	
SODIUM CHLORIDE 0.9% IRRIGATION 3L (FKB7528T) EASYFLO	Y	
SODIUM CHLORIDE 0.9% IRRIGATION 3L (B7127) UROMATIC	R	For use at NOC theatres only. Medicines Effectiveness, August, 2001.

SODIUM CHLORIDE 3% BRONCHIAL SOLUTION FOR
NEBULISATION 100ml

UNR For use by Lung Function Lab
only for Induced Sputum Testing
to assess bronchial
hyperresponsiveness MMTC, May
2014.

SODIUM CITRATE

SODIUM CITRATE GRANULES Y

SODIUM FLUORIDE

SODIUM FLUORIDE TOOTHPASTE 1.1% (5000ppm) NF
TOOTHPASTE 51g

Sodium glycerophosphate

SODIUM GLYCEROPHOSPHATE 20mmol (of
phosphate) in 20ml INJECTION Y

SODIUM NITRITE

SODIUM NITRITE 300mg IN 10ml INJECTION (UL) UNR For use by Accidents and
Emergency Department for
treatment of poisoning with
cyanides (used in conjunction
with sodium thiosulfate).
Medicines Effectiveness, October
2013.

SODIUM NITRITE 300mg IN 10ml INJECTION R For use by Accidents and
Emergency Department for
treatment of poisoning with
cyanides (used in conjunction
with sodium thiosulfate).
Medicines Effectiveness, October
2013.

SODIUM PHENYLBUTYRATE

SODIUM PHENYLBUTYRATE 2g in 10ml INJECTION UNR For the treatment of Urea Cycle
Defects as per BIMDG adult
emergency management
guideline. To be initiated
following discussion with
Metabolic Medicine or as per
patient's care plan from the
national centre. MMTC, July 2016

SODIUM THIOSULFATE

SODIUM THIOSULFATE 12.5g in 50ml INJECTION UNR
(Unlicensed)

SODIUM ZIRCONIUM CYCLOSILICATE

SODIUM ZIRCONIUM CYCLOSILICATE 10g POWDER R		For use in the emergency care of acute life threatening hyperkalaemia and for use in patients with persistent hyperkalaemia and chronic kidney disease or heart failure as
SODIUM ZIRCONIUM CYCLOSILICATE 5g POWDER R		For use in the emergency care of acute life threatening hyperkalaemia and for use in patients with persistent hyperkalaemia and chronic kidney disease or heart failure as per NICE TA599.
SOFTISAN		
S016 = SOFTISAN 649	Y	
SOLIFENACIN		
SOLIFENACIN 5mg/5ml LIQUID	NF	
Solriamfetol		
SOLRIAMFETOL 75mg TABLETS	R	For treatment of excessive daytime sleepiness caused by narcolepsy as per NICE TA 758. MMTC, September 2022
SOLRIAMFETOL 150mg TABLETS	R	For treatment of excessive daytime sleepiness caused by narcolepsy as per NICE TA 758. MMTC, September 2022
SOLU-BEEF		
SOLU-BEEF	Y	
SONOVUE		
SONOVUE 40microlitres/5ml INJECTION	R	Restricted to use by radiology (adults and paediatrics) and cardiac physiology only. MMTC, January 2018
Sotorasib		
SOTORASIB 120mg TABLETS (ORBIS FOC STOCK)	NF	
SOTORASIB 120mg TABLETS	NF	
SOTROVIMAB		

SOTROVIMAB 500mg in 8mL INJECTION	R	For treatment of COVID-19 in adults and young people aged 12 years and over and weighing at least 40 kg as per NICE TA878. MMTC, August 2023
SPILLAGE		
SPILLAGE PILLOWS 230 X 380mm (POWERSORB)	Y	
SUCROFERRIC OXYHYDROXIDE		
SUCROFERRIC OXYHYDROXIDE (iron 500mg) CHEWABLE TABLETS	R	For treatment of Hyperphosphataemia in CKD patients where the use of sevelamer and lanthanum are inappropriate. To be initiated only on recommendation of Renal team. MMTC, January 2022
SUPRASORB		
SUPRASORB X + POLYHEXANIDE 9cm x 9cm DRESSING	R	Following recommendation by Tissue Viability Team. MMCT, October 2009
TACHOSIL		
TACHOSIL 3cm X 2.5cm MEDICATED SPONGE	R	For adults with CSF leak or skull base defects undergoing ENT/Neuro surgery only. MMTC, November 2019
TALAZOPARIB		
TALAZOPARIB 250micrograms CAPSULES (COMPASSIONATE USE)	NF	
TALC		
STERILE TALC POUDRAGE KIT 2x3g	R	For dry powder pleurodesis during / after a thoracoscopy. Consultant use only. NB: plain pleurodesis is still carried out using the old sterile talc (DIB289) and added to NaCl 0.9%. MAC, September 2010.
STERILIZED TALC 4g	R	For pleuridesis. MAC, September 2010.
TARTRAZINE		
TARTRAZINE 2.5% DYE 10ml	UNR	
TELMISARTAN		
TELMISARTAN 40mg TABLETS	NF	

TELMISARTAN 80mg TABLETS	NF	
TEST STRIPS		
WAVESENSE JAZZ DUO TEST STRIPS 2X25	R	FOR USE IN WOMENS CENTRE ONLY
BLOOD GLUCOSE TEST STRIPS - FREESTYLE OPTIUM NEO H (100)	R	NOT FOR TRUST USE - FOR WHOLESALE ORDER USE ONLY
TETRACYCLINE		
TETRACYCLINE 3% IN W.S.P. OINTMENT	NF	
THALIDOMIDE		
THALIDOMIDE 50mg CAPSULES	R	For chronic myeloid leukaemia as per NICE TA228. Medicines Effectiveness, March 2011 A maximum of: * Four weeks of therapy for women of childbearing potential * Twelve weeks of therapy for all other patients. Approval from the Celgene Medical Director is a mandatory requirement prior to any deviation from these stipulated prescription lengths
TISEPT		
TISEPT SACHETS 100ml	Y	
Tralokinumab		
TRALOKINUMAB 150mg in 1ml PRE FILLED SYRINGES	R	For treating moderate to severe atopic dermatitis as per NICE TA814. MMTC, October 2022
TROPICAMIDE		
TROPICAMIDE/PHENYLEPHRINE 0.28mg/5.4mg OPHTHALMIC INSERT	R	WARD STOCK ONLY
TUBERCULIN		
TUBERCULIN 2tuberculin units in 0.1ml INJECTION 1.5ml	UNR	For Mantoux test. Medicines Effectiveness, July 2011.
Tucatinib		
TUCATINIB 50mg TABLETS	R	For treatment of HER2-positive locally advanced or metastatic breast cancer as per NICE TA786. MMTC, December 2022
U003 URETHANE		
U003 URETHANE DIACRYLATE 0.05	Y	

UBIQUINONE

UBIQUINONE 200mg CAPSULES	UNR	For use in mitochondrial diseases by consultants in mitochondrial genetics only. MMTC July 2012
UBIQUINONE 100mg CAPSULES	UNR	For use in mitochondrial diseases by Consultants in Mitochondrial Genetics only. MMTC, July 2012.
UBIQUINONE 30mg CAPSULES	UNR	For use in mitochondrial diseases by Consultants in Mitochondrial Genetics only. MMTC, July 2012.
UBIQUINONE 50mg/5ml LIQUID 500ml	UNR	For use in mitochondrial diseases by Consultants in Mitochondrial Genetics only. MMTC, July 2012.

Upadacitinib

UPADACITINIB 45mg TABLETS M/R	NF	For the treatment of moderate to severe active rheumatoid arthritis in adult patients as per NICE TA665. For treatment of active psoriatic arthritis after inadequate response to DMARDs as per NICE TA768. For treatment of active ankylosing spondylitis as per NICE TA829. For treatment of moderate to severe atopic dermatitis as per NICE TA814.
UPADACITINIB 30mg TABLETS M/R	R	For the treatment of moderate to severe active rheumatoid arthritis in adult patients as per NICE TA665. For treatment of active psoriatic arthritis after inadequate response to DMARDs as per NICE TA768. For treatment of active ankylosing spondylitis as per NICE TA829. For treatment of moderate to severe atopic dermatitis as per NICE TA814. For treatment of moderately to severely active ulcerative colitis as per NICE TA 856. MMTC, April
UPADACITINIB 30mg TABLETS M/R (EAS PRICE STOCK)	NF	

UPADACITINIB 45mg TABLETS M/R	R	For the treatment of moderate to severe active rheumatoid arthritis in adult patients as per NICE TA665. For treatment of active psoriatic arthritis after inadequate response to DMARDs as per NICE TA768. For treatment of active ankylosing spondylitis as per NICE TA829. For treatment of moderate to severe atopic dermatitis as per NICE TA814. For treatment of moderately to severely active ulcerative colitis as per NICE TA 856. MMTc, April
-------------------------------	---	--

UREA

UREA 10% CREAM 100g	NF	
---------------------	----	--

Vindesine

VINDESINE 5mg INJECTION (CTASU)	C	For CTASU use only.
---------------------------------	---	---------------------

VISIPAQUE

VISIPAQUE 270 INJECTION 50ml (PLASTIC)	R	For use in patients who are at risk of developing contrast induced nephropathy. MAC, July 2009.
--	---	---

Water

WATER FOR INJECTION PLASTIC AMP 10ml	Y	
--------------------------------------	---	--

WATER FOR INJECTIONS

WATER FOR INJECTION PLASTIC AMP 10ml	Y	
--------------------------------------	---	--

WATER FOR INJECTION 100ml VIALS	R	Only to be used for administration of Ribavirin. PPDU, March 2007.
---------------------------------	---	--

WATER FOR INJECTION PLASTIC AMP 20ml	Y	
--------------------------------------	---	--

WATER FOR INJECTION PLASTIC AMP 10ml	Y	
--------------------------------------	---	--

WATER FOR IRRIGATION

WATER FOR IRRIGATION FLOWFUSOR 1L	Y	
-----------------------------------	---	--

WATER FOR IRRIGATION 1L BOTTLES UKF7114	Y	
---	---	--

WATER FOR IRRIGATION 1L (EASIFLOW BAGS) FKB7515T	Y	
--	---	--

09.02.02 Parenteral preparations for fluid and electrolyte imbalance

SODIUM BICARBONATE

SODIUM BICARBONATE POWDER 200g Y

Unknown

ADALIMUMAB

ADALIMUMAB 40mg PRE-FILLED PEN for INJECTION NF

Beclometasone

BECLOMETASONE 5mg M/R TABLETS NF

BUPIVACAINE + FENTANYL

BUPIVACAINE 0.125% & FENTANYL 2microgram/mL SR
IN SODIUM CHLORIDE 0.9% 500mL (UNLICENSED)

Caplacizumab

CAPLACIZUMAB 10mg INJECTION R Restricted as per NICE TA667.
Medicines Effectiveness

Darolutamide

DAROLUTAMIDE 300MG TABLETS (PROJECT
ORBIS) FOC NF

Defibrotide

DEFIBROTIDE 200mg INJECTION (Compassionate
use) NF

Dipyridamole

DIPYRIDAMOLE 50mg/5ml S/F ORAL SOLUTION NF

Dobutamine

DOBUTAMINE 250mg IN 20ml INJECTION Y

DUTASTERIDE

DUTASTERIDE 500microgram CAPSULES NF

Estradiol

ESTRADIOL 50microgram PATCHES (EVOREL) Y

FOLLITROPIN ALFA

FOLLITROPIN ALFA 900units in 1.5ml PRE FILLED
PENS R

GRANISETRON

GRANISETRON 3mg in 3ml INJECTION NF

GRANISETRON 1mg TABLETS NF

Isoprenaline

ISOPRENALINE HYDROCHLORIDE 1mg/5ml INJECTION		R	For use in bradycardia in anaesthetics, critical care and resus areas only. . Medicines Effectiveness, October 2022""
Isosorbide dinitrate			
ISOSORBIDE DINITRATE 10mg in 10ml INJECTION	Y		
LIDOCAINE			
LIDOCAINE SPRAY NOZZLES	Y		
METARAMINOL			
METARAMINOL 25mg IN 50ml INJECTION PRE-FILLED SYRINGE (CTASU PREP)	SR		For use on critical care areas during covid-19. Medicines Effectiveness, April 2020
Pyridostigmine			
PYRIDOSTIGMINE 60mg/5mL ORAL SOLUTION SUGAR FREE	NF		
PYRIDOSTIGMINE 60mg TABLETS (UL)	UNR		
ROCURONIUM			
ROCURONIUM 400mg in 40ml INJECTION PRE-FILLED SYRINGE (CTASU PREP)	UNR		
SODIUM CHLORIDE			
SODIUM CHLORIDE 0.9% INJECTION 10ml (STERILE WRAP)	SR		
TAUROLIDINE			
TAUROLIDINE / CITRATE 4% & UROKINASE 25,000units PORT & CATHETER LOCK SOLUTION	R		
TAUROLIDINE + HEPARIN			
HEPARIN 500units AND TAUROLIDINE / CITRATE 4% PORT & CATHETER LOCK SOLUTION 5ml		R	Locking haemodialysis and haemofiltration lines. MMTC, August 2013.
TIOPRONIN			
TIOPRONIN 100mg TABLETS (NP)	UNR		Restricted for use in Renal patients for the treatment of cystinuria in patients who are intolerant of penicillamine. MMTC, August 2018
<i>Unknown</i>			
AJMALINE			
AJMALINE 50mg in 10ml INJECTION	UNR		Diagnostic test for Brugada syndrome. Medicines Effectiveness, February 2013.

CARDIOPLEGIA

CARDIOPLEGIA (BLOOD) PERFUSION SOLUTION - SR For use by perfusionists only.
HIGH STRENGTH POTASSIUM 500ml INFUSION Y Medicines Effectiveness, August 2008.

GAVISCON

GAVISCON ORIGINAL LIQUID (ANISEED) Y

HELICOBACTER

HELICOBACTER PYLORI 45mg BREATH TEST (CHILD) (INFAI) Y

HELICOBACTER PYLORI 75mg BREATH TEST (ADULT) (INFAI) Y

ISOPRENALINE

ISOPRENALINE HYDROCHLORIDE 2mg IN 2ml INJECTION SR For use in bradycardia only.
Medicines Effectiveness, July 2011

PATENT BLUE

PATENT BLUE DYE 2.5% INJECTION 2ml UNR For lymph node mapping.
Medicines Effectiveness, March 2013.

Phenol

PHENOL 6% INJECTION 5ml NF

SPILLAGE KIT

SPILLAGE KIT FOR CHEMOTHERAPY Y